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Abstract 
Mouse mammary gland morphogenesis at puberty is a complex developmental 
process, regulated by systemic hormones, local growth factors and dependent on 
the epithelial/epithelial and epithelial/stromal interactions. TEBs which invade 
the fat pad are important in laying down the epithelial framework of the gland 
at this time point. The objective of this thesis was to use a combination of 
„pathway-„ and „candidate gene analysis‟ of the transcriptome of isolated TEBs 
and ducts and associated stroma, combined with detailed analyses of selected 
proteins, to further define the key proteins and processes involved at puberty. 
Using GeneChip® Mouse Exon 1.0 ST Arrays we identified the epithelial-, 
epithelial-stromal- and stromal transcriptomes of TEBs and ducts and defined 
the major functional pathways/biological processes in each compartment. By 
ranking the transcripts according to their expression levels and known functions 
in other systems, we identified genes of potential importance for pubertal 
mammary morphogenesis. We focused our study on Upk3a and Fbln2 and their 
protein products. Upk3a could only be detected at mRNA level and thus further 
analysis was based on Fbln2. We demonstrated that Fbln2 V1 and Fbln2 protein 
are predominantly expressed in the epithelium and stroma of TEBs. Using 
hormone primed mice we demonstrated that Fbln2 expression and localisation in 
the mouse mammary gland is positively regulated by E2 and P. Furthermore, by 
a combination of further in silico analysis, in vitro functional assays, IHC and IF 
we identified Vcan, Lama1, Fbn1, ColVIαIII, ColIVαI, ColXVIIIαI, Eln, Per, Acan, 
Nid, Itgb3 and Itga5 as potential binding partners of Fbln2 in mammary gland. 
Finally, we reported lack of an obvious mammary phenotype in Fbln2 KO-/- mice 
at puberty but demonstrated that this may be attributed to the over-
compensation by Fbln1.         
This thesis demonstrates the benefit of DNA microarray analysis in studying 
pubertal development of mouse mammary gland. It identifies Fbln2 as a 
potential pubertal mammary regulator which by interacting with various ECM 
proteins at different sites of mammary milieu may contribute to an array of 
structural and migratory functions during mammary morphogenesis. These data 
substantially add to the understanding of the development of mammary gland at 
puberty and reveal many potential avenues for further investigations.  
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1 Introduction 
1.1 Overview of mouse mammary gland development 
The mammary gland is an epidermis derived organ that develops as a result of 
reciprocal epithelial-mesenchymal interactions and its primary function is to 
provide milk [1]. The mammary gland is exclusively present in mammals and it is 
the only organ where the majority of development occurs postnatally, with the 
onset at puberty. The mammary gland consists of an epithelial ductal tree which 
is surrounded by fat pad. The ductal tree forms a branched network of ducts 
that transport milk to the nipple to feed the new born. Mice have five pairs of 
mammary glands located to both thoracic (near forelimb) (3 pairs) and inguinal 
(next to hindlimb) (2 pairs) body regions. There is a gradient of differentiation 
between the murine glands, with the first being the least and fifth, the most 
differentiated [2]. The mammary glands initially develop in both female and 
male embryos. Sexual dimorphism arises as a result of androgen production by 
the testis and becomes apparent from embryonic day 14 (E14) [3].  
During embryogenesis and puberty the mammary gland undergoes a series of 
complex and dynamic morphological changes that result in epithelial invasion of 
the surrounding fat pad and development of a ductal network. During pregnancy 
alveolar structures establish. During lactation milk is produced and released and 
after the pups are weaned a regression to the mature virgin-like state, by a 
process called involution, takes place. Both the wide array of developmental 
stages and postnatal development make the mammary gland a valuable model to 
delineate general mechanisms of morphogenesis. Processes involved in the 
formation of embryonic mammary placodes are similar to these that orchestrate 
formation of other skin appendages, such as teeth and feathers [4]. Hallmarks of 
puberty include extensive elongation of ducts and secondary branching making 
the mammary gland a good model to study branching morphogenesis and 
cell/tissue migration or invasion. During pregnancy, on the other hand, the 
mammary gland can be used to study not only branching morphogenesis but also 
cellular proliferation, since elevated cell proliferation and formation of 
additional tertiary ductal side branches, terminating in alveolar buds are 
characteristic of this developmental stage. Involution is a perfect system to 
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study cell death by apoptosis as the post-lactational regression is the most 
dramatic example of physiologically regulated apoptosis in adult tissue. Finally, 
an understanding of the biological processes implicated in mammary 
morphogenesis may assist our understanding of cancer as similar processes of 
proliferation, apoptosis and invasion occur in both.  
Female mouse mammary gland morphology during the embryonic and postnatal 
development (pre-puberty, puberty, adulthood, pregnancy, lactation and 
involution) and its main regulatory cues are discussed below. Detailed analysis of 
pubertal mouse mammary development and its regulation, which this thesis 
focuses on, is presented in 1.2. 
1.1.1 Embryonic development of mouse mammary gland 
Mammary gland development begins at E10 with the formation of the 
milk/mammary lines. Milk lines arise from ectoderm and stretch between the 
anterior and posterior limb buds, on the ventral side of the embryo. The 
columnar, multilayered cells within the milk line are delineated by the 
expression of Wnt pathway members including Wnt 10a and Wnt 6. At E11.5 the 
mammary lines resolve into mammary placodes – lens-shaped epidermal 
structures consisting of several layers of large columnar cells which are not 
uniformly orientated and are likely to derive from epidermal cells that migrate 
along the milk lines [5]. There are five pairs of mammary placodes in the mouse 
embryo. The development of individual pairs is not simultaneous and occurs in a 
distinct order  [5] [6] [3]. Subsequently each mammary placode invaginates into 
the underlying mesenchyme to form a mammary bud [7]. From E12 to E14 the 
mammary buds submerge beneath the skin [5]. This is accompanied by two 
processes: formation of an epidermal-like cell stalk connecting the mammary 
bud to the skin and formation of the condensed primary mammary mesenchyme 
and embryonic fat pad [7]. Primary mesenchyme consists of multiple layers of 
fibroblasts [8]. It surrounds the basal lamina (BL) (laminin and heparan sulphate 
proteoglycans) of the stalk and ball of a mammary bud [9]. The fat pad, on the 
other hand, forms distally to the mammary bud and consists of loosely 
positioned preadipocytes [8]. At E16 mammary buds elongate to form mammary 
sprouts which invade primary mesenchyme and grow into the embryonic fat pad, 
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where they undergo branching to create a primary ductal tree with a lumen 
which opens on the surface of the skin. The ductal opening is surrounded by a 
nipple sheath which is formed by epidermal invagination [3] [10]. By E18.5 the 
rudimentary mammary tree consists of one short primary duct and about 10-15 
initial branches. The rudimentary tree grows very slowly until puberty when the 
next cycle of extensive branching and elongation occurs (reviewed in [3]). It 
forms a scaffold on which further postnatal developmental changes will occur. 
An overview of female embryonic mouse mammary gland development is 
demonstrated in Figure 1-1.      
Embryonic development of mouse mammary glands is fully dependent on the 
continuous communication between the ectoderm and mesenchyme of the 
developing mammary rudiment [11] [12], as shown by Sakakura et al. (1987), 
where mouse mammary epithelial explants fail to form buds when removed from 
its mesenchymal environment [7]. If recombined with mammary epithelial 
mesenchyme, epithelial explants from elsewhere in the embryo develop into 
mammary epithelium. The importance of primary mesenchyme in governing 
mammary cellular fate is also highlighted by the fact that the recombination 
experiments are only successful at E14-E17 – when the primary mesenchyme is 
formed [13]. The E17 mammary epithelium shows different morphological 
responses to the mammary mesenchyme and mammary fat pad. When grafted to 
an E14-E17 fat pad, normal ductal development can be seen, but when 
combined with E12-E17 mammary mesenchyme, ductal hyperplasia, 
characterised by frequent branching and lack of ductal elongation occurs [8]. 
Sustained epithelial-mesenchymal interactions direct and regulate expansion of 
placodes, formation of mammary buds and development of the rudimentary 
ductal tree.  
The canonical pathways which signal from epithelium to mesenchyme and 
orchestrate different stages of embryonic mammary morphogenesis include 
wingless-related (Wnt), fibroblast growth factor (Fgf), T-lymphocyte 
differentiation parathyroid hormone-related protein signalling (PTHrP) and 
Insulin growth factor 1/Rho GTPase activating protein 5 (IGF-1/p190-B) 
pathways. Proteins associated with Wnt and FGF signalling are known to be 
essential for the milk line specification and placode formation. Deficiency of t-
box transcription factor 3 (Tbx3) which can be induced by Wnt signalling results
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Figure 1-1 Overview of mouse mammary gland embryogenesis. 
The embryonic development of mouse mammary gland starts with the formation of a mammary 
placode at E11.5. By E12 a mammary bud is apparent as a swelling on the surface of the 
ectoderm. By E15 the mammary bud invaginates and mammary mesenchyme condenses to form 
primary mammary mesenchyme. The mammary bud elongates to form a mammary sprout which 
further elongates to invade the underlying fat pad (E16). Finally at E18.5 the mammary sprout has 
branched to form a rudimentary mammary tree. The newly formed mammary tree is composed of a 
primary duct with a lumen opening into the nipple and multiple branched secondary ducts.    
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in complete loss of placodes [14] while loss of lymphocyte enhancer factor 
factor-1 (Lef1), a Wnt target gene, leads to loss of two pairs of placodes and the 
underdevelopment of the remaining ones [15]. In addition to its role in 
mammary line and placode formation, Wnt signalling also contributes to 
mammary bud formation. The decrease in mammary bud size is associated with 
the loss of Wnt modifier - pygopus 2 (Pygo2) or Wnt coreceptors low density 
lipoprotein receptor-related protein 5 (Lrp5) and Lrp6 expression [16] [17] [18]. 
Furthermore, loss of Lrp6 or Pygo2 expression also impairs the formation of the 
primary ductal system [17] [16]. Finally, blocking of Wnt signalling at E14.5 with 
its inhibitor dickkopf 1(Dkk1) results in suppression of mammary bud formation 
[19]. Fibroblast growth factor 10 (Fgf10) is expressed at E10.5-E11, when it 
localises directly underneath the forming mammary line suggesting a function in 
early mammary line specification. Fgf10 and fibroblast growth factor 2b receptor 
(Fgfr2b) are also necessary for the development of mammary buds as their 
deficiency results in the failure of all but mammary bud number 4 to develop 
[20]. On the other hand, expression of transcription factor GATA binding protein 
3 (GATA3), which is implicated in regulation of T lymphocyte differentiation in 
response to parasitic infections, is essential for both placode and nipple sheath 
formation [21]. PTHrP signalling is essential for full differentiation of mammary 
mesenchyme (essential for determining of epithelial cell fate), formation of the 
nipple sheath and further ductal morphogenesis [10] [22]. The downstream 
target of PTHrP, bone morphogenic protein 4 (BMP4) also plays a role in 
regulation of embryonic mammary ductal morphogenesis [23]. Finally, disruption 
of the IGF-1/p190-B pathway by knock out (KO) of p190-B (inhibits Rho activity) 
or insulin receptor substrates 1 or 2 (IRS1 and 2) expression, results in formation 
of small mammary buds and disorganisation of the mammary mesenchyme [24]. 
Some of the other molecules which are critical for embryonic mammogenesis 
include: v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ErbB4) ligand 
- neuregulin 3 (Nrg3) [25], homeobox msh-like 2 (Msx2) and Msx1 the double    
KO-/- of which results in the formation of small placodes which fail to transform 
into mammary buds [26].  
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1.1.2 Postnatal development of mouse mammary gland 
The majority of mammary gland morphogenesis occurs postnatally. It begins 
during puberty with ductal proliferation, carries on through adulthood with 
oestrus cycle induced early alveolar development and is completed with the 
cycles of proliferation, differentiation and cell death with each pregnancy, 
lactation and involution. The summary of the subsequent stages of postnatal 
mouse mammary gland development is shown in Figure 1-2.              
At birth, the mammary gland consists of a rudimentary ductal tree which is 
similar to that seen at the E18.5 (Figure 1-1). During the first few weeks of 
postnatal life, up until the onset of puberty, the mammary rudiment grows 
allometrically. At the onset of puberty (~3-4 weeks) increased levels of 
gonadotrophins and oestrogen in the serum trigger formation of terminal end 
buds (TEBs), which in turn drive ductal elongation. The ductal tree expands via 
ductal elongation and branching up until week ~10-12 (adulthood) when the 
ductal system becomes fully developed. Detailed overview of pubertal mammary 
gland morphogenesis is discussed in Section 1.2.  
At ~10-12 weeks of age, depending on the mouse strain, the edges of the fat pad 
are reached, TEBs start regressing into terminal end ducts and ductal outgrowth 
ceases. In response to ovarian hormones, secreted with each oestrus cycle, 
mature ductal epithelium further undergoes cycles of proliferation, 
differentiation and involution that results in formation of small ductal branches 
and lateral buds [27]. Lateral buds then turn either into lateral branches or form 
alveolar buds. Lateral branches are characterised by the presence of a cap cell 
layer at its growing tip (as seen in TEBs). Alveolar buds are comprised of a single 
epithelial cell layer enclosing a hollow lumen [28]. During pregnancy-induced 
growth, alveolar buds progress into fully differentiated units capable of milk 
secretion called alveoli. Although the secretion of milk occurs during lactation 
the expression of milk proteins can already be observed during the oestrus cycle 
in murine adult virgin mammary glands [29].  
Pregnancy is further characterised by extended epithelial differentiation. In 
mice gestation lasts for 19-21 days. Its onset is defined by two events: extensive 
proliferation and branching of the ductal epithelium and formation of alveolar  
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Figure 1-2 Overview of the postnatal mouse mammary gland development. 
Figure shows the representative stages of mouse mammary gland morphogenesis. At pre-puberty, 
the mammary gland consists of a rudimentary tree that contains TEB-like structures and is similar 
to that seen at E18.5. Onset of puberty initiates TEBs formation and bifurcation, ductal elongation 
and branching, which collectively form a ductal tree. Upon reaching adulthood, most TEBs regress 
and ductal expansion ceases. Mature ductal epithelium undergoes estrus cycle dependent cycles 
of proliferation, differentiation and involution which gives rise to tertiary branching and development 
of lateral buds. With the onset of pregnancy, the rate of proliferation increases and lateral buds 
develop into alveoli. At parturition and during lactation, the whole gland is filled with alveoli that 
produce milk proteins and lipid which are secreted and transported through the ducts to feed the 
pups. Upon weaning, the alveoli regress and the gland undergoes remodelling in the process 
called involution, which returns the gland to a morphological state similar, but not identical, to that 
seen in mature virgin mice (adulthood). 
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buds, as seen in murine adult virgin mammary glands. Towards the middle part 
of pregnancy, alveolar buds cleave and further differentiate to form individual 
alveoli (lobuloalveolar phase of mammary gland morphogenesis). Alveoli 
synthesise and secrete milk from late pregnancy and throughout lactation. As for 
epithelial ducts and virgin alveolar buds, the alveoli are formed by the luminal 
(innermost cells enclosing the lumen) and myoepithelial cells (outermost cells). 
Here, however, the myoepithelial cells are less continuous. This enables the 
direct contact of luminal cells with the basement membrane (BM), which is 
critical for full differentiation and milk secretion  [30]. Alveoli are suggested to 
originate from the lobule-limited progenitor cells [31] (reviewed in [32]). By 
gestation day 18, the alveolar epithelial cells enlarge and produce milk proteins 
(whey acidic protein (WAP) and α-lactalbumin, ß-casein) and lipids in 
preparation for lactation [33]. At the final stages of pregnancy, alveoli occupy 
the majority of the fat pad. Secretion of milk proteins and lipids to the alveolar 
lumen starts one day prior to parturition. The main regulators of gestation 
include progesterone (P) and prolactin (PRL). Presence of progesterone 
receptors (PRs) is critical for mediating ductal outgrowth and lobuloalveolar 
differentiation (reviewed in [34]).  Furthermore, P suppresses active milk 
secretion. The absence of alveoli is also associated with lack of prolactin 
receptor (PRLR) expression [35].  
At parturition, the luminal epithelium becomes flattened due to the 
engorgement of alveoli and firstly colostrum and then milk and lipids are 
secreted to the lumen. PRL acts on luminal epithelial cells to sustain milk 
secretion [36]. In response to oxytocin, the surrounding myoepithelial cells 
contract to force milk out of the alveoli into the ducts, towards the nipple. This 
process of milk secretion is referred to as lactation and can occur for up to 3 
weeks. It is stimulated by suckling pups which cause the release of oxytocin [28].  
After natural or forced weaning (pup removal) and in response to milk stasis, the 
mammary gland enters a phase of dramatic cell death and tissue remodelling, 
called involution. At this time point, the expression of genes encoding milk 
proteins decreases to basal level.  The expression of genes associated with 
processes such as apoptosis (e.g. serum gp70 production 2 (SGP-2), signal 
transducer and activator of transcription 3 (STAT3)), regulation of proliferation 
and differentiation (e.g. tumour suppressor p53 (p53),               
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myelocytomatosis oncogene (c-myc), transforming growth factor ß (TGF-ß)) [37] 
increases. Inflammation/acute phase response proteins also increase at this time 
(e.g. CD 14 antigen (CD14), lipopolysaccharide binding protein (LBP)) [38] [39] 
(reviewed in [40]). Initially, during the first 2-3 days the process is reversible 
and lactation can be reintroduced upon suckling [41].  
Apoptosis of the alveolar secretory luminal cells commences just within hours 
after weaning and by day 3 it becomes irreversible [42]. The alveoli collapse into 
clusters of epithelial cells and the fat pad is thought to become refilled with 
adipocytes. The collapsed apoptotic epithelium is cleared mainly by 
neighbouring epithelial cells which recognise and engulf them into the 
specialised vesicles called the efferosomes [43] [44]. By day 4 of involution the 
clearance of apoptotic cells is completed and the epithelial, stromal and BM-
associated rearrangements occur [44] [37]. Involution lasts for 14-21 days 
approximately and at its conclusion, the mammary gland resembles a pre-
pregnant mature mammary gland. In comparison to the virgin gland, however, 
the involuted gland is more differentiated and contains the occasional remaining 
alveoli [28]. 
1.2 Mouse mammary gland morphogenesis at puberty 
The onset of puberty can be defined by three pubertal events: vaginal opening, 
first vaginal cornification and onset of cyclicity. The vaginal opening, first 
oestrus and the following increase in the production and secretion of 
gonadotrophins and oestrogen (E2) are the most frequently used measurements 
of puberty in mice. The timing of all three pubertal events depends on the strain 
of mice [45]. Generally, the onset of puberty arises at 3-4 weeks of age. In some 
mice, however, it can occur several weeks after vaginal cornification [46]. In 
C57BL/6 mice the vaginal opening, first vaginal cornification and first oestrus 
occur at approximately 4, 6 and 8 weeks of age respectively [45]. The murine 
oestrus cycle lasts for 4-5 days and comprises of four phases: proestrus, oestrus 
(ovulation), metoestrus and dioestrus. Each of these stages are characterised by 
distinct changes in vaginal cytology and mammary gland morphology. As 
described by Bronson et al. (1975), in virgin mice, proestrus is associated with 
appearance of small TEBs at the ducts located at the periphery of the gland 
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(similar structures can be seen at pre-puberty) and large, blunt projections on 
the main ducts at the nipple region. At oestrus, the mammary ducts become 
dilated and TEBs elongate. Epithelial growth regresses during metoestrus when 
ducts decrease in width and their endings collapse giving rise to the very open 
network of narrow, thread-like ducts seen in dioestrus [47]. At each subsequent 
oestrus cycle, a slight burst of proliferation and growth of mammary epithelium 
can be noted [48].  
Morphologically, the pubertal mouse mammary gland consists of two 
compartments: epithelial and stromal (fat pad). In addition each mammary 
gland has one or two lymph nodes (LN), blood vessels and nerves [49]. The 
epithelial compartment of the pubertal mouse mammary gland consists of TEBs 
and ducts. TEBs, which are situated at the ends of ducts, promote and direct the 
outgrowth of the ductal tree into the surrounding fat pad [50]. TEBs migrate 
forward and bifurcate while ductal epithelium elongates behind them thus 
producing secondary branches and a ductal network. Epithelial expansion peaks 
between ~ 4-7 weeks of age and takes place until the whole fat pad is filled 
(~10-12 weeks of age), when TEBs regress and the extensive mitotic activity, 
ductal outgrowth and branching cease, with only minor proliferative activity 
noted in response to the oestrus cycle [51]. The structure of pubertal mouse 
mammary gland is illustrated in Figure 1-3.  
1.2.1 The morphology and characteristics of pubertal mouse 
mammary gland 
1.2.1.1 Epithelium  
Although both TEBs and ducts are essential for pubertal outgrowth their role is 
very different. These differences are reflected in their morphology, the 
character of their surrounding stroma, the mechanisms underlying branching 
morphogenesis, outgrowth and its regulation.    
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Figure 1-3 Morphology of pubertal mouse mammary gland. 
Carmine alumn stained wholemount of a pubertal C57BL/6 mouse mammary gland (6 week old). 
(A) The asterisk denotes the nipple region; double asterisk represents the Fat pad; the thin arrow 
shows ducts; thick arrow denotes TEBs while arrowhead the LN. Scale bar is 2.5 mm. (B) 
Magnified image of two TEBs and a duct. Scale bar is 100 um.  
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1.2.1.1.1 TEBs 
 
TEBs are bulbous epithelial structures which range in size from 0.1 to 0.5mm 
[52]. They are mainly present at puberty, when they drive directional outgrowth 
of the ductal tree, at the rate of approximately 0.5mm/day [53]. Similar 
structures can be seen between late gestation and week 1 of pre-puberty where 
they appear in response to maternal hormones. The decrease in maternal 
hormones stops mitosis in the TEB-like structures, until the onset of cyclicity at 
puberty when cellular proliferation begins again [7] [54]. TEBs consist of two 
types of epithelial cells: inner body cells and outer cap cells (Figure 1-4 B and 
C). Cap cells are enveloped by a BM that belongs to the extracellular matrix 
(ECM), and this will be discussed in 1.2.1.2.4  
Cap cells are exclusively present in TEBs [55] and TEB-like structures where they 
form either a single or double layered envelope all around the body of the TEB. 
The number of cap cells is proportional to the size of TEB [54]. At the apical 
side, they are adjacent to the BM while at the lateral side, although slightly 
separated, they flank the bulk of the TEB. Cap cells located at the tip of TEB are 
characterised by loose organisation, presence of multiple intercellular spaces, 
and a lack of specialised cell junctions for adhesion or communication. As shown 
by Williams and Daniel (1983) they can be easily detached from the underlying 
bulk of the TEB and overlaying BM when treated with testicular hyaluronidase 
[53]. The nuclei of cap cells are round or oval with diffuse chromatin while their 
cytoplasm comprises of multiple free ribosomes, a moderate number of 
mitochondria, some rough endoplasmic reticulum and lipid droplets. Highly 
organised cytoskeletal elements are lacking. 
Cap cells exhibit poor apical-basal polarity evidenced by sporadic secretion of 
hyaluronate and laminin (Lama1) (BM molecules) to their interior surfaces [56]. 
At the tip of the TEB cap cells have a columnar shape. As the contour of TEB is 
followed to its lateral sides and neck, however, the columnar cells progressively 
transform into cuboidal (lateral) and spindle shaped (neck) cells. The spindle 
shaped cells exhibit the characteristics of myoepithelial cells (outer cell layer in 
ducts) suggesting that the myoepithelium of the subtending ducts originates 
from cap cells. In addition, it is suggested that individual cap cells are able to  
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Figure 1-4 Structure of TEB with duct and surrounding stroma. 
(A) (B) H&E stained section through (A) TEB and (B) duct. (C) Diagram representing structural 
characteristics of epithelial and stromal compartments of TEB and duct. TEB consists of a single 
layer of outer cap cells and multiple layered inner body cells. Cap cells give rise to myoepithelial 
cells of ducts, while body cells most likely differentiate into the ductal luminal cells. Both TEBs and 
ducts are surrounded by a BM. The stromal environment of TEBs and ducts consists of adipocytes, 
fibroblasts and mast cells. In addition, macrophages and eosinophils can be also seen in the 
stroma around TEB. The ECM provides a link between the epithelial and stromal cells. Scale bars 
are 50µm. 
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break away and migrate to deeper regions of the body of TEB. Cap cells stained 
using their molecular markers: P-cadherin (Cdh3)) (adhesion molecule specific 
for cap cells) [57] and Lama1 (BM component synthesised in epithelium) [58] 
translocated to the body cell layers, where they gradually lost the expression of 
cap cell markers in favour of acquiring a luminal identity. Similar observations 
were confirmed using phase-contrast time-lapse microcinematography of freshly 
isolated TEBs [53]. Together these events suggest that cap cells contribute to 
the body cells and therefore are likely to be progenitors of the luminal epithelial 
cells of ducts. Furthermore, due to their presence at the tips of migrating TEBs, 
but not ductal tips of mature adult epithelium [59] it is likely that cap cells play 
a pivotal role in directing and patterning of ductal outgrowth.                      
The main bulk of the TEB, however, is formed by tightly compacted and 
multilayered body cells (6-10 layers). Morphologically, body cells are similar to 
ductal luminal cells and they are proposed to be their progenitors. Body cells 
tend to be polarised and possess tight cell-cell junctions characterised by the 
expression of E-cadherins (Cdh1) [53] [57]. The outer layers, although, in some 
places separated by an intercellular space, are in contact with cap cells while 
the inner most layer of body cells surrounds the lumen of the TEB. Inner layers 
of body cells are characterised by a high apoptotic rate that can be detected by 
TUNEL assay and positive B-cell leukaemia 2 (Bcl-2), chemokine ligand 13 (Blc-x) 
and Bcl-2-associated X protein (Bax) expression (apoptotic checkpoint proteins) 
while the outermost body cells layers are more proliferative. Apoptosis is p53-
independent and most probably leads to lumen formation. Each TEB contains 
reciprocal zones of apoptotic and proliferative cells which, although dispersed 
throughout the TEB, tend to appear in close proximity to each other [60]. The 
observed rate of apoptosis (11.3 %) is higher than that calculated for any other 
stage of mouse mammary development (apoptosis detected for involution is 
4.5%) or that detected during kidney morphogenesis (3%) [61].    
1.2.1.1.2 Ducts 
 
Ducts account for the majority of the mammary epithelium at puberty where 
they form a branched ductal tree that serves as a scaffold on which secretory 
alveoli develop during pregnancy. In comparison to TEBs, however, ductal 
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epithelium is relatively growth quiescent [62]. Ducts are composed of an inner 
luminal and outer myoepithelial layer. Myoepithelial cells are surrounded by BM 
(Figure 1-4 A and C). Myoepithelial cells form a thin monolayer of basally 
arranged cuboidal cells. They are likely to play a part in signal transition 
between the BM and the internally located luminal epithelium. Cytologically, 
myoepithelial cells are characterised by desmosomes, hemidesmosomes, 
myofilaments, irregular nuclei with marked heterochromatin, peripheral 
cytoplasmic caveoli and ragged basal borders. Luminal epithelial cells, on the 
other hand, exhibit short, blunt microvilli on their apical surface and display 
well-developed cell-cell junctions [63]. Generally they form a monolayer but in 
some regions 1-3 layer thick wall of ductal epithelium around the hollow lumen 
can be seen. The layer closest to the lumen exhibits a higher apoptosis rate than 
that seen in the more outer cell layers which is consistent with a role of 
apoptosis in lumen formation [61] [60]. In addition, the ductal lumen may 
originate from the lumen of the advancing TEBs. One of the markers of luminal 
epithelial cells is keratin 18 (Krt18) [64] while the smooth muscle α-actin (SMA) 
marks the myoepithelial cells [65].   
Both TEBs and ducts, i.e. the entire pubertal mammary epithelial tree contain 
stem cells which further persist through the subsequent stages of mammary 
morphogenesis and are capable of reconstructing a complete and functional 
gland when transplanted into cleared mammary fat pad of recipient host [66] 
[67] [68]. Mammary stem cells are defined as undifferentiated, pluripotent, 
relatively quiescent and long lived cells. As shown by the experiments based on 
the serial transplantation of mammary epithelium from the MMTV infected mice 
to the fat pads of recipient host, the mammary stem cells are capable of 
producing 5-8 transplant generations before senescing [68]. Furthermore, they 
exhibit the capacity to self maintain and proliferate – it is suggested that when 
transplanted, a stem cell initially divides symmetrically to repopulate the gland 
but any of their subsequent divisions, if and when they happen, are most 
probably asymmetric (with the template DNA strand being retained) (reviewed in 
[32]). Moreover, apart from the „mother‟ stem cells that act as initial 
progenitors that give rise to cellular make up of mammary gland, as firstly 
demonstrated by transplantation studies using limiting dilution of mammary 
epithelial cells, the following generations of the „daughter‟ mammary stem cells 
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produce two distinct lineage-limited progenitor cells: duct-limited and lobule-
limited (also called – the parity induced mammary epithelial cells- PI-MEC) 
progenitors. Duct-limited progenitors produce oestrogen receptor (ER)+/- and 
PR+/- luminal cells and cap cells but are unable to produce progeny capable of 
sustaining epithelial growth at pregnancy and during alveologenesis, while the 
lobule-limited progenitors give rise to ER+/- and PR+/- luminal epithelial and 
myoepithelial cells, but are incapable of generating cap cells and thus can not 
give rise to ductal tree [31]. Both progenitor cell types are therefore essential to 
create mouse mammary gland in its entirety.       
1.2.1.2 Fat pad  
Fat pad (stroma) is a crucial component of the mouse mammary gland. Not only 
does it provide the structural scaffold for the ductal epithelial tree but it also 
regulates its morphogenesis. Numerous studies in which pre-pubertal fat pads 
were cleared from their endogenous epithelium and engrafted with exogenous 
epithelium demonstrated its magnificent role in sustaining and directing 
epithelial cell fate and promoting growth [69] [66]. As demonstrated by Daniel 
et al. (1968), transplantation of a small fragment of ductal epithelium into the 
cleared fat pad results in reconstitution of the whole ductal tree. In this 
experiment epithelial growth is induced at puberty and the mature ductal tree is 
formed within 10-12 weeks after transplantation [59]. This phenomenon was 
further elucidated by Kordon et al. (1998) who suggested the capability of the 
cleared fat pad (mature) to allow growth of the whole mammary gland from a 
single pluripotent mammary stem cell [68] which in 2006 has been demonstrated 
to be true by Shackleton et al. [70]. Furthermore, it has also been shown that 
testicular cells, when mixed with mammary epithelial cells (MECs) and 
transplanted into denuded fat pad, acquire an epithelial cell fate and contribute 
to ductal outgrowth [71]. Similar results were also obtained firstly with murine 
fetal and adult neural stem cells combined with equal numbers of MECs and 
engrafted into the clear fat pad [72] and secondly with the MECs mixed with 
human embryonic carcinoma cells (NTERA2cl) which, when inoculated into 
denuded fat pad, reprogrammed to normal MECs and contributed progeny to the 
resulting functional mammary outgrowths [73]. It is worth noting, however, that 
no outgrowths could be seen if the exogenous implants were not mixed with 
MECs upon the transplantation. Recently, it was also shown that mammary 
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morphogenesis can be induced and promoted by transplantation of mouse stem 
cells which are undergoing hematopoietic differentiation into the receptive 
cleared murine mammary fat pads [74].  This phenomenon of cell fate regulation 
by the stromal environment can be also seen in reverse experiments where 
mammary embryonic epithelium cotransplanted into salivary gland mesenchyme 
and grafted under the renal capsule of a host mouse, formed structures that 
resembled salivary glands [75].  
This ability to impose and regulate cell fate is attributed to stem cell niche – a 
milieu, which based on current knowledge, includes the stromal environment, 
pluripotent cells, lineage-specific progenitors and fully differentiated cells which 
all contribute and signal together to support, maintain and control the stem 
cell/progenitor fate (reviewed in [32]).  
Pubertal mouse mammary stroma is very heterogeneous in its composition. 
Adipose tissue is the most abundant mesenchymal cell type followed by 
fibroblasts, ECM, immune cells, endothelial and neural cells (Figure 1-4 C) [76].  
1.2.1.2.1 Adipose tissue 
 
There are two types of adipose tissue: brown adipocytes which are energy 
dissipating cells and white adipocytes which store energy [77]. Brown 
adipocytes, as opposed to white ones, are highly innervated and functionally 
controlled by the sympathetic nervous system [78]. They contain numerous well 
developed mitochondria and multilocular lipid inclusions whereas white 
adipocytes consist of a single, large inclusion and a low number of mitochondria 
[79]. Both are present throughout pubertal mouse mammary development. 
Brown adipocytes are most prevalent during pre-puberty where they surround 
the ductal tree (between the nipple and lymph node) but their structural 
contribution to mammary stroma decreases as the mice age and prior to 
adulthood they are undetectable [80]. White adipocytes, on the other hand, are 
present throughout mammary development where they are known to secrete a 
range of hormones, cytokines and growth factors, such as leptin, adiponectin, 
hepatocyte growth factor (HGF), collagen type VI (ColVI), interleukin 6 (IL-6) and 
tumour necrosis factor alpha (TNFα) and metabolise androgen to E2 [81].  
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1.2.1.2.2 Fibroblasts 
 
The second most abundant type of stromal cells present in pubertal mouse 
mammary glands are fibroblasts - principal components of all connective tissues. 
Fibroblasts are spindle shaped. They are embedded within the ECM which they 
synthesise and maintain. They secrete collagen type I (ColI), III and V, 
fibronectin (Fn) and matrix metalloproteases (MMPs) which are essential for ECM 
maintenance; Lama1 and ColIV for BM formation. They are also involved in 
wound healing, regulation of inflammation and epithelial morphogenesis via 
secretion of growth factors (reviewed in [82]).          
1.2.1.2.3 Migratory cells of the immune system 
 
Migratory cells of the immune and haemopoietic system such as macrophages, 
eosinophils and mast cells are other crucial components of the mammary 
stroma. Macrophages and eosinophils detected by the marker protein F4/80 are 
associated with morphogenesis of numerous tissues. Initially, expression of 
macrophages in the mouse mammary gland can be detected at 2.5 weeks of age 
where they gather around the rudimental ductal tree. At puberty, however, 
macrophages cluster at the neck of TEBs where they support epithelial 
development, angiogenesis and matrix remodelling. The macrophages secrete 
trophic factors which are thought to play a role in ColI assembly and organisation 
into fibrillar bundles, which in turn are suggested as a part of the mechanism 
which directs the shape of TEBs and provides a framework for their outgrowth 
[83]. Furthermore, macrophages also intersperse among the adipocytes where 
they are involved in the phagocytosis of dying tissue [84]. Some macrophages 
also locate inside TEBs within the population of body cells that are proximal to 
the lumen. The recruitment of macrophages to the TEB is paralleled by the 
appearance of eosinophils which localise at the tips of TEBs. Initial recruitment 
of macrophages to the pre-pubertal mammary gland is regulated by colony 
stimulating factor 1 (CSF-1) [85]. It is expressed by the developing ducts and 
secreted as biologically active cell surface protein while the CSF-1 receptor 
(CSF-1R) is exclusively expressed on the macrophages [86] [85]. Specialised 
recruitment of macrophages to the TEBs, on the other hand, depends on the 
chemo-attractant action of chemokine C10 the expression of which depends on 
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the eosinophil recruitment around TEBs [87]. The recruitment of eosinophils, in 
turn, is regulated by interleukin 5 (IL-5) and eotaxin. IL-5  mobilizes eosinophils 
and their progenitors from the bone marrow while eotaxin directs their homing 
around TEBs [88] [87]. Similar spatial localisation and regulatory dependency 
suggest that macrophages and eosinophils could act synergistically [87].  
Recently, further examination of immune response cells in pubertal mouse 
mammary gland morphogenesis identified mast cells in the stromal 
microenvironment [89]. Mast cells are produced in the bone marrow and 
released into the blood stream to be delivered into tissues, where they mature 
i.e. acquire a granular phenotype. The granules consist of histamine, 
proteoglycans, growth factors, proteases and many other factors which are 
secreted into the surrounding microenvironment through the process of 
degranulation. Mast cells are normally present around blood vessels, nerves, 
epithelial cells and muscle cells [90]. In the mammary gland, a few (scattered 
around the stroma) mast cells can be detected during pre-puberty. Peak of their 
activity, however, occurs at puberty when most mast cells gather in the stroma 
surrounding the BM of TEBs and ducts, the stroma ahead of the advancing TEB 
and around blood vessels. Some mast cells can be also seen at the periphery of 
the LN [89].  
1.2.1.2.4 ECM 
 
Stromal cells surrounding mammary epithelium are embedded in cell-secreted 
interstitial ECM. ECM can be divided into two compartments: BM and fibrous 
connective tissue (reviewed in [91]). BM can be also referred to as basal lamina 
(BL). The two names are often used interchangeably; BM refers to an ECM 
structure visualised by light microscopy while BL is visualised only by electron 
microscopy. BM is a highly organised outermost component of TEB and ducts that 
lies directly outside cap cells and myoepithelial cells respectively. It consists of 
three layers. Namely, lamina lucida interna, formed by periodically arranged 
stalks, lamina densa and anionic globular lamina externa. (reviewed in [91]). 
Lamina lucida interna and -externa contain high levels of proteoglycans which 
facilitate the attachment of lamina densa to both epithelial cell surface and 
collagen fibres which are part of the ECM fibrous connective tissue. There are 
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two types of proteoglycans: hyaluronate – present at the tip of the advancing 
bud and sulphate-rich glycosaminoglycans (S-GAGs) which are present towards 
the neck of the bud where ductal morphogenesis takes place [50]. S-GAGs are 
linear polysaccharides which consist of repeating hexuronic acid and hexosamine 
and are generally associated with cellular differentiation, tissue stabilisation and 
collagen fibrillogenesis [92]. The affinity of BM to ECM proteins also differs with 
the spatial location.  
As shown by Williams and Daniel (1983), when TEBs were teased away from the 
surrounding stroma the anterior part of BM was free of stromal adhesions while 
the neck region was still attached to ECM fibres and adipocytes. Furthermore, 
transmission electron microscopy carried out by the same research group, on the 
TEBs that were surgically removed from fat pad, demonstrated heterogeneity in 
the thickness of BM and the composition of its associated ECM depending on 
whether the tip or neck of TEBs was studied. BM at the anterior side was 104nm 
thick and its associated stromal cells appeared undifferentiated and 
mesenchyme derived. In contrast, at the neck of TEB, BM consisted of multiple 
folded layers (14 times thicker) and its associated  stromal environment 
exhibited cytoplasmic specialisation [53]. In the ducts, BM was 130nm thick [53] 
and synthesised by myoepithelial cells while around TEBs, it was synthesised by 
cap cells and fibroblasts [93] [50] [94]. Major constituents of BM are Lama1, 
ColIV, nidogens (Nid) and perlacan (Per) (reviewed in [91]).  
The second type of mammary ECM, the fibrous connective tissue, is 
characterised by the absence of epithelial cells and presence of fibroblasts and 
immune cells. It is rich in collagen content. Some of its other components 
include Fn, fibrillar collagens, tenascin-C (Tn), elastin fibres (Eln), Small 
Leucine-Rich Proteoglycan (SLRP) such as decorin and biglycan type I  [95] and 
Secreted Protein Acidic and Rich in cysteine (SPARC) [95] (reviewed [91]). These 
proteins are then cross linked via covalent chemical bonds to organise, stabilise 
and regulate the tension of the ECM scaffold. The cross linking is catalysed by 
lysyl oxidase (LOX) and tissue transglutaminase 2 (tTG2) [96] [97]. The 
composition of the fibrous connective ECM also varies depending on its spatial 
location in the growing mammary gland. It is denser at the neck region of TEBs 
or around the ducts and looser at the tips of TEBs. ECM interacts with the 
cytoskeleton of epithelial cells via integrins.  
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ECM not only anchors the epithelial cells and provides them with physical 
support, but is also essential for signal transmission between stromal and 
epithelial cells which is a prerequisite to normal mammary gland development. 
As demonstrated by Emerman et al. (1977), mammary epithelial cells collected 
from pregnant or lactating glands failed to synthesise milk proteins in response 
to lactogenic hormones when cultured on a plastic substrate, but did so when 
cultured on floating collagen membranes [98].  
Fibrous connective ECM is also capable of cleaving, binding and sequestering 
signalling molecules. Some of these molecules that can bind to ECM include: 
Amphiregulin (Areg), IGF-like binding proteins, TGF-ß, Wnts and FGFs. Binding of 
TGF-ß to ECM is facilitated by transglutaminase while growth factors and 
cytokines bind to ECM through GAGs [99] [50]. GAGs are thought to act as “glue” 
that enables the attachment of secreted molecules to BM or fibrillar matrix [50]. 
Most of these molecules are then released and activated as a result of ECM 
remodelling by enzymes, mostly MMPs (reviewed in [100] [91]). Some molecules, 
such as TGF-ß, however, can be also released from ECM by altering its 
mechanical tension [101].   
1.2.2 Motility in the mouse mammary gland at puberty 
1.2.2.1 TEBs 
TEBs serve as the driving force of ductal development during puberty. These 
highly motile structures pattern the open architecture of the mammary gland by 
driving the linear forward growth and undergoing dichotomous bifurcation, 
hence giving rise to the major branches of the ductal tree and preferentially 
directing ductal outgrowth into the epithelium-free fat pad. The motile 
behaviour of TEBs is dynamic and highly receptive to the surrounding 
environment. As shown by Hinck and Silberstein (2005), introduction of a plastic 
obstacle into the fat pad that surrounds advancing ducts alters normal ductal 
architecture. Not only do the ducts change their migratory path in an attempt to 
avoid the obstacle, but they still manage to recreate the normal ductal spacing 
pattern similar to that seen in the unaffected part of the gland [102].  
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1.2.2.1.1 Forward movement 
 
Motility of TEBs encompasses three behaviours: forward movement, bifurcation 
and turning. There are two different hypotheses for the mechanism of forward 
movement. It is suggested that TEBs either pull themselves forward or push 
forward [102]. The first theory, however, is unlikely as no cellular extensions 
(filopodia) or actin protrusions (lamelliopodia) which are usually associated with 
the leading edge of single or groups of collectively migrating cells have been 
demonstrated on the TEB‟s surface to date. The second hypothesis, on the other 
hand, is supported by the electron microscopy demonstration of adipocytes‟ 
imprints on the BL that surrounds the tip of advancing TEBs [102]. It is 
speculated that this forward movement of TEBs results from the increased cell 
mass, produced by intensive mitosis in both cap and body cells of TEBs [102] 
[62]. The level of mitotic activity translates into the size of TEBs and depends on 
the phase of oestrus cycle. The highest mitotic activity of TEB can be seen 
during the transition from proestrus to late oestrus when TEBs reach their 
maximum size, acquire an elongated shape and the border between epithelium 
and surrounding stroma becomes indistinct and straddled by the multiple 
replicating cells [103] and it is likely that forward outgrowth occurs at this time 
point. At metoestrus and dioestrus TEBs have a low mitotic index and small size. 
This shrinkage of TEBs could potentially be attributed to the migration of cells 
out of the bud to form a new segment of duct [103]. It is also likely that TEBs 
push forward using the pressure generated during reshaping of the TEB into the 
dimensions of a duct. This phenomenon takes place at the neck of the TEB and is 
characterised by the addition of new cells into the subtending ducts, extensive 
ECM remodelling and ColI deposition at the flanks and neck of the TEB which, 
taken together create a girdle to contain and direct the pressure and hence 
contribute to the elongation [53].    
The forward movement of TEBs may also result from the unusual composition of 
its BM. BM surrounding the tip of TEBs is rich in hyaluronan while that enclosing 
the neck region is associated with collagens [50] [53]. Both the documented 
association of hyaluronic acid with cell mobility during embryogenesis and the 
observation that during microdissection or enzymatic digestion the tip of TEB 
separates much easier from the surrounding stroma than its neck suggest that 
  44 
 
hyaluronan may facilitate forward movement by reducing friction and epithelial-
stromal adhesion during cellular migration  [104] [53].  
Recent experiments carried out using 3D Matrigel cultures of mammary 
epithelial organoids suggested collective cell migration and cellular 
rearrangements as two possible mechanisms facilitating the forward movement 
of TEBs [105]. This type of cellular migration has been already described for 
neuronal precursors in the zebra fish lateral line, epithelial cells during dorsal 
closure and migrating border cells in Drosophila melanogaster [106] [107] [108]. 
Collective cell migration is characterised by coherent movement of a group of 
cells where cells at the front show cellular extensions or protrusions projected in 
the direction of movement. In the cultured TEB-like organoids, however, the 
leading edge of cells, although lacking cellular protrusions, remained adherent 
as demonstrated by positive Cdh1 and Cdh3 staining and showed presence of 
dynamic cellular rearrangements [105]. It must, however, be stressed that 
organoids in vitro are not a good model of TEBs in vivo. Thus, it is crucial to 
develop appropriate in vitro models to aid the study of TEBs migration and the 
first step towards this goal would be to isolate and maintain pubertal mammary 
glands in vitro. During the course of the work for this thesis, pilot experiments 
were carried out to maintain TEB explants in culture (4.1.2.5).  
1.2.2.1.2 Bifurcation 
 
Bifurcation of TEBs is a defining morphogenetic event in the patterning of ductal 
branching during puberty (Figure 1-5). The appearance of a cleft creates an 
indent in the epithelium which in turn marks the site where the primary 
branching will occur and from which two new TEBs will elongate. Newly formed 
TEBs continue to invade stroma and give rise to two subtending primary ducts. 
The exact mechanism underlying TEB bifurcation, however, has not yet been 
elucidated. 
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Figure 1-5 Branching morphogenesis in pubertal mouse mammary gland. 
High-magnification carmine alum-stained wholemount (6 weeks) showing a fragment of duct with 
lateral branches forming (arrow and arrow head) and a bifurcating TEB (asterisk). Scale bar is 
200um. 
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The few existing studies suggest the importance of the BM and ECM composition 
in driving the process [50] [109]. Silberstein (2001) proposed the formation of a 
cleft in the distal surface of the TEB to result from highly localised presence of 
S-GAG and ColI in this region. According to this model, the focal induction of S-
GAG in the BM of TEB, followed by the deposition of ColI in the surrounding ECM 
would retard the growth advancement at the induction point and, on the other 
hand, promote the directional elongation of newly bifurcated lobes [56].  
Further insights into the process of TEB bifurcation were delivered using 3D 
culture of EpH4. EpH4 cells derive from normal mammary epithelium of a mid-
pregnant mouse and when embedded in the cavities of ColI gel and cultured 
under specified conditions, they form hollow epithelial tubes of defined 
geometry. Upon the addition of epidermal growth factor (EGF) or HGF, these 
tubules are able to undergo branching morphogenesis similar to that seen during 
TEB bifurcation or ductal branching in vivo. Parts of these tubules are also 
shown to express vimentin [110], one of the main markers used to identify a 
mesenchymal phenotype. In these experiments the sites of vimentin expression 
were identified by real time imaging of the expression of green fluorescent 
protein (GFP) under the control of a vimentin promoter. Cells present at 
subsequent bifurcation/branching sites were shown to acquire an invasive 
mesenchymal phenotype, suggesting that cells are instructed to branch 
depending on their spatial location and ability to attain the invasive phenotype. 
Furthermore, it was also demonstrated that an increase in tubule length resulted 
in increased magnitude of branching and curved tubules branched preferentially 
from the convex side of the curve, suggesting that the magnitude and position of 
bifurcation/branching is dependent on the initial geometry of the tubule. 
Further analysis revealed that the observed bifurcation/branching did not 
coincide with increased epithelial proliferation or enhanced signalling by growth 
factor receptors. The bifurcation/branching position, however, was determined 
by the concentration gradient of stromal inhibitory morphogens, such as TGF-ß, 
as their concentration was shown to be lowest in the position where 
bifurcation/branching was induced [110]. Taken together, these results suggest 
that an epithelial-to-mesenchymal (EMT)-like transition event is required at the 
branch points for bifurcation/branching to occur and TEB (or duct) geometry, 
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length and stromal composition are likely to control the position of 
bifurcation/branching. 
EMT can be identified during certain other events that require epithelial 
remodelling and multilayering, such as embryogenesis, organ development, 
tissue regeneration and cancer progression and metastasis. It is characterised by 
a series of biochemical changes that enable polarised epithelial cells which 
normally interact with BM to acquire a mesenchymal phenotype, consistent with 
enhanced migratory capacity, invasiveness, increased resistance to apoptosis 
and elevated production of ECM components. The completion of EMT is marked 
by ECM degradation and the detachment of the mesenchymal-like cells away 
from the epithelial cell layer [111]. 
Epithelial bifurcation is also essential for the formation of lungs, kidneys or 
salivary glands [112].  
1.2.2.1.3 Turning 
 
Another area which has not yet been extensively researched is the mechanism 
underlying the coordinated, directional turning of TEBs and spatial patterning of 
ductal branches in response to other approaching epithelial branches. No clear 
explanation for this phenomenon has been proposed to date. However, the 
stromal environment surrounding the tips of TEBs may act as a source of chemo-
attractants or inhibitors which could govern the direction of the outgrowth. In 
fact, various guiding molecules such as cytokines (CSF-1 or eotaxin) or axonal 
guidance proteins (small proline rich protein 1A - Sprr1A, semaphorin 3B - 
Sema3B or brain abundant membrane attached signal protein - BASP) have been 
reported in this region [87] [113]. Moreover, when EpH4 cells were cultured on 
ColI matrices to form epithelial tubules in response to FGF or HGF (See 
1.2.2.1.2), an increase in the local concentration of the inhibitor - TGF-ß by 
decreasing the distance between tubules, ceased the growth/branching when 
the distance between epithelial tubules was ≤~75µm [110]. Although highly 
speculative, the asymmetric deposition and remodelling of S-GAG and ColI may 
control the turning of TEB as the extended synthesis and deposition of ColI on 
one side of the end bud might channel its extension in the opposite direction. 
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Asymmetric mitosis has also been considered as a potential effector of 
directional outgrowth. No obvious correlation, however, was observed between 
mitosis and turning when mitotic patterns were examined [102].   
In conclusion, although numerous suggestions have been made to unravel the 
mechanism underlying the motility of TEBs, in the absence of solid scientific 
evidence, all these questions still remain to be elucidated.          
1.2.2.2 Ducts 
Motile behaviour exhibited by ducts at puberty is limited to branching 
morphogenesis. There are two types of branch-point that form on the ductal 
scaffold during this time point – secondary (lateral branching) and tertiary 
branching. The former process is fundamental for epithelial tree formation and 
occurs throughout the whole of puberty until the entire fat pad is filled with an 
extensive system of branched ducts. Tertiary branching, on the other hand, 
takes place after the margins of mammary fat pad are met. It occurs in response 
to recurrent oestrus cycles and gives rise to a much less pronounced form of 
epithelial growth – short tertiary branches ending with initial alveolar buds.   
Secondary branches originate from primary ducts. The formation of lateral 
branches can be seen in Figure 1-5. Secondary branches most probably bud out 
from the basal myoepithelial cell layer and while keeping the BM intact invade 
the surrounding stroma, but the exact mechanism underlying this phenomenon is 
still to be elucidated [114]. Newly formed secondary branches have end buds 
which, like TEBs on primary ducts, are characterised by cap cells and smooth-
surfaced BM. In this case, the cap cells may form by reverse differentiation of 
ductal basal myoepithelium, although the lack of scientific evidence means the 
involvement of other underlying epithelial cells in this process can not be 
excluded.  
The branching mechanism has been shown to be fairly conserved between organs 
(salivary gland, lung, kidney, pancreas, and mammary glands) and species 
(Drosophila Melanogaster) hence it is likely that, for example, cell migration, 
cell rearrangement and change of cell shape, as suggested for D. melanogaster 
[115] [116], could be the underlying events of ductal branching in mouse 
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mammary gland too [112]. It is likely therefore, that the research on branching 
morphogenesis in other systems may be the key facilitator for its understanding 
in mammary gland development. Finally, as previously discussed in 1.2.2.1.2 it 
is suggested that the EMT-like transition event is required at the branch points 
for branching to occur and the ductal geometry, ductal length and stromal 
composition are likely to control the position of branching [110]. 
1.2.3 Regulation of ductal morphogenesis at puberty 
Normal pubertal morphogenesis of mouse mammary gland, i.e. ductal 
outgrowth, branching morphogenesis and patterning of the open architecture of 
the ductal tree depends fully on the correct regulation of TEB motility, 
bifurcation and patterning and lateral ductal branching. The nature of these 
regulatory signals is very complex. For normal pubertal development to occur, 
both proper communication between the epithelial cells and cross-talk between 
epithelial and stromal compartments needs to be maintained. Epithelial-
epithelial cross-talk encompasses cell-cell interactions within the TEB. The 
communication between epithelium and stroma, on the other hand, is 
multifactorial. It occurs through the ECM and encompasses hormonal and local 
growth factor signalling and other stroma-derived signalling.  
1.2.3.1 Epithelial-epithelial communication    
Maintenance of cellular integrity within TEB is essential for normal ductal 
outgrowth. As demonstrated by experiments which disrupt cellular adhesion 
protein function, e.g. cadherins (Cdh), Netrin-1 (Ntn1) or its receptor Neogenin 
(Neo1), erythroblastic leukemia viral oncogene homolog 2 (ErbB2) or 
erythroblastic leukemia viral oncogene homolog 3 (ErbB3), deregulation of 
cellular communication between epithelial cells compromises ductal elongation 
[57] [117] [118] [119].  
Cadherins 
Cadherins are an integral part of adherent junctions and desmosomes which 
contribute to joining cells together physically. There are at least two types of 
cadherins expressed in the TEB – E-cadherin and P-cadherin. The former is 
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expressed by the body cells while the latter is synthesised in the cap cells. As 
demonstrated by Daniel et al. (1995), using slow-release implants containing 
function blocking antibody surgically inserted ahead of advancing ducts, lack of 
E-cadherin resulted in significantly disrupted adhesion between body cells. This 
was followed by an abrupt decline in DNA synthesis and disruption of ductal 
elongation. The observed phenotype was reversible upon withdrawal of the 
function blocking antibodies. Similar experiments, designed to ablate the 
expression of P-cadherin in cap cells resulted in much less disruption of cellular 
morphology and a much smaller decline in DNA synthesis than following E-
cadherin depletion. No aberrant phenotype could be seen, suggesting that 
although tissue integrity is essential for ductal outgrowth either the modest 
perturbation in TEB structure can be accommodated or other molecules 
compensate for the loss of cadherin expression [57].  
Netrin 1 and Neogenin 1 
Disorganisation of TEB structure and retarded ductal elongation was caused by a 
homozygous loss-of-function mutation in either Ntn1 or its receptor, Neo1. 
Although, initially identified as guidance cues for developing neurons, this family 
of proteins has recently been identified in TEBs at puberty [120] [117]. Ntn1 was 
expressed by body cells and secreted to its cell membranes and ECM while Neo1 
was expressed in a complementary pattern by the overlaying cap cells. In TEBs, 
loss of function of either gene resulted in significantly disrupted adhesion 
between the cap and body cell layers, followed by the appearance of large 
spaces below the cap cell region which were filled with dissociated cap cells. 
Breaks in BM were also seen. However, the rate of DNA synthesis stayed 
constant. These observations highlight the crucial role of Ntn1 and Neo1 
signalling in mediating cellular contact between cap and body cells which in turn 
is essential for maintenance of TEB integrity, but has no obvious effect on the 
outgrowth of the ductal tree, as suggested by the normal ductal elongation seen 
in either Neo1 or Ntn1 KO-/- mice [117].  
Erythroblastic leukemia viral oncogene homolog 2 and 3 
Similar loss of adhesion between the cap and body cells of TEB was also 
demonstrated in mouse mammary gland harbouring homozygous loss-of-function 
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mutations in either ErbB2 or ErbB3 - orphan receptors which form heterodimers 
with epidermal growth factor receptor (EGFR), ErbB3 and ErbB4 allowing them 
to respond to EGF- and Nrg1 - like growth factors. In both mice, TEBs were small 
and disorganised, with exaggerated spaces between the two cellular 
compartments and ductal elongation was significantly reduced [118] [119]. The 
ErbB3 KO-/- mice, however, showed an additional increase in the number of TEBs 
and lateral branches [119]. Thus, suggesting presence of divergent roles of ErbB2 
or ErbB3 in controlling ductal morphogenesis.  
1.2.3.2 Epithelial-stromal interactions 
The second prerequisite for normal ductal morphogenesis during puberty is an 
uninterrupted cross-talk between epithelial-stromal compartments. This ability 
of stromal cells to communicate and signal to the outgrowing epithelium is an 
underlying mechanism for the morphogenic effect which hormonal and local 
growth factor signalling and other stroma-derived signals exert on the 
epithelium. 
1.2.3.2.1 Hormonal control of pubertal mouse mammary gland 
morphogenesis 
 
Oestrogen and Progesterone 
The two main sex hormones at puberty are oestrogen (E) and progesterone (P). E 
is produced from androgens during the process of aromatization catalysed by an 
enzyme called aromatase. Aromatase can be found in many tissues including 
gonads, brain, adipose tissue, placenta, endometrium skin or bone. There are 
three major members of the E family: estradiol (E2), estrone and estriol. E2 is 
the most potent one and is responsible for most E mediated signalling in women 
[121]. Most of the circulating E2 is produced by the ovaries. Other tissue such as 
the adrenal cortex, however, can also serve as a minor source. P is the major 
naturally occurring member of the progesterone family, and like E2, is mainly 
produced by the ovaries and secondly by the adrenal cortex. During pregnancy 
the placenta synthesises P. Since both hormones are mainly synthesised in the 
ovaries the hallmark for their production is the onset of puberty – the time when 
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the ovaries develop. At puberty, increased production of gonadotrophin-
releasing hormone (GnRH) by the hypothalamus stimulates the production of 
gonadotrophins- luteinising hormone (LH) and follicle stimulating hormone (FSH) 
in the pituitary gland. The gonadotrophins stimulate pubertal development of 
ovaries which in turn produce E2 and P. From then onwards levels of both 
hormones fluctuate depending on the levels of FSH and LH, i.e. the phase of 
oestrus cycle, causing changes in reproductive organs (vagina, uterus, and 
mammary glands). The normal oestrus cycle of the laboratory mouse lasts for 4-6 
days and it can be divided into four stages (proestrus, oestrus, metoestrus and 
dioestrus). Together, proestrus and oestrus contribute to the follicular phase 
while metoestrus and dioestrus constitute the luteal phase. The follicular phase 
is characterised by an increase in FSH levels which in turn stimulate aromatase 
production and thus E2 synthesis. Increased E2 suppresses further release of FSH 
while promoting LH synthesis and hence ovulation. Increased LH stimulates the 
synthesis of P and luteotrophic hormone (LTH) and initiates the onset of the 
luteal phase [47]. In return, P decreases the expression of aromatase and thus 
negatively regulates E2 levels [122]. If mating takes place at this time point, the 
rising level of LTH activates the corpus luteum which in conjunction with P 
prepares the uterus to receive the fertilised egg. In the absence of pregnancy, 
titers of gonadal hormones decrease terminating the luteal phase and allowing 
reabsorbtion of the endometrium and succession of a new cycle [47]. Mammary 
glands, like the uterus and vagina, undergo a series of anabolic and catabolic 
changes during the oestrus cycle (See 1.2).  
Since the E2 and P driven onset of puberty parallels TEB formation and ductal 
morphogenesis of mouse mammary gland, E2 was suggested as the main 
regulator of this process. The role of E2 in mouse mammary gland development 
has been studied since 1900 when it was demonstrated that ovariectomy causes 
cessation of mouse mammary gland development and exogenous E2 can restore 
it (reviewed in [123]). Classical endocrine ablation-replacement experiments 
carried out by Lyons (1958) and Nandi (1958) showed that mouse mammary 
glands underdeveloped due to simultaneous ovariectomy, hypophysectomy and 
adrenalectomy respond to combined treatment with E2 and growth hormone 
(GH) by restoring normal ductal morphogenesis. GH on its own induced only mild 
stimulation and pure E2 none at all [124] [125]. Taken together, these results 
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established the endocrine basis for ductal outgrowth that stands today. Since 
then, it has been shown that E2 triggers the development of TEBs, stimulates 
DNA synthesis in the mammary epithelium (mostly in TEBs) and proliferation of 
stromal cells  [126] [127] [128]. It has also been demonstrated that E2 signals 
through oestrogen receptor alpha (ERα) and its ablation results in formation of 
underdeveloped mammary glands comprising a truncated ductal rudiment which 
lacked TEBs [129]. The rudimentary ductal structure was comparable to that 
seen in wild type newborn mice. Further autoradiographic experiments, 
demonstrated that murine mammary ERα localises to mammary epithelium of 
TEBs and ducts (except for cap cells) and stroma surrounding TEBs. However, co-
transplantation of ERα KO-/- embryonic mammary epithelium with wild type 
stroma showed that stromal not epithelial, ERα is essential for normal ductal 
elongation as only wild type stroma supported epithelial outgrowth [130] [131] 
[132]. In contrast, other experiments based on tissue grafts collected from 
hormone stimulated adult mice indicated that both stromal and epithelial ERs 
were essential for normal pubertal outgrowth. Most recently, however, a newly 
engineered ERα KO-/- mouse model showed that ERα expression was not 
completely ablated in the early ERα KO-/- mouse models and in fact, it is the 
epithelial rather than stromal ERα that is essential for ductal outgrowth during 
puberty [133]. Moreover, despite its role in mediating cellular proliferation, 
most of the proliferating cells lacked ERα expression suggesting a paracrine 
manner of E2 signalling in which E2 promotes ductal outgrowth by signalling 
through epithelial ERα to promote proliferation in adjacent cells. EGF and Areg 
which are a locally produced growth factor are likely to act as the downstream 
effector of E2 in inducing cellular proliferation, whereas TGF-ß could be 
responsible for the proliferative quiescence of ERα expressing cells 
(See1.2.3.2.2) [134]. In 1996, a second oestrogen receptor, ERß was identified. 
Although to a much lesser extent, ERß was also expressed in the pubertal mouse 
mammary. Its ablation (ERß KO-/- mice), however, did not alter normal pubertal 
outgrowth, suggesting that it is dispensable for pubertal mouse mammary gland 
development. Double KO, ERα/ß KO-/- mice showed a mammary phenotype which 
was similar to that seen for ERα mice [131].  
In contrast to E2, P is mainly declared as non essential for pubertal mouse 
mammary development. More recent evidence showed that P orchestrates 
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morphological changes associated with both pre-pregnancy where it is involved 
in preparation of the uterus for egg implantation after fertilization, and 
pregnancy when it is essential for maintaining the placenta and inhibition of 
uterine contractility [47]. In the mammary gland, the action of P is mediated 
through PR. There are two isoforms of PR in mammary gland: PR-A and PR-B. PRs 
localise to both epithelium and stroma. Selective PR-A KO-/-, PR-B KO-/- mice and 
general PR KO-/- mice show that the exclusive interaction of P with stromally 
localised PR-B regulates tertiary side branching in virgin mice and lobuloalveolar 
development in pregnant mice [135] [136] [137] [138]. Evidence for a role of P in 
proliferation, however, is not straightforward. Administration of P to 
ovariectomised mice increases DNA synthesis in epithelial cells of TEBs and ducts 
which suggests P may play an intermediate role in regulating pubertal 
morphogenesis, possibly by mediating DNA synthesis [139]. However, since E2 
promotes the expression of PR-A, the regulation of this mitogenic effect would 
have to be PR independent [140]. Furthermore, when administered with IGF-1 to 
ovariectomised IGF-1 KO-/- mice, P enhances the action of IGF-1 and promotes 
ductal outgrowth during puberty by producing duct extension and branching 
equivalent to that seen with IGF-1 plus E2, but without an increase in the 
number of TEBs (See 1.2.3.2.2). No such effect on the ductal epithelium can be 
noted with P or IGF-1 acting independently [141]. This finding may explain the 
very rapid epithelial outgrowth during puberty when oestrus cycle P and E2 
acting together with IGF-1 could stimulate this outgrowth.   
Glucocorticoid 
Other systemic hormones such as glucocorticoids (G), GH or parathyroid hormone 
(PTH) have also been implicated in pubertal mouse mammary development. 
Glucocorticoids are adrenal hormones which were initially described as essential 
for inducing the expression of milk proteins during lactation [142]. They function 
by binding to glucocorticoid receptors (GRs) and stimulate target gene 
transcription either by direct binding to DNA or by protein-protein interactions. 
GR KO-/- results in postnatal lethality as mice die shortly after birth due to 
respiratory failure [143]. Further experiments, demonstrated that the GR KO-/- 
anlagen can be rescued from these mice when transplanted into the cleared fat 
pad of wild type mice where it produces abnormal mouse mammary glands, 
characterised by multiple layers of luminal epithelial cells along some of the 
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ducts, increased periductal stroma and a much higher rate of ductal outgrowth 
than that seen in the wild type epithelium. Furthermore, mice which were 
genetically engineered to express a mutated form of GR that lacked the ability 
to bind DNA but maintained the receptor-protein binding function, also exhibited 
reduced side branching and the presence of some TEBs in the adult gland [144]. 
Together these results provide strong evidence for the role of G signalling, 
through GR, in regulating normal mouse mammary gland morphogenesis at 
puberty [145]. 
Growth hormone 
GH is a pituitary hormone which binds to growth hormone receptors (GHRs) 
expressed in both epithelial and stromal compartments of virgin mouse 
mammary glands [146]. Research devoted to understanding the role of GH in 
pubertal mammary morphogenesis dates back to the early 1990s. In 1993 it was 
demonstrated that the implantation of GH release pellets into pubertal 
mammary glands of E2 treated hypophysectomised, ovariectomised rats 
stimulated an increase in TEB number [147]. Since the exogenous E2 alone failed 
to rescue this pubertal phenotype it was hypothesised that the GH driven 
phenotype arose independently of E2 signalling [148]. The importance of GH for 
normal pubertal mouse mammary gland development was further elucidated 
using GHR KO-/- mice. Loss of GHR produces severe retardation of ductal 
outgrowth and side branching impairment. Furthermore, tissue recombination 
experiments, in which GHR KO-/- epithelium was grafted into the cleared fat 
pads of wild type mice revealed that epithelial GHR is dispensable for normal 
pubertal morphogenesis [149]. These findings suggest that GH in conjunction 
with stromal GHR acts independently or synergistically with E2 and is necessary 
for the regulation of normal pubertal mouse mammary gland morphogenesis. In 
fact, GH is now considered as the second most important driver of pubertal 
morphogenesis after E2. 
Parathyroid hormone 
Although initially associated with mammary gland embryogenesis both PTH and 
PTHrP are implicated in pubertal mouse mammary gland development. PTH is 
secreted by the parathyroid gland while PTHrP is produced by numerous adult 
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and embryonic tissues including mammary glands where PTHrP expression is 
concentrated in the cap cells of TEBs and myoepithelial cells. The cognate 
receptors are located in the surrounding stroma which suggests paracrine 
signalling is important. In 1995 mice over-expressing either PTH or PTHrP under 
the control of a Krt14 promoter showed severe impairment of ductal elongation 
and branching at puberty [150]. More recently mice engineered to over-express 
PTHrP under the control of a Krt14 promoter in a tetracycline-regulated manner 
showed that this phenotype depended on the timing of PTHrP over-expression. 
When transiently over-expressed in prenatal mice, PTHrP impaired branching 
whereas the decreased rate of ductal elongation was seen exclusively in 
response to PTHrP over-expression at puberty. In addition, the defect in ductal 
elongation was associated with a failure to decrease apoptosis of epithelial cells 
in TEB and increase the proliferation in response to E2 and P [151]. 
Unfortunately the PTHrP KO-/- mouse model failed to provide further insights into 
the impact of PTHrP on pubertal morphogenesis due to its embryonic lethality 
[22].   
Vitamin D 
Although, endocrine glands determine the hormonal milieu for pubertal mouse 
mammary gland development additional systemic factors such as vitamin D3 are 
also involved in the orchestration of this process. Vitamin D3 can be either 
produced in skin of vertebrates after the exposure to ultraviolet B (UVB) light 
from the sun or artificial sources or occurs naturally in a small range of food 
(fatty fish, eggs, meat). Upon ingestion, vitamin D3 gets converted to its 
hormonally active form – 1,25- dihydroxyvitamin D3 (calciol) which interacts 
with the vitamin D3 receptor (VDR). VDR is a nuclear steroid hormone receptor 
which localises to pubertal stroma and epithelium of TEBs and subtending ducts. 
The expression of VDR in TEBs is much higher in mitotically quiescent than 
proliferating cells. VDR KO-/- mice display enhanced development of mammary 
glands during puberty after supplementation with dietary Ca2+ to regulate 
fertility, serum E2 and neonatal growth. This pubertal phenotype is 
characterised by extensive ductal elongation and branching and an increase in 
the number of TEBs. Further growth enhancement is seen on exposure of VDR 
KO-/- mice to ovarian hormones in vivo or during whole mammary gland organ 
culture [152]. Collectively, these results suggest that vitamin D3 signals through 
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VDR to oppose E2 driven proliferation and to maintain cellular differentiation, 
hence participating in negative regulation of pubertal outgrowth of mouse 
mammary gland [153].      
1.2.3.2.2 Local growth control of pubertal mouse mammary gland 
development 
 
Although systemic hormones play a central role in pubertal mouse mammary 
gland morphogenesis (See 1.2.3.2.1) this observation was challenged by the 
discovery that proliferating cells in TEBs and ducts are in fact those that lack 
expression of steroid hormone receptors and that the receptor-expressing cells 
are often those adjacent to these cells. This suggested that systemic hormones 
regulate cellular proliferation in a paracrine manner using local mediators. Since 
some of the locally produced growth factors were able to mediate the effect of 
some of the hormones, they were thought to play the role of local mediators of 
hormone signalling. Further evidence for this was that the expression of these 
growth factors could rescue several of the mammary phenotypes seen in the 
steroid mouse models while their ablation produced mammary phenotypes that 
were similar to these seen in steroid mouse models. Since then, mammary gland 
growth factors that signal via their receptors have been demonstrated to play a 
pivotal role in pubertal mouse mammary gland morphogenesis by acting both as 
a part of and independently of systemic hormone signalling. 
There are four main families of growth factors and their receptors that regulate 
pubertal mouse mammary gland development.  These include: FGFs and FGF 
receptors (FGFRs); HGF and its receptor – met proto-oncogene (c-Met); IGFs and 
IGF receptors (IGFRs) and EGF-related proteins and their EGFRs (also called ErbB 
family of proteins and ErbB receptors). All of these receptors belong to the 
receptor tyrosine kinase superfamily (reviewed in [154]). 
Fibroblast growth factors 
The FGF ligand family consists of 18 members. These can be further subdivided 
in to six subfamilies called FGF1, FGF4, FGF7, FGF8, FGF9 and FGF19. Each FGF 
ligand binds to a specific FGFR. The receptors are encoded by four different 
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genes which are alternatively spliced to produce at least seven FGFRs (reviewed 
in [154]). Initially, FGFs and FGFRs were established as critical during mouse 
mammary gland embryogenesis (See 1.1.1). Subsequent research, however, 
revealed that FGF1, FGF2, FGF4, FGF7 and FGF10 as well as receptors FGFR1 
and FGFR2 were also expressed in mouse mammary gland during puberty 
(reviewed in [155]). Conditional over-expression of FGF3 in the mouse mammary 
epithelium during puberty resulted in cessation of ductal elongation. Ductal 
epithelium was expanded, multilayered and full of cysts (severe epithelial 
hyperplasia). The phenotype was proposed to arise from the imbalance between 
mitogenic and apoptotic signals [156]. The pubertal phenotype of mammary 
glands lacking FGF3 (FGF3 KO-/- mice), however, has not yet been elucidated due 
to the severe lethality of these mice [157].  
Other members of the family have also been shown, mainly through genetically 
engineered mice, to have impact on mammary development. Mice over-
expressing FGF4 under the control of the WAP promoter which initiates WAP-
FGF4 expression at the onset of puberty (~ 4 weeks) showed decreased apoptosis 
within TEBs which in turn led to the inhibition of ductal elongation after a week 
of FGF4 expression. TEBs were present in normal numbers but exhibited 
impaired morphology. The decrease in apoptotic index was attributed to the 
increase in Bcl2 which serves as an anti-apoptotic factor [158]. More recently, 
Parsa et al. (2008) demonstrated high expression of FGF10 and its receptor 
FGFR2IIIb in the stroma and epithelium of pubertal mouse mammary gland 
respectively. Induced, by using a transactivator/tetracycline promoter (mice 
homozygous for FGFR null allele die at midgestation), reduction of pubertal 
FGFR2IIIb triggered a 40% reduction in ductal outgrowth compared to wild type 
controls and complete loss of TEBs. The phenotype was reversible upon removal 
of doxycycline [159]. A related study, based on the novel mosaic mouse model 
for FGFR2IIIb expression, confirmed expression of FGFR2IIIb in TEB and duct 
epithelium and was first to identify the advancing tip of TEB as a main site of 
epithelial FGFR2IIIb expression whilst demonstrating its lack of function in 
mature ducts. In TEBs, the FGFR2IIIb null cells were at a competitive 
disadvantage to their heterozygous counterparts showing decreased cellular 
proliferation followed by growth retardation, whereas null cells present in the 
duct did not alter their cellular activity [160].  
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FGF ligands and their receptors regulate tracheal branching in Drosophila 
melanogaster and lung sac development in mice. As seen in Drosophila mutants 
breathless (encodes FGFR homologue) and branchless (encodes FGF homologue), 
alteration of either of these genes results in complete ablation of tracheal 
branching. Similarly, the ablation of FGF10 in mice (FGF10 KO-/- mice) strikingly 
inhibits branching in the lung, demonstrating the critical role of this growth 
factor in the bifurcation of buds during lung morphogenesis [161]. The signalling 
mechanism of bifurcation in the mammary gland has not been yet elucidated, 
however, since primary branching shows evolutionary conservation between 
species it is likely that FGF ligands and receptors take part in TEB bifurcation.  
Hepatocyte growth factor 
HGF (also known as scatter factor) and its receptor c-Met are also expressed and 
regulated during pubertal morphogenesis of mouse mammary gland. HGF is 
expressed by mesenchymal cells while c-Met is produced by the epithelium 
[162]. KO of either HGF or c-Met have not been studied due to their prenatal 
lethality resulting from liver and placental defects. Insight into the role of HGF 
in pubertal morphogenesis, however, has been gained using mammary gland 
organ culture, cell culture and transplantation experiments. In organ culture, 
branching morphogenesis of ductal epithelium was promoted on addition of 
exogenous HGF, but abolished when antisense nucleotides which blocked 
endogenous HGF expression were used [162]. In transplant experiments where 
retrovirally infected epithelial cells were transplanted into clear fat pads, the 
over-expression of HGF in the mammary gland epithelium resulted in an increase 
in the size of TEBs and the number of ductal branch points compared to controls 
[163]. Furthermore, HGF was also able to promote proliferation of epithelial 
cells and production of tubular/ductal morphology when epithelial cells, co-
cultured with mammary fibroblasts or supplemented with fibroblast conditioned 
medium were grown in collagen gels using a minimally supplemented serum-free 
medium. Treatment of epithelial cultures with HGF neutralizing antibody 
reversed this morphogenic effect. Treatment of mammary fibroblasts with E2 
increased the production of HGF [164] and more recently, it was demonstrated 
that together HGF and EGF act synergistically to enhance proliferation, scatter 
and invasion of HC11 cells (non-tumourigenic mammary epithelial cells) in 
culture [165]. Thus HGF is capable of regulating pubertal mammary gland 
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development by acting downstream from E2 and potentially cooperating with 
EGF to mediate cellular proliferation.    
Insulin like growth factor 1 
IGF-1 is a local mediator of GH signalling. GH increased IGF-1 mRNA levels within 
the mammary glands of hypophysectomised rats [166] and this effect was further 
enhanced by the presence of E2 [167]. Given the pivotal role of GH in pubertal 
mouse mammary gland morphogenesis, it was not surprising that IGF-1 also 
emerged as an important player in pubertal development. In fact, IGF-1 
signalling was demonstrated to be potent enough to substitute for GH and mimic 
GH-induced mammogenesis [167].  
Early studies of IGF-1 function, carried out using hypophysectomised, castrated, 
sexually immature male rats, demonstrated that when administered with E2, 
IGF-1 induced development of TEBs [168]. On its own, IGF-1 exhibited a smaller 
although still significant effect on pubertal mouse mammary gland 
morphogenesis. With E2, however, the morphogenic effect of IGF-1 was 
significantly enhanced and similar to that seen when E2 and GH were 
administered [167]. More recently, IGF-1 was shown to be expressed in the 
epithelium and stroma of the pubertal mouse mammary gland [169]. Loss of IGF-
1 expression (IGF-1 KO-/- mice) was associated with impaired TEB development 
and limited ductal outgrowth with fewer branches than wild type controls. This 
phenotype was reversible upon administration of exogenous IGF-1 or IGF-1 with 
E2. No stimulatory effect was seen, however, when a combination of GH and E2 
was administered to mice, indicating that the morphogenic effect of GH is fully 
mediated by IGF-1 [170]. Similarly, embryonic mammary buds rescued from 
prenatally lethal IGF-1R KO-/- mice and grafted into cleared fat pads of wild type 
hosts, showed limited ductal branching and decreased size, number and 
proliferative index of TEBs [171]. IGF-1 also permits the morphogenic action of P 
in the mammary gland (See 1.2.3.2.1). In addition, the reduction in ductal 
branching, but not elongation seen in IGF-1R KO-/- mice means it is likely IGF-1 
may play a role in governing TEB bifurcation. This hypothesis, however, is still to 
be proven. Collectively, these studies suggest that IGF-1 in conjunction with IGF-
1R acts downstream of GH and when administered with E2 is responsible for TEB 
formation and ductal morphogenesis during pubertal mouse mammary gland 
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development. Furthermore, IGF-1 acting independently of E2 can promote 
pubertal morphogenesis to some extent, but as for GH, E2 is required for a full 
effect.  
EGF-related ligands and receptors  
There are four types of EGF receptors: EGFR, ErbB2, ErbB3 and ErbB4. Peptides 
in the EGF family are produced as transmembrane precursors that, upon 
cleavage, bind and activate EGF receptors. Some of the proteases that are 
known to facilitate this cleavage include A Disintegrin and Metalloprotease 
(ADAM) and MMP families [172] [173]. EGF-like ligands are characterised by the 
presence of a six-cysteine residue motif, the EGF domain, and depending on 
their receptor specificity can be divided into three groups. Group one binds 
EGFR and consists of: EGF, Areg, TGF-α and epigen (EPG); group two binds either 
EGFR or ErbB4 and consists of betacellulin (BTC), heparin-binding EGF (HB-EGF) 
and epiregulin (EPR) while the third group binds ErbB3 or ErbB4 – Nrg-1 and Nrg-
2 or just ErbB4 – Nrg-3 and Nrg-4 [174]. Some of these EGF-family ligands (EGF 
and Areg) and ErbB receptors – (EGFR and ErbB2) are expressed in and are 
essential for normal pubertal mouse mammary development.       
The EGFR is strongly expressed in the epithelium and adjacent stroma of TEBs. 
Some expression is also noted in ductal myoepithelium and its surrounding 
stroma [175]. As demonstrated in waved-2 mutant mice which express a 
truncated form of EGFR (lacks the functional tyrosine kinase domain) under the 
control of a mammary gland specific promoter (the mouse mammary tumour 
virus (MMTV) promoter), impairment of EFGR leads to a significant inhibition of 
ductal morphogenesis with reduced outgrowth and branching [176]. A similar 
phenotype was also seen with complete EGFR loss. Since EGFR KO-/- mice are not 
viable, their mammary glands have to be transplanted into a wild type host to 
study epithelial morphogenesis. EGFR null mammary glands show severe 
cessation of ductal outgrowth but when transplanted into the wild type stroma, 
the pubertal phenotype of EGFR KO epithelium can be rescued. However, this is 
not true for reciprocal experiments. Thus, it was suggested that signalling 
through stromal EGFR is critical for normal pubertal ductal morphogenesis while 
the epithelial EGFR is not essential for this process [177].  
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The importance of EGFR signalling was further highlighted when EGF-like ligands 
(EGF and Areg) were shown to be capable of promoting ductal outgrowth at 
puberty and to act as a downstream effector of E2 signalling. Coleman et al. 
(1988) showed that the administration of EGF rescued the mammary gland 
phenotype seen in ovariectomised mice. The delivery of EGF via slow-release 
pellets stimulated formation of new TEBs, restored normal TEB histomorphology 
and the reappearance of cap cells, reinitiated DNA synthesis in epithelial cells 
and led to an increase in ductal diameter [175]. In contrast, a neutralising 
antibody to EGF inhibited the stimulatory effect of E2 on TEBs [178] suggesting 
mitogenic and morphogenic properties of EGF, an ability to substitute for E2 and 
serve as a downstream effector of E2 signalling in mouse mammary gland.  
The most profound defect in pubertal ductal morphogenesis has been seen in 
Areg KO-/- mouse mammary glands. Targeted loss of Areg resulted in stunted 
ductal outgrowth, but the formation, shape and morphology of TEBs in Areg KO-/- 
glands remained unaffected. In contrast, implantation of Areg-secreting pellets, 
promoted ductal outgrowth in the pubertal mouse mammary gland [179]. When 
compared with other EGF-like ligands, Areg exhibited the highest pubertal 
expression. In the mammary gland, Areg expression is mainly associated with the 
epithelium of advancing TEBs but lower expression, can be also demonstrated in 
the ductal epithelium and its surrounding stroma [180]. In ovariectomised mice, 
Areg expression becomes strongly up-regulated after E2 treatment. The lack of 
Areg expression in ERα KO-/- mammary glands demonstrated that the induction 
of Areg occurred through the ERα. Furthermore, as Areg KO-/- epithelium 
engrafted into the cleared fat pad of the wild type host failed to rescue ductal 
outgrowth it was concluded that epithelial Areg expression is required to induce 
proliferation of mammary epithelium. Further research on mice containing 
mammary epithelium that was mosaic for wild type and Areg KO-/- cells, 
revealed that when in close vicinity to wild type cells, Areg KO-/- cells were able 
to proliferate and contribute to ductal outgrowth, suggesting a paracrine 
mechanism of Areg signalling [181]. Areg, like other EGF-like ligands is expressed 
as an inactive precursor which must be shed from the cell surface. In vitro 
cleavage of Areg by ADAM17 has been previously demonstrated [182]. In vivo, 
unprocessed Areg was found in the mammary glands obtained from ADAM17 KO-/- 
mice, showing ADAM17 also mediates the cleavage of Areg in mammary glands 
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and its absence leads to a pubertal phenotype which is similar to that seen in 
Areg KO-/- mice [183]. Collectively these data suggest that Areg acts downstream 
of E2 in the epithelial compartment, where it is released by ADAM17 to act in a 
paracrine manner on stromal EGFR to promote normal ductal morphogenesis at 
puberty.        
The role of ErbB2 in pubertal mouse mammary gland development has already 
been mentioned since a loss-of-function mutation in ErbB2 affects cell-cell 
adhesion causing severe alteration in TEB morphology and a delay in ductal 
outgrowth (See 1.2.3.1) [118]. Similarly, mammary-specific ablation of ErbB2 
through MMTV-Cre-mediated recombination resulted in a defect in ductal 
elongation and reduced branching [184]. In order to respond to growth factors, 
ErbB2 has to form a heterodimer with EGFR, ErbB3 or ErbB4. The pivotal role of 
EGFR in pubertal morphogenesis has already been described. Furthermore, ErbB3 
has also been demonstrated to be crucial for ductal outgrowth during puberty. 
When transplanted to the fat pads of wild type hosts, embryonic mammary buds 
of ErbB3 KO-/- mice showed increased impaired ductal elongation and increase in 
the number TEB and lateral branches [119]. ErbB4, on the other hand, exerts 
pro-differentiation and anti-proliferative effects on mammary epithelium [185]. 
Its expression is lowest during periods of epithelial outgrowth, such as puberty 
(reviewed in [186]) and its loss (ErbB4 KO-/- mice) does not impact ductal 
morphogenesis at puberty [187].  
1.2.3.2.3 Transcriptional control of pubertal mouse mammary gland 
development 
 
Correct transcriptional regulation of gene expression is a very important 
prerequisite of normal organ, tissue or cell morphogenesis. Since systemic 
hormones are pivotal in regulating pubertal mouse mammary gland 
morphogenesis the main group of associated transcription factors are nuclear 
hormone receptors, such as ER, PR, GR and VDR. Each of these receptors utilises 
a common mechanism of action. Classically, upon activation by the hormonal 
ligand, nuclear hormone receptors undergo a conformational change and working 
in synergy with specific co-activators and co-repressors bind to the hormone 
response element of a gene and so regulate its transcription. In some cases, 
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however, other non-genomic mechanisms of action can be used. Specific co-
activators can exert their function on particular downstream target genes of the 
individual receptor to determine a specific response to the hormone [188].  
Steroid receptor co-activator family 
SRC-1 and SRC-3 belong to the steroid-receptor co-activator (SRC) family and 
illustrate how these unique tissue specific responses to hormones occur. SRC 
proteins function as co-factors for steroid hormone receptors such as P, E2 and 
thyroid hormone receptor. SRC-1 KO-/- mice exhibited reduced ductal branching 
and ductal outgrowth at puberty. Their ability to respond to E2 or P treatment 
was also impaired compared to their wild type counterparts [189]. Similar 
cessation of ductal outgrowth was also seen in SRC-3 deficient (SRC-3 KO-/-) 
mouse mammary glands. In this case, however, the observed mammary 
phenotype was secondary to other associated defects, such as dwarfism, delayed 
puberty and reduced female reproductive function, since the E2 treatment 
rescued the mammary phenotype but not the other observed defects [190]. More 
recently, bigenic PRAI-SRC-1 KO-/- and PRAI-SRC-3 KO-/- mice were generated to 
compare the role of SRC family members on PR activity in the mammary gland 
and uterus by crossing PR activity indicator (PRAI) mice with SRC-1 KO-/- or SRC-3 
KO-/- mice. PRAI was linked to GFP to monitor its activity. Loss of SRC-1 impaired 
the E2- and P-induced activation of PR in the uterus but not in mammary glands. 
In contrast ablation of SRC-3 impaired the activation of PR by E2 and P in the 
mammary gland but not in the uterus. Together, these results reveal SRC-3 as a 
primary co-activator of PR in the mammary gland and show SRC-1 to be its 
primary co-activator in uterus [191]. The absence of a pubertal mammary 
phenotype in SRC-3 KO-/- mice can be explained by the minimal role that PR 
plays in pubertal mouse mammary gland development. The distinct pubertal 
mammary phenotype in SRC-1 mice, on the other hand, is probably due to the 
requirement for SRC-1 in ER activation and function. Furthermore, SRC-2 
appears to be an indispensable co-regulator of both uterine and mammary gland 
responses to P as demonstrated by a mouse model in which SRC-2 function is 
abrogated only in PR expressing cells. The absence of SRC-2 in uterus impaired 
embryo implantation while lack of SRC-2 in mammary gland resulted in defective 
branching morphogenesis [192].  
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Cbp/p300 –interacting transactivator with Glu/Asp-rich carboxy-terminal domain 
1 
Another co-activator of ER that is crucial for pubertal mouse mammary gland 
development is the Cbp/p300 – interacting transactivator with Glu/Asp-rich 
carboxy-terminal domain 1 (CITED1). Loss of CITED1 (CITED1 KO-/- mice) in 
mammary glands caused reduced ductal outgrowth and aberrant ductal 
patterning. Ducts appeared dilated and spatial patterning of subtending 
branches was lost [193]. This phenotype probably arose due to altered 
transcription of some ER target genes, such as Areg, EGFR/ErbB2 or 
stanniocalcin 2 (Stc2). Synergistic interaction between these two proteins during 
pubertal mouse mammary gland morphogenesis is supported by the observation 
that both CITED1 and ERα localise to the same mammary epithelial cells [194].  
The activator protein 1 
The activator protein 1 (AP-1) is also involved in E2 signalling at puberty either 
acting as a co-regulator for ER or as a downstream target. AP-1 is a transcription 
factor composed of dimers of the oncogenes Jun (cJun), FBJ osteosarcoma (Fos) 
or other factors such as activating transcription factor (ATF) proteins. Early 
experiments targeting cJun in AP-1 KO-/- mice resulted in their embryonic 
lethality so mammary gland development was not examined in these mice. More 
recently, a bi-transgenic mouse model, has been generated, expressing an 
inducible AP-1 inhibitor (Tam67) under the control of the MMTV promoter such 
that AP-1 could be inhibited in a controlled manner. If inhibited at puberty, AP-1 
deficiency resulted in reduced size of the ductal tree by decreasing cellular 
proliferation but increasing apoptosis which reflected onto pubertal 
morphogenesis by suppressing primary ductal branching and decreasing TEB 
formation. Inhibition of AP-1 also suppressed the expression of both AP-1 
dependent genes, such as vimentin, fibronectin or TIMP-1 and AP-1 dependent 
growth regulatory genes (cyclin D1 and c-myc) and reduced the ability of the 
mammary gland to respond to E2 and P treatment [195].      
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Mediator complex subunit 1 
Mediator complex subunit 1 (MED1) is another co-activator of nuclear hormone 
receptors. It may act as a main bridge for direct communication between the 
transcriptional activator and general transcription machinery (especially RNA 
Polymerase II) and facilitate nuclear receptor-mediated gene transcription [196]. 
The interaction between receptor and MED1 is mediated through the LxxLL motif 
that is present in MED1. In MED1 LxxLL motif mutant knockin mice, disruption of 
the LxxLL motif resulted in severe defects in pubertal mouse mammary gland 
development manifested by decreased ductal outgrowth and side branching and 
decreased cellular proliferation. Furthermore, aberration of normal LxxLL 
function down-regulated the expression of ERα-regulated genes (cyclin D1, PR) 
and, as seen in AP-1 KO-/- mice, reduced the ability of the mammary gland to 
respond to E2 stimulation and diminished E2-regulated ductal outgrowth. 
Together, these results show that MED1 is important for pubertal mouse 
mammary gland morphogenesis. Loss of its function decreased cellular 
proliferation and down-regulated E2 signalling, both of which resulted in delayed 
development of the mammary tree at puberty [197].     
Metastasis-associated protein 1 
Metastasis-associated protein 1 (MTA1) is an ER co-modulator which causes 
inappropriate mammary gland development if deregulated during puberty. 
Transgenic mice over-expressing MTA1 under the control of the MMTV promoter 
displayed increased proliferation of ductal epithelium leading to extensive side 
branching and precocious differentiation of mammary glands. The mammary 
glands of these pubertal transgenic mice strongly resembled those in wild type 
mid-pregnant mice. A similar phenotype could also be seen in mammary glands 
collected from ovariectomised female mice, suggesting that an E2-independent 
mechanism might cause these morphological changes. MTA1 over-expression also 
deregulated pubertal ß-casein, ß-catenin and cyclin D1 expression, decreased 
PR-B expression and increased PR-A expression [198]. 
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CCAAT-enhancer binding proteins 
CCAAT-enhancer binding proteins (C/EBPs) belong to the family of leucine zipper 
DNA binding transcription factors. There are six members, called C/EBPα to 
C/EBPζ which promote the expression of certain genes by interaction with the 
CCAAT box motif on their promoter. C/EBPα, C/EBPß and C/EBPδ are 
differentially expressed in mouse mammary gland (reviewed in [199]) but only 
C/EBPß, to date, is important for pubertal mammary morphogenesis. C/EBPß   
KO-/- mice showed disrupted ductal morphogenesis that was characterised by 
reduced outgrowth and branching [200]. This disruption persisted until 
adulthood, when enlarged ducts and a reduced number of side branches could 
be noted [201]. In tissue transplantation experiments, a pubertal phenotype 
arose mostly due to the absence of C/EBPß in the mammary epithelium, 
although partly induced by an ovarian defect. When wild type epithelium was 
grafted into the empty fat pad of C/EBPß KO-/- mice normal mammary epithelial 
outgrowth was seen. In contrast, C/EBPß KO-/- epithelium grafted into the empty 
fat pad of a wild type host failed to develop. The mechanism by which C/EBPß 
regulates pubertal ductal morphogenesis has yet to be elucidated. However, 
since E2 partially rescues the pubertal phenotype, C/EBPß may act downstream 
of hormone signalling cascades and compromised E2 signalling may be partially 
responsible for the observed pubertal phenotype [200].   
GATA binding protein 3 
GATA-3 is one of the six highly conserved transcription factors that belong to the 
GATA family. In mammary gland morphogenesis, GATA-3 expression marks the 
formation of the embryonic placode, which makes it the earliest transcription 
factor that is expressed. Its expression persists throughout the whole of 
mammary development. At puberty, GATA-3 is the most highly expressed 
transcription factor in the mammary epithelium, where it localises to the ductal 
luminal cells and the body cells of TEBs. Conditional deletion of GATA-3 
impaired TEB formation and hence severely compromised ductal morphogenesis. 
Furthermore, its prolonged loss led to large numbers of undifferentiated luminal 
cells and compromised cellular attachment to the BM which in the long term led 
to caspase-activated cell death [202]. GATA-3 is therefore important for normal 
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mouse mammary gland development by maintaining differentiation of luminal 
epithelial cells.  
Activating enhancer binding protein 2 gamma 
Another transcription factor pivotal for normal mouse mammary gland 
development at puberty is the activating enhancer binding protein 2 gamma (AP-
2γ). AP-2γ regulates gene expression during embryogenesis. In the mammary 
gland, AP-2γ localises to cap and body cells of TEB. Mice lacking AP-2γ (AP-2γ 
KO-/- mice) displayed reduced proliferation within the cells of TEB leading to 
impaired ductal branching and elongation. Although these mice expressed ER, 
normal mammary development could not be restored by adding of exogenous E2, 
suggesting AP-2γ may regulate ductal outgrowth by acting downstream of 
ovarian hormones [203].      
1.2.3.2.4 Immune response cells and cytokines in the regulation of 
pubertal mammary gland development 
 
Although, it has been comprehensively documented that the combined activities 
of stroma/epithelium expressed systemic hormones and locally acting growth 
factors are pivotal for normal mammary epithelial morphogenesis at puberty, a 
number of mouse models with uncompromised hormonal signalling have still 
demonstrated abnormalities in pubertal mammary morphology. This suggests 
that other molecular players may be involved in normal mammary gland 
morphogenesis.  
Both positive and negative signalling is crucial for regulating epithelial 
outgrowth and maintenance of ductal tree open architecture. The growth-
promoting signalling factors within pubertal mouse mammary gland development 
have been well researched and the key players have been described in this 
section. In contrast, the mechanisms by which mammary epithelial outgrowth 
ceases, as a response to ductal patterning or reaching the end of the fat pad, 
are much less clear. To date, the best candidate for an inhibitory factor that 
regulates epithelial outgrowth at puberty and consequently ductal patterning is 
TGF-ß.  
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Transforming growth factor beta family 
TGF-ß proteins belong to the superfamily of multifunctional secreted cytokines 
that compromises TGF-ß (TGF-ß1, TGF-ß2 and TGF-ß3), BMPs, activins, inhibins, 
nodals, myostatin and others [204]. Members of the TGF-ß superfamily signal 
through their heteromeric type I and type II serine/threonine kinase receptors. 
TGF-ß binding to the type II receptor results in the recruitment of a type I 
receptor to the complex. The receptor type II further facilitates phosphorylation 
of the receptor type I on the serine and threonine residues which results in its 
activation and hence initiation of signalling to the downstream components of 
the pathway, mainly Sma/Mad-related (Smad) proteins. Several copies of Smads 
aggregate to form complexes which translocate to the nucleus to regulate gene 
transcription [205]. TGF-ß mediated cellular processes are very diverse and 
include: cell division, differentiation, proliferation, migration, adhesion, 
morphogenesis and programmed cell death. Five of the TGF-ß family members: 
TGF-ß transcripts, inhibins, activins, nodal and BMPs are expressed in the 
mammary gland.  
Transforming growth factor beta  
TGF-ß transcripts show overlapping expression within epithelium of TEBs and 
ducts. TGF-ß1 and TGF-ß3 mostly localise to body cells of TEBs and luminal and 
myoepithelial cells of ducts with higher TGF-ß levels in the former than the 
latter. Some TGF-ß3 expression further associates with cap cells and 
myoepithelial cells while the additional expression of TGF-ß1 can be also 
denoted in stroma that surrounds epithelium, where it forms a complex with 
ECM around ducts that are rather growth quiescent at puberty (in contrast to 
TEBs). TGF-ß2 expression although weak is detectable over both the epithelial 
and stromal compartments of pubertal mammary gland. In contrast, no TGF-ß 
peptides could be seen in the stroma at the front of advancing TEBs [206]. In 
fact, TEBs were shown to regress upon the administration of TGF-ß1, TGF-ß2 or 
TGF-ß3 releasing pellets. The growth inhibited mammary epithelium was 
histologically normal and the inhibitory effect was fully reversible [206] [207]. 
The administration of exogenous TGF-ß1, however, had an impact on the 
morphology of stroma surrounding the tip of TEBs. As demonstrated by 
Silberstein G. B. et al. (1990), an epithelium-dependent fibrous connective 
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tissue cap, that consisted of S-GAGs, ColI and chondroitin sulfate which was 
indistinguishable from that seen on the flanks of TEBs and ducts was identified in 
front of the manipulated TEBs [208].  
A marked suppression of TEB outgrowth and lateral branching resulting in the 
impairment of normal ductal patterning and duct hypoplasia has also been 
demonstrated in mouse models engineered to over-express TGF-ß1, using simian 
TGF-ß1 mutated to produce a constitutively active product under the control of 
the MMTV promoter/enhancer [209]. The inhibitory effect of TGF-ß on mammary 
epithelium was further confirmed when endogenous TGF-ß levels in mammary 
gland were manipulated. Mice carrying a function-ablating dominant-negative 
mutation in TGF-ß receptor type II, expressed under the control of a 
metallothionein-derived promoter, showed a dramatic increase in lateral 
branching of ductal epithelium that overrode normal ductal spacing. 
Furthermore, TGF-ß receptor type II localised to stroma, suggesting a paracrine 
manner of TGF-ß signalling [210]. In contrast, a decrease of TGF-ß1 expression, 
in TGF-ß1 KO+/- mice, which expressed only 10-30 % of TGF-ß1 protein levels, 
caused accelerated ductal development and cellular proliferation at puberty. 
Tissue transplantation experiments showed this TGF-ß1-deficient phenotype was 
intrinsic to the epithelium. Further analysis, based on the use of antibodies 
raised against the latent (active) form of TGF-ß1 revealed that TGF-ß1 
expression in these mice was modulated by the oestrus cycle. Together with the 
increased epithelial proliferation seen on administration of E2 and P to 
ovariectomised TGF-ß1 KO+/- mice, this suggested a role for ovarian hormones in 
the expression of TGF-ß1 which in turn regulates the proliferative response to 
hormones [211]. 
Investigation of the effect of complete loss of TGF-ß1 on pubertal mammary 
gland morphogenesis has been difficult due to the early lethality of TGF-ß1 KO-/- 
mice which die from a gross inflammatory response before reaching 3 weeks of 
age [212]. Recently, however, this pathological phenotype has been rescued by 
immunocompromising the mice. TGF-ß1 KO-/- mice exhibited fairly normal ductal 
outgrowth at puberty. When transplanted to wild type recipients, however, TGF-
ß1 KO-/- epithelium exhibited a much higher rate of outgrowth than that seen for 
TGF-ß1 epithelium. Thus, two opposing roles of TGF-ß1 in pubertal mouse 
mammary gland morphogenesis can be suggested: autocrine inhibition of ductal 
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outgrowth and endocrine/paracrine stimulation of ductal morphogenesis [213]. 
The autocrine nature of TGF-ß1 signalling is confirmed by co-localisation of TGF-
ß1 and phosphorylated Smad 2/3 (downstream target of activated TGF-ß) to the 
same cells. Since, nuclear Smad co-localised with ERα, and ERα positive cells do 
not proliferate, it was further investigated whether TGF-ß1 could inhibit the 
proliferative capacity of these cells. In fact, the number of proliferating, ERα 
positive cells increased in mature ducts of TGF-ß1 KO-/- glands (especially during 
oestrus) and was significantly reduced in mouse models over-expressing active 
TGF-ß1. At puberty, however, no evidence for TGF-ß1-regulated proliferation of 
ERα positive cells was denoted [214]. Thus, although TGF-ß1 appears to act in an 
autocrine manner to inhibit the proliferative index of ERα expressing cells, in 
mature mammary glands, at puberty this regulatory effect appears to be 
independent of TGF-ß1 expression. TGF-ß1 has been recently shown to regulate 
spacing of ductal branching. Using an in vitro 3D assay to reconstruct ductal 
structures characteristic of mammary epithelium, local, low gradients of TGF-ß1 
were demonstrated to control the positional milieu of  ductal lateral branching 
[110]. Collectively, these results provide evidence for the role of TGF-ß in 
regulating TEB outgrowth and lateral ductal branching. TGF-ß seems to act 
through its type II receptor in both an autocrine and paracrine manner and as 
recently suggested, HGF is likely to play a role in TGF-ß paracrine signalling. 
HGF stimulates ductal branching morphogenesis in vitro and its expression is 
significantly increased in mutant TGF-ß receptor transgenic mice [215] [210]. 
Thus inhibition of epithelial outgrowth may be a result of HGF inhibition by TGF-
ß.     
Inhibins and Activins 
Inhibins and activins also regulate mouse mammary gland development at 
puberty. Activins function as dimers of two subunits: ßA and ßB. There are three 
types of activins that have been identified to date, namely activin A (ßA ßA), 
activin B (ßB ßB) and activin AB (ßA ßB). The inhibin family, on the other hand, 
consists of two members who share a common α subunit: inhibin A (α ßA) and 
inhibin B (α ßB). Inactivation of the activin/inhibin gene ßB and thus loss of 
activin B, activin AB, inhibin B or a combination of the three affects ductal 
architecture during puberty. Ductal elongation was incomplete and TEBs showed 
abnormal morphology and failed to regress upon reaching the end of the fat pad 
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persisting up until postpartum. This mammary phenotype, however, could be 
rescued by transplantation of ßB-deficient epithelium into the cleared fat pads 
of wild type hosts, suggesting stromal regulation of ßB-dependent epithelial 
morphogenesis at puberty [216].  
Nodal 
Nodal is a potent embryonic regulator which is also crucial for normal mouse 
mammary gland morphogenesis. It is expressed in ductal epithelium at puberty 
and transgenic mice, carrying lacZ floxed nodal alleles that display 25% 
decreased expression of Nodal, exhibited impaired ductal branching at puberty. 
Furthermore, when administered into the mammary gland in the form of slow-
release pellets, nodal influenced both the direction and development of 
branching [217].  
Bone morphogenic proteins 
BMP2 and BMP4 are also expressed during pubertal mouse mammary gland 
morphogenesis [218]. BMP-4 potentiated the mitogenic activity exerted by 
several growth factors on mammary epithelium. When added in combination 
with suboptimal concentrations of FGF2, FGF7, FGF10, EGF or HGF, growth 
factor induced proliferation of epithelial cells in low density in vitro culture was 
significantly enhanced confirming its potential role in ductal morphogenesis 
[219].  
Macrophages and Eosinophils 
The formation and outgrowth of TEBs during puberty is closely paralleled by the 
homing of macrophages and eosinophils to the mammary gland where they 
localise to the extracellular regions of TEBs (See 1.2.1.2.3). Because of their 
spatial location and timing of expression, many research groups have focused on 
their role in puberty and demonstrated that both macrophages and eosinophils 
are essential for the normal outgrowth of the ductal tree. As demonstrated by 
Gouon-Evans et al. (2002), mice depleted of a hematopoietic system, by gamma 
irradiation, showed significant curtailment of pubertal morphogenesis with 
complete absence of TEBs and therefore an arrest of ductal outgrowth. This 
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phenotype, however, could be rescued by bone marrow transplantation that 
replaced the population of leukocytes [85].  
The critical role of macrophages during puberty was further highlighted by 
analysis of CSF-1 null mice (osteopetrotic mice which are deficient in CSF-1 due 
to a naturally occurring inactivating mutation). These mice showed impaired 
formation and outgrowth of TEBs and defective ductal branching [220] [85]. This 
TEB-associated phenotype has, more recently, been suggested to result from the 
impaired ColI fibrillogenesis which is at least partly promoted by macrophages 
(and thus reduced in CSF-1 null mice) and provides a framework for TEBs 
elongation [83].  
Macrophages contribute to ECM remodelling during wound healing and produce 
ECM components, such as Fn or thrombospondin 1 as well as ECM degrading 
proteases such as MMP-7 which degrades collagen. Given the importance of ECM 
remodelling during ductal outgrowth, the association of macrophages with ColI 
fibrillogenesis and the dramatic phenotype of CSF-1 null or hematopoietic 
system depleted mice it is very likely that the ECM remodelling is the way that 
macrophages take part in regulation of mouse mammary ductal morphogenesis 
at puberty.  
Mammary gland branching and TEB formation are also reduced in mice 
homozygous for a null mutation in eotaxin, i.e. deficient in eosinophils [85]. 
Mast cells 
Another immune system response element that has been recently discovered to 
localise to TEB stroma during puberty are mast cells [89]. Previously, mast cells 
were thought only to contribute to allergy, inflammatory disease or cancer 
development. However, using two transgenic mice models - Kit +/W-sh and Kit W-
sh/W-sh , Lilla et al. (2009) showed that mast cells are also required for normal 
mammary development [89]. Complete or partial ubiquitous deficiency of mast 
cells was seen in transgenic mice which were either heterozygous or homozygous 
for a spontaneous inversion mutation in the regulatory region of the c-kit proto-
oncogene, which is located at the white spotting (W) locus and encodes a 
putative tyrosine kinase receptor [221] [222]. Wholemount analysis showed no 
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abnormal phenotype in pre-pubertal mouse mammary glands. At puberty (5 
weeks), however, the mammary glands collected from mast cell deficient mice 
(Kit W-sh/W-sh) showed a significantly reduced number of TEBs and ducts than their 
wild type counterparts while Kit +/W-sh mice showed an intermediate phenotype. 
These phenotypes persisted until adulthood, where the reduced ductal length 
and number of duct ends were still present. The observed growth impairment 
was independent of macrophage or eosinophil recruitment (mast cells serve as 
key recruiters of leukocytes) as no differences in the amount of these cells could 
be seen in the Kit W-sh mutant mice. These phenotypes most likely resulted from 
decreased cellular proliferation noted in TEBs and ducts in these mice [85] [89].  
In addition, treatment of 3 week old female CD1 outbred mice with cromolyn 
sodium for 2 weeks revealed that degranulation is critical for mast cells to affect 
ductal mouse mammary gland morphogenesis, because of essential mediators 
(such as serine protease) of TEB outgrowth within the mast cells‟ granules.  As 
demonstrated by the wholemounts, TEB formation and ductal outgrowth were 
significantly inhibited in response to the treatment [89].  
1.2.3.2.5 The role of other stromal components in regulation of 
pubertal mammary morphogenesis 
 
Further insight into the mechanisms regulating pubertal morphogenesis was 
gained when the growth-promoting potential of the TEB stroma and its 
associated cells was researched in more detail. Not only immune response cells, 
but all types of stromal cells found in close proximity to outgrowing mammary 
epithelium, namely adipocytes, fibroblasts and ECM, play a dynamic and 
essential role in promoting and regulation this outgrowth. 
Adipocytes 
Experiments based on FAT-ATTAC mice, designed to facilitate inducible and 
reversible loss of adipocytes (induced by dimerisation of caspase 8 fusion protein 
and thus apoptosis), showed that the absence of adipocytes resulted in failure of 
TEBs to redevelop at puberty and impaired ductal elongation and branching 
[223]. In this mouse model, in which adipocytes can be reversibly ablated at any 
point during the mouse‟s life span a significant reduction in ductal branching, 
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number of TEBs and changes in proliferation and apoptosis associated with TEB 
epithelium were seen when adipocytes were ablated (both white and brown) in 2 
week old mice [224]. The dynamic and growth promoting character of mammary 
fat pad, however, is not only due to the morphogenic activity of its resident 
cells, but also depends on extensive DNA synthesis. As shown by Berger et al. 
(1983), extensive DNA synthesis was detected in the stroma surrounding the 
invading TEB while far less DNA synthesis was detectable around growth-
terminated ducts in the adult gland [225].    
ECM 
BM and the fibrous connective tissue of ECM are also essential for TEB 
maintenance, pubertal outgrowth in vivo and epithelial mammary tubulogenesis 
in vitro. ECM and its components provide a scaffold for epithelial cells, play an 
active role in regulating cellular shape, proliferation and polarity and are 
essential in mediating the cross-talk between epithelial and stromal 
compartments. ECM remodelling is believed to be pivotal in enabling the 
epithelial invasion of the fat pad during pubertal mammary morphogenesis.  
ECM signalling 
There are many studies that show uninterrupted ECM signalling and normal ECM 
composition to be important in normal pubertal development. Both Streuli 
(1998) and Klinowska (1999) used antibody mediated ablation of ß-integrin, the 
main mechanotransducer that relays ECM cues, to demonstrate reversibly 
inhibited TEB development in vivo and blocked tubulogenesis in vitro [226] 
[227]. Mammary epithelial cells cultured on Lama1-ColI based ECM showed 
increased cell growth, inhibition of lumen formation and loss of cellular polarity 
when the structural characteristics of ECM, such as its stiffness, were altered 
[228]. Disruption of ColI/Lama1 signalling in pubertal mouse mammary glands of 
mice lacking their exclusive receptor (α2 integrin subunit KO-/- mice) resulted in 
reduced branching of the epithelial tree [229]. In contrast, mouse mammary 
gland explants formed branched “spikes” when minced, 3D cultured in ColI gels 
and stimulated with any of the growth factors [230]. Moreover, the impairment 
in ColI fibrillogenesis has been shown to delay the outgrowth of TEB [83] in vivo. 
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Taken together, these results indicate that ColI is an important regulator of 
epithelial outgrowth and branching during puberty.  
Compromised branching morphogenesis has also been noted with Fn deficiency 
in the salivary gland. Ex vivo down-regulation of Fn expression using siRNA, anti-
Fn antibody or anti-ß1 integrin subunit antibody (α5ß1 integrin serves as Fn 
receptor) blocked cleft formation and branching in the salivary gland [231]. The 
similarity between salivary gland and mammary gland branching morphogenesis 
suggests that Fn may also be involved in the latter. In fact, recent experiments 
based on conditional KO of Fn in mammary epithelium (Cre-loxP-mediated gene 
KO technology) showed Fn deletion to cause a moderate retardation of pubertal 
mammary morphogenesis manifested by delayed ductal outgrowth and 
decreased branching [232]. Disruption of Tn-C in mice did not produce any 
visible abnormalities [233], while the functions of the remaining mammary gland 
ECM-associated molecules, Lama1, Per, Nid, SLRP, SPARC, Eln and other fibrillar 
collagens are yet to be elucidated in pubertal mouse mammary gland 
development. 
ECM remodelling 
ECM remodelling is essential for normal development of the mouse mammary 
gland. Degradation and remodelling of ECM at puberty provide a permissive 
environment for ductal elongation and branching facilitated by proteases. There 
are two main types of matrix degrading proteases that are activated during 
mammary gland remodelling. These are MMPs and a serine protease called 
plasmin. MMPs are synthesised as zymogens and their activity is regulated mostly 
by transcription and the action of their endogenous inhibitors, the tissue 
inhibitors of metalloproteases (TIMPs). Plasmin is also activated from its 
precursor, plasminogen and is involved in the degradation of fibrin and laminin 
and activation of pro-MMP3, -MMP9 and -MMP13 precursors (reviewed in [234]). 
Mouse mammary glands treated with the broad spectrum MMP inhibitor, GM6001 
displayed arrested ductal outgrowth and impaired branching [235]. Five MMPs 
can be identified in the normal mouse mammary gland at puberty: MMP2, MMP3, 
MMP9, MMP11 and MMP14.  
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Mice lacking MMP2 (MMP2 KO-/- mice) were characterised by delayed ductal 
outgrowth, increased number of apoptotic cells in TEB but an elevated number 
of secondary branches. The phenotype, however, does not persist for long, as by 
late puberty, normal ductal morphogenesis is restored.  
The mammary glands of MMP3 deficient mice (MMP3 KO-/-), on the other hand, 
displayed a ductal tree that is thinner and characterised by a lower number of 
side branches than that seen in the wild type control. The rate of ductal invasion 
as well as the number and size of TEBs in these mice, however, were normal 
[235]. The opposite phenotype, ducts with supernumerary side branches, could 
be seen in transgenic mice expressing an autoactivated form of MMP3 controlled 
by the WAP promoter [236]. Similarly, an increased number of epithelial 
branching compared to wild type littermates could also be detected in mice 
expressing activated MMP3 under the regulation of a MMTV promoter [237]. It 
should be noted, however, that the normal MMP3 expression is associated with 
the stromal compartment of the pubertal mouse mammary gland while these 
two studies were designed to express MMP3 in epithelium using MMTV or WAP 
promoters [235]. None-the-less, it appears that MMP2 stimulates TEB migration 
whilst also inhibiting lateral branch formation and MMP3 directs spatial 
localisation of branch points.  
In addition, MMP9 may also stimulate epithelial branching in vitro. Using a 3D 
primary culture model of rat mammary epithelial organoids that were grown on 
reconstituted BM, it was shown that TNF-stimulated secretion of activated MMP9 
coincided with increased proliferation and branching morphogenesis of epithelial 
cells. This effect was blocked by adding MMP9 neutralizing antibody [238]. The 
effect of MMP9 on epithelial branching morphogenesis in vivo, however, is yet to 
be elucidated. Using a similar culture system Simian et al. (2001) showed that 
the addition of plasmin or plasminogen to primary mammary organoid cultures 
mediated branching morphogenesis whereas the MMP inhibitor, galardin blocked 
this morphogenic effect. Thus, plasmin stimulated epithelial branching 
morphogenesis in culture by MMP activation rather than by direct ECM 
degradation [230].  
The endogenous expression of TIMPs during pubertal mouse mammary gland 
development is differentially regulated. At pre-puberty, TIMP1 and TIMP2 are 
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minimally expressed but show significantly high expression at both puberty and 
adulthood while TIMP3 and TIMP4 are highly expressed at pre-puberty and 
remain abundant at puberty. All TIMPs are produced by mammary epithelial cells 
and fibroblasts except for TIMP2 which is exclusively synthesised by epithelial 
cells. Implanting TIMP1 releasing pellets into the outgrowing mouse mammary 
gland led to decreased proliferation in TEBs which then resulted in attenuated 
ductal expansion. In contrast, transgenic mice generated to reduce TIMP1 levels 
by using TIMP1 antisense RNA expression under the control of the MMTV 
promoter displayed augmented mammary ductal expansion and an increase in 
the number of ducts as well as disruption of BM integrity [239]. Moreover, the 
complete loss of TIMP1 in TIMP1 KO-/- mice produced morphologically altered 
TEBs that were bigger than those seen in wild type controls [235].  
In addition, the enzymatic degradation of hyaluronate in situ disrupted the 
cellular organisation of TEBs [52] [50], whilst S-GAG-degrading enzymes, ß-
glucuronidase and N-acetylglucosaminidase, strongly localised to cap cells of TEB 
and myoepithelial ductal cells [102]. This suggests that correct regulation of 
polysaccharides turnover in BM and within the fibrous ECM (some ECM molecules 
possess the ability to bind S-GAGs) is also important for normal ductal 
morphogenesis. Collectively, these results demonstrate that proteases and their 
inhibitors are critical in regulating ductal elongation and branching during 
normal pubertal mouse mammary gland morphogenesis, at least in part, by 
regulating BM integrity.           
Finally, ECM mediated regulation of pubertal outgrowth can also be executed by 
regulating the morphogenic activity of growth factors and cytokines which are 
known to commonly bind to ECM (reviewed in [100] [91]).  
1.2.3.2.6 Axonal guidance proteins  
 
Microarray experiments have shown that axonal guidance proteins, expressed in 
neural growth cones and previously thought to function only in neuronal 
guidance, can also play a key role in regulating mouse mammary gland 
development at puberty.  
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Netrin 1 and Neogenin 1 
As previously discussed in 1.2.3.1, Ntn-1 and Neo-1 appear to play important 
roles other than just guiding neurons and axons during nervous system 
development, although, their role in pubertal mammary gland morphogenesis is 
most likely to be associated with adhesion rather than guidance.  
Ephrin family of receptor tyrosine kinases and their ligands 
Another group of axonal guidance proteins involved in embryonic development 
and morphogenesis of many adult organs including pubertal mouse mammary 
gland development is the ephrin (Eph) family of receptor tyrosine kinases and 
their ligands [240]. Both the Eph receptor B4 (EPHB4) and its cognate ligand 
ephrin B2 (EFNB2) are expressed in the ductal epithelium of pubertal mouse 
mammary gland. EPHB4 localises predominantly to the myoepithelial cells while 
the expression of EFNB2 is associated with luminal epithelial cells. Their 
expression commences with the onset of ductal elongation at puberty and 
appears to be further differentially regulated during the oestrus cycle. 
Furthermore, mammary gland associated expression of both the receptor and 
ligand is abolished in ovariectomised mice but can be restored with E2 
treatment [241]. Over-expression of the EPHB4 receptor under the control of the 
MMTV-LTR promoter resulted in delayed epithelial morphogenesis at puberty 
manifested  by delayed ductal outgrowth and reduced secondary and tertiary 
branching when compared to the wild type controls [242]. Thus, EFNB2 signalling 
via EPHB4 is regulated in an oestrogen dependent manner and this interaction is 
important for normal epithelial outgrowth and ductal patterning at puberty.  
Brain acid-soluble protein 1, Small proline rich protein 1A and Semaphorins 
Further insights into the role of axonal guidance proteins during pubertal mouse 
mammary gland morphogenesis were gained from the microarray study by Morris 
et al. (2006) who demonstrated high expression of BASP1 and Sppr1A, Sema(s): 
Sema3B, 3C, 4A, 4F and their receptors- plexins and neuropilins in the 
epithelium of TEBs [113]. However, the effect that these proteins exert on 
mouse mammary gland development has yet to be elucidated in vivo.   
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1.2.3.2.7 Other regulators of pubertal mouse mammary gland 
morphogenesis 
 
Other proteins which have been shown through KO models to regulate mouse 
mammary gland development include actin binding protein - gelsolin (Gsn) [243]; 
pro-apoptotic factor – Bcl2-like 11 (Bim) [244]; secreted milk fat globule - EGF 
factor 8 (MFGE8) [245] and Crk splice variant II [246].  
Gelsolin 
Mice with a targeted deletion of Gsn (Gsn KO-/- mice) displayed inhibited ductal 
elongation. The ductal tree resembled a rudimentary structure up until week 9 
when TEBs become evident and ductal outgrowth begun. Cellular proliferation in 
TEBs was also diminished when compared to their age-matched wild type 
controls. Transplantation of Gsn null epithelium into the fat pad of wild type 
mice, however, resulted in the restoration of normal ductal morphogenesis, 
suggesting that stromal Gsn is required for pubertal mouse mammary 
development [243].  
Pro-apoptotic factor-Bim, Crk splice variant II, Secreted milk fat globule-EGF 
factor 8 
Delayed ductal outgrowth paralleled by the increased deposition of ColI at the 
front of TEBs was also shown in Crk II over-expressing mice [246]. Deficiency of 
Bim, on the other hand, prevented induction of apoptosis and proper lumen 
formation in TEB and ducts at puberty [244] while loss of MFGE8 led to a severe 
reduction in ductal branching and formation of thin and poorly developed TEBs 
[245].    
1.2.4 Summary 
Pubertal mouse mammary gland morphogenesis is a complex process that 
involves ductal elongation, TEB bifurcation and ductal branching and epithelial 
patterning. Its regulation is facilitated by a wide range of factors that are 
expressed in the epithelium and stroma, including hormones and growth factors; 
ECM molecules and proteases with their inhibitors; immune cells and other 
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stromal cells. The cross talk between epithelial and epithelial-stromal cells 
provides global and directional cues for this development. A summarised list of 
pubertal regulators of mouse mammary gland and the effect they exert on TEB 
motility or ductal branching can be seen in Table 1-1. 
1.3 Microarray analysis of gene expression to study 
pubertal mouse mammary gland development 
In order to fully understand regulatory mechanisms that control organ 
development an understanding of the genome, the products it encodes and the 
way they interact to produce the complex living organism is crucial. Since 
protein based research is often less sensitive, more difficult and time 
consuming, gene expression profiling emerged as an effective way of studying 
genetic make-up of cells. Gene expression analysis can be performed either on 
an individual gene basis, using techniques such as northern blot or reverse 
transcription polymerase chain reaction (RT-PCR), or more efficiently, on the 
whole genome level using DNA microarrays. Both northern blotting and RT-PCR 
require the design of primers and probes for each individual gene, making the 
process of analysis of multiple genes timely and rather expensive. Thus, since 
the completion of the human genome project and sequencing projects in other 
species that identified many genes of unknown function, DNA microarray has 
become a very popular tool for transcriptome analysis. In fact it has 
revolutionised the whole area of genomic research. 
The DNA microarray technique is based on one of the most fundamental 
biological laws which is a high hybridisation affinity between two 
complementary strands of nucleic acids. In microarray technology, single 
stranded DNA sequences, in the form of either cDNA fragments (~ 100 
nucleotides) or synthesised oligonucleotides (most commonly 25 nucleotides) 
that represent specific genomic coding sequences, called probes, are 
immobilised (spotted) or directly synthesised onto the solid surface of an array 
[247]. The surfaces most commonly used to produce microarrays are 
nitrocellulose or charged nylon membranes or coated glass slides. Once 
extracted from the biological material, purified RNA is converted into single 
stranded cDNA, labelled using either fluorescent dye or more rarely a  
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Effect on 
motility 
Overexpression of 
protein/ gene 
Deficiency/Function impairment of 
protein/gene 
TEB 
Reduced ductal 
elongation 
PTH [150], PTHR [150], 
FGF3 [156], FGF4 [158], 
TIMP-1 [239], EPBHB4 
[242], TGF-ß [209] [206] 
E-cadh [57], ErbB2 [118], ErbB3 [119], 
ERα [129], GHR [149], FGFR2IIIb [159], 
Areg [179], IGF-1 [170], EGFR [176], 
ADAM17 [183], SRC-1 [189], SRC-3 [190], 
MED-1 [197], CITED-1 [194], C/EBPß 
[201], AP-2γ [203], Fn [232], MMP-2 
[235], TIMP-1 [239], Gsn [243], Activin B 
[216], Activin AB [216], Inhibin B [216], 
Macrophages [85], Eosinophils [85], 
Adipocytes [223], Fibroblasts [248], 
CrkII [246]                 
Increased ductal 
elongation 
IGF-1 with P [141], Areg 
[179] 
GR [144], VDR [152], TGF-ß [211] 
Disorganisation 
of TEB 
morphology and 
structure 
FGF4 [158] ErbB2 [118], ErbB3 [119], MFGE8 [249], 
Ntn1 [117], Neo1 [117], IGF-1 [170], 
Inhibin B [216], Activin AB [216], Activin 
A [216] 
Decrease in TEB 
formation 
TGF-ß [206] [209], EGF 
[175], Itgb [226] 
GATA-3 [202], CSF-1 [85] [220], Eotaxin 
[85], Mast cells [89], AP-1 [195], IGF-1R 
[171], VDR [152] 
Absence of TEBs  ERα [129], FGFR2IIIb [159], Adipocytes 
[223], Macrophages [85], Eosinophils 
[85] 
Decrease in TEB 
size 
 ErbB2 [118], ErbB3 [119], IGF-1R [171] 
Increase in TEB 
size 
HGF [163] TIMP-1 [235] 
Aberrant ductal 
patterning 
TGF-ß [209], Nodal [217] CITED-1 [194] 
Reduced 
branching 
PTH [150], PTHrP [150], 
TGF-ß [209], EPHB4 
[242] 
GR [144], GHR [144], IGF-1 [170], IGF-
1R [171], EGFR [176], SRC-1 [189], SRC-
3 [190], SRC-2 [192], AP-1 [195], MED-1 
[197], C/EBPß [201], AP-2γ [203], Nodal 
[217], CSF-1 [220] [85], Eotaxin [85], 
Adipocytes [223], α 2 integrin subunit 
[229], Fn [232], MMP-3 [235], MFGE8 
[245] 
Increased 
branching 
IGF-1 with P [141], MMP-
3 [236] [237], HGF [162] 
[163], MMP-9 [238], 
MTA-1 [198], Nodal [217] 
ErbB2 [118], ErbB3 [119], VDR [152], 
TGF-ß [210], MMP-2 [235] 
Table 1-1 List of pubertal regulators of mouse mammary gland and the effect they exert on 
TEB motility or ductal branching. 
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radioactive isotope and hybridised to the array chip [250]. Upon hybridisation 
the array is scanned to detect the location of hybridisation sites to determine 
which gene is expressed in the sample of interest. The intensity of the signal 
detected at each hybridisation site further translates into the level of gene 
expression, enabling the researcher to determine whether the gene is expressed 
and at what magnitude. Fluorescence data can then be normalised, verified and 
analysed by a variety of methods.  
Currently there are 5 main types of DNA microarray platforms that differ in the 
type of solid surface, the length of probe and the method of manufacture, 
namely: printed arrays, in situ synthesised arrays, high density bead arrays, 
electronic arrays and liquid bead suspension arrays (reviewed in [251]). Printed 
arrays are the first microarrays that were used in research laboratories. They are 
made of glass slides printed with DNA probes (cDNA or 25-80 nt long 
oligonucleotides) [252]. For in situ synthesised arrays, the oligonucleotides are 
directly synthesised on the quartz surface using photochemistry. Multiple probe 
sets are used per individual gene to improve sensitivity, specificity and 
statistical accuracy [253]. The length of probes depends on the manufacturer; 
Affymetrix GeneChips contain 25 nt long probes, Agilent ~ 60 nt probes and 
Roche NimbleGen 60-100 nt long probes (reviewed in [251]). Furthermore, the 
recently developed Affymetrix GeneChip Exon arrays allow the analysis of gene 
expression at the exon as well as the whole transcript level. High density bead 
array technology, on the other hand, is based on the sequence tagged beads 
randomly assorted on silicon slides [254]. In electronic microarrays, the 
hybridisation and immobilisation of the DNA onto the array surface is facilitated 
by an electric field and streptavidin-biotin bonds respectively. The NanoChip 400 
is one of the platforms that operate using this system [255]. Finally, the most 
advanced microarray technology, the liquid-bead suspension arrays are 3D arrays 
that utilise microspheres as a solid support for the application of probes and 
flow cytometry for bead and target detection (reviewed in [251]). Affymetrix 
GeneChip Exon arrays are the arrays of choice in this study. They accommodate 
oligonucleotide sequences that translate into 17500 well-annotated transcripts 
and every exon of each transcript is represented by four probe-sets (each 
consisting of 3-4 25 nt long probes) (For further details on the platform and 
microarray data generation workflow see 3.2.1.3 and 2.2.5.3 respectively).     
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The main advantage of microarray technology is the quick and reproducible 
analysis of literally thousands of genes in one experiment. This increases the 
efficiency with which potential trends in cellular functions, regulatory 
mechanisms and pathways can be identified. The high sensitivity of microarrays 
minimises the amount of starting material that is required to carry out the 
analysis, while the high-throughput nature of the data provides an overview of 
the transcriptome which is useful for selection of potentially important gene 
targets. As with every technique, microarray analysis also has limitations and 
they include: i) quality of RNA – degraded mRNA can produce false microarray 
data, and ii) occurrence of discrepancies between mRNA and protein expression 
levels.  
Microarray based gene expression profiling has been used to study mouse 
mammary gland development in the past. To date, most of these studies are 
time course microarray experiments that utilise whole mammary glands obtained 
from various stages of development, ranging from pre-puberty up to involution. 
There are only six published microarray studies, however, that address pubertal 
mouse mammary gland development. Four of these: Morris et al. (2006) [113], 
Kouros-Mehr et al. (2006) [256], McBryan et al. (2007) [194] and Deroo et al. 
(2009) [257] focus directly on puberty. The two former ones use isolated TEB and 
ducts and compare gene expression in TEBs with the gene expression elsewhere 
in the gland whereas the latter two compare gene expression in whole mouse 
mammary glands collected at different pubertal time points. The two remaining 
microarray studies by Master et al. (2002) [258] and Howlin et al. (2006) [193] 
present gene expression analysis across the whole development of mouse 
mammary gland, including puberty. 
The study by Morris et al. (2006) was carried out to identify new genes 
associated with migration of TEBs and ductal differentiation at puberty [113]. It 
used a novel digestion-based technique to isolate TEBs and ducts from their 
surrounding stroma [259]. After digestion with type II collagenase isolated 
epithelial structures were collected under a dissecting microscope and when the 
sufficient amount of isolates was obtained, RNA extraction was performed.  The 
gene expression profile of isolated TEBs and ducts was then compared using in 
situ synthesised, oligonucleotide microarrays (Affymetrix). To confirm the 
results and ensure that the removal of epithelium from its natural environment 
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did not alter gene expression, the RNA expression was additionally compared 
between whole mammary gland strips. Pairs of mammary glands were collected 
from 5-6 week old mice. One of the mammary glands was wholemounted and 
stained with carmine alumn to assess the position of the TEB advancement front. 
Based on this morphology, the contralateral gland from the same mouse was 
then cut transversely into four tissue strips: Pre-LN (ductal epithelium and 
stroma), LN (epithelium and stroma of ducts and LN), Post-LN (TEB and ducts 
epithelium and stroma) and Fat pad (epithelium free stroma). 91 genes were 
shown to be expressed more highly in TEB than duct epithelium. Functional 
analysis of this gene set revealed that the majority of these genes (57%) were 
associated with DNA replication, cell division or cell cycle regulation. More 
interestingly, however, this was the first study that highlighted expression of 
axonal guidance proteins in TEBs at puberty. Three genes in particular: BASP-1, 
Sprr1A and Sema3B were associated with TEB epithelium. However, TEB 
associated expression of a number of other semaphorins (Sema3C, 4A, 4F and 4d) 
along with their receptors, Plexins A2, A3, B2 and D1 and Neuropilins 1 and 2 
were also detectable [113]. This was consistent with the findings of the 
proteomic study that was previously published by the same research group [259] 
which led to the conclusion that axonal growth cone associated proteins are 
likely to regulate the migration of TEBs at puberty. 
Kouros-Mehr and Werb, on the other hand, used ß-actin-GFP reporter mice (5 
week old) to surgically microdissect TEB, mature ducts and epithelium-free 
stromal compartments [256]. These mice show ubiquitous expression of GFP in 
their mammary glands which enables their visualisation and facilitates precise 
dissection of TEB or duct microenvironments (epithelium and its proximal 
stroma) and epithelium free stroma. RNA was extracted from the different 
microenvironments and the transcriptomes of TEB and mature duct 
microenvironments were compared with epithelium free stroma to identify novel 
genes involved in the regulation of mouse mammary branching morphogenesis. 
This microarray study was performed using long-oligonucleotide (80 nt long) in 
situ synthesised arrays (Operon) and it identified 1074 genes exclusively 
expressed in the TEB microenvironment and 222 genes in the mature duct 
microenvironment. A further 385 genes were up-regulated in both the TEB and 
duct microenvironments when compared to empty Fat pad. Some of the main 
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gene families identified within these gene sets and further verified using in situ 
hybridisation included: Wnt (Wnt-2, 5a, 7b, Dsh-3, Frizzled-1 and Frizzeld-2) and 
hedgehog (Dhh), ephrin (Ephrin-B1 and A2) family members and EMT molecules 
(Twist-1, Twist-2 and Snail) [256]. This suggested that the Wnt family members 
which have also shown a similar expression pattern in the developing lung [260] 
[261]; Dhh, which is likely to act as an activator of hedgehog signalling which is 
important for mammary gland development [262]; ephrins, which belong to 
axonal guidance proteins [263], and Twist and Snail transcription factors, which 
are the markers of mesenchymal phenotype [264], all may play a potential key 
role in the orchestration of mouse mammary gland morphogenesis. 
McBryan et al. (2007) carried out an expression microarray time course analysis 
on the whole mouse mammary glands to assess gene expression changes 
associated with the onset of puberty. Five representative stages of pubertal 
development were chosen (V3, V4, V5, V6 and V7). As shown by wholemount 
analysis, TEBs were absent from the 3 week old mammary glands, present at 4, 5 
and 6 weeks and had regressed by the week 7. Gene expression analysis was 
carried out using Affymetrix MOE430A arrays and a pubertal gene set consisting 
of 930 unique transcripts was identified. Further analysis showed Wnt-, TGF-ß 
and oestrogen signalling pathways members to be enriched at puberty and 
highlighted biological functions such as growth factor activity, cell growth, fatty 
acid metabolism, proteolysis and peptidolysis as over-represented in mouse 
mammary gland transcriptome at puberty. Moreover, the pubertal gene set was 
further analysed to identify genes that were expressed or repressed specifically 
upon the presence or absence of TEBs, i.e. „TEB profile‟ genes. As a result, 15 
expressed and 9 repressed „TEB profile‟ genes were found and the „apoptosis‟ 
and „cell cycle regulation‟ were identified as the main biological functions 
associated with TEB associated genes [194].   
The latest microarray analysis carried out using biological material obtained 
from pubertal mouse mammary glands was published by Deroo B. J. et al. (2009) 
[257]. The main focus of this study was the identification of an E2-responsive 
pubertal gene set. Thus, mice were ovariectomised at pre-puberty and treated 
with 17-ß estradiol hormone pellets from 2 to 28 days. RNA was extracted from 
whole mammary glands collected at 2, 5, 7, 14 and 28 days after implantation 
and global gene expression was analysed using in situ synthesised 
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oligonucleotide microarrays (Agilent). This showed that the observed gene 
expression changes mimicked those that appear at puberty in normal mice. Both 
overlapping and distinct gene profiles were identified at different time points, 
i.e. at varying extents of ductal elongation. The most common functional 
categories associated with the E2 regulated genes that were over-expressed 
included: cell proliferation, immune response and metabolism/catabolism while 
the carbohydrate-metabolism associated genes were down-regulated in response 
to E2. Collectively, this analysis confirmed that E2 has a crucial role in ductal 
outgrowth of the mouse mammary gland at puberty and identified pubertal 
genes whose expression is regulated by E2 signalling [257].        
Some further insights into the pubertal transcriptome of mouse mammary gland 
were also provided by the two time course experiments: the early study of 
Master et al. (2002) [258] and more recent microarray analysis carried out by 
Howlin et al. (2006) [193]. Although the former study performed microarray 
analysis on 12 time points that were chosen across the whole mouse mammary 
development it focused mainly on pre-puberty. The most important finding was 
that brown adipose tissue is a component of pre-pubertal stroma and that the 
mammary gland functions in adaptive thermogenesis [258]. The study carried out 
by Howlin et al. (2006) consisted of two separate microarray analyses. The 
initial study compared gene expression across the whole development of mouse 
mammary gland and the main finding was the role of CITED1 in mouse mammary 
gland development at puberty. The importance of CITED1 in pubertal 
morphogenesis has previously been discussed in 1.2.3.2.3.  
A summary of the microarray studies carried out to examine the transcriptome 
of pubertal mouse mammary gland and their main characteristics is shown in 
Table 1-2.   
At the beginning of the work for this thesis, in November 2006, it had been 
demonstrated in our laboratory that it was possible to isolate TEBs and ducts 
that could be rapidly processed to generate high quality RNA. The Morris et al. 
(2006) paper had limitations in terms of the restricted transcriptome 
represented on these early microarray chips and the methods available for 
analysis [113]. It was therefore decided that one objective of this thesis would 
be to use novel exon in situ synthesised, oligonucleotide microarrays, which 
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provide a much wider gene range and also enable the differential examination of 
gene expression at the exon level, use wild type mice to collect isolated TEB and 
duct epithelium and GFP mice to accurately microdissect TEBs and ducts 
contained within the stroma and to carry out their in depth analysis. In addition 
to elucidating the signalling pathways and biological processes that were 
differentially over-represented in the TEB and duct epithelium and surrounding 
stroma it was also hypothesised that this approach would identify new genes of 
interest that could be followed up at a functional level. As a result, we 
identified new genes expressed in both epithelial compartments of TEBs and 
ducts and the main biological functions and processes that these genes are 
involved in. Furthermore, with our study we also added to the understanding of 
pubertal mouse mammary morphogenesis by carrying out, a completely novel 
identification of the gene expression signature of TEB and duct associated 
stroma (See Chapter 3).               
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Study Biological material used Main findings Ref 
Morris et 
al. (2006) 
Enzymatically isolated 
epithelium of TEBs and ducts 
Pre-LN, Post-LN and Fat pad 
tissue strips  
Association of axonal guidance 
proteins with TEB migration at 
puberty 
[113] 
Kouros-
Mehr et al. 
(2006) 
Microdissected 
microenvironments of TEBs, 
mature ducts and epithelium-
free stroma 
Association of Wnt, hedgehog, 
ephrin family members and EMT 
markers with branching 
morphogenesis at puberty  
[256] 
McBryan et 
al. (2007) 
Whole mouse mammary glands 
collected at 5 pubertal time 
points (V3, V4, V5, V6 and V7) 
Association of Wnt, TGF-ß and 
oestrogen signalling pathway 
members with epithelial outgrowth 
at puberty  
[194] 
Deroo et 
al. (2009) 
Pubertal whole mammary glands 
collected from ovariectomised 
17-ß estradiol treated mice  
Identification oestrogen-response 
genes at puberty and 
characterisation of common 
functional categories 
[257] 
Master S. 
R. et al. 
(2002) 
Whole mammary glands 
collected throughout whole 
mammary gland development  
Overview of gene expression 
pattern 
[258] 
Howlin J. 
et al. 
(2006) 
Whole mammary glands 
collected throughout whole 
mammary gland development, 
Whole mammary gland collected 
from CITED1 null heterozygous 
and homozygous mice. 
Identification of CITED1 as a key 
regulator of pubertal mammary 
development, 
Involvement of CITED1 in the 
regulation of E2 and TGF-ß 
response genes 
 
[193] 
Table 1-2 Summary of the microarray studies carried out on the pubertal mouse mammary 
glands, to date, and their main characteristics. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents and materials 
 
Animal husbandry 
 
Beekay Rat and Mouse diet No 1 B & K Universal Ltd., Hull, UK 
M3 cages North Kent Plastic Cages Ltd., Kent, UK 
Wood chips The Andersons, Inc; Maumee, Ohio, USA 
 
Sample collection 
 
Collagenase type II  Sigma Aldrich Company Ltd., Dorset, UK 
Fetal Bovine Serum (FBS) (0.1%) Sigma Aldrich Company Ltd., Dorset, UK 
Gridded contact dish  Nalge Nunc International, Hereford, UK 
Histobond®+ glass slides  Paul Marienfeld GmbH & Co. KG; Landa-
Königshofen, Germany 
Leibovitz L15 medium  Invitrogen Ltd.; Paisley, UK 
Neutral buffered formalin (10%) Genta Medical; York, UK 
RNaseZap  Applied Biosystems/Ambion; Austin, USA   
Scalpel blades Swann-Morton, Ltd.; Sheffield, England 
Surgical instruments John Weiss International; Milton Keynes, 
UK 
Trizol® Reagent  Invitrogen Ltd., Paisley, UK 
 
Cell culture and Explant Culture  
 
75 cm2 tissue culture filter flasks Corning Incorporated, Corning, USA 
Dulbecco‟s Modified Eagle medium 
(DMEM)  
Invitrogen Ltd., Paisley UK 
Dulbecco‟s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) 
Invitrogen Ltd., Paisley UK 
Epidermal growth factor (EGF)  PeproTech EC Ltd., London, UK 
FBS (10%) Sigma Aldrich Company Ltd., Dorset, UK 
Fibronectin Sigma Aldrich Company Ltd., Dorset, UK 
Haemocytometer Superior, Marienfield, Germany 
Insulin  Sigma Aldrich Company Ltd., Dorset, UK 
Lab-Tek-II Chamber Slide™ System  Nalge Nunc International Corp., 
Naperville, USA 
Leukaemia Inhibitory factor (LIF) Donated by Dr. J. Mounthford 
L-glutamine  Invitrogen Ltd., Paisley UK 
Phosphate Buffered Saline (dPBS) Invitrogen Ltd., Paisley UK 
Roswell park memorial institute 1640 
(RPMI-1640) medium 
Invitrogen Ltd., Paisley UK 
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Trypsin-EDTA Solution (0.25%) Sigma Aldrich Company Ltd., Dorset, UK 
 
Cloning 
 
Ampicillin Sigma Aldrich Company Ltd., Dorset, UK 
Bacterial culture dishes Sterilin Ltd. UK, Aberbargoet, UK 
Competent DH5α E. coli cells Invitrogen Ltd., Paisley, UK 
Ethylenediaminetetraacetic acid 
(EDTA) (2mM) 
Sigma Aldrich Company Ltd., Dorset, UK 
HiSpeed® Plasmid Maxi kit Qiagen Ltd., Crawley, UK 
Luria Bertani (LB) Broth Sigma Aldrich Company Ltd., Dorset, UK 
Microbiological spreader Microspec, Elesmere Port, UK 
NaCl VWR International Ltd., Dublin, Ireland 
pcDNA3 Invitrogen Ltd., Paisley UK 
pEGFP  Clontech-Takara Bio Europe, Saint-
Garmain-en-Laye, France 
pRc/CMV-Fbln2 Donated by Dr. Mon-Li Chu, Thomas 
Jefferson University, Philadelphia, USA 
QIAprep Miniprep kit Qiagen Ltd., Crawley, UK 
S.O.C. medium  Invitrogen Ltd., Paisley UK 
Tryptone ForMedium™, Norfolk, UK 
Yeast extract Sigma Aldrich Company Ltd., Dorset, UK 
 
Cell transfections and Adhesion assays 
 
10 cm cell culture plate  Corning Incorporated, Corning, USA 
12 well tissue culture plate  Corning Incorporated, Corning, USA 
25 cm2 tissue flask Corning Incorporated, Corning, USA 
DharmaFECT® Duo Transfection 
Reagent  
Thermo Fisher Scientific Inc., Surrey, UK 
Extracellular Matrix (ECM) Cell 
Adhesion Array Kit  
Millipore Ltd, Livingstone, UK 
Lipofectamine™ 2000 Transfection 
Reagent 
Invitrogen Ltd., Paisley UK 
Opti-MEM® I Reduced Serum Medium  Invitrogen Ltd., Paisley UK 
 
Protein work 
 
Amersham ECL Western blotting 
detection reagents and analysis 
system  
GE Healthcare UK Limited, Little 
Chalfont, UK 
Anti-Actin (C-20) antibody Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
Anti-C-terminus of Fbln2 antibody Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
Anti-Fbln2 antibody 
 
Donated by Dr. Mon Li Chu (Thomas 
Jefferson University, Philadelphia, USA) 
Anti-goat (HRP-labelled) rabbit 
polyclonal antibody 
Dako UK Ltd., Eli, UK 
Anti-mouse (HRP-labelled) rabbit 
polyclonal antibody 
Dako UK Ltd., Eli, UK 
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Anti-N-terminus of Fbln2 antibody Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
Anti-rabbit (HRP-labelled) donkey 
polyclonal antibody  
GE Healthcare UK Limited, Little 
Chalfont, UK 
Anti-Upk3a (AU1) antibody 
 
Donated by Dr. T. Sun (New York 
University Medical School, New York, USA) 
BCA™ Protein Assay Kit Thermo Fisher Scientific Inc., Surrey, UK 
Bis-Tris-HCl buffered (pH 6.4) (4-
12%) gel 
Invitrogen Ltd., Paisley UK 
Bovine Serum Albumin (BSA)   Thermo Fisher Scientific Inc., Surrey, UK 
Cell lifters  Corning Incorporated, Corning, USA 
Dithiothreitol (DTT) Sigma Aldrich Company Ltd., Dorset, UK 
Glycine Sigma Aldrich Company Ltd., Dorset, UK 
Marvel Original dried skimmed milk Premier International Foods Ltd., Susson, 
UK 
Methanol Thermo Fisher Scientific Inc., Surrey, UK 
Microcon® Centrifugal Filter Device 
equipped in the Ultracel YM-3 
membrane  
Millipore Ltd, Livingstone, UK 
Novex NuPage™ Electrophoresis 
system  
Invitrogen Ltd., Paisley UK 
Novex XCell II™ Blot module  Invitrogen Ltd., Paisley UK 
Novex® Sharp Pre-stained Protein 
Standards  
Invitrogen Ltd., Paisley UK 
NP-40 Sigma Aldrich Company Ltd., Dorset, UK 
NuPage LDS sample buffer (4x) Invitrogen Ltd., Paisley UK 
NuPage MES SDS running buffer (20X) Invitrogen Ltd., Paisley UK 
NuPage transfer buffer (20X) Invitrogen Ltd., Paisley UK 
Phosphatase inhibitor cocktail 2 Sigma Aldrich Company Ltd., Dorset, UK 
Ponceau S stain Sigma Aldrich Company Ltd., Dorset, UK 
Protease inhibitor cocktail tablets Roche Diagnostics Ltd., Burgess Hill, UK 
Sodium deoxycholate Sigma Aldrich Company Ltd., Dorset, UK 
Sodium dodecyl sulfate (SDS) Sigma Aldrich Company Ltd., Dorset, UK 
TRIS (TRIZMA base) Thermo Fisher Scientific Inc., Surrey, UK 
NuPage Tris-Acetate polyacrylamide 
gel (3-8%) 
Invitrogen Ltd., Paisley UK 
NuPage Tris-Acetate SDS Running 
Buffer (20X) 
Invitrogen Ltd., Paisley UK 
Tween-20 Sigma Aldrich Company Ltd., Dorset, UK 
Urea Sigma Aldrich Company Ltd., Dorset, UK 
Whatman® Protran® Nitrocellulose 
Transfer Membrane (0.2 µm) 
Sigma Aldrich Company Ltd., Dorset, UK 
 
 
RNA and DNA 
 
0.5 ml microcentrifuge tube Thermo Fisher Scientific Inc., Surrey, UK 
Acetylated BSA (10µg/µl) Promega Corporation, Madison, USA 
Agilent RNA 6000 Nano Kit Agilent Technologies. Inc. UK, UK 
Dimethyl sulfoxide (DMSO) Sigma Aldrich Company Ltd., UK 
DNA-free™ Kit Applied Biosystems/Ambion; Austin, USA   
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dNTPs mix (10mM) Invitrogen Ltd., Paisley UK 
Electrophoresis grade agarose Invitrogen Ltd., Paisley UK 
Ethidium bromide (10mg/ml) Sigma Aldrich Company Ltd., Dorset, UK 
GoTag® DNA Polymerase (5U/µl) Promega Corporation, Madison, USA 
Green GoTag® Flexi Buffer (5X) Promega Corporation, Madison, USA 
J Buffer (1X) Promega Corporation, Madison, USA 
LightCycler® 480 96 Well Plates Roche Applied Science, Mannheim, 
Germany 
LightCycler® 480 Probes Master (2X) Roche Applied Science, Mannheim, 
Germany 
LightCycler® 480 Sealing Foil Roche Applied Science, Mannheim, 
Germany 
MgCl2 (25mM) Promega Corporation, Madison, USA 
Oligo dT primer (0.5 µg/µl) Invitrogen Ltd., Paisley UK 
Random primer (1 µg/µl or 100 
ng/µl) 
Invitrogen Ltd., Paisley UK 
Reaction Buffer (cDNA synthesis) Roche Diagnostics Ltd., Burgess Hill, UK 
RNase OUT (40U/µl) Invitrogen Ltd., Paisley UK 
RNase-free 1.5 microcentrifuge tube Applied Biosystems/Ambion; Austin, USA   
RNase-free H2O Applied Biosystems/Ambion; Austin, USA   
RNeasy® Micro Kit Qiagen Ltd., Crawley, UK 
RNeasy® Mini Kit Qiagen Ltd., Crawley, UK 
Sma I enzyme (10U/µl) Promega Corporation, Madison, USA 
Transcriptor Reverse Transcriptase 
(20 U/µl) 
Roche Diagnostics Ltd., Burgess Hill, UK 
 
Microarray analysis of pubertal gene expression 
 
Biotinylated LNA RiboMinus probes 
(100 pmol/µL) 
Invitrogen Ltd., Paisley, UK 
GeneChip® Hybridisation, Wash and 
Stain Kit 
Affymetrix UK Ltd., High Wycombe, UK 
GeneChip® IVT cRNA Cleanup Kit Affymetrix UK Ltd., High Wycombe, UK 
GeneChip® Mouse Exon 1.0 ST Array Affymetrix UK Ltd., High Wycombe, UK 
GeneChip® Whole Transcript (WTr) 
Sense 1 µg Total RNA Target 
Labelling Assay 
Affymetrix UK Ltd., High Wycombe, UK 
GeneChip® WTr cDNA Synthesis Kit Affymetrix UK Ltd., High Wycombe, UK 
GeneChip® WTr Terminal Labelling 
Kit 
Affymetrix UK Ltd., High Wycombe, UK 
RiboMinus Human/Mouse 
Transcriptome Isolation Kit  
Affymetrix UK Ltd., High Wycombe, UK 
Streptavidin coated RiboMinus 
Magnetic Beads 
Invitrogen Ltd., Paisley, UK 
T7 RNA Polymerase GeneChip® WTr 
cDNA Amplification Kit 
Affymetrix UK Ltd., High Wycombe, UK 
 
Tissue processing and staining 
 
3.3-Diaminobenzidine 
tetrahydrochloride (DAB) + 
Dako UK Ltd., Eli, UK 
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Chromogen 
Acetic Acid (analytical grade) VWR International Ltd., Dublin, Ireland 
Acid Alcohol (1%) Sigma Aldrich Company Ltd., UK 
Alexa Fluor 488 dye Invitrogen Ltd., Paisley, UK 
Alexa Fluor 594 dye Invitrogen Ltd., Paisley, UK 
Anhydrous MgSO4 Thermo Fisher Scientific Inc., Surrey, UK 
Antibody Diluent Dako UK Ltd., Eli, UK 
Anti-Fbln1 antibody 
 
Donated by Dr. Mon-Li Chu, Thomas 
Jefferson University, Philadelphia, USA 
Anti-Fibronectin (ab2413) antibody Abcam Inc; Cambridge, USA 
BD Microlance™ 3 needle Becton Dickinson UK Ltd., Oxford, UK 
Carmine Sigma Aldrich Company Ltd., UK 
Chloroform (analytical grade) Thermo Fisher Scientific Inc., Surrey, UK 
Coplin Jar Raymond A. Lamb Ltd., Eastbourne, UK 
Elastica van Gieson (EVG) kit Merck KGaA; Darmstadt, Germany 
Eosin (1%) CellPath Ltd.; Newtown, UK 
Ethanol (analytical grade) Hayman Ltd., Witham, UK 
Haematoxylin Z CellPath Ltd.; Newtown, UK 
Horse Serum (2.5%) Vector Laboratories Ltd.; Peterborough, 
UK 
Image-iT ™ FX Signal Enhancer Invitrogen Ltd., Paisley, UK 
KAI(SO4)2 Sigma Aldrich Company Ltd., UK 
NaHCO3 Sigma Aldrich Company Ltd., UK 
Pertex CellPath Ltd., Newtown, UK 
ProLong® Gold antifade reagent with 
4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI)  
Invitrogen Ltd., Paisley, UK 
Superfrost® Plus slides Thermo Fisher Scientific Inc., Surrey, UK 
Thymol Sigma Aldrich Company Ltd., UK 
Twin Frost Microscope Slide Raymond A. Lamb Ltd., Easbourne, UK 
Weigert‟s solution A Merck KGaA; Darmstadt, Germany 
Weigert‟s solution B Merck KGaA; Darmstadt, Germany 
Xylene Genta Environmental Ltd., York, UK 
 
In vivo hormonal treatment of mouse mammary glands 
 
21 day release oestrogen (E2) 
(0.72mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
21 day release oestrogen-
progesterone (E2+P) (0.1mg/pellet, 
10 mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
21 day release placebo (10.01 
mg/pellet) pellet 
Innovative Research of America, Sarasota, 
Florida, USA 
Biogel®P Suretech surgical gloves Marigold Industrial Ltd., Broxbourne, UK 
Polyamide 6 blue monofilament non-
absorbable suture 5-0 Ethicon 
Johnson & Johnson; Langhorne, PA, USA 
Table 2-1 List of reagents and materials. 
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2.1.2 Solutions and Buffers 
Name of solution Method of preparation 
 
Cell culture 
 
EDTA-PBS buffer (2mM) 2mM EDTA in dPBS, sterilized by filtration 
 
Cloning 
 
LB-Agar (1.5%) 10g of Tryptone, 5g of yeast extract and 
10g NaCl and 15g of Agar in 1L of dH2O, 
sterilised by autoclaving, pH 7.5 
 
Protein work 
 
2.5% BSA blocking solution 2.5% BSA in 1X TBS Tween-20 wash buffer 
3% milk blocking solution 
 
3% Marvel Original dried skimmed milk in 
1X TBS Tween-20 wash buffer 
EDTA buffer 10mM EDTA, protease inhibitor and 
phosphatase inhibitor cocktail in TBS 
NP-40 buffer 50mM TRIS pH 7.5, 150mM NaCl, 5mM 
EDTA, 1% NP-40, protease inhibitor and 
phosphatase inhibitor cocktail in dH2O 
RIPA buffer 25mM TRIS pH 8, 150mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS, 
protease inhibitor and phosphatase 
inhibitor cocktail in dH2O 
Stripping buffer pH 2.2  5M Glycine, 0.1% SDS, 1% (v/v) Tween-20, 
pH 2.2 in dH2O   
Tris Buffered Saline (TBS) buffer 
(10X) 
50mM Tris-HCl, 150mM NaCl, pH 7.4 in 
dH2O 
TBS Tween-20 wash buffer (1X) 1X TBS, 0.1% (v/v) Tween-20 in dH2O 
Transfer buffer (western blotting) 
(1X) 
1X NuPage transfer buffer, 10% methanol 
in dH20 
Urea buffer 6M Urea, protease inhibitor and 
phosphatase inhibitor cocktail in TBS 
 
Tissue processing and staining 
 
1 mM EDTA buffer (pH 8) 1mM EDTA disodium salt, 4.5mM TRIS, pH 
8 in dH2O  
Carmine dye 2mM Carmine, 5mM KAI(SO4)2 in dH2O, boil 
for 20 min, filter and add crystal of 
Thymol (preservative) 
Carnoy‟s fixative 6 parts of 100 % (v/v) ethanol, 3 parts of 
chloroform and 1 part of acetic acid 
Scott‟s tap water 81.14mM anhydrous MgSO4, 41.66mM 
NaHCO3 in dH2O 
TBS buffer pH 7.6 (10X) 50mM Tris-HCl, 150mM NaCl, pH 7.6 in 
dH2O 
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TBS Tween-20 buffer pH 7.6 (1X) 1X TBS, 0.1% (v/v) Tween-20 detergent in 
dH2O 
Weigert‟s A&B solution Weigert‟s solution A (Alcoholic 
Haematoxylin Solution) and Weigert‟s 
solution B (Hydrochloric Acid Iron(III) 
Nitrate Solution) mixed 1:1 
Table 2-2 List of solutions and buffers. 
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2.1.3 Electric equipment 
Agilent 2100 bioanalyser  Agilent Technologies. Inc. UK, South 
Queensferry, UK 
Biometra T 3000 Thermocycler Thistle Scientific Ltd., Glasgow, UK 
C-28 centrifuge  Boeckel and Co; Hamburg, Germany 
CKX41 microscope Olympus UK Ltd., Surrey, UK 
Dissecting microscope  Olympus UK Ltd., Surrey, UK 
Dynatech MR7000 Plate Reader  Primera Scientific LLC, Princeton, NJ, 
USA 
Electrisaver E30 Thermostat heated 
chamber 
RS Components Ltd., Corby, UK 
Fluosorber vaporiser  The Harvard Apparatus, Kent, UK 
Fujifilm Fla-5000  Raytek Scientific Ltd., Sheffield, UK 
Galaxy S tissue culture incubator  New Brunswick Scientific, Cambridge, 
UK 
Intelligent Dark Box LAS-3000  Fujifilm UK Ltd., Manchester, UK 
Labophot-2 light microscope  Nikon UK Ltd.; Kingston upon Thymes, 
UK 
Leica ASP300 tissue processor  Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica DMD108 Digital Microimaging 
Network  
Leica Microsystems Ltd.; UK 
Leica EG1150C cold plate  Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica EG1150H  heated paraffin 
dispensing module  
Leica Microsystems Ltd.; Milton 
Keynes, UK 
Leica TCS SP2 confocal microscope  Leica Microsystems Ltd.; UK 
Leitz 1512 microtome  Leica Microsystems Ltd.; Milton 
Keynes, UK 
LightCycler® 480 Instrument Roche Applied Science, Germany 
Mikro-Dismembrator  B. Braun Biotech International GmbH, 
Melsungen, Germany 
NanoDrop ND 1000 Spectrophotometer NanoDrop Technologies, USA 
NanoZoomer Digital Pathology scanner  Hamamatsu; Bridgewater, USA 
ND-1000 Spectrophotometer  NanoDrop Technologies, USA 
IX51 inverted microscope Olympus UK Ltd., Southend-on-Sea, UK 
Shaking incubator Certomat BS-1 B. Braun Biotech International, 
Allentown, USA 
Stemi SV6 fluorescent dissecting 
microscope  
Carl Zeiss Ltd., Welwyn Garden City, UK 
Water bath  Thermo Fisher Scientific Inc., Surrey, 
UK 
Table 2-3 List of electric equipment. 
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2.2 Methodology 
2.2.1 Sample Collection 
2.2.1.1 Mouse husbandry 
Wild type C57BL/6 (WT), transgenic EGFP expressing C57/BL6 (TG) and Fibulin 2-
null C57BL/6 (Fbln2 KO-/-) mice were used for the purpose of this research. The 
WT mice were supplied by Harlan UK Limited Breeding Laboratories while the TG 
colony was derived from a breeding pair kindly donated by Prof. Cathrin Brisken 
(EPFL/ISREC, Lausanne, Switzerland). TG animals were of C57BL/6 background 
and constitutively expressed the EGFP transgene under the control of a CAG 
promoter (combination of -actin promoter and hCMV enhancer) [265]. Males 
heterozygous for EGFP expression were mated with WT female mice in order to 
establish our own colony of transgenic mice. WT and EGFP heterozygous female 
littermates were used for further experiments. The male offspring were culled 
before weaning unless needed for breeding purposes. The mice were 
accommodated and bred at the Biological Services Central Facilities at 
Gilmorehill Campus and the Veterinary Research Facility on the Garscube Estate, 
Glasgow.  
Animals were kept in conventional M3 cages bedded with wood chips and paper 
nesting material. Each of the cages was equipped ad lib with food; Beekay Rat 
and Mouse diet No 1 and ad lib tap water containers. Mice were housed in a 
temperature-controlled environment at 21 1ºC with humidity of 45% to 55% on a 
12-hour (h) light, 12-h dark exposure cycle. All WT mice were allowed a 7 day 
acclimatisation period after their arrival on site prior to being used for 
experiments. The transgenic founder breeders were screened for the presence 
of pathogens upon their arrival.    
Fbln2 KO-/- mice were initially generated by Dr. Chu (Thomas Jefferson 
University, Philadelphia, USA) [266] but bred and kindly made available for 
mammary gland collection by Dr. Tsuda (Nemours/Alfred I. DuPont Hospital for 
Children, Wilmington, USA). Tissue collection for wholemounting and paraffin 
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embedding was carried out in Nemours/Alfred I. DuPont Hospital for Children in 
Wilmington in USA by Mrs. Joyce. 
2.2.1.2 Dissection of mouse mammary glands 
The weight and age of the animals was recorded prior to culling. Surgical 
instruments were sterilized by autoclaving prior to performing the dissections. 
Mammary tissue was obtained from both left and right fourth inguinal glands of 
WT and TG females. Tissue was collected at the following stages of 
development: virgin (between 2 and 12 weeks old), pregnancy (day 3, 8.5, 12.5, 
14.5 17.5), lactation (day 1 and 7) and forced involution (day 1, 2, 3, 4, 10 and 
20). The first day of pregnancy was denoted by the appearance of a vaginal plug 
(counted as day 0.5). The collection of mammary glands from pregnant, 
lactating and involuting mice was performed by Marie-Anne Pringle. Mice were 
euthanized by a schedule 1 method of killing, either cervical dislocation or rising 
concentration of carbon dioxide. Death was confirmed by checking for absence 
of heart beat, respiration and paw withdrawal due to pinching the toe. The 
cadaver was placed on a corkboard in dorsal recumbent position and secured to 
the board using metal pins. 70% ethanol (v/v) was applied to the body and a 
midline inverted Y incision into the skin was performed using blunt scissors. The 
incision began halfway between the fourth and fifth nipples and continued 
rostrally to the thorax and laterally to each thigh. The skin flaps with mammary 
glands attached were then pulled away from the peritoneum and secured to the 
corkboard (Figure 2-1). Mammary tissue was gently excised using dissecting 
scissors and forceps. Glands to be used for isolation of epithelium were chilled 
on ice in Leibovitz L15 medium. Glands to be used for microarray studies and 
protein or RNA extraction had their lymph nodes removed prior to being snap 
frozen in liquid nitrogen. Glands to be used for immunohistochemistry (IHC) or 
immunoflurescence (IF) were transferred to 10% Neutral Buffered Formalin upon 
removal. Glands to be used for tissue imaging, tissue strips collection or organ 
culture were gently dissected out and immediately used for further applications. 
Glands to be used for carmine alum stained wholemount analysis were spread 
out on microscope slides and placed in Carnoy‟s fixative. 
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Figure 2-1 Dissection of the 4-th (inguinal) mouse mammary gland. 
(A) The image illustrates a mouse carcass secured to the corkboard in the recumbent position, 
ventral side up. (B) Image demonstrates carcass with 4-th mammary gland exposed by incision. 
Insert shows a higher magnification of the left mammary gland.  
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2.2.1.3 Dissection of other mouse organs and tissues 
All tissues and organs used in this research were excised from adult WT or TG 
mice at the Veterinary Research Facility, Garscube Estate, Glasgow, UK. Surgical 
instruments were sterilised by autoclaving prior to performing the dissection. 
Animals were weighed and euthanized by cervical dislocation. Collected organs 
of interest were either fixed in 10% Neutral Buffered Formalin or snap frozen in 
liquid nitrogen depending on their further application.    
2.2.1.4 Collection of mouse mammary gland tissue strips 
Pre-pubertal and pubertal mouse mammary gland can be divided into the 
following sections: pre lymph node (Pre-LN), post lymph node (Post-LN) and 
empty fat pad (Fat pad). The Pre-LN tissue strip contains ductal epithelium and 
stroma, the Post-LN tissue strip consists of TEBs, duct epithelium and 
surrounding stroma while Fat pad consists of epithelium-free stroma (Figure 2-2 
A). Mammary gland tissue strips were collected from 7 week old TG mice. Mice 
were transferred to the Beatson Animal Facility (Beatson Institute for Cancer 
Research, Glasgow, UK) immediately before commencing the experiments where 
they were culled by cervical dislocation. Glands were excised as described above 
in the designated area of Dr. Tomoko Iwata‟s laboratory (Beatson Institute of 
Cancer Research, Glasgow, UK). The 4-th mammary gland was gently spread 
onto a HistoBond®+ glass slide, visualised using Stemi V6 fluorescent dissecting 
microscope and imaged (Figure 2-2 B). Tissue strips were cut using sterile 
scalpel blades under the fluorescent dissecting microscope (See 2.2.8.1) and 
snap frozen in liquid nitrogen. Collected tissue was used for microarray analysis 
or RNA and protein extraction. All work surfaces and instruments used in the 
collection of tissue strips for use in RNA extraction were cleaned using RNaseZap 
prior to commencing work.  
2.2.1.5 Collection of isolated epithelium 
Two types of epithelial structures, TEBs and ducts, were extracted from the 
mammary tissue dissected from WT mice, aged between 6-8 weeks as described 
above. 20 glands were removed for each experiment and chilled in Leibovitz L-
15 medium. Collected tissue was coarsely minced using surgical non-sterile 
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Figure 2-2 7 weeks old 4-th mouse mammary glands. 
(A) Mouse mammary gland wholemount stained with Carmine stain, collected from WT mice (B) 
Mammary gland collected from TG mice imaged with a fluorescent dissecting microscope. 
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scalpel blades and subjected to 1mg/ml (w/v) collagenase type II digestion in 
Leibovitz L-15 medium. The enzymatic reaction was carried out at 37ºC for 35 
min using a shaking incubator Certomat BS-1 at max speed. The tissue soup was 
then shaken by hand to encourage the release of the epithelial structures from 
the tissue. The obtained suspension was split between two universals, diluted in 
fresh, ice-cold Leibovitz L-15 medium supplemented with 0.1% FBS to inhibit the 
collagenase activity and centrifuged for 5 min at room temperature (RT) at 
250rcf using a C-28 centrifuge. The resulting supernatants were then gently 
aspirated and pellets gently resuspended in 1 ml of Leibovitz L-15 medium and 
combined prior to being transferred into a gridded contact dish. The released 
TEBs and ducts were visualised by means of a dissecting microscope and 
manually collected using a 10µl Gilson pipette. Isolated epithelial structures 
were stored in 50-100µl volume of TRIzol® Reagent at –80C prior to extraction of 
RNA or fixed in 10% Neutral Buffered Formalin to be used in IHC or IF. 
2.2.2 Cell culture 
2.2.2.1 Cell lines and Cell maintenance 
Cell lines used in this study comprised three mouse non-tumourigenic cell lines: 
EpH4 and HC11, derived from mouse mammary epithelium, and NIH3T3 derived 
from mouse embryonic fibroblasts. NIH3T3 were kindly supplied by Dr. Iglesias 
while EpH4 and HC11 cells were kindly supplied by Prof. Birchmeier (Max-
Delbrück-Centrum für Molekulare Medizin, Berlin, Germany) and Dr. Allan 
(formerly Hannah Research Institute, Glasgow, UK) respectively. 
Unless stated otherwise, all cells were routinely grown in 75cm2 tissue culture 
filter flasks in a Galaxy S tissue culture incubator at 37°C in a humidified 
atmosphere with 5% CO2. Growth conditions applied to each cell line were as 
follows: EpH4 cells - DMEM, 10% FBS, 2mM L-glutamine; HC11 cells - RPMI-1640, 
10% FBS, 2mM L-glutamine, 5µl/ml insulin, 10ng/ml EGF and NIH3T3 cells - 
DMEM, 10% FBS, 2mM L-glutamine. All cell culture maintenance and in vitro 
experiments were performed under sterile conditions.  
For maintenance purposes, all cells were grown until nearly confluent. They 
were then washed twice with sterile dPBS (1X), detached from the tissue culture 
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flask via enzymatic proteolysis facilitated by incubation with 0.25% Trypsin-EDTA 
Solution for 2 min at 37°C and passaged into the fresh tissue culture flask by 
splitting 1:7 for NIH3T3, 1:12 for EpH4 and 1:5 for HC11 cells. 
2.2.2.2 Cell Counting 
Cells were then counted using a haemocytometer as follows: 10µl of cell 
suspension was applied to the upper and lower chambers of the 
haemocytometer, the number of cells per 1mm2 square was counted in 3 
different areas and the mean number of cells was calculated. The number of 
cells in 1ml of medium was calculated by multiplying mean number of cells with 
104.  
2.2.2.3 Plasmid information and plasmid DNA purification 
Plasmid Information 
The eukaryotic expression vectors used in this study were pEGFP, pcDNA3 and 
pRc/CMV-Fbln2 (Appendix 1). pEGFP encoded Enhanced Green Fluorescent 
Protein (EGFP) under the control of a cytomegalovirus (CMV) promoter while 
pcDNA3 is an empty vector and hence was used as a negative transfection 
control. pRc/CMV-Fbln2 contains variant 1 (V1) of the mouse Fbln2 gene 
(NM_007992) under the control of a CMV promoter. 
Preparation of LB Agar plates 
1.5% LB-Agar was prepared (See Solutions and Buffers) and autoclaved. The mix 
was then preheated in the microwave, left to cool down and then supplemented 
with 100µg/ml of Ampicillin. Finally it was poured onto bacterial culture dishes, 
allowed to solidify and stored upside down at 4°C.   
Purification of plasmid DNA 
PRc/CMV-Fbln2 was obtained as DNA blotted onto filter paper. DNA was eluted 
from the filter paper by placing the area of filter paper containing the plasmid 
in a 1.5ml Eppendorf tube and incubating in 50µl of dH2O for 30 min at RT, 
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followed by centrifugation for 3 min at 13,000rcf. 1µl of eluted plasmid DNA was 
then transformed into 50µl of competent DH5α E. coli cells. Transformation was 
performed by incubating the cells with the DNA on ice for 20 min, heat shocking 
for 90 sec at 42°C to facilitate plasmid entry and returning to ice for a further 2 
min. Transformed cells were then incubated with 250µl of S.O.C. medium for 45 
min at 37°C with agitation at 220rpm using a Certomat® BS-1 shaking incubator 
to assist cell recovery. Finally, 50µl of the transformation mix was transferred 
onto prepared LB-Agar (1.5%) plates containing 100µg/ml of Ampicillin, spread 
using a sterile disposable microbiological spreader and incubated upside down 
overnight at 37°C. After the incubation period the plate was investigated for the 
presence of single bacterial colonies. Four colonies were picked and each one 
was transferred to 10ml of LB medium supplemented with 100µl/ml of Ampicillin 
and cultured overnight at 37°C with agitation at 220rpm using Certomat® BS-1 
shaking incubator. 100µl of each culture were kept at 4°C. Obtained bacterial 
cultures were then centrifuged at 5,000rcf at 4°C for 15 min. Supernatant was 
removed and plasmid DNA was retrieved from the bacteria and purified using 
QIAprep Miniprep kit as per manufacturer‟s instructions. Briefly, bacteria were 
lysed under alkaline conditions. The lysate was neutralised and adjusted to high 
salt binding conditions and cleared from the cell debris by centrifugation. 
Plasmid DNA was then selectively bound to a QIAprep silica-based membrane, 
washed to remove endonucleases and salts and eluted in RNase-free H2O (low 
salt conditions).  
The DNA was quantified using a NanoDrop ND-1000 Spectrophotometer (See 
2.2.4.4). 
Each plasmid preparation was checked using restriction digestion (See 
2.2.4.11).  
Once the correct clone was identified by restriction digestion, 25µg of plasmid 
DNA was sent for sequencing to confirm the sequence of the insert (See 
2.2.4.10). Six primers were designed (See 2.2.4.7) (Table 2-5) to amplify the 
full sequence of Fbln2 V1 publicly available at the Nucleotide Database of the 
National Centre for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) (NM_007992). Sequencing results were 
visualised and examined using Chromas Lite 2.01 (Technelysium Pty Ltd) and 
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compared to the publicly available Fbln2 V1 GeneBank nucleotide sequence 
using Basic Local Alignment Search Tool (BLAST), blastn algorithm 
(http://blast.ncbi.nlm.nih.gov/) to assess the degree of similarity.      
Once the correct clone was identified, the aliquot of bacteria set aside before 
DNA purification, was transferred to a flask containing 150ml of LB medium 
supplemented with 100µg/ml of Ampicillin and grown overnight at 37°C with 
agitation at 220rpm. Bacterial cultures were then centrifuged at 5,000rcf at 4°C 
for 15 min. Supernatant was removed and plasmid DNA was extracted from the 
bacteria and purified using HiSpeed® Plasmid Maxi kit as per manufacturer‟s 
instructions. Briefly, bacteria were lysed under alkaline conditions and the DNA, 
proteins and cell debris were precipitated from the lysate. Lysate was filtered 
through the Anion Exchange Resin under the appropriate low salt and pH 
conditions to facilitate DNA binding to the Resin. Resin was then washed to 
remove the remains of RNA, proteins and low molecular weight impurities. 
Plasmid DNA was eluted in high salt buffer, concentrated and desalted via 
isopropanol precipitation and finally eluted in RNase-free H2O.  
Purified DNA from the pEGFP and pcDNA3 was kindly supplied by Dr. Camille 
Huser. 
2.2.2.4 Transfections 
Transfections were performed on HC11 cells using 3 different plasmids: pEGFP, 
pcDNA3 and pRc/CMV-Fbln2 and a liposomal transfection reagent. 
2.2.2.4.1 Optimisation of transfections 
 
The optimisation of transfection efficiency and toxicity was performed for 
DharmaFECT® Duo Transfection Reagent and Lipofectamine™ 2000 in order to 
find optimal transfection conditions for HC11 cells. All optimisation experiments 
were performed using the pEGFP. HC11 cells were plated in growth medium in 6 
well tissue culture plates at the same density per well 24-48h before 
transfection. Cells at the time of transfection were 60-80% confluent. 
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Optimisation of Transfections using Lipofectamine™ Transfection Reagent 
Optimisation of the transfection protocol for Lipofectamine™ was performed as 
follows: 4µg of DNA of pEGFP and varying volumes of Lipofectamine™ transfection 
reagent (2µl, 4µl, 6µl, 10µl and 12µl) were diluted in 250µl of Opti-MEM® I 
Reduced Serum Medium by gentle mixing. All mixes were incubated at RT for 5 
min. Diluted pEGFP DNA samples were then added to each of the diluted 
transfection reagent mixes and incubated at RT for a further 20 min in order to 
facilitate generation of the DNA-liposomes complexes. Finally 500µl of 
complexes were added directly to each well containing HC11 cells and fresh 
standard cell culture medium. Cells were then returned to incubator. After 5h 
the culture medium was changed. Cells were then further incubated to be tested 
for the transgene expression by fluorescence microscopy (See 2.2.8.1). 
Optimisation of Transfections using DharmaFECT® Duo Transfection Reagent 
Optimisation of the transfection protocol for DharmaFECT® Duo Transfection 
Reagent was performed as follows: 100µl of 20µg/ml of pEGFP was mixed with 
100µl of serum free culture medium. Increasing volumes of DharmaFECT® Duo 
Transfection Reagent (2µl, 4µl and 6µl) were each diluted in 200µl of serum free 
culture medium and incubated at RT for 5 min. The DNA dilutions were then 
added to the transfection reagent mixes and incubated at RT for an additional 
20 min. Finally, 1.6ml of fresh standard cell culture medium was added to each 
mix and the diluted complexes were added to each well containing HC11 cells. 
Cells were then tested for transgene expression after 48h of incubation.  
The efficiency of transfections, i.e. estimation of the EGFP transgene expression 
levels was performed using an inverted fluorescent microscope. Each well was 
visualised and imaged at x400 magnification (See 2.2.8.1). The number of EGFP 
expressing cells was counted at 3 chosen random fields within the well and the 
mean number of cells and standard errors of the mean (S.E.M.) were calculated.  
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2.2.2.4.2 Fbln2 over-expression in HC11 cells 
 
Fbln2 was over-expressed by transfecting HC11 cells with pRc/CMV-Fbln2 using 
Lipofectamine™ transfection reagent for 48h. The plasmid DNA to transfection 
reagent ratio was 1:1 and it was adjusted for the size of each tissue culture 
plate or dish. PcDNA3 DNA was used as a negative control in all experiments.  
The experimental procedure was carried out as described above (See 
2.2.2.4.1). Transfected HC11 cells were then incubated for 48h prior to being 
collected in RIPA buffer (See Solutions and Buffers) for protein extraction or 
used for further applications. Transgene expression was determined by Western 
blotting. 
2.2.2.5 Wound Healing Assay 
HC11 cells were plated in 6 well cell culture plates at equal density per well and 
transfected in triplicates with either pRc/CMV-Fbln2 or pcDNA3 using 
Lipofectamine™ transfection reagent as described above (See 2.2.2.4.1). 48h 
after the transfections, when cells had become confluent, a double cross was 
marked on the surface of each well using a sterile 200µl pipette tip. As Fbln2 is 
an ECM molecule, the culture medium was collected from each well, spun down 
at RT for 5 min at 1,100rcf to discard floating cells, mixed with fresh culture 
medium and placed back on the cells. Two areas around the double cross were 
selected for each well to be imaged over time. Images were acquired straight 
after performing the scratch, i.e. at 0 h and after 4, 7, 11, 24 and 36h. The 
width of the gap was measured in triplicate for each selected area at x400 
magnification (See 2.2.8.3). The experiment was repeated 3 times. Mean values 
and S.E.M. were calculated for each well, and the percentage of gap closure 
over time in each well was plotted. Upon completion of the assay, cells were 
collected in RIPA buffer for protein extraction to determine transgene 
expression by Western blotting.   
  109 
 
2.2.2.6 Adhesion Assays 
2.2.2.6.1 Adhesion of pRc/CMV-Fbln2 transfected HC11 cells to 
plastic surface 
 
HC11 were plated in 75cm2 tissue culture flasks prior to being transfected with 
either pRc/CMV-Fbln2 or pcDNA3 with Lipofectamine™ transfection reagent as 
described above (See 2.2.2.4.1). 48h after transfection, the cells were washed 
twice with sterile dPBS (1x), detached from the tissue culture flask by 
incubation with filtered 2mM EDTA-PBS buffer (See Solutions and Buffers) for 10 
min at RT, resuspended, centrifuged at 150rcf for 3 min at RT, washed twice in 
filtered 2mM EDTA-PBS buffer and resuspended in 2ml of DMEM. Cells were then 
counted (See 2.2.2.2) and plated at a final concentration of 1.5x106 cells/ml in 
96-well tissue culture plate in quintuplicates at 100µl/well and incubated for 2h. 
Adherent cells were then washed, stained and quantified using the methodology 
and reagents from the ECM Cell Adhesion Array Kit as described below (See 
2.2.2.6.2). 
2.2.2.6.2 Adhesion of pRc/CMV-Fbln2 transfected HC11 cells to ECM 
proteins 
 
Influence of Fbln2 over-expression on the adhesiveness of HC11 cells to human 
ECM proteins, such as ColI, ColII, ColIV, Fn, Lama1, Tnc and vitronectin (Vtn) 
was studied using ECM Cell Adhesion Array Kit. The ECM Cell Adhesion Array Kit 
utilises colorimetric detection of the amount of experimental cells adherent to 
wells coated with seven human ECM proteins in a 96-well cell culture plate. BSA-
coated wells are used as a negative control. The main experimental steps of the 
assay include: plating of the cells at a given constant density per well, cell 
attachment, washing, staining and determination of the relative cell attachment 
via absorbance reading.  
Determination of the optimal cell density was performed using untransfected 
HC11 cells at three different concentrations (0.5x106 cells/ml, 1x106 cells/ml 
and 2x106 cells/ml) and the relative cell attachment was determined according 
to the manufacturer‟s instructions. Briefly, HC11 cells were plated in 75cm2 
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tissue culture flasks and cultured until confluent. Cells were then detached from 
the flask using filtered 2mM EDTA-PBS buffer (See 2.2.2.6.1), counted (See 
2.2.2.2) and plated at the final concentration in the supplied strips in 
100µl/well and incubated for 2h. Each strip was rehydrated with 200µl of dPBS 
for 10 min prior to being used for the experiment. After incubation, culture 
medium was aspirated from the wells and cells were washed three times with 
200µl/well of supplied Assay Buffer to remove unattached cells. The remaining 
attached cells were then stained for 5 min with 100µl/well of the supplied Cell 
Stain Solution, washed three times with deionised H2O to remove excess staining 
solution and allowed to air dry. Finally, the stain was released from the cells and 
solubilized by the addition of 100µl of supplied Extraction Buffer to each well 
and incubating the plate at RT for 15 min while shaking. The amount of released 
stain was directly proportional to the amount of attached cells and it was 
determined using absorbance readings at 560nm.   
The amount of Fbln2 over-expressing HC11 cells adherent to different ECM 
proteins was determined as follows: HC11 cells were plated in 75cm2 cell culture 
flasks prior to being transfected with either pRc/CMV-Fbln2 or pcDNA3 as 
described above (See 2.2.2.4). 48h after transfection, both cell lines were 
washed twice with sterile dPBS (1x), detached from the flask using filtered 2mM 
EDTA-PBS, washed, resuspended in DMEM and counted as described above. Both 
cell lines were then resuspended in DMEM to a final concentration of 1.5x106 
cells/ml, plated in triplicates, incubated, washed, stained and analysed 
following the experimental steps described above. The mean amount of cells 
and S.E.M. for each condition were calculated and plotted.  
2.2.3 Protein work 
2.2.3.1 Protein extraction from the cell lines 
Protein extracts were collected from untransfected cell lines grown to sub-
confluency in either 6 well plates or 10cm cell culture dishes. Protein extraction 
from transfected cells was performed upon completion of transfections or wound 
healing assays.  
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Cells were washed twice with dPBS and incubated on ice with either 0.25ml/per 
well (6 well tissue culture plate) or 0.5ml/plate (10cm tissue culture) of ice cold 
RIPA lysis buffer until the cells were lysed, i.e. the buffer became viscous due to 
the nucleic acid release and the cell membranes appeared digested when viewed 
under an Olympus CKX41 microscope at x400 magnification. The cell lysates 
were then scraped off from the tissue culture dishes or plates using cell lifters, 
transferred to 1.5 Eppendorf tubes and incubated on ice for a further 15 min 
with occasional mixing. The cell lysate was finally centrifuged at 4°C for 20 min 
25,000rcf to separate the fraction of extracted proteins (supernatant) from cell 
debris (pellet). The supernatant, i.e. protein lysate was then quantified (See 
2.2.3.3), concentrated, used for Western Blotting or stored at -80°C. 
 
2.2.3.2 Protein extraction from the frozen tissues 
Frozen tissues were pooled or individually crushed in liquid nitrogen using a 
mortar and pestle cooled on dry ice. The obtained tissue powder was transferred 
to a Down‟s Homogeniser chilled on dry ice and resuspended in 0.5ml of ice cold 
NP-40, RIPA, EDTA or Urea lysis buffers (See Solutions and Buffers). 
Homogenised samples were transferred to ice chilled 1.5ml microcentrifuge 
tubes and placed on dry ice. The obtained tissue lysates were then defrosted, 
incubated on ice for 30 min to facilitate further cell lysis and centrifuged at 
25,000rcf at 4ºC for 20 min to separate out the fraction of extracted proteins 
from the cell debris. The resulting supernatant was retained, quantified, 
concentrated, used in Western blotting or stored at -80ºC.   
2.2.3.3 Protein Quantification 
The concentration of proteins was determined with the BCA™ Protein Assay Kit 
that utilises the ability of proteins in alkaline medium to facilitate Cu2+ to Cu1+ 
reduction (Biuret reaction). Briefly, 10µl of each sample (diluted 1:5) was plated 
in the 96 well tissue culture plate along with equal volumes of eight BSA protein 
standards (0, 25, 125, 250, 500, 750, 1000 and 1500µg/ml). Each sample and 
protein standard was plated in duplicate and triplicate respectively and mixed 
with 200µl of BCA reagent (prepared by mixing Reagent A and Reagent B in a 
50:1 ratio). The plate was then incubated at RT for 30-40 min. The absorbance 
of each well was read at 570nm using a Dynatech MR7000 Plate Reader and 
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Revelation Version 3.04 software (Revelation UK, London, UK). Finally, the 
absorbance readings of BSA standards were used to plot a standard curve and 
calculation of sample protein concentration was based on a linear line of best fit 
using Microsoft Excel®.  
2.2.3.4 Concentration of Protein Extracts 
Cellular protein extracts of a concentration too low to be used for further 
applications were concentrated using a Microcon® Centrifugal Filter Device with 
Ultracel YM-3 membrane according to the manufacturer‟s instructions. The 
Ultracel YM-3 membrane has a cut off of 3kDa. Briefly, a maximal volume of 
0.5ml of protein extract was transferred into the sample reservoir assembled 
with the collection vial and sealed with the attached cap. The column was then 
centrifuged at 14,000rcf for 40 min at RT with the cap strap aligned to the 
centre of the rotor. The reservoir was then removed from the column, placed 
upside down in the new collection vial and spun at 1,000rcf for 3 min to retain 
the concentrate. The concentration of the resulting extract was once more 
determined by the BCA™ Protein Assay Kit.                
2.2.3.5 Electrophoresis and Western blotting 
One dimensional electrophoresis under denaturing conditions and in the 
presence of 0.1% SDS was performed to enable separation of the proteins 
according to their molecular weight.  The separation and blotting of proteins 
was carried out using the Novex NuPage™ Electrophoresis system.  
Sample preparation 
Prior to SDS polyacrylamide gel electrophoresis (PAGE), 25-50µg of each protein 
extract was mixed with 0.33 volumes of 4xNuPage LDS sample buffer and 0.1 
volume of 1M DTT. The mix was incubated at 70ºC for 10 min to facilitate 
protein denaturation.  
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SDS polyacrylamide gel electrophoresis 
The prepared protein samples were resolved on either 4-12% Bis-Tris-HCl 
buffered (pH6.4) gels in the presence of 1xNuPage MES SDS running buffer or 3-
8% Tris-Acetate polyacrylamide gels in the presence of 1X Tris-Acetate SDS 
Running Buffer. Molecular weight markers, Novex® Sharp Pre-stained Protein 
Standards, were separated alongside the samples. The choice of polyacrylamide 
gel type was dependent on the molecular weight of the protein of interest and 
the level of resolution required.  500µl of NuPage Antioxidant was added to the 
inner chamber of the gel apparatus. 4-12% Bis-Tris gels were electrophoresed at 
a constant voltage of 200V for approximately 45 min, while the 3-8% Tris-Acetate 
polyacrylamide gels were run for 60 min at a constant voltage of 150V.  
Protein Transfer 
Upon completion of electrophoresis, proteins were transferred from the SDS 
polyacrylamide gel onto Whatman® Protran® Nitrocellulose Transfer Membrane 
(0.2µm) using a Novex XCell II™ Blot module, protein transfer buffer (See 
Solutions and Buffers), sponges and filter papers. Filter papers, transfer 
membrane and sponges were pre-soaked in protein transfer buffer and protein 
transfer was carried out at a constant voltage of 30V for 60 min.  
Membrane Blocking and Incubation with Antibodies 
After protein transfer the nitrocellulose membrane was removed from the 
module and briefly stained with Ponceau S stain (0.1% Ponceau S (w/v) in 5% 
acetic acid (v/v)) to determine the efficiency of the transfer. 1xTBS Tween-20 
wash buffer (See Solutions and Buffers) was used to remove the stain. The blot 
was incubated for 40 min at RT in 3% Marvel Original dried skimmed milk 
blocking solution (See Solutions and Buffers) or 2.5% BSA blocking solutions (See 
Solutions and Buffers). It was then incubated for 2h at RT or overnight at 4ºC 
with primary antibody, washed three times with 1xTBS Tween-20 wash buffer for 
10 min, incubated for 1h at RT with horseradish peroxidase (HRP)-labelled 
secondary antibody and finally washed three more times with 1xTBS Tween-20 
wash buffer for 10 min. All of the above incubations and washes were performed 
using horizontal or oscillating shakers. Both primary and secondary antibodies 
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were diluted in 1xTBS Tween-20 wash buffer to the final working concentrations 
shown in (Table 2-4). 
Signal Detection 
The HRP activity of the secondary antibodies allow antigen detection to be 
carried out using chemiluminescence, i.e. emission of light resulting from 
dissipation of energy from the product of chemical reaction. In this system, HRP 
catalyses oxidation of luminol in the presence of phenol (chemical enhancer) in 
alkaline conditions.  
Signal detection was performed using the Amersham ECL Western blotting 
detection reagents and analysis system as per manufacture‟s instructions. The 
membrane was incubated with the prepared detection mix (equal volume of 
detection solution 1 and 2) for 1 min at RT. Excess solution was removed from 
the membrane prior to and after the incubation. The membrane was then 
wrapped in Saran wrap and the chemiluminescence signal was detected using an 
Intelligent Dark Box LAS-3000 equipped with a cooled to -30°C charge coupled 
device, camera and FO.85 Fujinon Lens. Images were acquired and analysed 
using LAS-3000 v.2.2 software (Fujifilm UK Ltd., UK) after 4-20 min of exposure 
under standard sensitivity. Densitometry was performed using MacBiophotonics 
ImageJ (http://rsb.info.nih.gov/ij/). 
Stripping for re-probing of membranes  
In order to be re-used, the membranes were transferred into 1xTBS Tween-20 
wash buffer immediately after performing the signal detection step of Western 
blotting and stored at 4°C for up to 48h. When needed, membranes were briefly 
rinsed twice in 1xTBS Tween-20 wash buffer, washed for 5 min in 1xTBS Tween-
20 wash buffer and stripped of attached primary and secondary antibodies by 
two separate 10 min incubations in stripping buffer (pH2.2) (See Solutions and 
Buffers), rinsing in-between. Membranes were then finally washed using 1xTBS 
Tween-20 wash buffer three times for 5 min to fully remove detached antibodies 
and eliminate the remains of stripping buffer. All washes and incubations were 
performed at RT, using an oscillating shaker. Stripped membranes were then  
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Primary antibody and Source Blocking 
solution 
Final 
concentration 
Anti-Upk3a (AU1) 
Mouse monoclonal, donated by Dr. T. Sun (New York 
University Medical School, New York, US) 
2.5% BSA 1: 1000 
Anti-Fbln2 
Rabbit polyclonal, donated by Dr. Mon Li Chu (Thomas 
Jefferson University, Philadelphia, US) 
3% milk 1:5000 
Anti-Actin (C-20) 
Goat polyclonal, Santa Cruz Biotechnology Inc., Santa Cruz, 
USA  
3% milk 1:1000 
Anti-N-terminus of Fbln2 
Rabbit polyclonal, Santa Cruz Biotechnology Inc., USA 
3% milk 1:400 
Anti-C-terminus of Fbln2 
Goat polyclonal, Santa Cruz Biotechnology Inc., USA 
3% milk 1:200 
Secondary antibody and Source Blocking 
solution 
Final 
concentration 
Anti-goat (HRP-labelled) 
Rabbit polyclonal, Dako UK Ltd., Eli, UK  
3% milk 1:3000 
Anti-rabbit (HRP-labelled) 
Donkey polyclonal, GE Healthcare UK Ltd., UK 
3% milk 1:5000 
Anti-Mouse (HRP-labelled) 
Rabbit polyclonal, Dako UK Ltd 
3% milk 1:3000 
Table 2-4 Primary and secondary antibodies used for Western Blotting. 
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blocked and re-probed with primary and secondary antibodies and used to 
detect other proteins of interest as described above.   
2.2.4 RNA and DNA  
2.2.4.1 Preparation of total RNA  
To prevent contamination by environmental RNAses, all instruments and working 
surfaces were cleaned using RNaseZap and RNase-free 1.5 microcentrifuge tubes 
were used as standard throughout the experimental procedure. 
2.2.4.1.1 Preparation of collected frozen tissue for RNA extraction 
 
Frozen tissues were pooled or individually crushed in liquid nitrogen using a 
pestle and mortar previously cooled on dry ice. The obtained tissue powder was 
transferred to a liquid nitrogen chilled polytetrafluoroethylene capsule and 
further homogenised using a Mikro-Dismembrator for 20 sec at 15,000rpm. 
According to the amount of starting material, the homogenate was resuspended 
in 1-3ml of TRIzol® reagent transferred to 1.5ml tubes and stored at -80ºC until 
all samples were ready for further processing.  
Once all samples were collected, they were thawed on ice, mixed by vortexing 
and incubated at RT for 5 min in order to facilitate the complete dissociation of 
nucleoprotein complexes. 
2.2.4.1.2 Preparation of isolated mammary gland epithelium for 
RNA extraction 
 
Isolated TEBs and ducts (See 2.2.1.5) previously collected in TRIzol® reagent 
and stored at -80°C were thawed on ice and mixed by vortexing. All TEBs were 
pooled together in a final volume of 1ml of TRIzol® reagent. The ducts were 
pooled in the same way. Samples were then incubated at RT for 5 min. 
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2.2.4.1.3 Extraction of RNA from frozen tissue and isolated 
epithelium 
 
Extraction of RNA was performed as follows: 0.2ml of chloroform was added per 
1ml of TRIzol® reagent to each sample. Tubes were manually shaken for 15 sec, 
incubated for 2-3 min at RT and centrifuged at 12,000rcf for 15 min at 4ºC in 
order to separate the mixture into the three phases: a lower red phase that 
contained phenol-chloroform, intermediate phase containing DNA and proteins 
and an upper aqueous transparent phase containing RNA. The latter colourless 
phase was transferred to a new tube and the RNA was precipitated by mixing 
with 0.5ml of isopropanol and incubated for 10 min at RT. The precipitated RNA 
was then sedimented by centrifugation at 12,000rcf for 10 min at 4ºC. The RNA 
pellet was washed by adding 1ml of 75% (v/v) ethanol (RT) and vortexing. 
Finally, the RNA pellet was retained by centrifugation at 7,500rcf for 5 min at 
4ºC, careful removal of the supernatant and air drying. The RNA obtained from 
frozen tissue was then resuspended in 10-40µl of RNase-free H2O. The RNA 
extracted from isolated mammary gland epithelium was resuspended in 10µl of 
RNase-free H2O. All RNA extracted from TEBs was then combined and all RNA 
obtained from the ducts was combined.  Extracted RNA was quantified (See 
2.2.4.4) and quality assessed (See 2.2.4.5), snap frozen and stored at – 80°C 
until used for further applications.  
2.2.4.1.4 Extraction of RNA from cell lines 
 
RNA extraction from cell lines was performed using an RNeasy® Mini Kit as per 
manufacturer‟s instructions. Briefly, once grown close to confluency the cells 
were washed twice with dPBS (1x) and lysed using 0.6ml RLT Buffer. The 
obtained cell lysates were transferred in 1.5ml Eppendorf tubes, homogenised by 
pipetting, mixed with 1 volume of 70% of ethanol (aids RNA binding to the 
membrane) and transferred onto RNeasy spin column. Membrane bound RNA was 
washed and residual ethanol was removed. RNA was then eluted in 20-30µl of 
RNA-free H2O. Eluted RNA was quantified, subjected to DNase I digestion (See 
2.2.4.2), snap-frozen, and stored at – 80°C until used for further applications.    
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2.2.4.2 DNase I treatment 
All RNA to be used for cDNA production (RT-PCR) was subjected to DNase I 
treatment using a DNA-free™ Kit as per manufacturer‟s instructions to eliminate 
DNA contamination. Briefly, 0.1 volume of 10xDNase I Buffer and 1µl of DNase I 
(2U/µl) were incubated with the RNA for 20 min at 37°C. 0.1 volume of DNase 
Inactivation Reagent was then incubated with the reaction mix for 2 min at RT. 
The purified RNA was then retained by centrifugation at 9,300rcf for 1.5 min, 
snap frozen and stored at – 80°C until used for further applications.  
2.2.4.3 RNA purification, concentration and on column DNase I digestion  
All RNA extracted for use in microarray experiments was purified, DNase I on 
column digested and concentrated using an RNeasy® Micro Kit, as per 
manufacturer‟s instructions. The RNeasy® Micro Kit is used to purify small 
amounts of RNA and remove genomic contaminants as well as RNAs < 200 
nucleotides, including 5.8S rRNA, 5S RNA and tRNA. Briefly, RNA was bound to an 
RNeasy silica-based membrane using the appropriate binding conditions of a 
high-salt buffer supplemented with ethanol. Membrane bound RNA was then 
DNase I digested with RNase-Free DNase, washed on the column and eluted in 
13µl of RNA-free H2O. The eluted, purified and concentrated RNA was quantified 
(See 2.2.4.4) and its quality assessed (See 2.2.4.5) prior to snap freezing and 
storing at – 80°C until used for further applications.    
2.2.4.4 Quantification of the nucleic acid (RNA or DNA) 
Both concentration as well as purity of the extracted nucleic acid was estimated 
using a NanoDrop ND-1000 Spectrophotometer. Based on the absorbance at 
260/280 nm the concentration of 1l of extraction product was calculated using 
ND-1000 U3.3.0 software (NanoDrop Technologies, USA). RNase-free water was 
used as a blank control. The ratio of the readings at 260nm and 280nm was used 
to estimate the purity of nucleic acid.  
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2.2.4.5 Quality assessment of RNA 
The quality and integrity of RNA was assessed using an Agilent 2100 bioanalyser 
and Agilent RNA 6000 Nano Kit, as per manufacturer‟s instructions. The Agilent 
RNA kit consists of RNA chips containing a set of interconnected micro channels 
that are used to electrophoretically separate RNA fragments according to their 
size. The assessment of total RNA quality is based on the calculation of 28S rRNA 
to 18S rRNA ratio and the estimation of integrity of the total RNA sample, i.e. 
RNA integrity number (RIN). RIN is estimated taking into consideration the entire 
electrophoretic trace of the RNA sample.  
2.2.4.6 cDNA Synthesis - Reverse transcription polymerase chain reaction 
(RT-PCR) 
The process of RT-PCR is catalysed by reverse transcriptase and involves the 
synthesis of single stranded cDNA from RNA template. Obtained cDNAs can then 
be used in further applications that require the direct comparison of samples as 
the amounts of cDNA produced are linear.   
Briefly, 1µg/µl or 100ng/µl of isolated, DNase I treated RNA of interest was 
transferred to 0.5ml microcentrifuge tubes, mixed with 1µl of either oligo dT 
primers (0.5µg/µl) (used to produce full length cDNA to be send for sequencing) 
or random primers (used to produce fragments of cDNA to be used for 
Quantitative Real Time Polymerase Chain Reaction (Q RT PCR)) and 
supplemented with dH2O to a final volume of 13µl. To denature the RNA, the 
reaction mix was incubated at 65ºC for 5 min and chilled on ice. Each sample 
was then supplemented with 7.6µl of the reaction master mix, containing the 
following (final concentrations are shown): 1xReaction Buffer, 1mM dNTPs mix 
(10mM), 1U/µl of RNase OUT (40U/µl), 0.03% of DMSO and 0.5U/µl of 
Transcriptor Reverse Transcriptase (20U/µl). The resulting mix was incubated at 
25ºC for 10 min, followed by 50ºC for 30 min, to allow primer annealing, and 
85ºC for 5 min to inactivate Transcriptor Reverse Transcriptase. In each reaction 
run, a negative control that lacked reverse transcriptase (-RT) was prepared 
along with the samples of interest to measure the presence of any DNA 
contamination. 
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2.2.4.7 Standard PCR 
Primer Design 
Design of the primers was performed either using Primer3 software developed at 
the Whitehead Institute for Biomedical Research (http://frodo.wi.mit.edu/) 
(Rozen S., Skaletsky H. J., 2000) or manually using either Ensemble Genome 
Browser (http://www.ensembl.org/index.html) or the Gene database at the 
National Centre for Biotechnology Information (NCBI) (National Library of 
Medicine, Bethesda, USA) available at: http://www.ncbi.nlm.nih.gov/ to view 
the gene sequence and BLAST algorithm 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure that the designed primers 
were sequence specific. The characteristics of the designed primers, such as 
melting temperature (Tm), likely presence of secondary structure or probability 
to form primer-dimer complexes were examined either by Primer 3 software or 
using the DNA calculator application available from Sigma-Aldrich® 
(http://www.sigma-genosys.com/calc/DNACalc.asp). A list of primers used for 
PCR is shown in Table 2-5.   
PCR conditions 
All the reactions were prepared in a final volume of 50µl in 0.5ml PCR tubes. 
Each reaction contained the following: 2µl of cDNA template, 1xGreen GoTag® 
Flexi Buffer (5x), 1mM MgCl2 (25mM), 0.2mM dNTPs mix, 1µM of forward (10µM) 
and 1µM of reverse primers (10µM) (Table 2-5), 0.025U/µl GoTag® DNA 
Polymerase (5U/µl) and dH2O. For each PCR run, a control reaction that lacked 
template cDNA was prepared to ensure that no contamination was present. The 
cycling was performed using a Biometra T 3000 Thermocycler under the 
following conditions: initial denaturation at 95ºC for 2 min followed by multiple 
cycles of 95ºC for 15 sec (denaturation), 60ºC for 30 sec (annealing), 72ºC for 
1min/1kb of amplicon (extension) and a final step of extension at 72ºC for 10 
min. The number of cycles employed in each PCR varied from 28 to 30 depending 
on the abundance of transcript.  
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2.2.4.8 DNA Agarose Gel Electrophoresis 
PCR products were separated by size using agarose gel electrophoresis with 1% 
or 1.5% agarose gels and 0.5xTAE running buffer (Tris-acetate-EDTA, pH8.5). 
Agarose gels were prepared by diluting electrophoresis grade agarose in 0.5X 
TAE buffer and adding 1-2µl of intercalating dye ethidium bromide (10mg/ml) to 
the gel to facilitate visualisation of amplicons. 10-20µl of each PCR product was 
then mixed with 0.4 volumes of 5xGreen GoTag® Flexi Buffer and loaded into 
each well of the gel and electrophoresis was carried out at 90-110V. Gels were 
examined using Fujifilm Fla-5000 and FLA5000 Image Reader software v. 2.0 
(Fujifilm UK Ltd., Sheffield, UK). Images were manipulated using Advanced 
Image Data Analyser v. 4.13 (Aida) (Fujifilm UK Ltd., UK) or Adobe Photoshop 
CS2 (Adobe Photoshop Systems Inc., Mountain View, US). Either a 100bp or 1kb 
DNA ladder was used as a size marker. 
2.2.4.9 Q RT PCR 
Real time PCR is a quantitative method used to determine transcript expression 
levels using cDNA synthesised from the sample of interest as template for gene 
amplification via PCR. For the purposes of this project a hydrolysis probe-based 
system was chosen for the detection and quantification of amplicons. Each 
hydrolysis probe is sequence specific, with labelled probes, designed to anneal 
to template cDNA flanked by the two primer sites. Hydrolysis probes contain a 
fluorescent reporter dye at their 5‟ end and a quencher label at their 3‟ end. 
The 3‟ end of each probe is phosphorylated, hence it can not be extended during 
the PCR. When the probe is not annealed, fluorescence is suppressed by the 
close proximity of the quencher and is undetectable. During the annealing 
process of the PCR the probe hybridises to the template before the primers due 
to its lower Tm. FastStart Taq DNA Polymerase cleaves the probe due to its 5‟-3‟ 
exonuclease activity, while extending the primer, hence releasing the dye, 
whose fluorescent emission can then be measured. The fluorescent signal 
increases exponentially with each PCR cycle until the reagents are used up. 
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Transcript 
name 
Species Forward primer Reverse primer Amplicon 
size 
(bp) 
Tm 
(°C) 
Upk3a mouse tctgtgcatgtttgatagctca gaagcttgctggagaacacc 710 63,63 
Fbln2 V1 mouse cctgcaaagacaatggaccc tcgtccacgtctgtgcattc 394 66,67 
Fbln2 V2 mouse cctgcaaagacaatggaccc tcgtccacgtctgtgcattc 256 66,67 
Table 2-5 Primers used in Standard PCR. 
Tm stands for melting temperature. 
Transcript 
name 
Species Forward primer Reverse primer Probe 
sequence 
Amplicon 
position 
(bp) 
Fbln2 V1 M.m. tgttgttggggacacagcta ccatcaaacactcgtcttggt ctgcttcc 2202-2296 
Fbln2  M.m. tctgtccccagaggtgatct ctgcacaacaggtctcgattag ctccacca 1402-1462 
Fbln2 V1 H.s. caggtggcctctaacaccat ttgcagggtccattgtcttt tgccactg  2124-2193 
Fbln2 H.s. Agctgcaccacggagagt cctctgtgcccagtgaca tggtgatg 4732-4803 
Ect2 M.m. cgacatgtagccaacaccat tttgtatttacttcaaaggattct tgtggctg 2371-2456 
Upk3a M.m. Ttcctgctcgtgggtttc catttccccatcagaactgc tcctcagc 740-811 
Upk3a H.s. ccctgcccttctttctacttg atcagaactccccatgtcca cctcagcc 656-729 
Fbn2 M.m. gcctgtcctgtcagaggttc cacccatcggaagaccat ctgtgcct 1331-1394 
Emb M.m. tgggtaatgaaaccgcaca gtggcacgacaccagtagg ggagga 804-945 
Dlg7 M.m. gttgcgacattgttgtggat aaaccgactggcaaaacg ggatgctg 264-330 
Itih2 M.m. aagagcaaagggcaagacg tcacctctgtgttgaagttctcc aggagcag 553-626 
ß actin M.m. aaggccaaccgtgaaaagat gtggtacgaccagaggcatac tgctgtcc 416-525 
ß actin H.s. Attggcaatgagcggttc tgaaggtagtttcgtggatgc cttccagc 832-922 
Krt18 M.m. agatgacaccaacatcacaag cttccagaccttggacttcct agctggag 600-709 
Krt18 H.s. tgatgacaccaatatcacacga ggcttgtaggccttttacttcc agctggag 682-793 
Ltf M.m Gggcaagtgcggtttagtt ccattgcttttggaggattt tggcagag 1294-1353 
Sema3B M.m. Ttcttcttccgcgagtcc gccacccaggtcattcct ggaagcag 939-1034 
Sprr1A M.m cctgaagacctgatcaccaga aggcaatgggactcataagc ggctgctg 504-566 
Table 2-6 Probes and primers used in Q RT PCR. 
For species, M.m. stands for Mus musculus while H.s. stands for Homo sapiens. Amplicon position 
refers to the position of amplicon on mRNA with regards to the 5’ end of the genes which 
corresponds to transcription start site on DNA. 
Name of the 
primer 
Primer sequence Primer annealing 
site (bp) 
Tm 
(°C) 
Fbln2 V1 684 gtaacttctcggatgctgagg 684 64 
Fbln2 V1 1607 caaggagggtgagacctgtg 1607 65 
Fbln2 V1 2060 atagaggtgccccacaagttg 2060 64 
Fbln2 V1 3192 gcatacctgcacagacatcg 3192 64 
Fbln2 V1 3488 tcacggaatgtcaaacctca 3488 64 
T7 promoter  taatacgactcactataggg  51 
Upk3a gaagcttgctggagaacacc 714 63 
Table 2-7 Primers used in sequencing. 
For Fbln2 and Upk3a based primers the start of primer annealing site refers to the position on 
cDNA. Primer annealing site on T7 promoter refers to the position on the plasmid (pRc/CMV-
Fbln2). Tm stands for melting temperature. 
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Probe and primers design for Q RT PCR 
The selection of hydrolysis probes and the design of the primers were performed 
using ProbeFinder software (Roche Applied Science, Germany) (www.roche-
applied-science.com). ProbeFinder software uses transcript information 
deposited in NCBI Reference Sequence Database to find the optimal set of probe 
and primers for each transcript of interest. Primers were selected to be on 
either side of exon-exon splice junctions to eliminate false positive signals from 
DNA contamination. A list of the primers and probes used is shown in Table 2-6. 
All primer sequences were designed to have a melting temperature (Tm) of 60°C 
and flank probe hybridisation sites. All primers were purchased from Sigma 
Aldrich Company Ltd., Dorset, UK.     
Q RT PCR Conditions 
Q RT PCR for each sample was performed as follows: 1µl of template cDNA was 
added in triplicate to the wells of LightCycler® 480 96 Well Plates. A negative 
control that lacked reverse transcriptase (-RT) during cDNA preparation was 
included on each plate to measure the presence of any residual, contaminating 
DNA and estimate the level of background noise. Each well was then 
supplemented with the following reaction mix: 0.1µM of probe (2µM), 0.36µM of 
the forward (7.2µM) and 0.36µM of the reverse (7.2µM) primers (See Table 2-6), 
1xLightCycler® 480 Probes Master (2x) and H2O to a final reaction volume of 20µl. 
The stock 2xLightCycler® 480 Probes Master contained dNTPs (10mM), 6.4mM 
MgCl2 and FastStart Taq DNA Polymerase which is a thermostable polymerase 
only activated at high temperatures.  
The Prepared 96-well plate was then sealed using LightCycler® 480 Sealing Foil 
and centrifuged at RT at 850rcf for 2 min. The PCR was carried out using a 
LightCycler® 480 Instrument as follows: 1 cycle at 95°C for 10 min to activate the 
FastStart Taq DNA Polymerase, 40-50 cycles at 95°C for 15 sec followed by 60°C 
for 30 sec to perform primer and probe annealing and cDNA amplification and 1 
cycle at 40°C for 30 sec to cool down.  
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The cDNA of each sample was amplified using probes and primers designed to 
amplify the gene of interest and house keeping genes:  ß-actin or Krt18. The raw 
data for each sample was then analysed using LightCycler® 480 software v.1.5 
(Roche Applied Science, Germany), measuring the level of detected fluorescence 
over each PCR cycle and plotting an amplification curve for each sample. Every 
reaction profile consisted of three phases: lag phase (background phase), 
exponential log phase and plateau phase (Figure 2-3 A). The fluorescence values 
of the log phase only were retained for analysis.  
Relative Gene Expression Analysis 
The fluorescence signal was analysed as follows: PCR cycles from the beginning 
up to 5 cycles before the beginning of the log phase, showing irregular 
fluorescence were excluded (Figure 2-3 A); the noise band was set to eliminate 
background noise (Figure 2-3 B); 6 fit points were selected to calculate the 
fitted log-line of the exponential portion of each amplification curve and the 
threshold line was manually fitted in the middle of the calculated log-line and 
the crossing point (Cp) values (cycle number at which given sample crosses given 
fluorescence threshold) were calculated for each sample along with the standard 
deviation (SD) (Figure 2-3 C). 
Cp values obtained for individual samples amplified, using both primers of 
interest and house keeping primers, were used to calculate the relative 
concentration of transcripts. Calculations were performed with Microsoft Excel® 
using the 2-ΔΔCp method as follows: the difference in Cp (ΔCp) between the 
transcript of interest and a house keeping gene was calculated for each sample. 
The difference in ΔCp (ΔΔCp) between compared samples was then calculated 
and the relative gene expression (expression fold change) was calculated 
between the compared samples by setting ΔΔCp of the reference sample to 0 
and following 2-ΔΔCp equation. 
2.2.4.10 DNA Sequencing 
Sequencing of linear DNA or plasmid DNA was performed via the GATC Biotech 
sequencing service (http://www.gatc-biotech.com/en/home.html) using  
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Figure 2-3 Histograms showing comparison analysis of amplification curves of Q RT PCR 
product amplified from two distinct samples. 
Y axis shows level of detected fluorescence. X axis shows number of PCR cycles (A) Amplification 
curves showing lag, log and plateau phases. Setting of the cut off band for exclusion of signal 
generated during initial PCR cycles (B) Setting of the background noise band cut off (C) Selection 
of fit points and calculation of Cp values. Cp value for each sample corresponds to number of PCR 
cycles calculated at the crossing point of amplification curve with purple horizontal line. Figures 
were exported from LightCycler® 480 software v.1.5. 
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30ng/µl subjected DNA and 10pmol/µl of forward primer. Obtained 
chromatograms were visualised using Chromas Lite v.2.01 software 
(Technelysium Pty Ltd., Tewantin, Australia). A list of primers used in 
sequencing is shown in Table 2-7. 
2.2.4.11 Restriction Digestion   
Restriction digestion was performed using Sma I enzyme to identify the correct 
clones of pRc/CMV-Fbln2 DNA (See 2.2.2.3). 1µg/µl of plasmid DNA, 1xJ Buffer 
(10mM Tris-HCl, 7mM MgCl2, 50mM KCl, 1mM DTT, pH7.5), 0.1µg/µl of 
acetylated BSA (10µg/µl) and 0.25U/µl of Sma I enzyme (10U/µl) were mixed 
with dH2O to a final volume of 20µl. The reaction mix was then incubated at 
25°C for 4h. The differently sized restriction digestion products were resolved 
and visualised via electrophoresis, using 1% agarose gel (See 2.2.4.8).  
2.2.5 Microarray analysis of pubertal gene expression 
Gene expression profiling was performed on the isolated pubertal epithelium of 
TEBs and ducts, pubertal mammary gland tissue strips (Pre-LN, Post-LN and Fat 
pad) and whole adult mouse mammary glands (negative control for pubertal 
gene expression) collected from female mice. Biological material was then 
processed to extract good quality RNA. RNA was converted to single strand (ss) 
cDNA which was then hybridised to microarray chips. Obtained data was 
normalised, assessed in terms of its quality and analysed.      
2.2.5.1 Collection of the experimental material 
All experimental material was obtained from both left and right 4th mammary 
glands collected from pubertal or adult virgin WT or TG female mice. The 
excision of mammary glands from WT and TG mice was performed at the 
Biological Services Central Facilities at Gilmorehill Campus, Glasgow and at the 
Beatson Institute for Cancer Research in Glasgow respectively, following the 
methodology described before (See 2.2.1.2). 
WT females were used for isolation and collection of the mammary gland 
epithelial structures, i.e. TEBs and ducts (See 2.2.1.5) and whole mammary 
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glands (See 2.2.1.2). Epithelium was collected into 100µl of TRIzol® reagent and 
stored at –80C until subjected to RNA extraction. Whole mammary glands were 
subjected to central LN removal upon dissection, snap freezing in liquid nitrogen 
and storing at -80°C until RNA extraction. TG mice were used to collect the 
tissue strips (See 2.2.1.4) which were snap frozen in liquid nitrogen upon 
collection and stored at -80°C until RNA extraction. 
2.2.5.2 Extraction, purification, concentration, quantification and quality 
assessment of RNA 
RNA was extracted from isolated epithelium stored in TRIzol® reagent, mammary 
gland tissue strips and whole mammary glands stored at -80°C, as described 
previously (See 2.2.4.1.1-2.2.4.1.3). Extracted RNA was quantified using the 
NanoDrop ND-1000 Spectrophotometer (See 2.2.4.4), purified, subjected to on-
column DNase I treatment, combined and concentrated using an RNeasy® Mikro 
Kit (See 2.2.4.3). The RNA was then re-quantified as described above and its 
quality assessed using the Agilent 2100 bioanalyser (See 2.2.4.5).     
2.2.5.3 Microarray data generation workflow 
Samples of extracted and purified RNA were used as a matrix to generate single 
strand, sense, biotin labelled cDNAs that were hybridised to GeneChip® Mouse 
Exon 1.0 ST Arrays, following GeneChip® Whole Transcript (WTr) Sense 1µg Total 
RNA Target Labelling Assay Manual (Affymetrix UK Ltd., High Wycombe, UK) 
(Figure 2-4) and using appropriate Affymetrix kits. All of the experimental 
procedures described in sections 2.2.5.3.1-2.2.5.3.8 were performed at the 
Henry Wellcome Functional Genomics Facility by Mrs. Wang.     
Briefly, 1.5µg of each total RNA resuspended in a maximum volume of 3.2µl of 
RNase-free H2O was mixed with 2µl of supplied, freshly diluted Poly-A RNA 
controls (4 different transcripts) mix.  
2.2.5.3.1 Reduction of ribosomal RNA (rRNA) 
 
Total RNA/Poly-A RNA controls mix was then subjected to reduction of 28S and 
18S ribosomal RNA (rRNA) populations using a RiboMinus Human/Mouse  
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Figure 2-4 GeneChip
® 
WTr Sense 1µg Total RNA Target Labelling Assay Manual – Schematic 
representation of the experimental steps.   
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Transcriptome Isolation Kit which facilitates hybridisation of four biotinylated 
LNA RiboMinus probes (100pmol/µL) to abundant 18S and 28S rRNA species in the 
total RNA of interest, in the presence of betaine to increase hybridisation 
stringency. Probe bound rRNAs were then removed from the hybridisation mix 
using streptavidin coated RiboMinus Magnetic Beads and supernatant containing 
rRNA-Reduced Total RNA/Poly-A RNA Controls Mix was concentrated using 
GeneChip® IVT cRNA Cleanup Kit. The quality of recovered RNA was analysed 
with the Agilent 2100 bioanalyser (See 2.2.4.5). 
2.2.5.3.2 Synthesis of double stranded cDNA (ds cDNA) 
 
rRNA-reduced total RNA/Poly-A RNA Controls Mix was then used as a template 
for the synthesis of the ds cDNA using GeneChip® WTr cDNA Synthesis Kit. First-
strand cDNA synthesis was performed using random primers tagged with 
T7promoter sequence (500ng/µl), SuperScript II reverse transcriptase, dNTPs 
(10mM), DTT (0.1M) and 5x1st Strand Buffer. Second-strand cDNA synthesis was 
carried out using MgCl2 (17.5mM), dNTPs (10mM) and DNA Polymerase I to 
facilitate the synthesis and RNase H to degrade the mRNA hybridised to the first-
strand DNA.  
2.2.5.3.3 Synthesis of cRNA 
 
Obtained ds cDNA was subsequently used as a template for antisense cRNA 
production. cRNA synthesis was facilitated by T7 RNA Polymerase using a 
GeneChip® WTr cDNA Amplification Kit. cRNA was then purified by means of a 
GeneChip® Sample Cleanup Module and quantified using a NanoDrop ND-1000 
Spectrophotometer (See 2.2.4.4). 
2.2.5.3.4 Synthesis of ss cDNA 
 
Purified cRNA was reverse transcribed by means of a GeneChip® WTr cDNA 
Synthesis Kit using random primers (3µg/µl), SuperScript II reverse transcriptase, 
DTT (0.1M), dNTP+dUTP (10mM) and 5x1st Strand Buffer. ss cDNA containing 
incorporated dUTP was then hydrolyzed from cRNA-cDNA hetero-duplexes by 
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means of RNase H, purified using the GeneChip® WTr cDNA Synthesis Kit and the 
GeneChip® Sample Cleanup Module as per manufacturer‟s instructions and 
quantified using a NanoDrop ND-1000 Spectrophotometer (See 2.2.4.4). 
2.2.5.3.5 Fragmentation and terminal labelling of ss cDNA 
 
The ss cDNA was then subjected to fragmentation and labelling using a 
GeneChip® WT Terminal Labelling Kit. Fragmentation was facilitated by the 
combination of uracil DNA glycosidase (UDG) (10U/µl) and apurinic/apyrimidinic 
endonuclease 1 (APE 1) (1000U/µl) which recognise exogenous dUTP residues. 
The efficiency of fragmentation, i.e. the size range of obtained ss cDNA 
fragments, was profiled using an Agilent 2100 bioanalyser (See 2.2.4.5). 
The labelling of DNA was performed by terminal deoxynucleotidyl transferase 
using an Affymetrix® DNA labelling reagent covalently linked to biotin.   
2.2.5.3.6 Hybridisation of ss cDNA to microarray chips  
 
Fragmented and biotin labelled ss cDNA was hybridised to GeneChip® Mouse Exon 
1.0 ST chips using a GeneChip® Hybridisation, Wash and Stain Kit. Internal 
hybridisation quality controls such as bioB, bioC, bioD, cre and oligonucleotide 
B2 were hybridised to the chips alongside the target cDNA in the presence of 7% 
DMSO and 2xHybridisation Mix. Biotinylated oligonucleotide B2 hybridises to 
features around the edge, inside and in the corners of the chip and the signal 
that it emits is used to align the grid of the array (See 2.2.5.3.8). BioB, bioC, 
bioD and cre are probe sets for prokaryotic genes. Pre-prepared at varied 
concentrations, ss cDNAs of BioB, bioC, bioD and cre serve as internal 
hybridisation controls (See 2.2.5.8). Array hybridisation was performed by 16h 
long incubation in 45°C in a hybridisation oven with agitation at 60rpm. 
2.2.5.3.7 Washing, staining and scanning of the arrays 
 
Hybridised arrays were washed, stained and scanned using a GeneChip® 
Hybridisation, Wash and Stain Kit. Staining of the arrays was performed by using 
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Streptavidin Phycoerythrin (SAPE) that binds to biotin on hybridised cDNA. SAPE 
signal was amplified by using anti-streptavidin biotinylated antibody and anti-
biotin SAPE conjugated antibody. The amplified signal intensity emitted by SAPE 
was detected and measured during scanning of the arrays. All above procedures 
were performed with a GeneChip® Fluidics Station 450/250 and GeneChip® 
Scanner 3000 7G, operated by GeneChip® Operating Software (GCOS) (Affymetrix 
UK Ltd., UK). All samples were washed, stained and scanned together to reduce 
technical variability.     
2.2.5.3.8 Signal detection and calculation of the cell intensity data 
(.CEL file)  
 
Signal intensity emitted by SAPE bound to each probe was detected by the 
scanner and imaged using GCOS which displays a picture of each scanned array 
(.DAT file) and superimposes the grid on the image. The main grid and sub-grids 
are generated using an Alignment Algorithm which uses check board images of 
oligonucleotide B2 positive hybridisation controls located at the corners of the 
array to superimpose the grid on the scanned image and align it so that each 
square in the grid delineates a probe cell.   
A Cell Intensity Algorithm was then used to compute a single intensity value for 
each probe cell using fluorescence intensity values from each pixel on the array 
to calculate the cell intensity data (.CEL file).   
2.2.5.4 Background correction, normalisation and probe set summarisation 
The .CEL file was further analysed using a Robust Multichip Analysis (RMA) 
algorithm, a multi-chip approach that consists of three steps: background 
correction, normalisation and data summarisation.  
The RMA algorithm was computated using either Expression Console™ software 
v.1.0 (Affymetrix UK Ltd., UK), Partek® Genomics™ Suite (Partek Incorporated, 
St Louis, US) or XRAY Excel® Array Analysis v.2.5 (Biotique Systems Inc. Reno, 
USA). All analyses were performed at the core level, i.e. only taking into 
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consideration probe sets mapped to BLAST alignments of mRNA with annotated 
full length gene coding sequences.  
Background correction of intensities of perfect match (PM) probes was used to 
remove systematic effects that could not be explained by biological variation 
within each individual chip. It uses only information contained on the given chip 
and it is based on the model O = S+N, where O stands for overall intensity; S 
stands for signal and is assumed to be exponentially distributed (α); N means 
background noise which is assumed to be normally distributed (µ σ2) [267] 
Normalisation was used to remove the non-biological variation throughout all 
microarray chips used for the experiment. In this experiment non parametric 
quantile normalisation was used, which is based on the assumption that there is 
a common pattern of distribution of intensities across the microarray chips 
[268]. For each input array, for each probe expression value the „ith‟ percentile 
probe expression value is replaced by the average of all „ith‟ percentile points 
across all of the arrays. When all the probe scores are sorted, a master 
distribution of intensity is created and the distribution of intensity for each 
probe is mathematically fitted to the master distribution of intensity.   
Summarisation of the probe intensity levels across each microarray chip obtained 
summarised expression values (.CHP files) for each transcript ID or exon cluster 
ID. This was performed using Median Polish which takes into consideration probe 
and chip effects, predicting transcript ID or exon cluster ID expression and 
combining the information across the chips. Median Polish is an algorithm that 
takes log2 of the probes‟ signal intensity and fits a robust linear model. 
In summary, the process of computing the expression data using RMA provides 
final signal intensity data which can be interpreted as                                           
           E = S(N(B(X)))  
Where E is the final intensity data of either the transcript ID or exon cluster ID, S 
is Median Polish summarization, N is quantile normalisation, B is the RMA 
background correction process and X is the raw intensity of probes across the 
whole array. 
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2.2.5.5 Gene expression analysis at the gene level - The identification of ‘up- 
regulated gene sets’ 
This section and the following section 2.2.5.6 should be read in conjunction 
with Figure 3-1 (p.151). 
Gene expression analysis at the gene level was performed using transcript IDs. 
The „up-regulated gene sets‟ - list of genes are up-regulated above the set level 
in one environment when compared to the other environment. „Up-regulated 
gene sets‟ were identified for the epithelial transcriptomes of TEBs and ducts 
(See 2.2.5.5.1), epithelial-stromal transcriptomes of TEBs and ducts (See 
2.2.5.5.2) and the epithelium-free Fat pad (See 2.2.5.5.3). 
2.2.5.5.1 TEB and duct epithelium ‘up-regulated gene sets’ 
 
Transcripts whose expression was higher in the epithelium of TEBs than in ducts 
or higher in ducts than in TEBs were identified using signal intensity data 
obtained from isolated epithelium of TEBs and ducts. Differentially expressed 
transcripts were identified using a 5% Limit Fold Change (5% LFC) Model [269] 
and the transcript ID expression data obtained using the RMA algorithm 
(Expression Console™ software v.1.0). 
The 5% LFC Model was calculated as follows: First, signal intensity data for all 
transcripts obtained from duplicate TEB samples (T1 and T2) and duplicate duct 
samples (D1 and D2) were evaluated to exclude transcripts characterised by too 
low an expression intensity (background expression), i.e. average difference 
intensity (ADI). As recommended, to reduce background noise the ADI threshold 
was set to 20 and transcript IDs with ADIs equal to or lower than 20 were set to 
20 across all experiments (T1, T2, D1, D2) and therefore eliminated [269]. ADIs 
of each transcript were then compared between the replicates of individual 
samples (T1 vs T2 and T2 vs T1) and (D1 vs D2 and D2 vs D1) to exclude 
transcripts of expression level variation between replicates greater or equal to 
2. ADIs of the remaining transcripts were then used to calculate the mean ADI 
for TEBs and mean ADI for ducts. The mean ADI for each transcript over-
expressed in either TEBs or ducts was computed using the expression data of T1 
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and T2 or D1 and D2 respectively. Non-annotated internal Affymetrix controls, as 
enlisted by Affymetrix UK Ltd were subtracted from the 2 transcript IDs lists. 
The mean ADI values for the TEB and duct associated transcripts were then 
utilised to calculate the highest fold change (HFC), i.e. a maximum change in 
gene expression between the compared samples. The HFC for the TEB associated 
transcripts was obtained by calculating the ratio of the mean ADI in TEBs to 
mean ADI in ducts for each transcript. The HFC for each ducts-associated 
transcript was obtained by calculating the ratio of the mean duct ADI to mean 
TEB ADI for the given transcript. The remaining transcripts in each data set (TEB 
or duct) were then sorted according to their mean ADI, divided into 200 gene 
rich bins and sorted within each bin, descending according to HFC. The top 5% of 
transcripts within each bin were considered as significantly over-expressed. 
Finally gene rank was assigned to each transcript. Gene rank was calculated by 
multiplying HFC by ADI therefore incorporating both the magnitude of fold 
change (FC) and expression value. 
All of the above calculations were performed using Microsoft Excel. Transcript 
IDs were annotated using the NetAffx Analysis Centre tool developed by 
Affymetrix.  
2.2.5.5.2 TEB and duct epithelial-stromal ‘up-regulated gene sets’ 
 
To compare transcripts of epithelial genes within a stromal environment rather 
than in isolation, mammary gland tissue strips were analysed using transcript ID 
signal intensity data. Expression levels of each transcript were compared 
between Pre-LN and Post-LN of mammary gland tissue strips and transcripts 
whose expression was differentially expressed between TEBs and duct 
environments were identified. The RMA algorithm, statistical analysis and 
identification of significantly differentially expressed transcripts were performed 
using Partek® Genomics™ Suite. Bioinformatic analysis of the data sets was 
performed at the core level, using 2-Way Alternative Splice Paired ANOVA. 
Transcripts of at least 1.5 fold change in expression and with p-value<0.05 were 
considered as significantly differentially expressed.    
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2.2.5.5.3 Epithelium-free Fat pad ‘up-regulated gene set’ 
 
To identify genes differentially expressed in the epithelium-free Fat pad of the 
pubertal mouse mammary gland the expression levels (signal intensity data) of 
each transcript ID were compared between the Fat pad and Post-LN tissue strips 
data sets. Gene expression analysis was performed using Partek® Genomics™ 
Suite as described above (2.2.5.5.4). Transcripts of at least 1.5 fold change in 
expression and with p-value<0.05 were considered as significantly differentially 
expressed.     
2.2.5.6 Gene expression analysis on the gene level – The identification of 
‘expressed gene sets’  
The „expressed gene sets‟ are defined as lists of genes expressed ≥ 1.1 fold 
change cut off in one environment when compared to the other environment 
2.2.5.6.1 TEB- and duct-only epithelium ‘expressed gene sets’ 
 
Genes expressed in the epithelium of TEB and ducts were identified using signal 
intensity data obtained from the microarrays performed on the epithelium of 
isolated TEBs and ducts. Signal intensity data was obtained using RMA performed 
by Expression Console™ software v 1.0. All transcript IDs corresponding to non-
annotated internal Affymetrix controls were excluded from the data sets as 
described above. ADIs lower than 20 were set to 20. The signal intensity levels of 
each transcript ID were compared in multiple ways between replicates in the 
TEB and duct data sets (T1 vs D1) (T1 vs D2) (T2 vs D1) and (T2 vs D2) to 
calculate the minimum change in gene expression between the compared data 
sets, i.e. MFC. All transcript IDs with a FC equal to 1 across all four comparisons 
were excluded from the analysis. The remaining transcript IDs were divided into 
genes expressed only in either TEBs or ducts. All transcripts with a MFC increase 
of 1.1 in the TEBs compared to ducts were considered to be only expressed in 
TEBs, while the ones with a MFC decrease in expression of 1.1 were considered 
as only expressed in the ducts.  
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All of the above calculations were performed using Microsoft Excel. Transcripts 
IDs were annotated using the NetAffx Analysis Centre tool developed by 
Affymetrix.  
2.2.5.6.2 TEB- and duct-only stroma ‘expressed gene sets’ 
 
Transcripts expressed in the stroma surrounding TEBs and the stroma around 
ducts were identified using signal intensity data obtained from the mammary 
gland tissue strips and isolated epithelium. For the purpose of this analysis RMA 
was performed using Expression Console™ software v 1.0 and the obtained signal 
intensity data sets were used to identify TEB-only stroma- or duct-only stroma-
associated transcripts.  
Transcript ID expression levels obtained from the Post-LN, isolated epithelium of 
TEBs and ducts data sets were compared and used to identify stromal genes 
around TEBs and ducts in the Post-LN strip. Stroma expressed transcripts were 
identified by subtracting all transcript IDs whose expression was associated with 
epithelium of TEBs or ducts from the list of Post-LN transcript IDs, as follows. 
Transcript IDs corresponding to non-annotated internal Affymetrix controls were 
excluded from the data sets, as described above. ADIs lower than 20 were set to 
20 and any transcripts with an ADI value of 20 across all replicate data sets 
within each experimental condition (Post-LN 1, Post-LN 2, Post-LN 3) (T1, T2) 
(D1, D2) were eliminated to reduce background noise. Expression levels of each 
transcript ID were compared in multiple ways between replicates for Post-LN 
and TEB data sets (Post-LN 1 vs T1, Post-LN 2 vs T1, Post-LN 3 vs T1, Post-LN 1 vs 
T2, Post-LN 2 vs T2, Post-LN 3 vs T2) and Post-LN and duct data sets (Post-LN 1 
vs D1, Post-LN 2 vs D1, Post-LN 3 vs D1, Post-LN 1 vs D2, Post-LN 2 vs D2, Post-LN 
3 vs D2) to calculate the minimum change in gene expression between compared 
data sets, i.e. MFC. Expression ratios of each transcript ID between Post-LN and 
TEB data sets and Post-LN and duct data sets were examined and used to 
exclude the transcript IDs expressed in epithelium from the Post-LN data set. All 
transcripts with a minimum of 1.1 FC increase in the Post-LN data set in 
comparison to their expression in TEBs or ducts were considered as stromal. The 
epithelial expression marker, cytokeratin 14 (CK14) expression level was used to 
identify the FC cut off between epithelial and stromal genes. CK14 expression 
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was 2.6 and 2.7 times lower in the Post-LN data set than in TEB and duct data 
sets respectively and thus a FC cut off of 1.1 ought to minimise the number of 
the epithelial genes falsely identified as stromal. 
Transcript ID expression levels obtained from the Pre-LN, isolated duct 
epithelium and TEB epithelium data sets were compared and used to identify the 
stromal genes expressed around ducts and occasional TEBs in the Pre-LN strips. 
Stroma expressed transcript IDs were identified by subtracting all transcript IDs 
whose expression was shown to be associated with the epithelium of ducts or 
TEBs from the list of Pre-LN transcript IDs, as described above.  
Finally the lists of transcript IDs expressed in the Post-LN strip stroma and Pre-
LN strip stroma were compared using GeneVenn List Diagram (University of 
Southern Mississippi, http://mcbc.usm.edu/genevenn/genevenn.htm) to exclude 
the common transcript IDs and identify those associated with only the stroma 
around either TEBs in Post-LN tissue strips or ducts in Pre-LN tissue strips.  
All of the above calculations were performed using Microsoft Excel. Transcript 
IDs were annotated using the NetAffx Analysis Centre tool developed by 
Affymetrix.  
 
2.2.5.7 Expression Analysis at the exon level 
Gene expression analysis at the exon level was performed for isolated TEBs and 
ducts using exon cluster ID signal intensity data. Gene expression analysis at the 
exon level was performed to analyse alternative splicing and differential 
expression of each exon within a gene throughout the data sets. 
After converting probe cell signal intensity data into exon cluster ID signal 
intensity data using the RMA algorithm, expression analysis was performed by 
comparing Pre-LN, Post-LN and mammary fat pad tissue strip data sets with 
isolated TEB and isolated duct data sets, to identify transcript IDs which had 
alternative splice variants differentially expressed in TEB and duct 
environments. The RMA algorithm, statistical analysis and identification of 
significantly differentially expressed transcripts and alternatively expressed 
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splice variants were performed using XRAY Excel® Array Analysis v.2.5 Microsoft® 
Excel® add-in. Bioinformatic analysis of the data sets was performed at the core 
level, using a Nested Mix Model ANOVA and the Benjamini and Hochberg False 
Discovery Rate (FDR) Multiple Test Correction. Probe sets not significantly 
expressed above background, i.e. of a p-value≥0.05 derived using the Fisher Test 
were excluded from the analysis. Whole transcripts and splice variants of at 
least 2 fold change in expression and p-value<0.05 were considered to be 
significantly differentially expressed.    
2.2.5.8 Microarray data quality assessment 
Quality and reliability of the data generated during microarray analysis was 
assessed using six different quality assessment metrics: 
 Visual assessment of microarray chips. 
 Quality of hybridisation was estimated by investigating the probe set 
signal intensity values for prokaryotic internal hybridisation controls 
(bioB, bioC, bioD, cre) throughout the arrays. The signal intensities were 
graphed using Expression Console™ software v 1.0.  
 The degree of similarity between the replicates of each biological sample 
and the variation between different biological samples was investigated 
and graphed using PCA (Principal Component Analysis). PCA is a method 
designed to capture the variation in the datasets by reducing the 
dimensionality of the data to capture the most important features. PCA 
analysis was performed using Partek® Genomics™ Suite.  
 Reliability of the generated gene lists was verified by screening these 
lists for the presence of previously published genes known to be 
associated with epithelium of TEBs, epithelium of ducts, stroma of TEBs 
and stroma of ducts.  
 The accuracy of the generated data was assessed by comparing lists of 
genes found to be over-expressed in TEB epithelium, duct epithelium and 
Post-LN tissue strip to ensure that epithelial genes expressed in isolated 
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TEB and duct were also present in Post-LN strip but no ductal genes were 
present in TEB and vice versa. The comparison was computated using 
GeneVenn List Diagram (University of Southern Mississippi, 
http://mcbc.usm.edu/genevenn/genevenn.htm). 
 Finally, the observed over-expression of chosen genes in given 
compartments was verified using Q RT PCR.  
2.2.5.9 ‘Functional’ analysis of identified genes  
Further analysis of identified gene lists was performed to gather more 
information about the biological functions and characteristics of the data sets of 
interest as well as individually selected genes. 
2.2.5.9.1 Ingenuity Pathway Analysis (IPA) 
 
The groups of genes whose expression was characteristic of either epithelial or 
stromal environment of TEBs or ducts were analysed to identify the over-
represented molecular, cellular functions and processes. The analysis was 
performed using IPA v 8.0 (Ingenuity Systems Inc., Redwood, US). IPA uses its 
own data repository, Ingenuity Knowledge Base (IKB), to assess biological 
functions that are most significantly represented in the analysed data. Data sets 
are screened for the presence of mapped (identified within IKB), 
function/pathway eligible molecules, i.e. genes that have at least one functional 
annotation in IKB and the over-represented functions are identified and ranked 
according to the p-values. P-values are calculated with a right-tailed Fisher‟s 
Exact Test and Benjamini-Hochberg False Discovery Rate multiple testing 
correction. This takes into account the following parameters: the number of 
function eligible genes that are known in IKB to comply with a particular 
functional category, the total number of molecules in the IKB with potential to 
be associated with the functional category of interest, the total number of 
molecules in IKB database and the total number of function eligible molecules in 
IKB data set.  
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2.2.5.9.2 EMT signature 
 
Gene sets shown to be differentially expressed in the TEB environment were 
further screened for the presence of EMT signature genes. The EMT signature, 
used in this study, consists of the EMT core signature genes identified by Taube 
et al. (2010) (87 and 159 genes up- and down-regulated respectively in breast 
cancer cells when manipulated to undergo EMT) [270] and 10 other mesenchymal 
markers which were absent from this signature but previously shown by other 
research groups as associated with EMT (9 genes up- and 1 down-regulated in 
response to EMT). The EMT signature genes are listed in Table 2-8. 
2.2.5.9.3 Literature Search 
 
Genes were also studied on an individual basis using a literature search approach 
to identify those not previously associated with mammary gland biology but 
exhibiting related biological functions. The main search engines used to gather 
information comprised of: PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and 
AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) 
applications developed by NCBI, GeneCards® 
(http://www.genecards.org/index.shtml) (Crown Human Genomics Centre, 
Bioinformatics Unit of the Weizmann Institute of Science in Rehovot, Israel) and 
Google Scholar (http://scholar.google.co.uk/). 
2.2.5.9.4 Oestrogen responsive genes  
 
Oestrogen responsive genes were identified using the Estrogen Responsive Gene 
Database v.2 (ERGDB), an integrated knowledge database which includes genes 
whose expression levels have experimentally been proven to be either up-
regulated or down-regulated by E2 [271]. 
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 EMT Signature Genes Ref 
Up-
regulated 
in response 
to EMT 
Fbln5, Grem1, Col3a1, Col1a2, Dcn, Cdh2, Enpp2, Postn, Rgs4, 
C5orf13, Prrx1, Fbn1, Srgn, Spock1, Prr16, Dlc1, Bin1, Rgl1, 
Igfbp4, Pvrl3, Cdh11, Olfml3, Mmp2, Myl9, Col5a2, Ctgf, Plekhc1, 
Zeb1, Ror1, Ptger2, Chn1, Pmp22, Tram2, Tagln, Tnfaip6, 
Creb3l1, Ugdh, Has2, Dnajb4, Cdkn2c, Ccdc92, Wnt5a, Igfbp3, 
Ppm1d, Filip1l, Pdgfc, Tbx3, Xylt1, Fap, Dpt, Stc1, Krt81, Mmp1, 
Hs3st2, Lmcd1, N-Pac, Sept6, Nr2f1, Sccpdh, Mlph, Ltbp2, Tpm1, 
Ankrd25, Ddr2, Sema5a, Tgfb1i1, Pcolce, Stard13, Nid1, Sync1, 
Enox1, Fstl1, Vim, Mme, C10orf56, Ltbp1, Nrp1, Thy1, Nebl, Tns3, 
Ecm1, Fbln1, Tuba1a, Copz2, Cybrd1, Ppap2b, Ptx3, Fads2, Bgn, 
Tshz1, Zbtb38 
[270] 
Twist [272] 
Snail3 [273] 
Slug [274] 
ZEB2 [275] 
Gsc [276] 
FOXC1 [277] 
TCF3, Ctnnb1 [278] 
FOXC2 [279] 
Down-
regulated 
in response 
to EMT 
C20orf19, Snx10, Tp73l, Kcnk1, Bdkrb2, Anxa8, Anxa8l1, 
Loc728113, Rhbdf2, Loc653562, Slc6a10p, Slc6a8, Krt18, Cds1, 
Thbd, Nefm, Rps6ka1, Smpdl3b, Abca12, Rhod, Krt14, Prkch, 
Zbed2, C10orf10, Lrrc1, Stap2, Jup, Il4r, Perp, Fgfbp1, Myo1d, 
Fat2, Wwc1, Fzd3, Znf165, Snca, Kiaa1815, Prss8, Sh2d3a, Gnal, 
Bik, Cdh3, Kiaa0888, Krt5, Gjb3, Kiaa0040, Celsr2, F11r, Nup62cl, 
Serpinb1, Spint2, Polr3g, Elmo3, Il1rn, Tspan1, Ifi30, Pls1, 
Loc729884, Tmprss11e, C1orf116, Alox15b, Col17a1, Rtel1, 
Tnfrsf6b, Lad1, Ptpn3, Mst1r, Epha1, E2f5, Krt6b, Stac, Itgb4, 
C6orf105, Gls2, Anxa3, Dst, Arhgap25, Dsc2, Slc6a8, Lsr, Cldn1, 
Flj20366, Cyp4f11, Ccnd2, Fgfr2, Ablim1, Xdh, Camk2b, Dsg3, 
Naip, Ocln, Krt17, Saa1, Saa2, Prrg4, Ank3, C10orf116, Tmprss4, 
Cst6, Ndrg1, S100a8, Coro1a, Klk5, Exph5, Irx4, Irf6, Hook1, Artn, 
Flj12684, Slc2a9, Klk8, Tmem40, Trim29, Hbegf, Aldh1a3, 
Rbm35b, Myo5c, Cyp27b1, Il1b, Nmu, Krt16, Cdh1, Jag2, Vsnl1, 
Rln2, Ctsl2, Syk, Saa1, Epb41l4b, Rnf128, St14, Leprel1, Pi3, 
Ap1m2, Ckmt1a, Ckmt1b, Grhl2, Arhgap8, Loc553158, Igfbp2, Il18, 
Ca9, S100a14, Ca2, Krt15, Eva1, Tmem30b, S100a7, Klk7, Lgals7, 
Fst, Cxadr, Slpi, Rbm35a, Rab25, Uchl1, Klk10, Tacstd1, Serpinb2, 
Sprr1a, Fgfr3, Sprr1b 
[270] 
E-cad [280] 
Table 2-8 EMT signature genes. 
The EMT signature consists of the EMT core signature genes identified by Taube et al. (2010) (87 
and 159 genes up- and down-regulated respectively in breast cancer cells when manipulated to 
undergo EMT) [270] and 10 other mesenchymal markers which were absent from this signature but 
previously shown by other research groups as associated with EMT (9 genes up- and 1 down-
regulated in response to EMT). 
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2.2.6 Tissue processing and staining 
2.2.6.1 Preparation of mouse mammary gland wholemounts stained with 
carmine 
Immediately after dissecting from WT or Fbln2 KO-/- mice, the fourth inguinal 
mammary glands were placed individually on a Twin Frost Microscope Slide. The 
tissue was spread out using metal BD Microlance™ 3 needles, the slide was 
placed into a Coplin Jar containing Carnoy‟s fixative (See Solutions and Buffers) 
and fixed for 3h on an orbital shaker at RT. The gland was then hydrated through 
decreasing concentrations of ethanol [40 min in 70% (v/v), 50% (v/v), 30% (v/v) 
ethanol], followed by distilled water, and stained overnight with Carmine dye 
(See Solutions and Buffers). The gland was then de-hydrated by serially placing 
the tissue for 40 min in dH2O and increasing concentrations of ethanol [30% 
(v/v), 50% (v/v), 70% (v/v) and 100% (v/v)] to remove excess H2O. The 
wholemount was finally placed in xylene for at least 12h to remove all traces of 
alcohol. The tissue was mounted using Pertex mounting medium, cover slipped 
and stored.   
2.2.6.2 Tissue fixation, paraffin wax embedding and sectioning 
Excised glands were fixed in 10% Neutral Buffered Formalin for 4-24h prior to 
being transferred into a plastic cassette, processed and paraffin wax embedded 
using a Leica ASP300 tissue processor as follows: tissue was de-hydrated through 
a graded concentration of ethanol (50 min in 50% (v/v), 50 min in 80% (v/v) 
ethanol and 1h in 100% ethanol (v/v)) and placed in xylene for 2h at 37°C, under 
vacuum conditions, transferred into paraffin wax for 4h and stored at -60°C 
overnight.  
Paraffin wax embedded tissue was then placed at the bottom of chilled metal 
grids and additional wax was used to embed it into paraffin wax blocks using a 
Leica EG1150H heated paraffin dispensing module. Paraffin tissue blocks were 
left to solidify for 30 min on Leica EG1150C cold plate, chilled to -5°C and 
stored at RT until required.  
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Sectioning of paraffin wax blocks was performed using a Leitz 1512 microtome. 
3-4µm sections were routinely cut but 10µm were used for 3D structure 
reconstruction experiments 
Paraffin sections were cut and placed on the surface of a 40°C water bath, a 
metal blade was used to separate them and Superfrost® Plus electrostatically 
charged slides were used to pick the sections up from the water bath. Slides 
with paraffin embedded tissue sections were left to dry for 1h at 62°C.    
2.2.6.3 Preparation of paraffin embedded tissue sections for IHC and IF 
Paraffin embedded tissue sections were deparaffinized, rehydrated and 
subjected to antigen retrieval prior to being used in IHC or IF staining.  
Slides were deparaffinized by submerging in xylene 3 times for 5 min, and 
rehydrated in decreasing concentrations of ethanol (100% (v/v) twice for 3 min, 
70% (v/v) for 3 min) and running tap water for at least 2 min. Tissue sections 
were then pre-treated with 3% (v/v) hydrogen peroxide for 10 min to quench 
endogenous peroxidases, rinsed in running tap water and subjected to antigen 
retrieval to unmask epitopes that can be masked during the fixation process due 
to the cross linkage by formalin. Antigen retrieval was performed using 1mM 
EDTA buffer (pH8) (See Solutions and Buffers) as follows: 1L of 1mM EDTA 
buffer (pH8) was brought to boiling in a microwave pressure cooker, slides were 
added to the boiling EDTA buffer and heated in the microwave at full pressure 
for a further 7 min, of which 4 min were precisely timed for slides to be held at 
the retrieval pressure. Slides were placed in running tap water for 10 min to cool 
down prior to being used for IHC or IF staining.            
2.2.6.4 IHC on paraffin embedded tissue sections 
All incubations were performed at RT using a humidity chamber as follows: after 
antigen retrieval, slides were incubated in TBS-Tween 20 pH7.6 (See Solutions 
and Buffers) for 5 min. Excess wash buffer was drained off and tissue sections 
were blocked with pre-diluted 2.5% Horse Serum for 20 min to prevent non-
specific binding. Tissue sections were then incubated with the primary antibody 
of interest (Table 2-9) for 30 min and rinsed again with TBS-Tween 20 three 
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times for 5 min. Primary antibodies were diluted to their final concentrations 
(Table 2-9) using Antibody Diluent. Washed tissue sections were then incubated 
for 30 min with the appropriate secondary antibody diluted 1:500 in Antibody 
Diluent, washed using TBS-Tween 20 three times for 5 min and incubated in 
diluted (1 drop in 1ml of Antibody Diluent) DAB + Chromogen for 4 min. 
Secondary antibodies were conjugated with HRP that catalyzes oxidation of DAB. 
The oxidation product can be seen in the form of a brown stain. Stained tissue 
sections were then washed under running tap water for at least 5 min, 
counterstained with haematoxylin (See 2.2.6.6), de-hydrated through increasing 
concentrations of ethanol (1 min in 30 % (v/v), 50 % (v/v), 70 % (v/v) ethanol), 
dipped in xylene for 40 sec and mounted using Pertex mounting medium and 
cover slips. Stained tissue sections were visualised and imaged (See 2.2.8.3) and 
stored at RT.  
Negative control (lacking primary antibody) and positive control (tissue known to 
express protein of interest) were used in each staining run.  
2.2.6.5 IF on paraffin embedded tissue sections 
All incubations were performed at RT using a humidity chamber as follows: after 
antigen retrieval, tissue sections were rinsed in TBS-Tween 20 pH7.6. Excess TBS 
was drained off and tissue sections were incubated with Image-iT ™ FX Signal 
Enhancer for 30 min to block the unspecific background staining that can result 
from tissue autofluorescence. Sections were then washed with TBS-Tween 20 to 
remove the remaining Image-iT ™ FX Signal Enhancer, blocked with pre-diluted 
2.5% Horse Serum for 15 min, rinsed with TBS-Tween 20 and incubated with the 
primary antibody of interest for 30 min (Table 2-9). Primary antibodies were 
diluted to their final concentrations (Table 2-9) using Antibody Diluent. After 
the incubation, tissue sections were washed twice for 5 min with TBS-Tween 20 
and incubated for 20 min in darkness with fluorescent secondary antibody 
diluted 1:1000 in Antibody Diluent. Secondary antibodies were conjugated to 
either Alexa Fluor 488 dye (green) or Alexa Fluor 594 dye (red) to allow 
visualisation. Tissue sections were finally washed twice for 5 min with TBS-
Tween 20 and mounted using ProLong® Gold antifade reagent with DAPI to stain 
the nuclei. A cover slip was applied onto each slide and sealed with nail varnish  
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Primary antibody and Source Final concentration 
for ICH 
Final concentration 
for IF 
Anti-Upk3a (AU1) 
Mouse monoclonal, donated by Dr. T. Sun 
1:100  
Anti-Fbln2 
Rabbit polyclonal, donated by Dr. Mon Li Chu  
1:10 000 1:15 000 
Anti-Fbln1 
Rabbit polyclonal, donated by Dr. Mon Li Chu 
1:1 000  
Fibronectin (ab2413) 
Rabbit polyclonal, Abcam Inc; Cambridge, 
USA 
 1:1 000 
Table 2-9 Primary antibodies used for staining of paraffin embedded tissue sections using 
IHC and IF methods.  
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after 24h. Tissue sections were visualised, imaged (See 2.2.8.2) and stored at 
4°C in darkness. 
Negative control (lacking primary antibody) and positive control (tissue known to 
express protein of interest) were used in each staining run.  
2.2.6.6 Haematoxylin and Eosin (H&Eo) staining 
Every fifth section cut from paraffin embedded tissue blocks was stained with 
haematoxylin Z which stains negatively charged organelles such as nuclei (blue) 
and 1% eosin which stains positively charged cell compartments such as 
cytoplasm (pink) to study the morphology of the specimen. Staining of tissue 
sections with H&E was performed as follows: slides were immersed in xylene 3 
times for 5 min and 99% ethanol 3 times for 20 sec and rinsed in water. After 
incubation in haematoxylin for 2 min slides were washed under running tap 
water, dipped in 1% Acid Alcohol (HCl), rinsed again in running tap water, dipped 
in Scott‟s Tap Water (See Solutions and Buffers) for 30 sec and rinsed before 
examining under a light microscope to assess the intensity of haematoxylin 
staining. If the staining intensity was optimal, slides were transferred to eosin 
for 2 min and rinsed thoroughly using running tap water. Stained tissue sections 
were then de-hydrated through increasing concentrations of ethanol (1 min in 
30%  (v/v), 50% (v/v), 70% (v/v) ethanol), immersed in xylene for 40 sec, 
mounted using Pertex mounting medium, cover slipped, examined under a 
microscope (See 2.2.8.3) and stored.  
2.2.6.7 Elastica van Gieson (EVG) staining 
EVG staining was performed using the EVG kit as per manufacturer‟s 
instructions. Briefly, tissue section were immersed in xylene 3 times for 5 min, 
re-hydrated by dipping in 99% ethanol 3 times for 20 sec and rinsed with water. 
Tissue sections were then placed in Elastin according to Weigert‟s resorcin-
fuchsin solution for 10 min, rinsed under running tap water, immersed in 
Weigert‟s A&B solution (See Solutions and Buffers) for 5 min, rinsed again and 
placed in Picrofuchsin solution according to van Gieson for 2 min and 70% (v/v) 
ethanol for 1 min. Stained sections were then de-hydrated through increasing 
concentrations of ethanol (1 min in 30% (v/v), 50% (v/v), 70% (v/v) ethanol), 
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immersed in xylene for 40 sec, mounted using Pertex mounting medium, cover 
slipped, examined under a microscope (See 2.2.8.3) and stored.  
2.2.7 In vivo hormonal treatment of mouse mammary glands 
Hormonal treatment (priming) was performed using female TG and WT mice to 
study the regulation of Fbln2 by systemic hormones (E2 and P) in pubertal mouse 
mammary gland in vivo.  
2.2.7.1 Priming of mice with hormone pellets 
Hormones were administered to animals in the form of subcutaneous pellets to 
deliver standardized, continuous release of the active ingredient in the animal 
over a given period of time. For the purpose of this study, 21 day release 
oestrogen (E2) (0.72mg/pellet), oestrogen-progesterone (E2+P) (0.1mg/pellet, 
10mg/pellet) or placebo (10.01mg/pellet) hormone pellets were implanted in 
3.5 week old pubertal TG mice. 
Pellet implantation was performed on a single mouse at a time. After being 
weighed, the animal was anesthetised in an induction chamber via ISoFlo® 
isoflurane (Abbot Laboratories Ltd., Kent, UK) inhalation, marked by ear 
punching and shaved at the back of the neck. The animal was then transferred 
to the surgical table, covered with a sterile cloth and anaesthesia maintained 
using a slow gas rate delivered through a mask placed over its nose. The 
anaesthesia was monitored by pinching the toe of the animal and checking for 
lack of paw withdrawal. The exposed skin at the back of the neck was sterilized 
with 70% ethanol and an incision through the skin was made using sharp sterile 
scissors. The skin at the top part of the incision was then lifted with sterile 
forceps and, using the tip of a second pair of blunt-ended sterile forceps to 
separate the skin from the body wall, a pocket was created for the pellet. The 
hormone pellet was then gently placed in the created pocket and the skin on 
either site of the incision was sutured using Polyamide 6 blue monofilament non-
absorbable suture 5-0 Ethicon. The implanted mouse was transferred to an 
Electrisaver E30 thermostat heated chamber to recover from anaesthesia and 
then placed back into the breeding cage (See 2.2.1.1). Animal vital signs were 
closely monitored throughout the surgical procedure, recovery process and 
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thereafter. All animal work was carried out under personal licence PIL 60/11179 
and project licence PPL 60/3712. 
All of the surgical instruments used for mice priming were sterilized by 
autoclaving prior to performing the surgery. Surgical procedures were carried 
out in surgical gowns using Biogel®P Suretech surgical gloves at the Biological 
Services at Veterinary Research Facility in Garscube Estate in Glasgow under the 
supervision of a named veterinary surgeon residing at the facility or the facility 
manager. Isoflurane was administered in contained conditions at all times, using 
a calibrated thermostatically controlled Veterinary Fluosorber vaporiser, 
induction chamber, suitable circuit and scavenging system. 
Implanted mice were primed with hormones for 7 days prior to being culled to 
collect the mammary glands and use them for further applications. 
2.2.7.2 Mammary gland morphology assessment and tissue processing  
The excision of mammary glands (See 2.2.1.2) was performed at the Beatson 
Institute for Cancer Research, Glasgow, UK. Mice were culled by cervical 
dislocation to ensure minimal tissue deterioration. Both left and right 4th 
inguinal mammary glands were collected. Upon dissection, mammary glands 
were spread onto HistoBond®+ glass slides, visualised using a fluorescent 
dissecting microscope and imaged at x80 magnification (See 2.2.8.1). Glands 
were then either snap frozen in liquid nitrogen or fixed in 10% Neutral Buffered 
Formalin to be used in further applications.  
2.2.8 Visualisation and imaging 
2.2.8.1 Fluorescence microscopy 
Mammary glands excised from TG mice were visualised using a Stemi SV6 
fluorescent dissecting microscope and imaged with Axio Vision release 4.6.3 
software (Carl Zeiss Ltd., UK) 
To monitor the efficiency of transfections, an Olympus IX51 inverted microscope 
equipped with U-MNIBA3 filter for the detection of 470-495nm wave length 
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(green narrow) was used for visualisation while image acquisition was carried out 
using F-view Soft Imaging System (Olympus UK Ltd., UK) and CellP Imaging 
software (Olympus UK Ltd., UK).  
2.2.8.2 Confocal microscopy 
Tissue sections stained using IF methods were examined using a Leica TCS SP2 
confocal microscope with x63 oil immersion lens and imaged using Leica 
Confocal Software (Leica Microsystems Ltd.; UK). Multiple images were captured 
for each tissue section using 360nm (DAPI) and 488nm filters (green 
fluorescence).  
3D tissue structure reconstruction was performed using Volocity® 3D Imaging 
Software (PerkinElmer; Massachusetts, USA) using Z-stag data obtained via 
confocal microscopy. Z-stags were captured every 0.7-0.8µm. Confocal 
microscopy and 3D structure reconstruction was performed at the Beatson 
Institute for Cancer Research.   
2.2.8.3 Light microscopy 
Wound healing experiments were monitored using an Olympus IX51 inverted 
microscope. F-view Soft Imaging System and CellP Imaging software were used to 
acquire images and calculate the percentage of wound closure. 
Most of the tissue sections stained using IHC and the wholemounts were 
examined using a Labophot-2 light microscope and imaged and scanned using a 
NanoZoomer Digital Pathology scanner at x200 magnification. The obtained 
images were then manipulated and analysed using Digital Image Hub (SlidePath; 
Dublin, Ireland). Remaining tissue sections stained using IHC, EVG stain or H&E 
were examined and imaged using Leica DMD108 Digital Microimaging Network.  
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3 Pubertal transcriptome of mouse mammary 
gland - Microarray analysis 
3.1 Introduction 
One of the aims of this project was to study the pubertal transcriptome of the 
mouse mammary gland and to identify individual genes and biological 
functions/pathways that may be associated with TEB motility. Mouse mammary 
gland development during puberty, i.e. from 4 to 10 weeks of age, is a complex 
process of epithelial expansion into the surrounding stroma and differentiation. 
During this time TEBs provide the driving force for the invasion of the ductal tree 
into the empty fat pad. The whole process is tightly regulated by a multitude of 
cues, including systemic hormones and interactions between epithelial and 
stromal cells.     
3.2 Results 
This chapter should be read in conjunction with Figure 3-1 (p.151) which 
provides a paradigm of microarray data analysis carried out in this project.  
To study pubertal mouse mammary gland development different types of 
biological material were collected (isolated epithelium, mammary gland tissue 
strips and whole mouse mammary glands) (See 3.2.1) and the microarray 
analysis of TEB and duct epithelial and stromal transcriptomes was performed. 
And since TEBs are the driving force of ductal morphogenesis, this study focused 
on:  
 Identification of genes associated with TEBs and ducts transcriptomes 
(See 3.2.6.1 and 3.2.6.2). 
 Identification and classification of new, potential regulators of pubertal 
mouse mammary gland morphogenesis – (Candidate gene approach) (See 
3.2.6.3). 
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Figure 3-1 Microarray data analysis paradigm. 
Gene expression analysis was performed on RNA obtained from isolated TEBs (T), ducts (D), 
mammary gland tissue strips (Pre-LN, Post-LN and Fat pad). Gene expression analysis was 
performed using 5% LFC Model to identify TEB and duct epithelium ‘up-regulated gene sets’ (See 
2.2.5.5.1) and these were then used for ‘candidate gene approach analysis’ and ‘pathway analysis’. 
Gene expression analysis was performed using Partek
®
 Genomic™ Suite to identify TEB and duct 
stromal-epithelial ‘up-regulated genes sets’ (See 2.2.5.5.2) and these were then used for 
‘candidate gene approach analysis’. Finally Expression Console and manual analysis was used to 
compare gene expression in Post-LN, Pre-LN, isolated TEB- and isolated duct epithelium to 
identify TEB-only and duct-only stroma ‘expressed gene sets’ (See 2.2.5.6.2). Isolated TEB- and 
isolated duct epithelium gene expression was also compared to identify TEB- and duct-only 
epithelium ‘expressed gene sets’ (See 2.2.5.6.1). TEB- and duct-only epithelium and stroma 
‘expressed gene sets’ were then used in ‘pathway analysis’. The ‘expressed gene set’ is defined as 
list of genes expressed ≥ 1.1 fold change cut off in one environment when compared to other 
environment. The ‘up-regulated gene set’ is defined as a list of genes up-regulated above the set 
level, in one environment when compared to other environment. TEB and duct epithelium ‘up-
regulated gene sets’ and ‘expressed gene sets’ were used to study the epithelial transcriptome of 
TEBs and ducts. TEB and duct epithelial-stromal ‘up-regulated gene sets’ were used to study the 
epithelial-stromal transcriptomes of TEBs and ducts. TEB- and duct-only stroma ‘expressed gene 
sets’ were used to study the stromal transcriptomes of TEBs and ducts. 
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 Identification and comparison of functional characteristics of the 
epithelial and stromal transcriptomes of TEBs and ducts – (Pathway 
analysis) (See 3.2.6.4 - 3.2.6.7). 
As a result, the different types of transcriptomes, the epithelial-, stromal- and 
epithelial-stromal transcriptomes, were identified in this project to study gene 
expression in TEBs and ducts. This allowed us to gain further insights into the 
function of epithelium and stroma in ductal morphogenesis and to study stromal-
epithelial interactions during epithelial outgrowth at puberty. In addition, the 
Fat pad transcriptome was identified to study the gene expression in the distal, 
epithelium-free Fat pad at puberty.   
Each of these transcriptomes was represented using either of the two different 
types of gene sets, the „up-regulated gene sets‟ or „expressed gene sets‟.  
The „up-regulated gene sets‟, defined as lists of genes up-regulated above the 
set level in one environment when compared to the other environment, were 
identified to study epithelial and epithelial-stromal transcriptomes of TEBs and 
ducts and the epithelium free Fat pad (See 2.2.5.5).  
The „expressed gene sets‟, defined as lists of genes expressed ≥ 1.1 fold change 
cut off in one environment when compared to the other environment, were 
identified to study stromal transcriptomes of TEBs and ducts and epithelial 
transcriptomes of TEBs and ducts as the analysis used to select the stroma 
associated genes (manual screening of the raw gene expression data from the 
isolated epithelium and tissue strips) did not allow calculation of FCs but only 
enabled presence or absence of gene expression to be determined (See 
2.2.5.6).  
The TEB epithelium „up-regulated gene set‟ (TEBs vs ducts) and Post-LN „up-
regulated gene set‟ (Post-LN vs Pre-LN strips) were used for candidate gene 
approach. 
The degree of potential hormonal regulation of gene expression during puberty, 
based on the number of oestrogen responsive genes, as defined by ERGDB, 
within the generated gene list, was also established. 
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The TEB- and duct epithelium „up-regulated gene sets‟ (TEBs vs ducts) (ducts vs 
TEBs), TEB- and duct-only epithelium „expressed gene sets‟ (TEBs vs ducts) 
(ducts vs TEBs) and TEB- and duct-only stroma „expressed gene sets‟ (TEBs vs 
ducts) (ducts vs TEBs) were used in pathway analysis.  
3.2.1 Collection of biological material 
Gene expression profiling of ductal outgrowth in pubertal mouse mammary gland 
was performed using the following biological material:  
 Isolated epithelium of TEBs and ducts (Figure 3-2 A, 3-2B and 3-2C),  
 Mammary gland tissue strips containing either ductal epithelium and 
surrounding stroma (Pre-LN); ducts and TEBs‟ epithelium and surrounding 
stroma (Post-LN) or epithelium free stroma (Fat pad) (Figure 3-3 A)  
 Whole adult virgin mammary glands (Figure 3-3 B).  
TEBs, ducts and whole adult glands were isolated from WT mice. Mammary gland 
tissue strips were collected from TG mice. 
In WT mice visualisation of mammary gland epithelium is only possible with 
whole mounts fixed and stained for example with carmine alum. However, 
fixation of the tissue prior to imaging makes it unsuitable for use in further 
molecular applications. In TG mice, the mammary ductal tree is easily visible 
under UV light and so the stage of development, presence and size of TEBs can 
be easily assessed allowing increased precision in setting boundaries between 
the Pre-LN, Post-LN and Fat pad tissue strips. 
Microarray analysis of isolated TEBs and ducts was performed to characterise the 
specific epithelial transcriptomes. Microarray analysis of mammary gland tissue 
strips further permitted the study of epithelial-stromal interactions in the 
pubertal mammary gland. Gene expression analysis of both epithelial structures 
and tissue strips was used for the identification and characterisation of the 
stromal transcriptome around TEBs and ducts during puberty. Adult glands 
served as negative controls.  
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Figure 3-2 Isolated pubertal epithelium. 
Phase contrast microscopic images showing (A) (B) TEBs and (C) a duct isolated from pubertal 
mouse mammary gland following collagenase II treatment. Mammary glands were collected from 6-
7 week old WT female mice. Photographs were taken using an Olympus IX51 microscope. Scale 
bars are 50µm. 
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Figure 3-3 Whole mouse mammary glands. 
Fluorescent microscopic images showing (A) Mouse mammary gland tissue strips collected from a 
7 week TG. The ductal epithelium and the central LN are clearly visible and the vertical black lines 
(black arrows) illustrate where cuts were made to divide the gland into tissue strips. White arrow 
denotes TEB. (B) Whole adult mouse mammary gland obtained from 12 week old TG female 
mouse. Both photographs were taken using Stemi SV6 fluorescence dissecting microscope. Scale 
bars are 1mm. 
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3.2.2 Characterisation of pubertal development stages in WT and 
TG mice  
Prior to the collection of biological material, mammary glands obtained from 29 
WT and 23 TG mice were used to study the time course of the morphological 
changes during puberty in each mouse strain to ensure their comparability. 
Mammary glands were collected from 4, 5, 6, 7, 9 and 12 week old TG mice and 
visualised using a fluorescence dissecting microscope (Figure 3-4 A). Mammary 
glands from 5, 6 and 7 week old WT mice were wholemounted and stained with 
carmine alum (Figure 3-4 B). All mice were weighed at gland collection. 
The length of the ductal tree as well as the size and number of TEBs were 
compared between collected glands. Mammary glands obtained from 4 week old 
mice were characterised by an undeveloped, rudimentary ductal tree. Numerous 
TEBs and significant outgrowth of the ductal tree was noticeable at 5-8 weeks of 
age, with the most prominent TEBs observed at 6-7 weeks of age. Upon reaching 
9 weeks of age most of the mammary fat pad was filled with ductal epithelium 
and very few small TEBs were visible. At 12 weeks of age, the whole mouse 
mammary gland fat pad was filled with a ductal tree and hardly any TEBs were 
present. Furthermore, mammary glands collected from mice that weighed 16-18 
g had the largest and most numerous TEBs. The extent of ductal outgrowth at 
given developmental stages was comparable between WT and TG mouse 
mammary glands.    
Based on the above conclusions, mammary glands were collected from TG mice 
weighing 16-18g and aged 7 weeks to obtain tissue strips or WT mice aged 6-7 
weeks to collect isolated TEBs and ducts. Adult mammary glands, collected at 12 
weeks of age, which do not contain TEBs, were used as negative controls. 
3.2.3 Experimental set up for microarray analysis 
1145 TEBs and 1111 ducts were isolated from mammary glands collected from 
300 WT mice. 12 Pre-LN, 12-Post-LN and 12 Fat pad mammary gland strips were 
collected from 6 TG mice and 6 whole mammary glands were obtained from 3 
WT adult mice. 
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Figure 3-4 Wholemounts of different stages of pubertal mouse mammary gland 
development. 
(A) Wholemounts collected from TG mice. (B) Carmine stained wholemounts obtained from WT 
mice. Scale bars are 1mm. 
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The collected biological material was pooled as shown in Table 3-1 and 16 
samples of RNA were extracted, purified and hybridised to GeneChip® Mouse 
Exon 1.0 ST arrays (Figure 2-4) (p. 106).  
Isolated TEBs and isolated ducts were pooled prior to extracting RNA to ensure 
that a sufficient amount of RNA, 1.5 µg per microarray chip, was obtained. This 
experimental design also allowed the production of RNA samples representative 
of a 300 mice population, not biased by mouse to mouse biological variation. For 
both TEBs and ducts the amount of extracted RNA was only sufficient to be 
divided into 2 samples, generating technical duplicates. Prior to RNA extraction, 
mammary gland tissue strips were paired to enable a more comprehensive 
comparison of data between tissue strips and to ensure sufficient yield of 
extracted RNA and to minimise biological variation.  
Animal breeding, excision and handling of biological material and experimental 
conditions for preparation of RNA samples were maintained as similarly as 
possible to minimize data discrepancy that could occur due to technical 
variation. This included extraction of RNA from mammary gland tissue strips at 
the same time and within a very short time from the RNA extraction from pooled 
TEBs and ducts and adult mammary glands, using the same batches of reagents 
and equipment.  
The GeneChip® Mouse Exon 1.0 ST microarray platform was chosen for this 
project as it allows the investigation of the level of transcription at both whole 
transcript and exon levels. Each GeneChip® Mouse Exon 1.0 ST array contains 
only PM probes and accommodates oligonucleotide sequences that translate into 
17,500 well-annotated transcript IDs based on publicly available, empirically 
obtained annotations of the mouse genome sequence built in 2004. A single 
array consists of over 4.5 million probes (25 oligonucleotide long sequences 
complementary to each corresponding sequence from the genome) which are 
synthesised in situ. A set of four distinctive, perfect match probes makes a 
probe set and usually four probe sets make up an exon cluster, i.e. a number of 
probes of nucleotide sequences unique for each exon. Multiple exon clusters can 
be grouped into over 80,000 transcript clusters, i.e. groups of putative 
alternatively spliced gene isoforms and each gene is annotated by a transcript 
ID. 
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RNA 
sample 
number 
RNA sample source 
(See collection of 
experimental material) 
Characteristics  Replicate 
type 
1, 2 Isolated TEBs RNA extracted from pooled TEBs was 
divided into 2 samples 
Technical 
duplicate 
3, 4 Isolated ducts RNA extracted from pooled ducts was 
divided into 2 samples 
Technical 
duplicate 
5, 6, 7 Pre-LN mammary gland 
strips 
Each RNA sample (replicate) 
contained RNA extracted from a pair 
of mice. The same pair of mice was 
used for replicates 5,8,11, second pair 
for replicates 6,9,12 and third pair for 
7,10,13  
Biological 
triplicate 
8, 9, 10 Post-LN mammary gland 
strips 
Biological 
triplicate 
11, 12, 13 Fat pad mammary gland 
strips 
Biological 
triplicate 
14, 15, 16 Whole mammary glands Each RNA sample (replicate) was 
extracted from an individual mouse 
(both glands) 
Biological 
triplicate 
Table 3-1 Description of RNA samples used for microarray analysis of pubertal gene 
expression. Isolated epithelium of TEBs and ducts was collected from 6-7 week old WT mice. 
Mammary gland tissue strips were collected from 7 week old TG mice. Whole mammary glands 
were collected from 12 week old WT mice.  
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3.2.4 RNA hybridisation to GeneChip® Mouse Exon 1.0 ST Arrays  
All RNA samples were subjected to quality and integrity assessment using an 
Agilent 2100 bioanalyser (See 2.2.4.5). Quality assessment was based on the 
calculation of 28S rRNA to 18S rRNA ratio which ideally should be 2:1. RNA 
integrity number (RIN) was estimated taking into consideration the entire 
electrophoretic trace of the RNA sample. RINs were within the acceptable range 
for all of the RNA samples, i.e. between 6-10 as recommended by Qiagen Ltd.: 
for RNA samples obtained from TEBs and ducts they were 6.2; for RNA samples 
obtained from mammary gland tissue strips they varied between 7.7 and 9.0; 
and for RNA of adult glands they were between 8.4-8.8. Thus, all 16 RNA 
samples were able to be hybridised to the GeneChip® Mouse Exon 1.0 ST Arrays 
using appropriate Affymetrix kits (See 2.2.5.3). Efficiency and performance was 
monitored throughout the procedure by performing quality assessment after 28S 
and 18S rRNA reduction (See 2.2.5.3.1) and before and after ss cDNA 
fragmentation (See 2.2.5.3.5). Representative electrophoretograms, shown in 
Figure 3-5, illustrate that high quality of all samples was maintained throughout 
the experimental steps. The trace for total RNA showed low background noise 
between the clear 28S and 18S peaks and minimal low molecular weight 
contamination (Figure 3-5 A). The trace obtained after rRNA reduction, which 
was performed to minimise the background, increase specificity and sensitivity 
of the array and increase efficiency of cDNA synthesis, showed successful 
reduction of 28S and 18S peaks from 20 and 27 fluorescence units (FU) 
respectively to 2 and 3 FU respectively (Figure 3-5 B). Electrophoretograms of ss 
cDNA before and after fragmentation demonstrated successful elimination of 
large ss cDNA fragments in favour of accumulation of smaller size range of ss 
cDNA fragments (Figure 3-5 C and D). Successfully fragmented ss cDNAs were 
hybridised to the microarray chips. Arrays were washed, stained and scanned 
and the obtained .CEL files normalised, background corrected and summarised 
(See 2.2.5.4). Technical variability was minimised by processing all the samples 
together. 
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Figure 3-5 Assessment of hybridisation efficiency. 
Representative electrophoretograms showing RNA quality (A) after RNA extraction, (B) after rRNA 
reduction and cDNA quality (C) before cDNA fragmentation and (D) after cDNA fragmentation. (A) 
(B) Show good quality of the total and rRNA reduced RNA. The three visible peaks stand for the 
molecular weight marker, 18S rRNA and 28S rRNA. (C) (D) Demonstrate successful reduction in 
size of cDNA fragments. The two visible peaks stand for the molecular weight marker and a pool of 
cDNA fragments. (A) (B) Agarose gel separation of the total RNA and (C) (D) total cDNA are 
shown on the right hand side of each electrophoretogram.    
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3.2.5 Microarray data quality control 
A number of quality control measures were performed throughout the 
experimental stages of the microarray analysis to monitor and ensure good 
quality of the generated data (See 2.2.5.8). Visual inspection of the scanned 
arrays did not show any irregularities. Furthermore, the quality check of RNA 
hybridisation, performed by investigating the signal intensity of a probe set for 
prokaryotic internal hybridisation controls (bioB, bioC, bioD and cre) showed the 
cre control, which was hybridised to the array at the highest concentration, to 
be characterised by highest signal intensity, followed by bioD, bioC and bioB 
(Figure 3-6 A), thus, showing the expected rank order of spikes. Comparison of 
sample replicates at the whole genome level, performed after data 
normalisation, background correction and summarisation using PCA, showed all 
replicates of each biological sample to cluster together apart from the replicates 
of the isolated ducts, which showed higher variability. Although the two 
replicates failed to cluster precisely, the discrepancy was deemed slight enough 
that neither of them was considered an outlier. The variability between the 
replicates of each biological sample was therefore concluded to be minimal. 
Replicates of different biological samples, on the other hand, clustered away 
from each other. This was mostly apparent when comparing the clustering of 
replicates of isolated epithelium (TEBs and ducts) with replicates of tissue strips 
and whole virgin glands. Samples of TEBs and ducts were shown to cluster in the 
same area of the plot indicating similar pattern of gene expression. Samples of 
tissue strips and whole adult virgin glands were also shown to cluster together 
but at a distance from the TEBs and ducts clusters indicating, as expected, 
dissimilarity in gene expression between the two groups of samples and possibly 
reflected differences in sample preparation. Together this confirmed a 
reproducibility and reliability of the generated data (Figure 3-6 B and C). 
Final data quality control that was carried out after the analysis of the 
microarray data, using a list of genes previously published as associated with 
either epithelial or stromal compartments of TEBs or ducts, revealed presence of 
these genes within the appropriate gene lists generated in this study thus 
ensuring the reliability of our data. The list of reference genes screened for in  
  163 
 
 
Figure 3-6 Microarray data quality controls. 
(A) Quality check of RNA hybridisation. Figure illustrates the intensity of the hybridisation signal (Y 
axis) of Cre, bioD, bio C and bioB internal hybridisation controls across all the microarray chips (X 
axis). (B) (C) PCA based comparisons of clustering patterns of samples replicates. (B) Image 
shows TEBs (yellow) and ducts (red) replicates clustering together but away from Post-LN (green), 
Pre-LN (violet), Fat pad (blue) mammary gland tissue strips and whole adult gland (light blue) 
replicates. (C) Image illustrates close clustering of replicates of each tissue strip. Each tissue strip 
is represented as follows: Pre-LN (green), Post-LN (blue) and Fat pad (red). (D) Venn diagram 
comparison of lists of genes found to be differentially expressed in isolated TEB vs duct and Post-
LN vs Pre-LN tissue strips. Red, yellow and green circles illustrate genes associated with Post-LN 
(right) or Pre-LN (left) strips, isolated ducts and isolated TEBs respectively. Common parts 
between the circles represent genes that are commonly over- expressed in the compared gene 
lists.          
  164 
 
each compartment, their calculated FC and rank numbers are shown in Table 3-
2.    
Furthermore, Venn diagram comparisons of lists of genes found to be 
differentially expressed in TEB epithelium vs duct epithelium and Post-LN vs Pre-
LN tissue strips identified 20 genes commonly up-regulated in both Post-LN 
(Post-LN vs Pre-LN) and duct epithelium (Ducts vs TEBs) gene lists and 65 genes 
commonly up-regulated in both Post-LN (Post-LN vs Pre-LN) and TEB epithelium 
(TEBs vs Ducts). This was expected as Post-LN strips contain TEB as well as 
ductal epithelium. Furthermore, 41 and 2 of the over-expressed genes in ducts 
(Ducts vs TEBs) and TEBs (TEBs vs Ducts) respectively were shown to be also up-
regulated in Pre-LN when compared to Post-LN (Figure 3-6 D). This was also 
expected as although the Pre-LN strip contains mostly ductal epithelium it may 
contain a very low number of TEBs. 
Finally, to confirm the reproducibility of the microarray data, the expression 
levels of a selected set of genes was confirmed using QRT PCR analysis. Genes 
that were chosen for validation included some that had never been associated 
with mammary gland development previously, such as embigin (Emb) and Disk 
large homolog 7 (Dlg7), and others that had: Sema3B [113] and lactotransferrin 
(Ltf) [113]. Expression of the genes was validated using RNA extracted from 
Post-LN and Pre-LN strips collected from three animals, different from those 
used for the microarray study. Tissue strips were used to avoid using valuable 
RNA obtained from TEBs and ducts. Gene expression levels were normalised 
against the expression levels of the epithelial marker Ktr18 to measure the 
abundance of gene expression in relation to the amount of epithelium present. 
As seen in Figure 3-7 A expression of Emb, Dlg7 and Sema3B was higher in the 
Post-LN strip than Pre-LN strip while expression of Ltf was up-regulated in Pre-
LN strip compared to Post-LN. Those findings reflect the microarray analysis 
results which showed over-expression of Emb, Dlg7 and Sema3B in isolated TEB 
epithelium and Post-LN strip and up-regulation of Ltf in isolated duct epithelium 
and Pre-LN strip (Figure 3-7 B). The up-regulation of all genes but Dlg7 was 
identified as statistically significant.  
Together, all quality control measures that were carried out were deemed 
satisfactory. 
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Tissue 
Compartment 
Gene 
Symbols 
FC 
From TEB-Duct or           
Post-LN-Pre-LN 
analysis 
Rank number              
From TEB-Duct or       
Post-LN-Pre-LN 
analysis 
Literature 
reference 
TEB 
epithelium 
Sema3B 
Pcp4 
Itih2 
Wnt5a 
Cited1 
3.6 
2.4 
5.12 
3.09 
2.02 
69 
25 
23 
32 
89 
[113] 
[113] 
[113] 
[256] 
[194] 
Duct 
epithelium 
Btn1a1 
Lalba 
Ltf 
3.5 
4.25 
11.5 
60 
24 
3 
[113] 
[113] 
[113] 
TEB stroma Plexin C1 2.44 70 [113] 
Table 3-2 List of reference genes known to be associated with TEB and duct environments 
and the level of their up-regulation in the generated in this study gene lists. 
FC and Rank number for epithelium and stroma expressed genes were calculated using 5% LFC 
Model (See 3.2.6.1.1) and Partek
® 
Genomic™ Suite software (See 3.2.6.1.2) respectively.   
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Figure 3-7 Validation of microarray gene expression profiling by RT PCR analysis. 
(A) RT PCR. The graph illustrates mean expression levels of Sema3B, Ltf, Emb and Dlg7 in Post-
LN strip relative to Pre-LN strip. Krt18 expression was used as an internal control for normalisation. 
Error bars are S.E.M. (*) denotes statistical significance, (*) p≤0.05 (**) p≤0.01 (***) p≤0.001, n=3 
(B) Microarray analysis. The table shows the levels of Sema3B, Emb and Dlg7 up-regulation in the 
isolated TEBs (TEBs vs ducts) and Post-LN strip (Post-LN vs Pre-LN) and Ltf up-regulation level in 
the isolated ducts (ducts vs TEBs) and Pre-LN strip (Pre-LN vs Post-LN). All FCs are statistically 
significant. 
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3.2.6 Bioinformatic analysis of the pubertal mouse mammary 
gland transcriptome 
The bioinformatic analysis carried out in this project included three areas that 
are listed below and should be read in conjunction with Figure 3-1 (p.151) 
which provides an overview of the paradigm for data analysis adopted in this 
study. 
 Identification of genes associated with TEBs and ducts transcriptomes 
(See 3.2.6.1 and 3.2.6.2). 
 Identification and classification of new, potential regulators of pubertal 
mouse mammary gland morphogenesis – (Candidate gene approach) (See 
3.2.6.3). 
 Identification and comparison of functional characteristics of the 
epithelial and stromal transcriptomes of TEBs and ducts – (Pathway 
analysis) (See 3.2.6.4 - 3.2.6.7). 
3.2.6.1 Gene expression analysis – Identification of the ‘up-
regulated gene sets’  
Briefly, the „up-regulated gene sets‟ are defined as lists of genes up-regulated 
above the set level, in one environment when compared to the other 
environment. 
3.2.6.1.1 TEB and duct epithelium ‘up-regulated gene sets’ 
 
Due to the low yield of RNA, obtained from isolated TEBs and ducts, microarray 
analysis had to be performed in duplicate rather than triplicate which caused 
analysis limitations. Given that statistical tests can not be applied in analyses 
consisting of fewer than three samples, we employed the 5% LFC Model which is 
used for data analyses in the absence of large numbers of experimental 
replicates [269]. The 5% LFC Model aids identification of the significantly 
expressed genes by calculating the rank number (RN) based on the absolute 
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expression levels of transcripts across the compared conditions, „binning‟ them 
across their absolute expression levels and selecting the first 5% of the 
transcripts in each bin with the highest FC (HFC). Selected genes are ranked 
according to both FC and expression level and the most significantly over-
expressed genes are identified (See 2.2.5.5.1). The 5% benchmark is based on 
the finding brought by the survey of numerous publications on microarray 
analysis that shows that regardless of the gene selection method used, in 
general less than 5% of the total gene number show differential expression [269]. 
Initially 23,239 transcript IDs, i.e. genes, were employed in the analysis from 
which 3,038 were excluded after Average Difference Intensity (ADI) adjustment. 
A high level of variation in expression levels between the replicates resulted in 
further elimination of 1,425 transcript IDs in order to minimise false positive 
results. The remaining 18,777 genes (92.2%) were divided into transcripts up- 
regulated in TEBs or ducts. 11,738 and 7,039 genes were shown to be over-
expressed in TEBs and ducts respectively. All non-annotated, internal Affymetrix 
controls, as defined by Affymetrix UK Ltd, were subtracted from the lists. To 
identify the top 5% of TEB and duct up-regulated genes, the transcripts over-
expressed in TEBs were „binned‟ into 58 bins that contained 200 genes and one 
that consisted of 137 genes while the transcripts over-expressed in ducts were 
divided into 39 bins that were 200 genes rich and one that consisted of 37 genes 
(See 2.2.5.5.1). The gene expression analysis aided identification of 425 and 
186 genes over-expressed in isolated TEBs and ducts respectively (Table 3-3). 
The ranked top 20 genes from each gene list and their FC are shown in Table 3-
4. Full gene lists are shown in Appendix 2.  
3.2.6.1.2 TEB and duct epithelium-stroma ‘up-regulated gene sets’ 
 
The combined stromal-epithelial transcriptome of TEBs and ducts was identified 
using RNA extracted from Pre-LN and Post-LN mammary gland tissue strips. The 
yield of RNA obtained in each RNA extraction was sufficient to perform gene 
expression analysis in triplicate using Partek® Genomics™ Suite software (See 
2.2.5.5.2). Comparison of Post-LN vs Pre-LN gene expression aided the 
identification of 565 and 361 genes over-expressed in Post-LN strip (epithelial-
stromal signature of TEBs) and Pre-LN strip (epithelial-stromal ductal  
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Transcriptome 
Type 
Data comparison type 
TEBs - ducts Post-LN – Pre-LN Post-LN - Fat pad 
Isolated TEBs 425   
Isolated ducts 186   
Post-LN strip  565 670 
Pre-LN strip  361  
Fat pad strip   688 
Table 3-3 Number of genes up-regulated in each transcriptome. 
Transcriptomes of the isolated epithelium were identified by comparing gene expression levels 
across TEB and duct data sets. Genes up-regulated in Post-LN, Pre-LN and Fat pad mammary 
gland tissue strips were identified by comparing gene expression levels across Post-LN, Pre-LN 
and Fat pad data sets. Up-regulation of all identified genes was statistically significant, i.e. p≤0.05 
for genes over-expressed in Pre-LN and Post-LN and within the 5% LFC Model for genes over- 
expressed in TEBs and ducts isolated epithelium.   
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Table 3-4 Top 20 genes over-expressed in isolated TEBs, ducts, Post-LN and Pre-LN strips. 
FC(s) of gene expression were calculated from TEBs vs ducts and Post-LN vs Pre-LN gene 
expression comparisons. All FC(s) were statistically significant, i.e. p≤0.05 for genes over-
expressed in Pre-LN and Post-LN and within the 5% LFC Model for genes over-expressed in TEBs 
and ducts isolated epithelium.   
Gene 
symbol 
FC Gene name Gene bank 
symbol 
Isolated epithelium of TEBs 
Upk3a 
Fbg 
N/A 
Hist1h1b 
Ccna2 
Hist1h2ab 
Serpinb11 
 
Plk1 
Mt2 
Rrm1 
Ccnb2 
Crispld2 
 
Uhrf1 
 
Racgap1 
Top2a 
Ccnd1 
Tubb5 
Plrg1 
Gsta4 
Kif2C 
10.7 
5.4 
4.9 
2.6 
5.3 
6.5 
8.45 
 
5.7 
2.3 
3.1 
6.2 
4.4 
 
4.8 
 
4.6 
5.1 
2.1 
1.8 
1.9 
2.6 
6.4 
Uroplakin 3a   
Fibrinogen 
RIKEN cDNA 2810417H13 gene,  
Histone cluster 1, H1b 
Cyclin A2 
Histone cluster 1, H2ab 
Serine (or cysteine) peptidase inhibitor, clade B, 
member 11 
Polo-like kinase 1 
Metallothionein 
Ribonucleotide reductase M1 
Cyclin B2 
Cysteine-rich secretory protein LCCL domain 
containing 
Ubiquitin-like, containing PHD and RING finger 
domains 1 
RAC GTPase-activating protein 1 
Topoisomerase (DNA) II alpha 
Cyclin D1 
Tubulin beta 5 
Pleiotropic regulator 1 
Glutathione S-transferase alpha 4 
Kinesin family member 2C 
NM_023478 
NM_181849 
NM_026515 
NM_020034 
NM_009828 
NM_175660 
NM_025867 
 
NM_011121 
NM_008630 
NM_009103 
NM_007630 
NM_030209 
 
NM_010931 
 
NM_012025 
NM_011623 
NM_007631 
NM_011655 
NM_016784 
NM_010357 
NM_134471 
Isolated epithelium of ducts 
AY036118 
Dub2a 
Ltf 
Indo 
Dmbt1 
Cst3 
Slc7a2 
Clca2 
Tph1 
Cd79a 
Slc 5a5 
Pcgf1 
Ly6d 
Cp 
Agtr1a 
Abp1 
Trf 
Atp6v1b1 
Tmem86a 
Krt17 
4.6 
6.9 
11.5 
2.5 
2.5 
1.4 
3.1 
2.9 
9.6 
2.3 
2.5 
2.6 
1.4 
3.3 
3.0 
2.9 
2.2 
2.6 
2.1 
2.2 
cDNA sequence AY036118 
Deubiquitinating enzyme 2a 
Lactotransferrin 
Indoleamine-pyrrole 2,3 dioxygenase 
Deleted in malignant brain tumours 1 
Cystatin C 
Solute carrier family, member 2 
Chloride channel calcium activated 1 
Tryptophan hydroxylase 1 
CD79A antigen 
Solute carrier family 5 
Polycomb group ring finger 1 
Lymphocyte antigen 6 complex, locus D 
Ceruloplasmin 
Angiotensin II receptor, type 1a 
Amiloride binding protein 1 
Transferrin 
ATPase H+ transporting lysosomal V1 subunit B1 
Transmembrane protein 86A 
Keratin 17 
N/A 
NM_010089 
NM_008522 
NM_008324 
NM_007769 
NM_009976 
NM_007514 
NM_009899 
NM_009414 
NM_007655 
NM_053248 
NM_197992 
NM_010742 
NM_007752 
NM_177322 
NM_029638 
NM_133977 
NM_134157 
NM_026436 
NM_010663 
Post-LN strip 
N/A 
Cxcl13 
Ifit1 
 
C6 
Gm11428 
II1r2 
Lyve1 
5.1 
4.5 
3.9 
 
3.9 
3.7 
3.7 
3.6 
RIKEN cDNA 2810417H13 gene 
Chemokine (C-X-C motif) ligand 13 
Interferon-induced protein with 
tetratricopeptide repeats 
Complement component 6 
Predicted gene 11428 
Interleukin 1 receptor type II 
Lymphatic vessel endothelial hyaluronan 
NM_026515 
NM_018866 
NM_008331 
 
NM_016704 
NM_001081957 
NM_010555 
NM_053247 
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Tlr8 
Cd86 
Mgl1 
 
Fcna 
Tlr7 
Agt 
Akr1c14 
Cd163 
H19 
Ms4a6b 
 
Itgam 
Plek 
Emr1 
 
 
3.6 
3.5 
3.5 
 
3.3 
3.3 
3.2 
3.2 
3.2 
3.2 
3.1 
 
3.1 
3.1 
3.1 
 
receptor 1 
Toll-like receptor 8 
CD86 antigen 
Macrophage galactose N-acetyl-galactosamine 
specific lectin 
Ficolin A 
Toll-like receptor 7 
Angiotensinogen 
Aldo-keto reductase family 1, member C14 
CD163 antigen 
H19 fetal liver mRNA 
Membrane-spanning 4-domains, subfamily A, 
member 6B 
Integrin alpha M 
Pleckstrin 
EGF-like module containing, mucin-like, 
hormone receptor-like sequence 1 
 
NM_133212 
NM_019388 
NM_010796 
 
NM_007995 
NM_133211 
NM_007428 
NM_134072 
NM_053094 
NM_001592 
NM_027209 
 
NM_008401 
AK038804 
NM_010130 
 
Pre-LN strip 
Ucp1 
Fabp3 
Slc27a2 
Otop1 
Ltf 
N/A 
Cpt1b 
Chi3l1 
Acot11 
Cidea 
 
Dio2 
Elovl3 
 
Slc5a5 
Indo 
Muc13 
Scg3 
Slpi 
Tspan8 
Lgr5 
 
Ppara 
31.3 
8.4 
7.3 
7.2 
6.0 
6.0 
6.0 
5.6 
4.2 
3.8 
 
3.8 
3.5 
 
3.5 
3.4 
3.3 
3.2 
3.1 
3.0 
2.9 
 
2.8 
Uncoupling protein1 
Fatty acid binding protein 3 
Solute carrier family 27 
Otopetrin 1 
Lactotransferrin 
RIKEN cDNA 5439419D17 gene 
Carnitine palmitoyltransferese 1b 
Chitinase 3-like 1 
Acyl-CoA thioesterase 11 
Cell-death-inducing DNA fragmentation factor, 
alpha subunit-like effector 
Deiodinase, iodothyronine, type II 
Elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/elo3, yeast)-like 3 
Solute carrier family 5 
Indoleamine-pyrrole 2,3 dioxygenase 
Mucin 13 
Secretogranin III 
Secretory leukocyte peptidase inhibitor 
Tertraspanin 8 
Leucine rich repeat containing G protein coupled 
receptor 5 
Peroxisome proliferator activated receptor alpha 
NM_009463 
NM_010174 
NM_011978 
NM_172709 
NM_008522 
NM_175166 
NM_009948 
NM_007695 
NM_025590 
NM_007702 
NM_010050 
NM_007703 
NM_053248 
NM_007703 
NM_053248 
NM_008324 
NM_010739 
NM_009130 
NM_011414 
NM_146010 
NM_010195 
 
NM_011144 
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transcriptome) respectively (See Table 3-3). All of the above gene lists were 
created using FC≥1.5 and p≤0.05 cut off. The top 20 genes up-regulated in TEB 
and ductal stromal-epithelial signatures along with their FC are shown in Table 
3-4. Full lists of the above identified genes are shown in Appendix 3.  
3.2.6.1.3 Epithelium-free Fat pad ‘up-regulated gene set’ 
 
The Fat pad transcriptome was identified using RNA obtained from Fat pad, Pre-
LN and Post-LN mammary gland tissue strips. The yield of RNA obtained in each 
RNA extraction was sufficient to perform gene expression analysis in triplicate 
using Partek® Genomics™ Suite software (See 2.2.5.5.3). Gene expression was 
compared between Fat pad and Post-LN and 688 genes were found as over-
expressed in Fat pad compared to Post-LN strip (Table 3-3). Gene list was 
created using FC≥1.5 and p≤0.05 cut off. Full lists of the above identified genes 
are shown in Appendix 4. 
3.2.6.2 Gene expression analysis – Identification of the ‘expressed 
gene sets’  
Briefly, the „expressed gene sets‟ are defined as lists of genes expressed ≥ 1.1 
fold change cut off in one environment when compared to the other 
environment. 
3.2.6.2.1 TEB- and duct epithelium-only ‘expressed gene sets’ 
 
6,577 non-annotated internal Affymetrix controls were excluded from both data 
sets that initially consisted of 23,239 genes. The remaining 16,661 genes were 
further reduced by 11,020 genes that were considered to be expressed to the 
same level in the TEBs and ducts. A TEB-only expressed transcriptome was 
identified after subtraction of genes expressed in the ducts from the TEB data 
set. Genes only expressed in the ducts were identified by removing the TEB 
expressed genes from the ductal data set (See 2.2.5.6.1). This resulted in a set 
of 5,641 genes, which included 1,646 TEB associated genes (FC≥1.1) and 3,982 
duct associated genes (FC≤0.9). The full list of genes identified to be expressed 
specifically either in the epithelium of TEBs or ducts is shown in Appendix 5. 
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3.2.6.2.2 TEB- and duct stroma-only ‘expressed gene sets’ 
 
Stromal genes expressed around the epithelium of TEBs and ducts were 
identified by comparing Post-LN and Pre-LN expressed genes with the gene sets 
of isolated TEBs and ducts. Genes expressed in the epithelium of TEBs and ducts 
were subtracted from the Post-LN and Pre-LN gene data sets to remove the 
epithelium associated genes. Then the list of genes remaining in the Post-LN 
data set was compared with the Pre-LN data set (See 2.2.5.6.2). The Post-LN 
strip consists of the epithelium and stroma of TEBs and ducts while the Pre-LN 
strip predominantly consists of ductal epithelium and stroma. In addition both 
tissue strips contain stroma distant from the epithelial structures, i.e. distal 
stroma. The comparison of epithelium-free Post-LN and Pre-LN gene sets 
therefore permits the identification of stromal genes associated with TEBs in the 
Post-LN tissue strip and ducts in the Pre-LN strip after exclusion of stromal genes 
common to both environments (stromal genes expressed around both the 
epithelium of TEBs as well as ducts and genes of the distal stroma).  
Both, Post-LN and Pre-LN gene lists initially consisted of 23,239 genes, which 
was reduced to 16,661 genes after exclusion of 6,577 transcript IDs 
corresponding to non-annotated internal Affymetrix controls. Further elimination 
of 14,071 TEB and 537 duct epithelium expressed genes from the Post-LN data 
set and 14,219 duct and 756 TEBs epithelium expressed genes from the Pre-LN 
data set led to the identification of the 2,053 Post-LN expressed and 1,687 Pre-
LN expressed stromal genes. A Venn diagram based comparison of these stromal 
transcript IDs revealed the presence of 579 TEB- and 213 duct stroma-only 
associated genes (Figure 3-8). The full list of above identified stromal genes is 
shown in Appendix 6.  
3.2.6.3 Identification and classification of new, potential regulators of 
pubertal mouse mammary gland morphogenesis – candidate gene 
approach 
The main search for new genes, potentially involved in the orchestration of 
ductal tree outgrowth during puberty, was carried out using the list of genes 
identified to be over-expressed in the epithelium of TEBs. TEBs were chosen as a 
focus of the study due to the key role they play in governing directional ductal  
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Figure 3-8 Identification of TEB- and duct-associated stromal genes. 
The Venn diagram shows identification of 579 and 213 genes expressed only in the stroma of 
TEBs or ducts respectively. Common non-specific stromal genes (1,474) are represented by the 
eclipse. The list of stromal genes was created by subtracting the epithelium expressed genes of 
TEBs and ducts from the Post-LN and Pre-LN gene data sets and comparing lists of genes 
remaining in the Post-LN data set with Pre-LN data set. Full list of identified genes is deposited in 
Appendix 6. 
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outgrowth during puberty. The list of new genes that could potentially be 
involved in regulation of pubertal mammary morphogenesis was obtained by 
comparing the list of genes up-regulated in isolated TEBs (TEBs vs ducts) with 
genes up-regulated in Post-LN strips (Post-LN vs Pre-LN) and identifying the 
common gene set. The common gene set therefore contained transcripts whose 
expression was significantly up-regulated in both the epithelium of isolated TEBs 
and epithelium or stroma of TEBs placed within their natural environment, i.e. 
surrounded by stroma. This type of analysis also ensured that the up-regulated 
genes included in the final epithelial gene set were not influenced by any of the 
technical issues that could arise during the enzymatic isolation, collection or 
storage of the isolated TEBs. 
The Venn diagram comparison of 425 and 565 genes over-expressed in TEBs and 
Post-LN strips respectively revealed the presence of 65 common genes (Figure 3-
9). The molecular function of each gene and its involvement in other biological 
processes that share similarities with pubertal mammary gland development was 
researched using information deposited in publicly available databases and 
published scientific papers, and the potential significance in pubertal mammary 
gland morphogenesis was evaluated. Classification of the genes according to 
their main molecular functions identified 11 functional categories. The majority 
of genes (58.5%) encoded proteins that exhibited molecular functions connected 
with cell cycle and cellular proliferation, 15.3% were functionally implicated in 
cellular adhesion, 13.8% in cell death, 9.2% in intracellular transport and 7.7% in 
DNA repair. The remaining genes encoded proteins involved in signal 
transduction (6.1%), metabolism (6.1%), regulation of transcription (6.1%) and 
immune response (4.6%). A further 6.1% and 1.5% of the genes encoded 
structural proteins and growth factors respectively. The remaining 2 genes (3%) 
were left uncategorised due to unknown function (Figure 3-10 A). 
Furthermore, of particular interest was also each gene‟s involvement in other 
biological processes that share similarities with mammary gland development 
(See 2.2.5.9.3). The biological processes of interest included: cellular 
migration, lung and kidney morphogenesis or cancer, embryonic and branching 
morphogenesis, axonal guidance. Their association with pubertal mouse 
mammary gland will be discussed in 3.3.2.1. Literature available on each gene 
was also searched for previously documented evidence of a role in mammary  
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Figure 3-9 Identification of TEB epithelial gene set. 
The Venn diagram shows the identification of 65 genes common to gene lists of 425 up-regulated 
genes in isolated TEBs (TEBs vs ducts) and 565 up-regulated genes in Post-LN strip. Full list of 
identified genes is shown in Table 3.5.    
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Figure 3-10 Literature search based analysis of the 65 TEB epithelial gene set. 
Prevalence of all (A) molecular and (B) biological functions represented in the epithelial gene set 
assigned to genes using information obtained during literature search. TEBs epithelial gene set 
consists of the common genes identified to be up-regulated in both isolated TEBs (TEBs vs ducts) 
and Post-LN tissue strip (Post-LN vs Pre-LN). List of genes in each molecular, biological functional 
category is shown in Table 3-5. 
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gland development or breast cancer. Furthermore, since E2 is one of the main 
hormonal cues regulating pubertal morphogenesis potential oestrogen 
responsiveness based on ERGDB, a database which includes genes whose 
expression has been experimentally shown to be up-regulated or down-regulated 
by E2 (See 2.2.5.9.4), was noted for each gene. Literature searches for all 
genes except Lama1 and Ect2 oncogene (Ect2) were focused on information 
obtained from M. musculus and H. sapiens. Functional information on Ect2 was 
based on D. melanogaster and C. elegans while the functional information on 
Lama1 was obtained from G. gallus. As a result, it was revealed that 52% of 
identified genes were previously recognized to be associated with mammary 
gland morphogenesis and breast cancer. A further 30.7% and 16.9% were known 
to be involved in lung and kidney morphogenesis and cancer respectively while 
15.3%, 29.2%, 13.8% and 24.6% were known to be implicated in embryogenesis, 
cellular migration, branching morphogenesis and axonal guidance respectively. 
Finally, 35.4% of examined genes were identified to be oestrogen responsive as 
defined by ERGDB (Figure 3-10 B).  
The list of genes included in each molecular function and the type of biological 
functions they comply with are shown in Table 3-5. 
3.2.6.4 Comparison analysis of biological functions over-represented in the 
epithelial and stromal transcriptomes of TEBs and ducts. (Pathway 
analysis) 
IPA was used to perform a global characterisation of the biological functions 
over-represented within the following gene sets. See Figure 3-1 (p.151) for the 
overview. 
 the TEB and duct epithelium „up-regulated gene sets‟  
 the TEB-only and duct-only epithelium „expressed gene sets‟ 
 the TEB-only and duct-only stroma „expressed gene sets‟  
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Table 3-5 Categorisation of 65 TEB epithelial genes based on molecular and biological 
function. 
TEB epithelial gene set comprised genes identified as commonly up-regulated in both isolated 
TEBs (TEB vs duct) and Post-LN tissue strips (Post-LN vs Pre-LN). All genes except Ect2 were 
assigned a molecular and biological function using information obtained from a literature search 
based on M. musculus and H. sapiens. Some biological functions of Ect2 were studied using C. 
elegans (*). 
 Biological Function 
Gene 
Symbol 
Gene Name 
M
ig
ra
tio
n
 
Morphogenesis/Cancer 
A
x
o
n
a
l 
G
u
id
a
n
c
e
 
O
e
stro
g
e
n
 
R
e
fe
re
n
c
e
 
M
a
m
m
a
ry
 
G
la
n
d
 
E
m
b
ry
o
n
ic
 
L
u
n
g
 
K
id
n
e
y
 
B
ra
n
c
h
in
g
 
Molecular Function: Cell Cycle (mitosis, meiosis, replication) and Cellular Proliferation 
Anln Anilin x x  x x  x x [281] [282] 
[283] 
Asf1B Asf1 anti-silencing function 1 
homolog B 
         
AurkB Aurora kinase B  x  x    x [284] [285] 
Birc5 Baculoviral IAP repeat-
containing 5 
x x  x    x [286] [287] 
[288] 
Bub1 Budding uninhibited by 
benzimidazoles 1 homolog 
 x 
 
 x 
 
    [289] [290] 
[291] 
Bub1B Budding unihibited by 
benzimidazoles 1 homolog 
beta 
   x 
 
   x 
 
[292] 
Ccna2 Cyclin A2  x       [293] 
Ccnb2 Cyclin B2          
Cenpa Centromere protein A  x      x [294] 
Dlg7 Disk large homolog 7  x   x x   [295] [296] 
[297] 
Dna2L DNA2 DNA replication 
helicase 2-like 
 x      x [298] 
Ect2 Ect 2 oncogene x(*)   x   x  [299] [300] 
[301] [302] 
Fbxo5 F-box protein 5      x       [303] 
Fignl1 Fidgetin-like 1   x x     [304] [305] 
[306] 
H2afx H2A Histone family member X  x      x [307] 
Hells Helicase,  lymphoid specific          
Hist1H2ab Histone cluster, H2ab        x  
Incep Inner centromere protein  x  x     [308] [284] 
[285] 
Kif11 Kinesin family member 11 x x  x   x x [309] [310] 
[311] [312] 
Kif23 Kinesin family member 23          
Kif2C Kinesin family member 2C x 
 
      x [313] 
Mcm3 Minichromosome 
maintenance deficient 3 
 x  x x   x [314] [315] 
[316] 
Mcm5 Minichromosome 
maintenance deficient 5 
       x  
Ncaph Non-SMC condensing I 
complex, subunit H 
         
Nusap1 Nuclear and spindle 
associated protein 1 
       x  
Pbk PDZ binding kinase  x  x x   x [317] [318] 
[319] 
Plk1 Polo-like kinase 1 x x      x [320] 
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Prc1 Protein regulator of 
cytokinesis 1 
 x      x [321] 
Racgap1 Rac CTPase-activating 
protein 1 
x x x  x  x  [322] [323] 
[324] [325] 
[326] 
Sgol2 Shugoshin-like 2 (S. Pombe)          
Skp2 S-phase kinase-associated 
protein 2 
x x  x   x  [327] [328] 
[329] [330] 
Smc4 Structural maintenance of 
chromosomes 4 
         
Stil Scl/Tal1 interrupting locus   x    x  [331] 
Tk1 Thymidine kinase 1  x      x [332] 
Top2a Topoisomerase (DNA)II alpha  x     x x [333] [334] 
Tpx2 Microtubule-associated 
protein homolog (X. Laevis)  
          x 
 
x [335] 
Uhrf1 Ubiquitin-like, containing 
PHD and RING finger domains 
  
x 
  
x 
 
x 
  x [336] [337] 
[338] 
Zwilch Kinetochore associated, 
homolog (D. Melanogaster) 
         
Molecular Function: Cell Adhesion 
Dlg7 Disk large homolog  x   x x   [295] [296] 
[297] 
Emb Embigin x x x  x x   [339] [340] 
[341] 
Fbln2 Fibulin 2  x x x  x    [342] [343] 
[344] 
Fbn2 Fibrillin 2 x  x x x x   [345] [346] 
[347] 
Fgb Fibrinogen x x  x x  x  [348] [349] 
[350] 
Lama1 Laminin x x  x    x   [351] [227] 
Ppp2r2b Protein phosphatase 2 
regulatory subunit 
 x       [352] 
Reln Reelin x x    x x  [353] [354] 
Vcan Versican x x  x x x x  [355] [356] 
[357] 
Wnt5a Wingless-related MMTV 
integration site 5a 
x 
 
x 
 
x 
 
x 
 
 x 
 
x 
 
x [358] [261] 
[359] 
Molecular Function: Cell Death (apoptosis, ubiquitin proteosome pathway) 
Atad2 ATPase family, AAA domain 
containing 2 
 x  x    x [360] 
Birc5 Baculoviral IAP repeat-
containing 5 
x x  x    x [287] [286] 
[288] 
Bub1 Budding uninhibited by 
benzimidazoles 1 homolog 
  
x 
  
x 
    [292] 
Ccna2 Cyclin A2  x       [293] 
Fbxo5 F-box protein 5  x       [303] 
Fignl1 Fidgetin-like 1   x x     [304] [305] 
[306] 
Ppp2r2b Protein phosphatase 2 
regulatory subunit 
 x       [352] 
Skp2 S-phase kinase-associated 
protein 2 
x x  x   x  [327] [328] 
[329] [330] 
Tk1 Thymidine kinase 1  x      x [332] 
Molecular Function: Intracellular Transport 
Kif11 Kinesin family member 11 x x  x   x x [309] [310] 
[311] [312] 
Kif23 Kinesin family member 23          
Kif2C Kinesin family member 2C x 
 
      x [313] 
Racgap1 Rac CTPase-activating 
protein 1 
x x x  x  x  [322] [323] 
[325] [324] 
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[326] 
Slc7a5 Solute carrier family 7  x  x    x [361] [362] 
Smc4 Structural maintenance of 
chromosomes 4 
         
Molecular Function: DNA Repair 
H2aFx H2A Histone family member X  x      x [307] 
Hist1h2ab Histone cluster, H2ab        x  
Neil3 Nei like 3 (E. Coli)          
Top2a Topoisomerase (DNA)II alpha  x     x x [333] [334] 
Uhrf1 Ubiquitin-like, containing 
PHD and RING finger domains 
 x 
 
 x 
 
x 
 
  x [336] [337] 
[338] 
Molecular Function: Signal Transduction 
Arhgap11a Rho GTPase activating 
protein 11a 
         
Pcp4 Purkinje cell protein 4   x    x  [363] [364] 
Ppp2r2b Protein phosphatase 2 
regulatory subunit 
 x       [352] 
Wnt5a Wingless-related MMTV 
integration site 5a 
x 
 
x 
 
x 
 
x 
 
 x 
 
x 
 
x [358] [261] 
[359] 
Molecular Function: Metabolism 
Gfpt2 Glutamine fructose-6-
phosphate transaminase 2 
         
Ltb4dh Leukotriene B4 12-
hydroxydehydrogenase 
         
Nt5dc2 5‟-nucleotidase domain 
containing 2  
         
Tk1 Thymidine kinase 1  x      x [332] 
Molecular Function: Transcription Regulation 
Il33 Interleukin 33 x x       [365] [366] 
Mcm3 Minichromosome 
maintenance deficient 3 
 x  x x   x [314] [315] 
[316] 
Myef2 Myelin gene expression factor          
Uhrf1 Ubiquitin-like, containing 
PHD and RING finger domains 
 x 
 
 x 
 
x 
 
  x [336] [337] 
[338] 
Molecular Function: Structural Protein 
H2afx H2A Histone family member X  x      x [307] 
Hist1h2ab Histone cluster, H2ab        x  
Tubb6 Tubulin beta 6 x        [367] 
Upk3a Uroplakin 3a          
Molecular Function: Immune Response 
Fgb Fibrinogen x x  x x  x  [350] [348] 
[349] 
Il33 Interleukin 33 x x       [365] [366] 
Itih2 Inter-alpha trypsin inhibitor, 
heavy chain 2 
         
Molecular Function: Growth Factor 
Nrg1 Neuregulin-1 type 1 beta 1a x x x x  x x  [368] [369] 
[370] [371] 
Molecular Function: Unknown 
Mlkl Mixed lineage kinase 
domain-like 
 x       [372] 
Serpinb11 Serine (or cysteine) 
peptidase inhibitor clade B, 
member 11 
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Thus, epithelial transcriptomes of TEBs and ducts were represented by two gene 
sets each, i.e. an „up-regulated gene set‟ and „expressed gene set‟ while their 
stroma associated signatures were represented by the „expressed gene set‟ only. 
„Pathway analysis‟ of these gene sets was performed to depict and compare the 
functional characteristics between epithelial and stromal transcriptomes of TEBs 
and ducts. 
Each data set was screened for the presence of mapped, function eligible genes, 
which were then assigned to different functional categories depending on their 
molecular and cellular function or their role in development and function of 
physiological systems. The over-represented biological functions were ranked 
according to the calculated p-values (See 2.2.5.9.1). 
The following numbers of genes were shown to be mapped and allocated a 
function according to IKD: within the „up-regulated gene sets‟ of the TEB and 
duct epithelium respectively, 422 and 186 were mapped and 355 (83%) and 148 
(79%) were allocated a function. With the „expressed gene sets‟ of TEB and duct 
epithelium respectively, 1374 and 3470 genes were mapped and 1198 (72%) and 
2810 (70%) genes were allocated a function. Finally the stroma „expressed gene 
sets‟ of TEB and duct consisted of 568 and 211 mapped genes respectively, of 
which 443 (76.5%) and 149 (70%) were allocated a function.  
„Pathway analysis‟ revealed clear differences between biological functions over- 
represented in the data sets of the TEBs and ducts environments. Differences in 
the biological functions were prominent in both of the studied functional 
categories, i.e. molecular and cellular function and physiological systems 
development and function. The top 5 molecular and cellular functions and the 
top 5 functions associated with physiological systems development and function 
that were over-represented in the data sets along with the number of genes 
complying with each category are shown in Table 3-6 and Table 3-7 
respectively.   
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3.2.6.4.1 Molecular and Cellular Functions: Identification of the top 
5 over-represented categories  
 
Genes up-regulated in TEB and duct epithelium („up-regulated gene sets‟) 
Briefly, as seen in Table 3-6, the set of genes up-regulated in TEB epithelium 
was functionally mostly associated with cell cycle and cell proliferation („Cell 
Cycle‟, „Cellular Assembly and Organisation‟, „Cellular Growth and 
Proliferation‟) and „DNA Replication, Recombination and Repair‟. The duct 
epithelium up-regulated gene set was rather associated with cellular signalling 
(„Cell-to-Cell Signalling and Interaction‟, „Cell Signalling‟), „Molecular Transport‟ 
or „Cell Death‟ than „Cell Proliferation‟. Both of the above mentioned gene sets 
also contained genes functionally associated with „Cellular Movement‟ which was 
interestingly ranked higher in the ductal data set (#2) with 24.3% of genes than 
in the TEB data set (#4) with 6% of genes.  
Genes expressed in the TEB- and duct-only epithelium („expressed gene sets‟) 
More prominent differences between the epithelial transcriptomes of TEBs and 
ducts were revealed when the IPA results for the entire expressed 
transcriptomes of TEB- or duct-only epithelium were compared. The most 
apparent difference was seen in terms of „Cellular Movement‟ which was the 
most over-represented function in the TEBs data set (27.8% of genes) but was 
absent from the top 5 functions associated with the ductal data set. The 
remaining four top functional categories of the TEB data set were associated 
with cellular proliferation and signalling („Cellular Growth and Proliferation‟, 
„Cell-to-Cell Signalling and Interaction‟, „Cellular Signalling‟) and „Molecular 
Transport‟ which made it comparable to the functional profile of the TEB „up-
regulated gene set‟. In contrast, the duct-only „expressed gene set‟ was shown 
to share fewer similarities with the duct „up-regulated gene set‟ and 
represented a more regulatory profile („DNA Replication, Recombination and 
Repair‟, „RNA Post-Transcriptional Modification‟, „Cellular Assembly and 
Organisation‟) than the TEB-only „expressed gene set‟. „Cell Cycle‟ and 
„Molecular Transport‟ were the two remaining biological functions over- 
represented in the duct-only „expressed gene set‟.  
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TEBs DUCTS 
 
Molecular and Cellular Function 
Number 
of genes 
(% of 
function 
eligible)  
 
Molecular and Cellular Function 
Number 
of genes 
(% of 
function 
eligible) 
GENES UP-REGUATED IN THE ISOLATED EPITHELIUM ‘UP-REGULATED GENE SETS’ 
Cell Cycle  137 
(38.6%) 
Cell-to-Cell Signalling and 
Interaction 
45 
(30.4%) 
Cellular Assembly and Organisation 82  
(23%) 
Cellular Movement 36 
(24.3%) 
DNA Replication, Recombination 
and Repair 
122 
(34%) 
Cell Death 55 
(37.1%) 
Cellular Movement 22  
 (6%) 
Cell Signalling 39 
(26.3%) 
Cellular Growth and Proliferation 126 
(35.5%) 
Molecular Transport 52  
(35%) 
GENES EXPRESSED IN THE ISOLATED EPITHELIUM ‘EXPRESSED GENE SETS’ 
Cellular Movement 333 
(27.8%) 
DNA Replication, Recombination 
and Repair 
332 
(11.8%) 
Cell-to-Cell Signalling and 
Interaction 
334 
(27.9%) 
Cell Cycle 416 
(14.8%) 
Cellular Growth and Proliferation 414 
(34.5%) 
RNA Post-Transcriptional 
Modification 
113 
(4%) 
Cell Signalling 232 
(19.3%) 
Cellular Assembly and 
Organisation 
151 
(5.3%) 
Molecular Transport 209 
(17.4%) 
Molecular Transport 103 
(3.6%) 
GENES EXPRESSED IN THE STROMA ‘EXPRESSED GENE SETS’ 
Cell Death 148 
(33.4%) 
Lipid Metabolism 22 
(14.7%) 
Cell Morphology 76 
(17.1%) 
Small Molecule Biochemistry 42 
(28.9%) 
Cellular Growth and Proliferation 141 
(31.8%) 
Carbohydrate Metabolism 15 
(10%) 
Cellular Movement 96 
(20.5%) 
Cellular Compromise 7 
(4.7%) 
Cell-to-Cell Signalling and 
Interaction 
105 
(23.7%) 
Cell Morphology 11 
(7.4%) 
Table 3-6 Comparison of the top 5 cellular and molecular functions over-represented in the 
epithelial and stromal data sets of TEBs and ducts. 
The top 5 functions were identified using IPA. The over-representation of each functional category 
within the data set was shown to be statistically significant (p≤0.05). Functional analysis was 
performed on the three gene sets: genes up-regulated in the isolated epithelium of TEBs and ducts 
(3.2.6.1.1), genes expressed in the isolated epithelium of TEBs and ducts (3.2.6.2.1) and genes 
expressed in the stroma of TEBs and ducts (3.2.6.2.2). Only genes mapped and function eligible 
according to the IKD were used for the analysis. Number of genes and the calculation of the 
percentage of genes were based on the number of genes associated with the given function and 
the number of function eligible genes within the studied data set. The list of genes belonging to 
each functional category and the calculated p-values are shown in Appendix 7. 
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Genes expressed in TEB- and duct-only stroma („expressed gene sets‟) 
The biggest differences between the TEB and duct transcriptomes were 
identified in the stromal compartments. The stroma of the TEB-only, similarly to 
the epithelium, was characterised as a very dynamic and motile environment 
(„Cell Morphology‟, „Cellular Growth and Proliferation‟, „Cell Death‟, „Cell-to-
Cell Signalling and Interaction‟, „Cellular Movement‟). On the other hand, the 
stromal transcriptome of the ducts was mostly involved in sustaining the ductal 
epithelium by being involved in metabolic processes („Lipid Metabolism‟, „Small 
Molecule Biochemistry‟ or „Carbohydrate Metabolism‟), „Cellular Compromise‟ 
and „Cell Morphology‟.  
3.2.6.4.2 Physiological System Development and Function – 
Identification of the top 5 over- represented categories 
 
Functional differences between TEB and duct epithelial and stromal data sets 
were also noticeable with regards to their involvement in physiological system 
development and function. Only 1.1%-6.5%, 1.8%-2.9% and 0.7%-8.7% genes, 
however, were assigned to the top 5 functions in the TEB epithelium „up-
regulated genes set‟, duct-only epithelium „expressed gene set‟ and duct-only 
stroma „expressed gene set‟ respectively. 
Genes up-regulated in TEB and duct epithelium („up-regulated gene sets‟) 
As seen in the Table 3-7 most of the genes identified to be up-regulated in the 
TEB epithelium were involved in maintenance of tissue morphology and 
embryonic development. Furthermore, they were also found to play roles in 
regulating the function and development of connective tissue and 
cardiovascular, skeletal and muscle systems. Genes up-regulated in the duct 
epithelium were also shown to play roles in the „Development and Function of 
the Cardiovascular System‟ and to be functionally associated with „Tissue 
Morphology and Development‟. In addition, genes over-expressed in the duct 
epithelium were involved in „Haematological System Development and Function‟ 
and „Immune Cell Trafficking‟.  
  186 
 
TEBs DUCTS 
Physiological System 
Development and Function 
Number of 
genes  
(% of 
function 
eligible)  
Physiological System 
Development and Function 
Number 
of genes 
(% of 
function 
eligible) 
GENES UP-REGULATED IN THE ISOLATED EPITHELIUM ‘UP-REGULATED GENE SETS’ 
Tissue Morphology 12 
(3.4%) 
Haematological System 
Development and Function 
51 
(34.4%) 
Embryonic Development 23 
(6.5%) 
Tissue Morphology 34 
(23%) 
Cardiovascular System 
Development and Function  
4  
(1.1 %) 
Immune Cell Trafficking 35 
(23.6%) 
Connective Tissue Development 
and Function 
29  
(8.1%) 
Cardiovascular System 
Development and Function 
21 
(14.2%) 
Skeletal and Muscular System 
Development and Function 
4  
(1.1%) 
Tissue Development 23 
(15.5%) 
GENES EXPRESSED IN THE ISOLATED EPITHELIUM ‘EXPRESSED GENE SETS’ 
Immune Response 339 
(28.3%) 
Connective Tissue Development 
and Function 
83 
(2.9%) 
Immune and Lymphatic System 
Development and Function 
301 
(25.1%) 
Embryonic Development 65 
(2.3%) 
Tissue Morphology 245 
(20.4%) 
Tumour Morphology 53 
(1.8%) 
Haematological System 
Development and Function 
348 
(29%) 
Cardiovascular System 
Development and Function 
57 
(2%) 
Tissue Development 309 
(25.8%) 
Organ Development 57 
(2%) 
GENES EXPRESSED IN THE STROMA ‘EXPRESSED GENE SETS’ 
Organismal Survival 74 
(16.7%) 
Skeletal and Muscular System 
Development and Function 
13 
(8.7%) 
Haematological System 
Development  and Function 
102 
(23%) 
Tissue Development 10 
(6.7%) 
Cardiovascular System 
Development and Function 
51 
(11.5%) 
Organismal Development 9 
(6%) 
Tissue Morphology 75 
(16.9%) 
Auditory and Vestibular System 
Development and Function 
1 
(0.7%) 
Tissue Development 88 
(19.8%) 
Cardiovascular System 
Development and Function 
6 
(4%) 
Table 3-7 Comparison of the top 5 categories associated with the physiological system 
development and function shown to be over-represented in the epithelial and stromal data 
sets of TEBs and ducts. 
For the legend see Table 3-5. The list of genes belonging to each functional category and the 
calculated p-values are shown in Appendix 8.    
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Genes expressed in the TEB- and duct-only epithelium („expressed gene sets‟) 
The top functional categories over-represented in the epithelium of TEB- and 
duct-only „expressed gene sets‟ were different to these seen in the TEB and duct 
epithelium „up-regulated gene sets‟. Although, „Tissue Morphology‟ and „Tissue 
Development‟ were still within the functional categories over-represented in the 
TEB-only epithelium „expressed gene set‟, here the highest ranked functions 
were „Immune Response‟ (28.3% of genes) and „Immune System Development 
and Function‟ (25.1% of genes). In contrast to the analysis based on the up-
regulated epithelial genes, this analysis indicated that the „Haematological 
System Development and Function‟ was associated with the TEBs. Furthermore, 
functional categories, such as „Embryonic Development‟, „Cardiovascular- and 
Connective Tissue Development and Function‟ were also shown to be associated 
with ducts instead of TEBs, contradicting the results of the above presented 
analysis. The two remaining functional categories for the duct-only epithelium 
expressed gene data set were „Tumour Morphology‟ and „Organ Development‟.   
Genes expressed in the TEB- and duct-only stroma („expressed gene sets‟) 
Finally, functional analysis of genes expressed in the stroma failed to reveal any 
new functional characteristics of the TEB-only stroma, apart from implicating it 
in „Organism survival‟. It confirmed, however, the contribution of TEB associated 
genes (epithelial as well as stromal) to the regulation of tissue morphology and 
development and their involvement in the development and function of 
haematological and cardiovascular systems. Analysis of the duct-only stroma 
„expressed gene set‟, however, implicated this transcriptome in both - the 
previously mentioned functional categories („Skeletal- and Cardiovascular 
System Development and Function‟, „Tissue Development‟) and new ones, such 
as – „Organism Development‟, „Auditory and Vestibular System Development and 
Function‟. 
All functional categories found to be over-represented in this analysis were 
statistically significant. The list of genes implicated in each cellular/molecular 
process-based category and physiological system development and function 
based categories, alongside with the p-values calculated for each category are 
shown in Appendix 7 and Appendix 8 respectively.       
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3.2.6.5 ‘Cellular Movement’ during pubertal mouse mammary gland 
morphogenesis – Comparison of transcriptomes from TEBs and 
ducts 
The association of TEB and duct transcriptomes with the three key biological 
functions: „Cellular Movement‟, „Nervous System Development and Function‟ and 
„Embryonic Development‟ were chosen to be discussed in more detail (See 
3.2.6.5, 3.2.6.6 and 3.2.6.7) (Figure 3-11). 
One of the main events which characterises pubertal mouse mammary gland 
development is the expansion of the ductal tree. This ductal morphogenesis 
consists of ductal elongation mediated by TEBs outgrowth, branching and 
directional turning, and secondary ductal branching. None of these processes are 
yet fully characterised but based on their motile character they are likely to be 
associated with the expression of genes functionally involved in migratory 
processes, cellular movement or cellular invasion.  
Hence, to explore this hypothesis, the information obtained from IPA (See 
3.2.6.4) was used to examine the level and expression pattern of genes 
associated with „Cellular Movement‟ during pubertal mouse mammary gland 
development. Genes identified as associated with the „Cellular Movement‟ 
according to the IKD, were compared throughout all six gene sets (TEB or duct 
epithelium „up-regulated gene sets‟, TEB- or duct-only epithelium „expressed 
gene sets‟, TEB- or duct-only stroma „expressed gene sets‟). Furthermore, based 
on the emerging evidence which shows the association of EMT, which is a process 
in which the adherent epithelial cells shed their epithelial characteristics in 
favour of acquiring mesenchymal properties, with promoting cellular migration 
during embryonic development or cellular invasion during tumour metastasis 
formation (reviewed in [373]), the gene sets shown to be differentially 
expressed in TEB environment were manually screened for the presence of EMT 
signature genes. The EMT signature consists of EMT core signature genes plus 10 
additional key mesenchymal markers (See 2.2.5.9.2). The EMT core signature  
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Figure 3-11 Selective, Ingenuity Pathway Analysis (IPA)-based functional comparison 
analysis of the identified pubertal gene sets. 
IPA analysis was performed as described in 3.2.1.5 and the following functional categories were 
selected for the comparison analysis: (A) Cellular Movement (B) Nervous System Development 
and Function (C) Embryonic Development. The association of each functional category within the 
data set was shown to be statistically significantly (p≤0.05). Comparison analysis was performed 
using three gene sets: genes up- regulated in the isolated epithelium of TEBs and ducts (3.2.6.1.1), 
genes expressed in the isolated epithelium of TEBs and ducts (3.2.6.2.1) and genes expressed in 
the stroma of TEBs and ducts (3.2.6.2.2). Only genes mapped and ‘function eligible’ according to 
the IKD were used for the analysis. The calculation of the percentages of genes associated with 
each category was based on the number of genes associated with the given function and the 
overall number of function eligible genes within the studied data set. The full list of subcategories 
identified within each functional category, genes belonging to each subcategory and the calculated 
p-values are shown in Appendix 9.    
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was developed by Taube at al. (2010) and it consists of 87 and 159 genes that 
were found up-regulated and down-regulated respectively as a response to 
inducing EMT in breast cancer cells in vitro [270] (See Table 2-8). Based on the 
fact that a mesenchymal genotype can be characterised by both the up-
regulation of mesenchymal and down-regulation of epithelial markers both the 
TEB up- and down-regulated (i.e. duct up-regulated) gene lists were screened.  
The presence of mesenchymal markers (up-regulated in response to EMT) 
amongst the TEB down-regulated genes and the presence of epithelial markers 
(down-regulated in response to EMT) in the TEB up-regulated genes was also 
assessed. This served as a negative control.  
Terminal end buds 
In general, most genes associated with „Cellular Movement‟ were identified 
within the TEB gene sets. 27.8%, 21.7% and 6.2% of epithelium „expressed-‟, 
stroma „expressed-‟ and epithelium „up-regulated gene sets‟ respectively were 
shown to be functionally implicated in „Cellular Movement‟ (Figure 3-11 A). 
Some of the functional sub categories represented in the gene set expressed in 
the TEB-only epithelium were „cellular movement or migration of eukaryotic 
cells, -immune response cells, -cell lines (normal, embryonic, tumour)‟; 
„infiltration or chemotaxis of eukaryotic cells, „-immune response cells‟ and 
„invasion of eukaryotic cells, -cell lines (normal and tumour)‟. Some of the genes 
expressed in the TEB-only stroma were shown to be involved in the „movement 
of eukaryotic cells, -cell lines (normal and tumour)‟; „migration of normal cells, 
-cell lines (normal and tumour), -immune response cells‟; „cell movement of 
central nervous system cells, -immune response cells, -tumour cell lines‟; 
„invasion of normal cells and neuroglia‟ and „chemotaxis of eukaryotic cells, -
bone and nervous tissue cell lines‟‟. Genes up-regulated in the TEBs epithelium, 
on the other hand, were shown to be mostly implicated in the „chemorepulsion 
of neuritis‟ and „chemotaxis of bone marrow-derived macrophages‟. 
The screening of TEB environment up-and down-regulated genes lists for the 
presence of EMT signature genes revealed presence of 3 and 11 EMT up-
regulated markers within TEB epithelium (TEBs vs ducts) and TEB epithelium-
stroma (Post-LN vs Pre-LN) up-regulated genes respectively which accounted for 
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3 % and 11% of EMT signature genes respectively. As for the EMT down-regulated 
markers, 8 (5%) and 16 (10%) of them could be seen in TEB epithelium (ducts vs 
TEBs) and TEB epithelium-stroma (Pre-LN vs Post-LN) down-regulated genes 
respectively. Furthermore, 17 out of the 31 EMT marker genes found to be 
differentially expressed in TEB environment, have not yet been described or 
studied in mouse mammary gland before. These genes are: Col1a2, Col5a2, 
Extracellular matrix protein 1(Ecm1), Fibroblast activation protein (Fap), 
Fibulin 1 (Fbln1), Fibrillin 1 (Fbn1), Cytochrome b reductase 1 (Cybrd1), 
Adaptor protein complex AP1, mu 2 subunit (Ap1m2), Coxsackie virus and 
adenovirus receptor (Cxadr), Potassium channel, subfamily K, member 1(Kcnk1), 
Kallikrein-related peptidase 8 (Klk8), Ladinin (Lad1), Tripartite motif-
containing 29 (Trim29), Aldehyde dehydrogenase family 1, subfamily A3 
(Aldh1a3), N-myc downstream regulated gene 1 ( Ndrg1) and Synaptotagmin-like 
1 (Slp1).  
The negative experimental control, however, revealed that 4 (4%) and 3 (3%) of 
EMT up-regulated genes (mesenchymal markers) were down-regulated in TEB 
epithelium (ducts vs TEBs) and TEB epithelium-stroma (Pre-LN vs Post-LN) 
respectively and 6 (3.7%) and 5 (3%) of EMT down-regulated genes (epithelial 
markers) were up-regulated in TEB epithelium (TEBs vs ducts) and TEB 
epithelium-stroma (Post-LN vs Pre-LN) respectively.  
Full list of identified genes can be seen in Table 3-7. 
Ducts 
Looking at the gene expression for ducts, 24.3%, 5.3% and 0.9% of genes 
belonging to the epithelium „up-regulated-„, stroma „expressed-„, epithelium 
„expressed gene sets‟ respectively were shown to be functionally involved in 
processes associated with „Cellular Movement‟ (Figure 3-11 A). Genes up-
regulated in duct epithelium were shown to be associated with the following 
subcategories: „cell movement of immune response cells‟, „-cell lines (normal 
and tumour)‟; „cell rolling‟ or „infiltration of immune response cells‟; 
„chemotaxis of immune response cells and fibroblasts‟; „migration of immune 
response cells, -cell lines (normal and tumour), -astrocytes‟ and „invasion of 
normal cells, -cell lines (normal and tumour)‟. Subcategories for the stroma  
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EMT up-regulated markers up-regulated in 
Isolated TEB epithelium TEB epithelium and stroma 
Cytochrome b reductase 1 (Cybrd1) 
Hyaluronan synthase 1 (Has2) 
Wingless-related MMTV integration site 5a 
(Wnt5a) 
Collagen type1, alpha 2 (Col1a2) 
Collagen type 5, alpha 2(Col5a2) 
Discorin domain receptor family member 2 
(Ddr2) 
Extracellular matrix protein 1 (ECM1) 
Fibroblast activation protein (FAP) 
Fibulin 1 (Fbln1) 
Fibrillin 1 (Fbn1) 
Olfactomedin-like 3 (Olfml3) 
Procollagen C-endopeptidase enhancer 
protein (Pcolce) 
Paired related homeobox 1 (Prrx1) 
Wingless-related MMTV integration site 5a 
(Wnt5a) 
EMT down-regulated markers down-regulated in 
Isolated TEB epithelium TEB epithelium and stroma 
Annexin A8 (Anxa8) 
Aldehyde dehydrogenase family 1 subfamily 3a 
(Aldh1a3) 
Interleukin 1 beta (Il1b) 
Keratin 14 (Krt14) 
Keratin 15 (Krt 15) 
Keratin 17 (Krt17) 
N-myc downstream regulated gene 1 (Ndrg1) 
Stomatin-like 1 (Slp1) 
Annexin A8 (Anxa8) 
Adaptor protein complex AP-1, mu 2 subunit 
(Ap1m2) 
BCL-2 interacting killer (BIK) 
Coxsackie virus and adenovirus receptor 
(Cxadr) 
Interferon regulatory factor 6 (Irf6) 
Potassium channel, subfamily K, member 1 
(Kcnk1) 
Kallikrein related-peptidase 8 (Klk8) 
Keratin 17 (Krt17) 
Keratin 18 (Krt18) 
Keratin 5 (Krt5) 
Ladinin (Lad1) 
Prostasin (Prss8) 
Tripartite motif-containing 29 (Trim29) 
Stomatin-like 1 (Slp1) 
EMT up-regulated markers down-regulated in (negative control) 
Isolated TEB epithelium TEB epithelium and stroma 
Latent transforming growth factor beta binding 
protein 1 (Ltbp1) 
Latent transforming growth factor beta binding 
protein 2 (Ltbp2) 
Membrane metallo endopeptidase (Mme) 
Pentraxin related gene (Ptx3) 
Coiled-coil domain containing 92 (Ccdc92) 
Latent transforming growth factor beta 
binding protein 2 (Ltbp2) 
Melanophilin (Mlph) 
EMT down-regulated markers up-regulated in (negative control) 
Isolated TEBs TEB epithelium and stroma 
Cyclin D2 (Ccnd2) 
Desmocollin 2 (Dsc2) 
Insulin-like growth factor binding protein 2 
(Igfbp2) 
Keratin 5b (Krt6b) 
Rnf128 
S100 calcium binding protein A14 (S110a14) 
Annexin A3 (Anxa3) 
Gho GTPase activating protein 25 (Arhgap25) 
Coronin, actin binding protein 1A (Coro1a) 
Interferon gamma inducible protein 30 
(Ifi30) 
Interleukin 80 (Il80) 
Table 3-8 List of EMT core signature genes also identified as differentially expressed in TEB 
environment. 
EMT signature consists of the EMT core signature genes plus the 10 additional key mesenchymal 
markers (See Table 2-8). EMT signature consists of the up-regulated as well as down-regulated in 
response to EMT genes thus both the TEB up-regulated (TEBs vs ducts) (Post-LN vs Pre-LN) and 
down-regulated (ducts vs TEBs) (Pre-LN vs Post-LN) gene lists were screened. Genes that have 
not been studied in mouse mammary gland before are highlighted in grey. Screening for EMT up-
regulated markers identified as down-regulated in TEB environment and the EMT down-regulated 
markers identified as up-regulated in TEB environment was used as a negative control.  
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expressed genes around ducts only included: „cell movement of microtubules, -
epithelial cells‟; „migration of muscle cells, -gonadal cell lines, -hepatic stellate 
cells, -proepicardial cells‟; „invasion of hybrid cells, -smooth muscle cells‟ and 
„chemotaxis of keratinocytes‟. Finally, all of the „Cellular Movement‟ associated 
genes expressed in the duct-only epithelium were functionally connected with 
„cytokinesis‟.  
In summary, the following gene sets were identified as exhibiting the most 
motile character: TEB-only epithelium „expressed gene set‟, duct epithelium 
„up-regulated gene set‟, TEB-only stroma „expressed gene set‟ and duct-only 
stroma „expressed gene set‟.  
The full list of detailed functional categories, calculated p-values and genes 
complying with each category are shown in Appendix 9 A.       
3.2.6.6  ‘Nervous System Development and Function’ during mouse 
mammary gland morphogenesis – Comparison of transcriptomes 
from TEBs and ducts 
Several genes previously recorded to be associated with nervous system 
development or function, i.e. axonal guidance or axonal growth cones 
development, were recently suggested to be involved in a ductal morphogenesis 
of the mouse mammary gland [113] [259]. 
Based on those observations, we performed a detailed functional analysis of the 
„Nervous System Development and Function‟ associated genes in the 
transcriptomes of TEBs and ducts.  
The study was based on the information obtained from the IPA and the 
comparison analysis was performed as described in 3.2.6.4. As presented in 
Figure 3-11 B, the majority of nervous system associated genes were expressed 
within the stroma of TEBs (9.7%), duct epithelium up-regulated genes (5.4%) and 
the duct-only stroma (4%). In contrast, very few nervous system associated genes 
were expressed within the TEB epithelium „up-regulated gene set‟ (0.9%) and 
duct epithelium „expressed gene set‟ (0.1%).  
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Terminal end buds 
Thus, the clearest reference in pubertal mouse mammary gland gene expression 
to the pattern of gene expression characteristic for the nervous system 
development and function was seen in the stroma of the TEBs. In contrast, the 
epithelium of TEBs expressed only a single gene, implicated in chemorepulsion 
of sympathetic neurites (Sema3B). Some of the TEB-only stroma associated 
functional subcategories included: „outgrowth of neurites‟, „-sensory axons‟; 
„myelination‟; „activation, chemorepulsion or stimulation of neurons‟; „migration 
or survival of astrocytes‟ and „chemotaxis of neuronal tissue cell lines‟.  
Ducts 
Although fewer „Nervous System Development and Function‟ associated genes, 
were found in the ductal genes sets, they were expressed almost equally 
between epithelium and stroma. Some of the functional subcategories were as 
follows: „survival, migration of astrocytes‟; „activation and stimulation of 
neurons‟ (duct epithelium up-regulated genes), „maturation of synaptic vesicles‟ 
(duct-only epithelium expressed genes) and „axogenesis of neurons‟ and 
„communication of nervous tissue cell lines‟ (duct-only stroma expressed genes).  
The full list of detailed functional categories, calculated p-values and genes 
complying with each category are shown in Appendix 9 B.  
3.2.6.7 ‘Embryonic Development’ during pubertal mouse mammary gland 
morphogenesis – Comparison of transcriptomes from TEBs and 
ducts 
Embryonic development is known to be fully dependent on the presence of 
reciprocal signalling between the epithelial and mesenchymal environments 
[374]. Furthermore, stromal-epithelial interactions are vital for normal post 
natal ductal outgrowth and branching of the mouse mammary gland [126] and 
play an important role in creating a permissive environment for initiation and 
promotion of carcinogenesis (reviewed in [375]).  
  195 
 
Given the great importance of stromal-epithelial cross-talk during both mouse 
mammary morphogenesis and embryonic development, the TEB and ductal gene 
sets were also screened for the presence of genes, identified in the IKD as 
implicated in „Embryonic Development‟ (as described in 3.2.6.4). IPA based, 
comparison analysis identified „Embryonic Development‟ associated genes in all 
of the examined genes sets, i.e. both epithelial and stromal compartments of 
TEBs and ducts. The direct comparison of TEB and duct environments showed a 
slightly stronger association of TEB data sets with „Embryonic Development‟ than 
duct data sets. Furthermore, both epithelial and stromal compartments of TEBs 
or ducts contained a similar percentage of genes known to be involved in 
embryonic development.  
Terminal end buds 
Amongst TEB gene sets, 4.2%, 6.5% and 5.9% of epithelium expressed, epithelium 
up-regulated and stroma expressed genes respectively were shown to be 
functionally associated with the embryonic development (Figure 3-11 C). Some 
of the functional subcategories identified to be associated with the TEBs gene 
sets were as follows: „remodelling or patterning of the tissue (epithelium 
expressed genes)‟, „formation of embryoblast and mesenchyme‟; „survival of 
embryonic cells‟; „patterning of nervous tissue‟ (epithelium up-regulated genes) 
and „development of embryo‟.  
Ducts 
As for ducts gene sets, 2.3%, 4% and 4.7% of epithelium expressed, epithelium 
up-regulated and stroma expressed genes respectively were previously 
implicated in „Embryonic Development‟ (Figure 3-11 C). The following examples 
of functional subcategories were associated with identified genes: „survival or 
cell death of embryonic cells‟; „growth of embryo and blastocyst‟; „folding of 
embryonic tissue‟; „proliferation of morula‟ (epithelium expressed genes); 
„formation of forelimb bud‟, „‟morphology of branchial arch‟ (stroma expressed 
genes) while all of the „Embryonic Development‟ associated genes identified in 
the ductal epithelium „up-regulated gene set‟ were shown to be functionally 
implicated in „branching morphogenesis of carcinoma, -thyroid tumour, and 
kidney cell lines‟.  
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The full list of detailed functional categories, calculated p-values and genes 
complying with each category are shown in Appendix 9 C. 
3.2.7  Summary 
This study was performed to carry out detailed microarray analysis of the mouse 
mammary gland pubertal transcriptome. As a result, 6 individual gene sets, 
containing genes expressed or up-regulated in the epithelium or stroma of the 
TEBs or ducts were identified. Furthermore, 65 genes were selected as potential 
new regulators of pubertal mouse mammary gland morphogenesis, based on 
their association with the epithelium of TEBs. A literature search allowed 
classification of these genes according to their main biological function and 
involvement in other biological processes known to share similarities with 
mammary gland morphogenesis, i.e. lung, kidney morphogenesis and cancer, 
cellular migration, embryonic and branching morphogenesis and axonal 
guidance. Further „functional‟ analysis was performed on the epithelial and 
stromal gene sets using IPA to identify the top biological functions over-
represented in each gene set. Epithelial and stromal gene sets were also 
screened and compared for the presence of „Cellular Movement‟, „Nervous 
System Development and Function‟ and „Embryonic Development‟ associated 
genes and the main associated functional categories were identified. Finally, 
TEB environment up-regulated and down-regulated genes were screened for the 
presence of EMT-associated genes. 
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3.3 Discussion 
Gene expression profiling using DNA microarrays is one of the most successful 
tool for the analysis of global gene expression. Although it does have its 
drawbacks, such as decreased sensitivity of signal detection if the gene 
expressing cells comprise a small subset of cells within the tested tissue, and 
requirement for good quality RNA, it is the only method that allows simultaneous 
analysis of the expression levels for large numbers of genes. Since the 
completion of the human genome project and sequencing projects in other 
species, DNA microarrays aid quick and comprehensive analysis and comparison 
of multiple transcriptomes. This high throughput overview of the transcriptome 
can then be used to either identify the differentially expressed genes or over-
represented trends in cellular functions, regulatory mechanisms and pathways 
which taken together provide clues about the studied system and can serve as a 
scaffold for further investigations.  
The principal aim of this part of the project was to use oligonucleotide 
microarrays to study gene expression during ductal outgrowth of pubertal mouse 
mammary gland to investigate its underlying mechanisms. The main 
morphological characteristic of the mouse mammary gland at this stage is the 
presence of TEBs at the tips of the growing ducts. TEBs are only seen at puberty 
and generally regress upon adulthood when ductal epithelium reaches the edge 
of the fat pad. They are highly motile, and based on their localisation, they are 
thought to drive forward ductal outgrowth, promote primary branching by 
undergoing dichotomous bifurcation and turning and regulate spatial patterning 
of the ductal tree (reviewed in 1.2.2.1). Thus, it seems that a good 
understanding of TEB biology is fundamental to understanding the mechanisms 
that underlie and regulate the phenomenon of ductal morphogenesis. Despite 
that the function of individual genes in TEB formation and ductal outgrowth have 
been studied using several mouse models (for example: over-expression of FGF4 
or ErbB2 deficiency was shown to cause disorganisation of TEB morphology and 
structure [158] [118]) (Table 1-1) or in vitro experiments, such as 3D Matrigel 
gel cultures of mammary epithelial organoids [105], our current knowledge of 
TEB associated gene expression is limited to two microarray studies, carried out 
by Morris et al. (2006) [259] and Kouros-Mehr et al. (2006) [256]. Although, to 
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date, there are six microarray analyses that have been carried out to provide 
insights into the pubertal transcriptome, these are the only two that used 
isolated epithelium of TEBs and ducts, with the former using enzymatic digestion 
and the latter microdissection to isolate the epithelium. McBryan et al. (2007) 
[194]; Deroo et al. (2009) [257]; Howlin et al. (2006) [193] and Master et al. 
(2002) [258] used whole mouse mammary glands which although useful for 
comparing general gene expression patterns between samples, are limited in 
their detection of genes that are weakly expressed or present only within a 
minor population of cells, as for TEBs in the whole mammary gland.    
Given the importance of TEBs in pubertal mouse mammary gland morphogenesis 
and the currently limited understanding of the biology behind the TEB driven 
ductal patterning at puberty, this project was devised to present a 
comprehensive study of the TEB transcriptome. The experimental methodology 
that we used was based on that previously developed in our laboratory and 
published by Morris et al. (2006) using an enzyme-based technique for TEB and 
duct isolation. It uses collagenase II to digest collagen and mechanical force to 
further separate the epithelium from the stroma and as demonstrated in that 
early study is an efficient way to isolate the individual epithelial structures 
without compromising the quality of their RNA content [113]. Collagen fibres are 
major components of the fibrous ECM in the mouse mammary gland. They anchor 
the epithelial cells and provide them with physical support and thus, when 
digested, the epithelium can be easily separated from its surrounding stroma. It 
is worth noting, however, that the composition of the fibrous connective ECM 
and thus the amount of deposited collagen varies depending on its spatial 
location. It is denser at the neck region of TEBs or around the ducts and looser 
at the tips and flanks of TEBs [53]. Therefore, while it is fairly easy to isolate a 
clear TEB, it is often seen that the ductal epithelium requires longer exposure to 
enzyme to be successfully isolated from the stroma. The Morris et al. (2006) 
study, however, had limitations in terms of the restricted transcriptome 
represented on these early microarray chips - MG-U74Av2 chips from Affymetrix 
(10, 043 annotated transcripts) and the methods available for data analyses at 
the time.  
In our study, we used Affymetrix exon in situ synthesised oligonucleotide 
microarrays, which provide 17,500 well annotated transcript IDs and enable the 
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differential examination of gene expression at the exon level. Along with manual 
analysis, we used several types of bioinformatic software to facilitate a 
comprehensive analysis of the obtained microarray data. Although, similarly to 
Morris et al. (2006), we used WT mice to collect isolated TEB and duct 
epithelium, we employed TG mice instead of their WT counterparts to collect 
mammary tissue strips. TG mice express EGFP under the control of a CAG 
promoter (combination of -actin promoter and hCMV enhancer) [265]. Due to 
differences in cell density, EGFP expression is stronger in epithelium than in 
stroma, which facilitates the visualisation of the ductal tree under UV and thus 
enables more accurate assessment of tissue strip boundaries and hence more 
reliable comparison of microarray data. We used the RNA extracted from 
mammary tissue strips, Pre-LN (ductal epithelium and stroma) and Post-LN (TEB 
and duct epithelium and stroma) to validate gene expression patterns obtained 
from the isolated epithelium [113]. Both TEB and ducts are embedded in 
mammary stroma which not only provides physical support, but also serves as a 
signalling source which is a prerequisite for normal TEB formation and ductal 
outgrowth. It is, therefore, important to ensure that the removal of epithelium 
from its natural environment does not alter gene expression. In addition, Post- 
and Pre-LN tissue strips were used to identify the stroma associated genes 
around TEBs and ducts respectively.    
3.3.1 Identification of pubertal signature of mouse mammary 
gland - Main concept behind the analysis  
We compared gene expression levels between TEBs and ducts and identified 
genome wide epithelium- (See 3.2.6.1.1 and 3.2.6.2.1), epithelium-stroma- 
(See 3.2.6.1.2) and stroma associated (See 3.2.6.2.2) signatures of TEBs and 
ducts and thus presented the most comprehensive study of these structures to 
date. Reciprocal cross-talk between epithelial and stromal compartments is one 
of the prerequisites for normal ductal morphogenesis at puberty; however, most 
studies trying to decipher epithelial or stromal gene expression have mostly used 
IHC, IF or in situ hybridisation on mouse mammary gland tissue sections [152] 
[256] which is time consuming and can only investigate a restricted number of 
pre-chosen genes. More recently microarray analysis has been utilised to 
investigate TEB and duct associated gene expression. While both Kouros-Mehr et 
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al. (2006) and Morris et al. (2006) successfully isolated and studied epithelial-
stromal environments of TEBs and ducts, and Morris et al. (2006) further 
succeeded in the isolation and comparison of their epithelial transcriptomes, the 
characterisation of stromal transcriptomes has proven a bigger challenge and has 
not been previously reported. Our study therefore not only adds to the 
understanding of epithelial transcriptomes, but also identifies and characterises 
stromal signatures of TEB and ducts so providing detailed gene expression 
analysis of both epithelium and stroma of TEBs and ducts.  
We used various microarray analysis tools to identify different types of gene sets 
(either the „up-regulated gene sets‟ or the „expressed gene sets‟) and thus 
produced an extensive array of gene expression data that could be used to 
unravel and study the characteristics of each signature.  
Given the large amount of collected data, this project was mainly focused on:  
 Identification of new potential regulators of mouse mammary gland 
morphogenesis at puberty. 
 Identification and comparison of functional characteristics of the 
epithelial and stromal transcriptomes of TEBs and ducts.  
The overview of the experimental design of microarray analyses carried out in 
this project can be seen in Figure 3-1 (p.151). The entire expression database 
(.CEL and .CHP files) however, is made available in a Supplementary DVD.   
3.3.2 Identification and classification of new potential regulators 
of mouse mammary gland morphogenesis at puberty 
Numerous studies have identified stromal and epithelial genes that could 
orchestrate ductal morphogenesis to date (reviewed in 1.2.3). Some of the most 
recent findings include: the essential role of Reelin (Reln) signalling in normal 
extension and expansion of the ductal tree [353] and the requirement for CrkII 
expression in normal ductal elongation at puberty [246]. Here, we further 
contribute to this research by utilizing microarray gene expression analysis to 
search for new pubertal regulators of ductal outgrowth. Since this produced a 
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vast amount of gene expression data we focused our search solely on TEBs. It is 
important to note, however, that although when compared to TEBs, ducts are 
considered growth quiescent, they do give rise to secondary branching and thus 
play an important role in pubertal patterning of the ductal tree [114]. It may 
therefore be of benefit to repeat these analyses using the duct „up-regulated 
gene set‟. 
3.3.2.1 Comments on the methodology used 
We looked at two sets of TEB „up-regulated gene sets‟: the TEB epithelium- and 
TEB epithelial-stromal „up-regulated gene sets‟. These were identified using 
isolated epithelium and whole mammary tissue strips respectively (For the 
summary of experimental concept see Figure 3-1). We used the whole mammary 
tissue strips to ensure that the observed changes in gene expression were real 
and did not arise as a result of the isolation procedure or errors in data analysis. 
Although an original study by Morris et al. (2006) [113] had indicated this was 
not the case, it is possible that any potential difference in the handling or 
preparation of biological material might affect gene expression which in turn 
might influence the results. Although enzymatic digestion proved an excellent 
tool for the isolation of stroma-free TEBs and ducts, its efficiency posed a major 
limitation. Based on personal observations, only 2 TEB and 2 ducts on average, 
that were not contaminated by the remains of stroma, could be retrieved from 
each mouse mammary gland. The limited number, along with the small size of 
these structures (the size of TEBs ranges from 0.1 to 0.5 mm [52] and is thought 
to be affected by the phase of oestrus cycle [47]) mean that a large number of 
mice (~150) would be needed to collect the minimal amount of RNA (1.5µg) 
required for each GeneChip® Mouse Exon 1.0 ST microarray chip. In this project, 
therefore, to limit the use of animals we collected fewer epithelial structures 
and therefore attained only enough RNA to carry out the gene expression 
analysis of isolated epithelium in duplicate instead of triplicate.  
Since conventional statistical significance can only be assessed with a minimum 
of three replicates, in this project we employed an alternative method for 
microarray analysis - a 5% LFC Model (See 2.2.5.5.1). Briefly, FC for each gene 
is evaluated across the entire range of absolute expression levels for any number 
of experimental conditions and replicates. Genes are then systematically binned 
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across the entire range of expression values and the top 5% of genes with HFC in 
each bin are considered as significantly differentially expressed. The selected 
genes are then ranked by a calculation that combines the FC and absolute 
expression and the degree of importance for each gene is assigned. Compared to 
standard bioinformatical approaches, which select differentially expressed genes 
by setting a FC cut off and using p-value as a measure of statistical significance, 
the 5% LFC Model selects the differentially expressed genes on the basis of their 
FC and expression levels.  
In conventional analysis most of the inherent error in calculated gene expression 
results from two issues: at low expression intensities, genes tend to show a 
greater error in their measured expression levels and thus may falsely reach any 
given FC cut-off, while at higher intensities where fewer errors in measured 
gene expression levels are observed, genes whose expression is significantly 
changed might be missed [269]. By selecting differentially expressed genes on 
the basis of both their FC and expression levels to minimise their inherent 
errors, the 5% LFC Model enables confident analysis of microarray data, 
particularly where no standard measurement of inherent error can be used due 
to insufficient replicates.  
Despite its potential, however, there has only been one documented use of the 
5% LFC Model in microarray analysis since 2002, when it was first developed 
[376]. To ensure its experimental reliability we used whole mammary tissue 
strips and conventional microarray analysis to validate the data analysed using 
LFC Model. When collected from six animals, tissue strips provided enough RNA 
for the microarray analysis to be carried out in triplicate; hence gene expression 
profiling could be performed using standard parameters, such as FC and p-value 
and standard software, such as Partek® Genomics™ Suite software (See 
2.2.5.5.2). This served as good control to assess the performance and validate 
the reliability of the generated data.  It is important to note, however, that both 
the FC cut-off (Partek® Genomics™ Suite software) and X% (LFC Model) use 
arbitrary parameters and thus although set within their common range in this 
project (1.5 and 3.0 for FC and 5%-10% for LFC) the parameters may sometimes 
be inappropriate. Additional measures of data quality control are therefore 
necessary to validate the results of microarray analysis. Here, we performed a 
number of quality control measures throughout the experimental stages of the 
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microarray analysis and successfully confirmed the quality of our data (Figure 3-
6) (Figure 3-7) (Table 3-2).     
We identified a list of 65 genes with enriched expression in the epithelium of 
TEBs (See 3.2.6.3) (Table 3-5). These genes were chosen as initial gene targets 
due to their association with both the epithelium of isolated TEBs and Post-LN 
strip, which ensured a high level of stringency in our analysis. The remaining 360 
TEB epithelium up-regulated genes, however, can be seen in Appendix 2.  It is 
tempting to speculate that most of these TEB associated genes may be 
functionally involved in the regulation of TEB motility and ductal patterning. 
However, the term „TEB motility‟ still needs to be clearly defined and is quite 
complex in reality. Despite being at the centre of mammary gland associated 
research since the early 1970‟s, only a few suggestions have been made to 
explain the enigma of TEB movement (See 1.2.3) to date. For example: motile 
activities of TEBs may be explained by three actions: forward movement, 
bifurcation and turning; forward movement may be driven by the increased cell 
mass that results from intensive mitosis (as demonstrated by high mitotic rate 
and thymidine-labelling index [377] [126] [102] in the cells of TEB); guiding 
molecules (CFS-1 or eotaxin) [87] and growth factors (TGF-ß) [110] may be 
implicated in TEB turning; and BM and ECM composition may be important for 
TEB bifurcation [50] [56] [109]. More recently, microarray technology has 
provided data on gene expression function in TEBs that confirmed that most of 
the genes up-regulated in TEB environment associate with DNA replication, cell 
division or cell-cycle regulation as well as axonal guidance, actin remodelling, 
ECM interaction, nucleotide synthesis, protease activity, apoptosis and cellular 
adhesion [113] [256]. Here, we performed a literature search on the 65 TEB 
epithelium-associated genes to further characterise their functional groups and 
thus contribute to the scientific understanding of the enigma of TEB motility.  
Since no clear criteria could be used to select potential regulators of TEB 
motility, we took each gene in turn and searched the literature for an 
association with other biological processes that are known to share similarities 
with pubertal mouse mammary development, and could therefore serve as 
candidate regulators of ductal outgrowth. The processes that we focused on 
were: embryogenesis, branching morphogenesis, lung- kidney- development or 
cancer, migration and axonal guidance.  
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Embryogenesis and pubertal mouse mammary gland development both depend 
on uninterrupted cross-talk between endodermal or ectodermal/epithelial and 
mesenchymal/stromal cells [11] [12]. For example, during mammary gland 
embryogenesis, at day E16 mammary buds elongate to form mammary sprouts 
which invade primary mesenchyme to grow into the embryonic fat pad where 
they undergo branching to create a primary ductal tree. At puberty (~3 to ~10 
weeks) the ductal tree elongates and branches by epithelial invasion of 
surrounding stroma with forward movement, primary branching and turning 
being driven by TEBs. This forward movement of TEBs most likely occurs due to 
cell rearrangement and collective migration [105] (See 1.2.2.1.1) as recently 
also demonstrated for nephron formation during kidney morphogenesis of 
zebrafish (Danio rerio) using in vivo cell imaging [378]. It is worth noting, 
however, that in nephron formation, full epithelial polarisation of pronephric 
cells is preserved [378] whereas TEB-like organoids are multilayered and only 
partially polarised [105]. Branching morphogenesis in kidneys and lungs shares 
further similarities with mammary glands, including the dependence on 
epithelial-stromal cross talk in which MMPs are thought to be crucial, (reviewed 
in [379]) and the regulatory role of FGF family members (reviewed in [379]). As 
is the case for primary branch formation of mouse mammary gland, most of the 
renal tubular branches (~75%) that form during murine kidney development in 
vitro also result from bifurcation [380]. Not only are the fundamentals of 
branching morphogenesis hypothesised to be similar for different organs but they 
are also similar across a range of organisms. For example, Sprouty is a gene 
involved in both mammalian kidney branching [381] and tracheal branching 
morphogenesis in Drosophila m. [382]. Similar extrapolations can be applied to 
the basic aspects of migration. Cellular migration is essential for organism 
development and although fundamental to a diverse spectrum of processes such 
as organogenesis, wound healing or immune response it is conducted in different 
ways with some cells migrating as individuals (germ [383] and immune [384] 
cells) and others collectively as tightly or loosely associated groups (neural crest 
formation, wound healing [385], epithelial organogenesis [105] [378] [386]). 
Regardless of the process, some common features of migration include: a degree 
of polarity, active use of the cytoskeleton (actin, myosin) and dynamic 
interactions between migratory cells and their surrounding environment 
(reviewed in [387]). As is the case for single cell migration, collective cell 
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migration may also be involved in tissue invasion during tumorigenesis [388] 
[389]. Other processes that drive cancer progression in mammary gland, kidney 
or lung and which can assist our understanding of normal organogenesis of these 
organs include epithelial-mesenchymal interactions and ECM remodelling. In a 
comparison of genetic similarities  between embryonic lung development and 
lung carcinoma MYC, Hedgehog, Rb and Wnt pathways were highlighted in both 
the normal lung development and tumorigenesis [390]. Finally, axonal guidance 
molecules (Sprr1A, Sema3B, BASP1) which act on axonal growth cones and 
govern neuronal migration during nervous system development have also been 
detected in the TEB environment during mammary gland outgrowth at puberty 
[113] and thus may be important in directing its epithelial outgrowth, as 
recently shown for Reln - originally identified as crucial for neuronal migration 
[353].   
The similarities between these biological processes and pubertal mouse 
mammary gland development highlighted above, suggest that molecular 
regulators may also be conserved across different organs/biological processes. A 
few of such proteins have indeed been identified. For example, Fgf2br is 
essential both for the development of mammary buds during embryogenesis and 
maintenance of TEBs at puberty [20] [159]; p190B-RhoGAP is necessary for the 
development of embryonic mammary bud and TEB migration at puberty [24] 
[391]; both Ntn1 and Neo1 although initially identified as axonal growth 
guidance cues are also essential for the maintenance of TEB integrity and normal 
ductal morphogenesis at puberty [120] [117]; TGF-ß is a potent inhibitor is 
branching morphogenesis in mammary gland, kidney and lung (reviewed in [379]) 
while the increased levels of MMP2 and MMP14 are seen at the tips of both the 
uteric and mammary branches in vivo [235] [392].  
3.3.2.2 Comments on the results 
Firstly, we found that the majority (58.5%) of the 65 TEB epithelium enriched 
genes were associated with proliferation or cell-cycle activity which is consistent 
with the previous observations of Morris et al. (2006) [113]; Kouros-Mehr et al. 
(2006) [256] and McBryan et al. [194] . Also in agreement with the two latter 
studies, we showed that 15.3%, 13.8%, 9.2%, 6.1%, 6.1% and 6.1% of these genes 
encoded proteins that are implicated in cellular adhesion, cell death, 
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intracellular transport, regulation of transcription, structural proteins and 
metabolism respectively. A previously unreported finding, however, was that 
DNA repair (7.7%), signal transduction (6.1%) and immune response (4.6%) were 
significantly over-represented within the TEB epithelium associated genes 
(Figure 3-10 A) (Table 3-5). Secondly, we identified genes that have previously 
been associated with normal lung (19) and kidney (10) morphogenesis/cancer 
and others that are known to be implicated in cellular migration (19), nervous 
system development (16), embryogenesis (10) and branching morphogenesis (9) 
providing a wide array of candidate genes with potential as regulators of ductal 
pubertal development (Figure 3-10 B) (Table 3-5). Together, the strong 
association of TEB transcriptome with proliferation and cell cycle associated 
genes supports the hypothesis that the forward movement of TEBs may result 
from the increased cell mass, caused by intensive mitosis in both cap and body 
cells [102]. While the identification of immune response- and cellular adhesion-
linked genes as associated with TEB transcriptome may further highlight the 
importance of immune response for ductal outgrowth (Reviewed in 1.2.3.2.4) 
and the possibility of collective cell migration to serve as a mode for TEB 
elongation [105]. Finally, the strong link between the TEB transcriptome and the 
lung-, kidney-, nervous system-, branching morphogenesis, embryonic 
development or cellular migration associated genes supports the idea that the 
degree of conservation can be noted during the morphogenesis of different 
organs and for different developmental processes and further highlights the 
potential of these systems/processes to provide information on the TEB driven 
mammary morphogenesis at puberty.    
Finally, based on these findings, we identified Fbln2 as a candidate regulator of 
ductal morphogenesis at puberty and investigated its expression and function in 
mammary gland as discussed in detail in Chapter 4.  
3.3.2.3 Further analyses 
Other genes that share this potential and could be investigated in the future 
include Emb or Fbn2. Emb is a cell adhesion molecule that is expressed in the 
uteric bud of the developing kidney [341], mammary gland cancer- and 
embryonic cell lines [339] [340] and involuting mouse mammary gland [340] and 
is thought to be implicated in regulating cell-ECM interactions during 
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development [340], branching morphogenesis during kidney development [341] 
and migration of adipose tissue macrophages [393]. Fbn2 which also belongs to 
the family of cell adhesion molecules, is associated with epithelial-mesenchymal 
interactions during lung and kidney embryogenesis [346] [347]. It may also be 
involved in branching morphogenesis in lungs, since treatment with Fbn2 
antisense oligodeoxynucleotide leads to smaller lungs with only a rudimentary 
epithelial tree [346]. Its heparin- and integrin-binding sites also suggested a role 
in cellular migration [394].        
When screening for other potential regulators of mouse mammary gland 
development at puberty, in future it may be beneficial to include branching 
morphogenesis of salivary gland (reviewed in [379] [395]) or embryonic 
development of other skin appendages such as hair follicles and teeth 
respectively (reviewed in [396]) since there is considerable molecular 
conservation of branching morphogenesis between epithelial organs and 
similarities between embryonic development and pubertal morphogenesis of 
mouse mammary gland. Despite this, however, it must be noted, that several 
organ-specific cues can be distinguished for each biological process. For 
example, i) embryonic branching in lung and kidney is accompanied by an 
outgrowth of the whole organ whereas the dimensions of the mammary gland 
stroma in which epithelial branching occurs do not change or ii) epithelial 
branching in mammalian lungs and kidney takes place prenatally and adopts a 
rather conventional pattern in lungs (almost identical between the individuals) 
while most of the mammary gland development takes place after birth and 
appears non-stereotyped as its epithelial patterning depends on the milieu. 
Hence, using our comparative approach, any new genes identified as likely to 
serve an important role in pubertal mouse mammary gland development would 
be those conserved in various systems rather than specific to mammary 
morphogenesis. Furthermore, although genes up-regulated in TEB are an obvious 
primary target when studying the genomics behind TEB driven mammary 
morphogenesis, the TEB down-regulated (i.e. ducts up-regulated) genes may be 
equally important. Although no down-regulated genes have been described as 
essential for ductal morphogenesis as yet, this phenomenon has been reported in 
other systems. Down-regulation of Hox-A7, a gene involved in ECM regulation 
and cell migration during lineage commitment or maturation seems to be 
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essential for early HL-60 monocytic differentiation. As demonstrated in vitro 
using bone marrow stromal-like matrix sustained expression of Hox-A7 impaired 
cellular migration and adhesion to fibronectin and thus impaired monocytic 
differentiation [397]. Finally, it is also important to mention that not only the 
differentially expressed (i.e. up- or down-regulated) genes but also the genes 
that are globally expressed in the pubertal mammary epithelium may play a role 
in its morphogenesis. In fact, an example of such gene has previously been 
reported by Howlin et al. who showed that CITED1, which expression level is 
similar for the TEB and duct epithelium, is essential for pubertal outgrowth 
[193]. A comparison analysis of the pubertal and adult (V12) mouse mammary 
gland transcriptomes would therefore be needed in the future to further 
decipher this phenomenon.   
Other ways to search for candidate genes rather than looking for those showing 
similar cellular/biological functions are: i) by selecting on their level of over-
expression (we used this approach to identify Upk3a as a second target gene as 
discussed in detail in Chapter 4); ii) by chromosomal location or iii) by 
association with canonical pathways which are already known to be involved in 
the studied system.    
3.3.3 Identification and comparison of functional characteristics 
of the epithelial and stromal transcriptomes of TEBs and 
ducts 
Since little is known about differences in gene expression between the TEB and 
duct environments, especially between their epithelial and stromal 
compartments, as a third part of this project, we identified an array of 
biological functions that characterise each compartment. 
3.3.3.1 Comments on methodology used 
We identified four „expressed gene sets‟, namely: TEB-only stroma-, duct-only 
stroma- and TEB-only epithelium-, duct- only epithelium- in addition to two „up-
regulated gene sets‟, namely: TEB epithelium- and duct epithelium-. The „up-
regulated gene sets‟ were used to compare the epithelial gene expression only, 
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as discussed above. „The expressed gene sets‟, on the other hand, were used to 
find differences in gene expression between stroma and epithelium. This is 
because the analysis used to select the stroma associated genes (manual 
screening of the raw gene expression data from the isolated epithelium and 
tissue strips (See 3.2.6.2.2)) did not allow calculation of FCs but only enabled 
presence or absence of gene expression to be determined. To provide a suitable 
comparison we also identified epithelium expressed gene sets (See 3.2.6.2.1). 
For summary of experimental concept see Table 2-5. 
When using gene lists to elucidate the general trends in biological processes or 
pathways there are different sets of criteria that can be used. Firstly, rather 
than using the most highly expressed genes, it may be argued that a gene set 
consisting of the widest range of representative genes may be of more relevance 
to understand the biological system in question. Genes with large changes in 
expression values may not necessarily make the strongest contribution to 
biological processes and thus should not be prioritised over those that show less 
pronounced expression levels. Furthermore, it is not necessary for all genes 
within a given pathway or biological process to be highly differentially expressed 
in order for the pathway to be important. Thus, the „expressed gene sets‟, 
although initially used in this study because of the limitation of the methodology 
used for data analysis, actually provided a comprehensive and unbiased analysis 
since they include genes with a range of expression levels from the most highly 
expressed to those with expression only slightly altered.  
In contrast, the „up-regulated gene sets‟ used in „pathway analysis‟ helped to 
focus the analysis. By incorporating genes expressed over a certain level and 
thus excluding genes whose expression oscillated around the baseline level (of 
FC 1.1) and thus may have been associated with the specific environment just 
due to chance, the risk of non specificity in identified profiles was reduced. 
Moreover, since some biological processes, e.g. EMT require both the up-
regulation of mesenchymal genes (Twist [272], Snail 3 [273], Slug [274]) and 
down-regulation of the epithelial markers (E-cad [280], Sprr1a [270]), only the 
use of the „up-regulated gene sets‟ together with the corresponding „down-
regulated gene set‟ will fully unravel such mechanisms. This analysis could not 
be executed using the „expressed gene sets‟. 
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Therefore in this study, we used both the „expressed gene sets‟ and „up-
regulated gene sets‟ to provide a comprehensive novel analysis of the general 
trends and differences in the functional characteristics of TEB and duct 
epithelium and stroma („expressed gene sets‟). We also compared the biological 
processes associated with the genes identified as significantly up-regulated in 
TEB and duct epithelium („up-regulated gene sets‟). In addition to that, since we 
used both gene sets to functionally characterise the TEB and duct epithelium we 
enabled the comparison of the potential differences in generated data when 
using different gene list.  
3.3.3.2 Comments on results 
Since the motility of TEBs and ducts at puberty is very different we originally 
hypothesised that their gene expression would reflect different patterns of 
biological behaviour and indeed this was the case, as outlined below. 
„Pathway analysis‟ on the basis on microarray data is a valuable tool to establish 
the biological changes that occur in biological systems and has as such been 
widely used. However, it is also important to bear in mind its limitations.  
Firstly, it is based on mRNA expression only. Secondly, the association of genes 
with given processes is established depending on the information deposited in 
the manually created knowledge data base (See 3.3.3.5). Some of the genes 
selected by IPA as indicative of the given functional category are non specific 
and can often be found to associate with a range of different cellular functions 
and systems. It is therefore, important to note that this type of analysis may be 
biased and not fully representative of functional processes activated in vivo and 
thus should be interpreted with caution and only used as a starting point for 
further investigation. 
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3.3.3.2.1 Characterisation of the TEB and duct transcriptomes using 
‘expressed gene sets’  
 
Terminal end bud epithelium 
Comparison of the „expressed gene sets‟ showed both the epithelium and stroma 
of TEBs to be strongly associated with „Cellular Movement‟ (27.8% and 20.5% of 
genes respectively) and „Cell-Cell Signalling and Interaction‟ (27.9% and 23.7% of 
genes respectively) (Table 3-5). Thus, suggesting not only a high but also a 
comparable level of the motility associated genes in both milieus. In general, 
this finding would not be surprising as it is in agreement with the emerging idea 
of both the epithelial and stromal compartments of TEB being necessary for 
ductal outgrowth but playing different role in its regulation (reviewed in 
1.2.3.2). Here, however, the link between TEB transcriptome and „Cellular 
Migration‟ was mostly attributed to the presence of genes associated with the 
regulation of immune cell motility. 
As shown by IPA results, the sub-groups within the „Cellular Movement‟ category 
that were common for the epithelium and stroma of TEB included both positive 
and negative regulation of e.g. „the movement or migration of the immune 
system components‟ (eosinophils, mononuclear lymphocytes, phagocytes, 
leukocytes and monocytes) or „-nervous system components‟ (dendric cells). This 
association with immune cell motility was further seen in the TEB epithelium 
exclusive sub-categories, which consisted of both positive and negative 
regulation of the „movement/migration of neutrophils, -macrophages, -T 
lymphocytes, -antigen presenting cells, -bone marrow cells‟; „chemotaxis of 
blood cells, -dendric cells, -leukocytes‟ and „homing of phagocytes, -
lymphocytes, -blood cells‟ and „migration and chemotaxis of tumour cell lines‟ 
(Appendix 9 A).  
This striking association of TEB epithelium with the immune response gene 
signature was further supported in our analysis by an association of the 
epithelium expressed gene set with „Immune Response‟ (28.3%), „Immune and 
Lymphatic System Development and Function‟ (25.1%) and „Haematological 
System Development and Function‟ (29%). Together, these results are in 
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agreement with the emerging importance of innate immune response for 
pubertal mammary morphogenesis.  
As reviewed in Chapter 1 (1.2.1.2.3 and 1.2.3.2.4), the formation and 
outgrowth of TEBs during puberty is closely paralleled and dependent on the 
accumulation of macrophages, eosinophils and mast cells in the stroma around 
TEBs (macrophages, eosinophils) and ducts (mast cells) [85] [89]. Furthermore, 
inflammatory cells (neutrophils, eosinophils, macrophages and plasma cells) and 
acute-phase response genes, such as CD14, lipopolysaccharide-binding protein 
(Lbp) and STAT3 associate with early involution of mouse mammary gland 
suggesting a wound healing-like process to be a part of the early response to 
weaning [38]. The recruitment of haemopoietic cells may be regulated by the 
signalling cues expressed in mammary epithelium (reviewed in [87]). As 
demonstrated for macrophages, the growth factor which regulates their motility 
(CSF-1) [398] is expressed in mammary epithelial cells [87] and when ablated 
(null mutation in CSF-1 - Csf1op/Csf1op mice [220]) or dysfunctional (loss of CSF-1 
receptor - CSF-1R KO-/- mice [399]) a reduced macrophage density in mammary 
gland can be seen. Furthermore, a high expression of the cytokines IL-6, IL-8 and 
High in normal 1 (HIN-1) have been reported in human breast epithelial cells 
[400] [401].    
Here, we report that, as suggested by the results of IPA, epithelial transcriptome 
of TEBs may also encode proteins involved in positive regulation of 
„proliferation/activation/accumulation of mononuclear leukocytes  (Cd 2 antigen 
-Cd2, Cd 22 antigen - Cd22), -T lymphocytes (Cd 4 antigen - Cd4) and -B 
lymphocytes‟ (Bone marrow stromal cell antigen 1 - Bst1, Brutton 
agammaglabulinemia tyrosine kinase - Btk) and „adhesion of neutrophils‟              
(Chemokine (C-C motif) ligand 3 - Ccl3). It is important to note, however, that 
not all of these genes are specific to the identified process. While Cd4 and Bst1 
serve as markers of T and B cells respectively, Btk expression have been 
associated with both the B cell maturation and mast cell activation. Ccl3 has 
been associated with neutrophils and T-lymphocytes. Thus, although these data 
are in agreement with our „Cellular Migration‟ results which also suggested the 
high abundance of genes associated with the immune system components and 
their motility within the epithelium of TEBs (which in fact is higher than that 
seen for the stroma) it is important to note that some of these genes may not be 
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specific to the immune response. The other possibility is that because of the 
direct proximity of haemapoietic cells and mammary epithelium and as seen for 
macrophages, potential association of immune cells with ColI fibres which are 
deposited around the flanks of TEBs [83], some immune cells may have been 
isolated with mammary epithelium.    
Nevertheless, if confirmed, these data may not only further highlight the 
importance of the immune response in pubertal mammary morphogenesis but 
also support and add to the understanding of the emerging role of mammary 
epithelium in controlling the homing of migrating hematopoietic cells into 
adjacent stroma. Furthermore, since macrophages have also been shown to 
localise to the inside of the body of TEBs [87], it may be that the immune system 
components other than macrophages also associate with mammary epithelium 
but additional research should be carried out to validate these possibilities. T 
and B lymphocyte markers and neutrophil associated genes have been suggested 
as TEB epithelium expressed by both the results of „Immune Response‟ and 
„Cellular migration‟ groupings. Furthermore, these immune system components 
have previously been reported as involved in wound healing and shown to 
infiltrate the mammary gland during pregnancy (B lymphocytes) [402] and 
involution (neutrophils) [38] but have not yet been reported in the pubertal 
mouse mammary gland. In fact, a previous study, using leukocyte lineage 
markers (B220, CD3 and Gr1) demonstrated that while present in the mammary 
lymph node, no T-, B lymphocytes or neutrophils could be seen in the vicinity of 
its pubertal epithelium [87]. Despite this, since wound healing has previously 
been linked to mammary involution and several traits characteristic of wound 
repair are seen in pubertal mammary morphogenesis (epithelial growth, stromal 
reorganisation and immune cell infiltration) the repeated identification of T-, B 
lymphocyte or neutrophil associated genes in pubertal mouse mammary gland 
should be investigated further. 
Terminal end bud stroma 
A similar association with the immune system was detected by IPA, in the TEB-
only stroma „expressed gene set‟, where „Haematological System Development 
and Function‟ ranked to the top 5 over-represented processes and encompassed 
the 23% of TEB stroma and IPA eligible genes (Table 3-7). This was also 
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consistent with the results of the analysis, discussed above, that showed an 
association of TEB stroma with the migratory signature of immune system 
components. Most of the sub-categories associated with the stroma expressed 
genes were similar to these identified for the TEB epithelium gene set. Some of 
the stroma-exclusive categories, however, included positive regulation of 
„proliferation of natural killer T lymphocytes (NKTL)‟ (E74-like factor 4 - Elf4, 
Interleukin 18 - Il18), „recruitment/quantity of phagocytes (Glypican 3 - Gpc3) 
and -Langerhans cells‟ (Signal regulatory protein α - Sirpa, Interferon regulatory 
factor - Irf). The Langerhans cells are dendritic cells of the epidermis which are 
similar in morphology and function to macrophages. They capture, uptake and 
process antigens while the NTKL and phagocytes mark cells for destruction by 
apoptosis and ingest antigens respectively. As mentioned before, it is important 
to note, however, that neither Elf4 nor Il18 are exclusive to NKTL cells but can 
also be associated with T-lymphocytes while Gpc3 is a membrane associated 
proteoglycan which has also been suggested to play role in cell division in many 
cell types. Sirpa, furthermore, may also be involved in phagocytosis, mast- and 
dendritic cells activation. Thus, the association of TEB stroma with these 
immune cells should be taken with caution. Nonetheless, if confirmed, these 
results may add to the understanding of the role of phagocytosis (as suggested 
for macrophages [84] [87]) in contributing to stroma remodelling at the tip of 
the advancing TEB at puberty.  
As previously mentioned, the stromal transcriptome of TEBs has also been 
suggested to associate with „Cellular Movement‟ (Table 3-6). While it was 
partially suggested as being involved in regulating the „motility of immune 
system- and nervous system components‟ (See the first paragraph of this 
section) some of the other genes within the stroma of TEBs additionally 
appeared to be associated with „movement/chemotaxis of cancer cell lines‟ and 
„invasion of neuroglia‟ (provides support and protection for growing neurons). 
Given the emerging similarities between TEB outgrowth and breast cancer 
progression and neuronal development further investigation of these genes in 
ductal morphogenesis may prove beneficial.  
Finally, as proposed by IPA, association of TEB stroma with „Cardiovascular 
System Development and Function‟ (11.5%) (Table 3-7) may be suggestive of the 
presence of dynamic cardiovascular morphogenesis at puberty. To date, there 
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has only been one published study that looked into vessel development during 
mouse mammary gland development at puberty. It has reported, however, that 
no morphological evidence for active vascular development in pubertal mouse 
mammary gland can be seen, identifying embryogenesis, pregnancy and 
lactation as the highly angiogenic time points [403]. Our data further suggested 
that the epithelial transcriptome of ducts may also contain the angiogenesis 
associated genes (Table 3-7) and that TEB epithelium expresses high levels of 
Vascular endothelial growth factor (VEGF), which is a known stimulator of 
angiogenesis. Thus, if confirmed, these results could shine a new light on the 
area of vascular development during mammary gland morphogenesis and the role 
of TEBs in angiogenesis. Further research will be necessary to validate these 
possibilities.   
Some of the other processes identified in TEB stroma included „Cell Death‟ 
(33.4%), „Tissue Morphology‟ (16.9%) and „Tissue Development‟ (19.8%). These 
are in agreement with TEB stroma being an actively remodelling milieu (Table 3-
6) (Table 3-7).  
Duct epithelium 
In contrast to the TEB environment, neither the migratory nor the immune 
system associated gene signatures could be identified in the duct „expressed 
gene sets‟. Furthermore, as compared to TEBs, where both the epithelial and 
stromal compartments shared fairly similar functional characteristics, 
substantial differences were detected in the functional roles of ductal epithelial 
and stromal transcriptomes. Our analysis suggested that the processes that are 
highest in the ductal epithelial transcriptome are „Embryonic Development‟ 
(2.3%) (See 3.3.3.3) and „Connective Tissue Development and Function‟ (2.9%) 
(Table 3-7). It is important to note, however, that the association of ductal 
transcriptome with these categories is based on a very low percentage of genes 
and thus may not be fully reliable. Furthermore, all sub-categories within the 
„Connective Tissue Development and Function‟ group were associated with 
fibroblasts which may also indicate the contamination of ductal epithelium with 
stroma during the isolation procedure. 
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The rest of the duct-only epithelium „expressed gene set‟ was suggested to 
associate mostly with non-specialised mechanisms essential for cell survival, 
replication and regulation of gene expression. Namely, „Cell Cycle‟ (14.8%), 
DNA- or RNA-processing associated applications (11.8% and 4% respectively) or 
organogenesis - „Cellular Assembly and Organisation‟ (Table 3-6). These suggest 
that, although lower than in TEBs, considerable levels of cellular proliferation 
are sustained in ductal epithelium. 
Duct stroma 
The transcriptome associated with ductal stroma was mainly linked to „Lipid 
Metabolism (14.7%), „Carbohydrate Metabolism‟ (15%) and „Small Molecule 
Biochemistry‟ (28.9%) (Table 3-6) and thus indicated an intense metabolic 
activity. Lipid and carbohydrate metabolism has been reported in lactating 
mouse mammary glands in experiments dating back to 1950 [404] while the 
metabolism of brown adipose tissue (fatty acid metabolism) has been studied in 
2002 by Master et al. using the pre-pubertal mouse mammary glands [258]. More 
recently the expression of genes associated with „Lipid Metabolism‟ and 
„Carbohydrate Metabolism‟ was demonstrated to decrease during puberty in 
normal mice [258] or in response to estradiol in ovariectomised mice [257]. To 
our knowledge, however, a detailed biochemical study of metabolic changes 
accompanying pubertal mouse mammary gland morphogenesis has not yet been 
performed. Here, we identified the ductal stroma as the place of highest 
metabolic activity in pubertal mouse mammary gland and identified the list of 
associated genes (Appendix 7) which may provide a foundation for further 
investigations.  
3.3.3.2.2 Characterisation of TEB and duct transcriptomes based on 
the ‘up-regulated gene sets’  
 
Terminal end bud epithelium 
The suggested differences between TEBs and ducts were further highlighted by 
comparing the epithelium „up-regulated gene sets‟. As was the case for TEB 
epithelium-only „expressed gene set‟ the mRNAs up-regulated in the epithelium 
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of TEBs were mainly associated with cell survival and proliferation („Cell cycle‟ 
(38.6%), DNA Replication, Recombination and Repair (34%) and Cellular Growth 
and Proliferation‟ (35.5%)), which is consistent with the results of Morris et al. 
(2006) and Kouros-Mehr et al. (2006) [256], as well as „Cellular Movement‟ (6%) 
(Table 3-6). As opposed to the „expressed gene set‟, which was suggested to be 
closely associated with movement of immune- and nervous system components, 
the up-regulated genes of TEB epithelium were mainly associated with 
„promoting the cytokinesis‟ and „chemorepulsion of neurites‟ (Sema3A, Sema3B). 
„Embryonic Development‟ (See 3.3.3.3) which was not seen in the „expressed 
gene set‟, „Connective Tissue Development and Function‟ and „Skeletal and 
Muscular Development and Function‟ were also over-represented (Table 3-7). 
The sub-groups in „Skeletal and Muscular Development and Function‟ category 
were mostly associated with fibroblasts (which again may indicate stromal 
contamination) and promoting the „cell cycle progression in muscle cells‟.  
Duct epithelium 
Whereas the top functional characteristics of TEB epithelium „expressed-‟ and 
TEB epithelium „up-regulated gene sets‟ were reasonably comparable this was 
not the case for the ductal gene sets, where only one category, the „Molecular 
Transport‟ was common to both analyses (Table 3-6). The most striking result 
from this analysis was that „Cellular Movement‟ associated genes were the 
second highest functional group within the duct epithelium „up-regulated gene 
set‟ (Table 3-6). Furthermore, a wide array of functional sub-categories 
associated with cellular motility (immune cell, nervous system component, 
smooth muscle cell, cancer cell line, kidney morphogenesis) were over-
represented within the ductal epithelial transcriptome while the TEBs were 
suggested to associate mostly with immune cell migration (expressed genes), 
axonal guidance and cytokinesis (up-regulated genes). This was further surprising 
as the „Cellular Movement‟ signature appeared to be stronger in duct- rather 
than TEB up-regulated transcriptomes. Over all, these results suggest that ductal 
epithelium may play a bigger role in regulating pubertal morphogenesis in 
mammary gland than previously anticipated. Another possibility is that the duct 
epithelium „up-regulated genes‟ that were functionally classified under the 
„Cellular Migration‟ category rather than being the makers of motile behaviour 
they are common regulators of various processes and thus in vivo they may not 
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function to drive cellular migration in ductal epithelium. Further examination of 
individual genes involved in each category should be performed to validate these 
possibilities (Appendix 9 A).    
The suggested presence of immune system-associated genes in the duct 
epithelium „up-regulated gene set‟, as demonstrated by the contribution of the 
34.4% of genes to the „Haematological System Development and Function‟ and 
26.3% to „Immune Cell Trafficking‟ (Table 3-7) is in agreement with the 
previously discussed association of duct-only expressed genes with the immune 
response components (See above). While many of the functional sub-groups 
within the immune system category were similar to those identified for TEB 
environment (e.g. positive regulation of the „recruitment/activation of 
neutrophils, -phagocytes, -lymphocytes, -mast cells‟) the „change of shape of 
basophils‟ (Ccl3, Chemokine (C-C motif) receptor 2 - Ccr2) was specific to this 
gene set. Ccl3 is a chemokine.  Although, as seen for many other genes, 
mentioned in analysis, it is not entirely basophile specific (eosinophils, 
neutrophils), it has been shown to promote the chemotaxis of granulocytes. 
Thus, its expression by ductal epithelium may support the role of mammary 
epithelium in the recruitment of haemopoietic cells to the proximal mammary 
stroma. The expression of Ccr2 in ductal epithelium, however, is less clear (it 
has been previously shown to be expressed by mammary epithelium during 
inflammation [405]).  
Granulocytes may either act to induce an inflammatory reaction (mostly allergy) 
or ingest foreign particles. If confirmed, the association of mammary epithelium 
with phagocytes may suggest a possible role of phagocytosis in lumen formation. 
Pubertal epithelium and especially TEBs show very substantial apoptotic rate 
(11.3 %) which is higher than that calculated for any other stage of mouse 
mammary development (apoptosis detected for involution is 4.5%) [61]. It must 
be noted, however, that the association of immune cells with lumen formation 
has only been suggested by one study. Gouon-Evans et al. (2002) reported that 
macrophages which engulf apoptotic epithelial cells can be seen in the proximal 
area of lumen within the TEBs [87]. To date, it has been further proposed that 
lumen formation in pubertal epithelium is dependent on caspase-mediated 
apoptosis and Bcl2-like 11 (BIM) expression, which may induce the detachment 
of cells from its matrix, termed anoikis (as previously seen during involution) and 
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thus mark cells for degradation [244] [406]. This can be further supported by the 
recent finding showing that the body cells of TEBs lack matrix attachment [244]. 
The down-regulation or loss of BIM in vitro or in BIM KO-/- mice, however, 
although prevented apoptotic clearance of cells did not abrogate but only 
delayed lumen formation in both systems, thus suggesting presence of 
alternative mechanisms for lumen formation and clearing [244]. Hence, further 
research into its possible mechanisms should be warranted.    
In summary, the functional characteristics of TEBs and ducts appeared quite 
different depending on the type of gene sets used for the analysis. This suggests 
that both types of analysis ought to be completed for a comprehensive picture of 
gene expression patterns and the use of „pathway analysis‟ to aid functional 
characterisation of transcriptomes should be taken with a lot of caution.  
3.3.3.3 Association of pubertal development with embryogenesis 
Similarities between embryonic development and pubertal mouse mammary 
gland development have already been discussed in 3.3.2 with some of the 
embryogenesis associated genes suggested as potential regulators of mammary 
gland morphogenesis at puberty. For that analysis, however, we hypothesised 
that it is the TEB transcriptome that would contain the embryonic development 
associated genes. The identification of the duct-only epithelium „expressed gene 
set‟ as that most associated with this process suggested, however, that the 
morphogenic potential of embryogenesis associated genes should perhaps be 
assessed with respect to the ductal transcriptome rather than the TEB one. The 
embryonic signature identified within the duct-only epithelium „expressed gene 
set‟, however, associated with embryonic cell lines, which is general and did not 
hint towards any specific assumptions. What stands out, however, and may 
provide the foundation for further research is the association of ductal 
epithelium „up-regulated gene set‟ with the positive regulation of „branching 
morphogenesis‟ (kidney, carcinoma, thyroid and kidney cell lines) and the 
association of duct-only stroma „expressed gene set‟ with promoting the 
„morphogenesis of forelimb bud, branchial arch and cardiovascular system‟. 
Some, although fewer, „Embryonic development‟ related genes, and thus not 
complying with top 5 categories, could be also seen in the TEB transcriptome. As 
for the duct-only epithelium expressed genes, however, the link of TEB gene sets 
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with the „Embryonic Development‟ is fairly general (Appendix 9 C). In summary, 
these suggest that both TEB and duct transcriptomes associate with the 
„Embryonic Development‟ gene signature and as mammary gland is the only 
organ where the majority of development occurs postnatally these results 
reflect the highly morphogenic character of its development at puberty. 
3.3.3.4 Association of pubertal development with EMT          
Although, initially reported as fundamental for cellular migration during 
embryonic development, recent evidence, although highly controversial, has 
linked EMT with cellular invasion during tumour progression and metastasis 
formation (reviewed in [373] [407]). Not only do epithelial breast cancer cell 
lines express mesenchymal markers in vitro [270], but using different mouse 
models of breast cancer with genetically marked epithelial and mesenchymal 
cells, the presence of some EMT markers has been demonstrated in breast 
cancer cells in vivo [408] [409]. Since there are parallels between embryonic 
development, cancer progression and mammary gland outgrowth, i.e. epithelial 
invasion of surrounding stroma and poor polarity seen in the cap cells of TEBs 
(further discussed in 5.2.2) [56], it is tempting to speculate that EMT may serve 
as a mechanism underlying ductal outgrowth and that cap cells may serve as 
sites of this transition (they lack cell-cell junctions, show poor apical basal 
polarity and localise to the outer layer of TEBs). 
In fact, this possibility has already been addressed by two studies. Kouros-Mehr 
et al. (2006) found that Snail-1 and Twist-1, mesenchymal markers of EMT, were 
enriched in the TEB microenvironment when compared to its ductal counterpart 
[256] while Nelson et al. (2006), using epithelial tubules formed by EpH4 cells in 
3D culture, demonstrated that an EMT-like transition event is required at the 
branch points for branching to occur [110].  
Since the mesenchymal genotype can be characterised by both the up-regulation 
of mesenchymal- and the down-regulation of epithelial markers (The list of EMT 
markers can be seen in Table 2-8) in this project we further examined this issue 
by screening the TEB environment up- and down-regulated (i.e. duct 
environment up-regulated) gene sets for the presence of EMT signature genes. 
We looked at 256 EMT markers and thus performed the most comprehensive 
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analysis of the EMT response in pubertal mouse mammary gland development to 
date. We found that 13% of mesenchymal markers were up-regulated in TEB 
while 12% of epithelial markers were down-regulated in TEB environment (up-
regulated in ducts) highlighting the potential for TEB outgrowth to be promoted 
by EMT. However, our negative control showed that a further 6.25% of the 
epithelial makers were up-regulated in TEB compartment while a 6.8% of the 
mesenchymal markers were seen in the TEB down-regulated milieu (Table 3-7). 
Moreover, as further revealed by literature search, performed on the individual 
EMT associated genes differentially expressed in TEB transcriptome but not yet 
described or studied in mammary, i.e. 17 out of 31 EMT marker genes (Col1a2, 
Col5a2, Ecm1, Fap, Fbln1, Fbn1, Cybrd1, Ap1m2, Cxadr, Kcnk1, Klk8, Lad1, 
Trim29, Aldh1a3, Ndrg1 and Slp1) some of these markers were non specific. 
In summary, these results may suggest the individual EMT associated genes with 
the potential to be important for pubertal morphogenesis. For example, Prrx1, a 
member of homeobox gene family that is one of the mesenchymal markers found 
to be over-expressed in TEBs, has previously been shown to be critical for tooth 
morphogenesis [410]. Furthermore, homeobox genes in general have been 
associated with normal embryonic and postnatal mouse mammary gland 
development and carcinogenesis [411]. However, due to the lack of specificity of 
some genes in the EMT signature and a relatively high number of the negative 
control genes within the TEB transcriptome these results do not allow to make 
final conclusions about the involvement of EMT in pubertal mammary 
morphogenesis, but also they do not rule it out.   
3.3.3.5 Association of pubertal transcriptome with nervous system  
The „Nervous System Development and Function‟ was not identified amongst the 
top functions over-expressed in pubertal transcriptome. The known association 
of axonal guidance proteins with ductal outgrowth at puberty (See 3.3.2.1), 
however, prompted us to further screen the TEB and duct gene sets for the 
presence of the nervous system associated genes. In contrast to previous findings 
(3.3.2.1) which associated axonal guidance molecules with the epithelium of 
TEBs, our results suggested that, in fact, it is primarily the stroma of TEBs that 
shows this association. The stroma contained 43 genes involved in processes such 
as „outgrowth of neurites (projections from the cell body of a neuron), -sensory 
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axons‟; „survival/quantity of astrocytes (glial cells in brain or spinal cord), -
neurites‟ or „myelination‟ (formation of myelin sheath around axon or neuron). 
Fewer, but still a significant number of nervous system associated genes could 
be identified in both the epithelium and stroma of ducts and these appeared to 
be involved in „migration/survival of astrocytes‟; „stimulation/activation of 
neurons‟ (epithelium) and „axogenesis and branching of axons‟ (stroma). The TEB 
epithelium in comparison, had a transcriptome least associated with the nervous 
system, with only one gene - Sema3B, linked to chemorepulsion of neurites 
(Appendix 9 B). To fully appreciate the strength of these results, however, it is 
important to note that, to date, several genes identified as associated with 
neuronal development have been also implicated in angiogenesis. Neuropilin 1 
and 2 have been characterised as receptors for both semaphorins in axonal 
guidance and VEGF for angiogenesis (reviewed in [412]). Thus, it is possible that 
this neuronal signature may be indicative of vascular- rather than neuronal 
development. Further examination of individual genes identified within these 
subcategories should be warranted. Nonetheless, if confirmed, these results may 
provide further positive evidence that the axonal guidance/nervous system 
development gene signature is associated with pubertal mouse mammary 
development, highlight mammary stroma as its source and potentially provide 
new gene targets which could be studied in the future to help to further unravel 
the link between mammary and axonal development.  
3.3.3.6 Further analyses 
In general IPA is a powerful and desirable tool for post-analysis of microarray 
data and frequently appears as software of choice in published gene expression 
studies [413] [414] [415]. It is, however, based on a manually created database 
which although curated by PhD trained scientists, updated quarterly and based 
on information mined from 32 top peer-reviewed journals, is man-made and may 
therefore be prone to bias and not always up to date with the literature. In 
addition, genes can only be assigned a specific function based on the 
information deposited in the database. Thus, since IPA depends on its own 
comprehensive but biased knowledge database, the results may be limited and 
influenced by its content. Furthermore, it is important to note that some of the 
genes used by IPA as indicative of the given functional category are non specific 
and can often be found to associate with a range of different cells and 
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processes. Some of the other non specific genes not mentioned in this discussion 
include Endothelial-specific receptor tyrosine kinase (Tek) or Cyclin D1 (Ccdn1). 
Tek is normally associated with endothelial cells, but in our analysis defined a 
positive regulator of the „quantity of antigen presenting cells‟ while Ccdn1 is 
generally abundant throughout cell cycle but defined here as a maker of the 
„chemotaxis of bone marrow derived macrophages‟. This may introduce 
additional bias into the analysis. Having said that, it is also important to note 
that many genes, such as Cd4, Bst1, Elf4 which are specific markers of T 
lymphocytes, B lymphocytes and NKTLs respectively have also been found in our 
analysis. It must be stressed, therefore, that the results of IPA analysis and any 
other „pathway analysis‟, may be used to sketch the general picture that could 
highlight and suggest the potential avenues for further investigation, but has the 
potential to be biased and thus should be interpreted with caution. 
Furthermore, since this study was based entirely on RNA data and not all RNA 
undergoes translation or protein products from RNA may at times locate to sites 
different from their RNA matrices (as seen for extracellular proteins) it is 
important to note that the proteins transcribed from epithelial mRNA might 
localise to the stroma rather than the epithelium. The converse is also true as 
seen for some of the BM components, such as Lama1, which, although 
synthesised in stromal fibroblasts is detectable as protein in BM [82]. Thus, 
although transcriptomics might be used for initial studies, protein analysis is 
needed to fully decipher the characteristics of organ morphogenesis.  
In addition, it is important to note that all the results presented in this chapter 
were based on the up-regulated or expressed genes only. Hence, it may be 
beneficial to repeat the „pathway analysis‟ for TEB and duct epithelium up-
regulated genes using both the up- and down-regulated gene sets 
simultaneously.  
3.3.4 Summary 
In summary, our work has shown that microarray analysis can be used both to 
identify potential new regulators (e.g. Fbln2, Upk3a) and provide clues that may 
help to characterise complex processes and their drivers associated with mouse 
mammary gland development at puberty. We identified the genome wide 
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epithelium-, epithelial-stromal- and stroma-associated signatures of TEBs and 
ducts and compared the biological functions and processes associated with each 
transcriptome. As a result, not only did we add to the understanding of the 
epithelial transcriptomes of TEBs and ducts but also provided insights into the 
characteristics of their stromal gene expression and thus presented the most 
comprehensive gene expression analysis of TEBs and ducts to date.  
We highlighted the association of TEB transcriptome with kidney and lung 
morphogenesis/cancer, cellular migration, nervous system, embryonic 
development and branching morphogenesis associated gene signatures and 
suggested that these genes could provide new pubertal regulators of mammary 
morphogenesis.  
We suggested that the stroma and epithelium of TEBs associates with similar 
processes and these are mainly „Cellular Migration‟, „Immune System 
Development and Function‟ and „Embryonic Development‟ whereas the epithelial 
and stromal signatures of ducts may differ considerably. We suggested that the 
ductal epithelial transcriptome associates with „Embryonic Development‟- and 
immune system (especially the migration of immune system components) gene 
signatures while ductal stroma appears as a place of high metabolic activity. 
Thus, suggesting that mammary epithelium may express cues that promote the 
infiltration of haemapoietic cells into epithelium adjacent stroma and proposed 
that an active angiogenesis may occur in mammary gland at puberty. In addition, 
we presented the most comprehensive analysis of the EMT response associated 
genes in pubertal mouse mammary gland development, to date, but were not 
able to draw final conclusions from our data on its involvement in controlling 
TEB outgrowth. We addressed the potential association of the pubertal 
mammary transcriptome with neuronal development gene signature and 
suggested that the TEB stroma and duct epithelium may comprise the highest 
number of axonal guidance genes.  
Finally, we identified the potential presence of many cell types, including 
neutrophils, T-, B-lymphocytes and NTKLs; and genes, such as: Emb, Fbn2, Fap 
or Slt1 that have not previously been linked to pubertal mouse mammary gland 
but may be potentially important for its morphogenesis. These pose many 
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questions that still need to be answered and may suggest many potential 
avenues of investigation that could guide future work.    
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4 Identification of new potential regulators of 
pubertal mouse mammary gland 
morphogenesis: Uroplakin 3a and Fibulin 2 
4.1 Introduction 
One of the main focuses of the microarray analysis performed in this study was 
the identification of new genes with potential to regulate pubertal mouse 
mammary gland development (See 3.2.6.3). These were selected from the list 
of 65 TEB epithelium up-regulated genes based on two criteria such as: i) FC 
level ii) association with biological processes known to share similarities with 
pubertal mouse mammary gland morphogenesis (See 3.2.6.3) (Table 3-5). Two 
genes Uroplakin 3a (Upk3a) and Fibulin 2 (Fbln2) were identified and selected 
for further investigation.  
4.2 Results 
4.2.1 UROPLAKIN 3A 
4.2.1.1 Introduction 
Upk3a was selected as a candidate regulator of pubertal mouse mammary gland 
development because it was identified as the most over-expressed gene within 
the 65-gene list. In fact, as shown by 5% LFC Model-based microarray analysis, 
Upk3a was identified as the most up-regulated gene (10.74 fold up-regulated) in 
the epithelium of isolated TEBs (TEBs vs ducts) (Table 3-4). 
To date, Upk3a has only been detected and functionally associated with normal 
or impaired bladder development. It encodes a membrane protein consisting of 
287 amino acids (aa) and is characterised by a molecular mass of 47 kDa from 
which ~ 29 kDa and ~ 18 kDa account for apoprotein and complex glycans 
respectively. The mature Upk3a protein consists of a 189 aa long N-terminal 
domain that encloses all potential N-glycosylation sites and a 52 aa long C-
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terminal, cytoplasmic domain within which multiple phosphorylation sites are 
contained. The remaining ~ 46 aa make up a single transmembrane domain.  
Upk3a belongs to the uroplakin family, which consists of four additional 
proteins: Upk1a (27 kDa), Upk1b (28 kDa), Upk2 (15 kDa) and Upk3b (35 kDa) 
[416] [417]. The cytoplasmic domain is exclusive to Upk3a and was postulated to 
enable the interaction of Upk3a with the cell cytoskeleton [418]. N- and C-
terminal domains of Upk3a are joined by a single transmembrane domain [418] 
[419]. All five uroplakins are known to be integral, structural components of a 
differentiated bladder urothelium. The two dimensional (2D) crystals of 
hexagonally packed 16 nm uroplakin particles have been shown to assemble as 
plaques and are called asymmetric membrane units (AMU). Plaques line the 
apical side of terminally differentiated mammalian urothelial umbrella cells, 
called superficial cells [420] [421]. Urothelial plaques are postulated to function 
as a permeability barrier and serve as a means for stabilizing the luminal bladder 
surface during contractions and expansion [422]. In the urothelium, uroplakins 
exist and function as heterodimers (1a/2 and 1b/3) [423] [424]. This 
conformation enables them to exit from the endoplasmic reticulum and is a 
prerequisite to reach the cell surface [425]. Formation of Upk3a/Upk1b 
heterodimer triggers a conformational change in Upk3a and protein maturation. 
The 43 kDa immature, endoplasmic reticulum form of Upk3a gets converted to 
the 47 kDa glycosylated, mature and stable protein (Golgi form).  
Gene targeted ablation of Upk3a confirmed its functional association and vital 
role in normal plaque formation [422]. Examination of bladder structure and 
function in Upk3a deficient mice revealed a reduced size of the urothelial 
plaques causing increased urothelial permeability, increased proliferation of 
umbrella cells, presence of retrograde flow of urine from the bladder into the 
ureters (vesicoureteral reflux), accumulation of urine in the renal pelvis 
(hydronephrosis), abnormal voiding patterns and an increase in spontaneous 
contractions and pressure in the bladder [422] [420] [426] [427]. Furthermore, 
Matsumoto et al. (2008) showed that loss of Upk3a expression is associated with 
the occurrence of transitional cell carcinoma, a highly aggressive, invasive 
bladder cancer [428]. In contrast, Lai et al. (2010),  however, identified Upk3a 
as a novel promising marker for the detection of bladder carcinoma from urine 
[429]. 
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Given the lack of an established, precise biological function and its exclusivity in 
association with the urothelium derived structures, such as renal pelvis, urethra, 
urinary bladder and prostate urethra [430] when all other human tissues with an 
exception for ovarian Brenner tumour, which however, is thought to be of 
urothelial origin, have to date been demonstrated as negative for Upk3a 
expression [431], Upk3a emerged as an interesting target for mouse mammary 
gland associated research. Our aim was to confirm the up-regulation of Upk3a 
expression in the mouse mammary gland during puberty, determine its precise 
localisation in TEBs and identify its role in normal mouse mammary gland 
development at puberty.       
4.2.1.2 Validation of Upk3a expression in pubertal mouse mammary gland. 
The association of Upk3a with the TEB transcriptome was further supported by 
microarray comparison analysis of Post-LN and Pre-LN data sets (Partek® 
Genomics™ Suite software) (See 2.2.5.5.2) where Upk3a was shown to be 3.01 
fold over-expressed in the Post-LN strip – ranking (#) to position 21 (p-value< 
0.001) (Figure 4-1 A). 
The TEB associated increase of Upk3a expression was also seen very clearly when 
the level of absolute gene expression was compared across all microarray 
replicates. The expression level was shown to be uniform across the replicates of 
each biological sample except for one 12 week old virgin replicate. The highest 
expression level of Upk3a was noted in the isolated epithelium of TEBs. The 
isolated ductal epithelium and Post-LN strips showed the second highest Upk3a 
expression level (10.74- and 11.1- fold lower than isolated TEB epithelium 
respectively). Upk3a expression in Pre-LN strips was 3.01 and 3.1 fold lower than 
that seen in Post-LN strips and isolated ducts respectively. The lowest Upk3a 
expression, however, was noted in the Fat pad with the Upk3a gene expression 
level similar to the one detected in the negative control - adult (V12) mammary 
glands (Figure 4-1 B).  
Further validation of TEBs-associated pattern of Upk3a expression in the mouse 
mammary gland was performed using Q RT PCR. As seen in Figure 4-2 A, Upk3a 
mRNA levels displayed a 4-fold increase in expression levels in the Post-LN strips  
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Figure 4-1 Upk3a expression profiling in the pubertal mouse mammary gland by microarray 
analysis. 
(A) Level of Upk3a up-regulation in the TEBs (TEBs vs ducts) and Post-LN strips (Post-LN vs Pre-
LN). Microarray analysis of TEB and duct data sets were performed using 5% LFC Model (See 
2.2.5.5.1), while the Post-LN and Pre-LN data sets were compared using Partek® Genomics™ 
Suite software (See 2.2.5.5.2). Rank number was assigned based on the FC level. Calculated FCs 
were statistically significant i.e. p-value≤0.05 for genes over-expressed in Post-LN and within 5% 
LFC Model for genes over-expressed in the TEBs isolated epithelium. (B) Absolute Upk3a 
expression levels for all microarray replicates. Absolute gene expression in each microarray 
replicate was calculated using Expression Console™. RMA was performed prior to gene 
expression analysis and the gene expression is denoted as log2 value. 
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Figure 4-2 Validation of Upk3a mRNA expression in the pubertal mouse mammary gland by 
Q RT PCR. 
(A) Mean expression level of Upk3a, Sema3B and Ltf mRNA in the Post-LN strips relative to Pre-
LN tissue strips. Sema3B and Ltf served as controls. Krt18 expression was used as an internal 
control for normalisation. Error bars are S.E.M. (*) denotes statistical significance, (*) p-value≤0.05 
(**) p-value≤0.01 (***) p-value≤0.001, n=3 
(B) Representative illustration of the mean expression level of Upk3a in Post-LN strip and bladder 
relative to Pre-LN strip. The cDNA produced from bladder RNA without addition of Reverse 
Transcriptase (RT) served as a negative expression control. Krt18 expression was used as an 
internal control. Error bars are S.E.M. calculated between the technical replicates, n=1.  
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in comparison to the Pre-LN mouse mammary gland tissue strips. Expression 
levels of Sema3B and Ltf that are known to be expressed in the TEB and duct 
epithelium respectively were used as experimental controls. Due to the 
prevalent association of Upk3a expression with the TEB epithelium, the Upk3a 
expression was measured by normalising the calculated gene expression level 
against that of Krt18. In addition mouse bladder was used as a positive control. 
Krt18 is a marker of both epithelial cells and urothelial umbrella cells [432] 
[433]. The calculated expression of Upk3a in the Post-LN mouse mammary gland 
tissue strip, although higher than that in the Pre-LN strip, was 17-fold lower than 
in the mouse bladder (Figure 4-2 B).  
Despite the presence of Upk3a mRNA in pubertal mouse mammary gland and its 
TEB-associated expression pattern, its expression in the mammary epithelium 
could not be confirmed at the protein level. Western blot analysis of protein 
extracts from Post-LN and Pre-LN mouse mammary gland tissue strips showed a 
lack of Upk3a expression in the mammary gland although the protein was 
present in murine bladder (positive control) (Figure 4-3 A). The antibody used in 
this study (AU1) is an Upk3a specific mouse IgG1 monoclonal antibody that 
recognizes an unspecified epitope residing within the extracellular domain [419]. 
Upk3a in the bladder protein extract was detected on the western blot as bands 
of between 43-47 kDa which corresponded to the size of the immature 
(Endoplasmic reticulum) or mature (Golgi) forms of Upk3a. These bands were 
absent from the Post-LN and Pre-LN blots. The lack of Upk3a protein expression 
in the pubertal mouse mammary glands was further confirmed using IHC. 
Paraffin wax embedded tissue sections of mammary gland and bladder, collected 
from 6 week old mouse were stained with AU1. In the bladder the umbrella cell 
region stained very strongly and uniformly for Upk3a (Figure 4-3 D). Although 
faint staining was also visible in the apical side of the mammary gland luminal 
epithelium (Figure 4-3 B) the same staining pattern was present in the negative 
control section (no primary antibody) and it was therefore considered as non 
specific secondary antibody reactivity (Figure 4-3 C).  
In order to ensure that the discrepancy between the mRNA and protein levels of 
Upk3a in the mouse mammary gland was not attributed to a tissue specific 
alteration in the gene sequence affecting the epitope recognised by the AU1 
antibody, full length Upk3a cDNA was synthesised from pubertal mammary gland  
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Figure 4-3 Validation of Upk3a protein expression in the pubertal mouse mammary gland. 
(A) Western Blotting. Representative analysis of Upk3a expression in the bladder (positive control), 
Post-LN strip and Pre-LN strip. Upk3a protein (47kDa) was identified using mouse monoclonal AU1 
antibody. ß-actin was used as loading control. n=2 
(B) (C) (D) IHC. (B) (C) Longitudinal sections through a 6 week old mouse mammary gland, 
showing fragment of representative epithelium and (D) mouse bladder showing part of urothelium. 
(B) (D) were stained using AU1 antibody. (C) serves as negative control (no primary antibody). (D) 
serves as positive control. Upk3a staining was prominent in urothelial umbrella cell region. Staining 
seen on the apical border of luminal epithelial cells in the mouse mammary gland was unspecific as 
it is also visible in the negative control. Secondary antibody was horseradish peroxidase 
conjugated. At least 3 animals were examined. Scale bars are 100 µm.  
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Pre-LN and Post-LN tissue strips and urinary bladder and sequenced. The length 
of cDNA obtained from all three sites was equal and there were no major 
differences in the nucleotide sequence or nucleotide rearrangements between 
the sequences. 
In summary, although Upk3a had potential to be a pubertal, TEB-associated 
regulator of mammary gland morphogenesis its expression could only be 
detected at the mRNA level.  
4.2.2 FIBULIN 2  
4.2.2.1 Introduction 
Fbln2 was selected as a candidate regulator of pubertal mouse mammary gland 
development because it was identified within the 65 TEB epithelium up-
regulated genes and has previously been reported to associate with other 
biological processes known to share similarities with ductal morphogenesis, such 
as cell adhesion and migration, embryonic development and kidney 
morphogenesis (Table 3-5).  
Fbln2 belongs to the highly conserved, ancient family of ECM glycoproteins.  The 
family name originates from the word fibula which in Latin means „clasp‟ or 
„buckle‟ and refers to their ability to act as a linker for other proteins. The 
Fibulin family incorporates six known members (Fbln1-Fbln6), all of which are 
characterised by the presence of a series of EGF-like motifs, followed by the 
carboxy-terminal fibulin-type module. The closest relative to Fbln2 is Fbln1C 
which shares 43 % aa sequence identity (Figure 4-4 A). 
Fbln2 cDNA was originally cloned from mouse fibroblasts in 1993 [434] and the 
gene was located to the mouse chromosome 6 band D-E [435]. Fbln2 was shown 
to exist as two alternatively spliced variants: V1 and V2, consisting of 18 and 17 
exons respectively. Based on the cDNA sequence, Fbln2 V1 was predicted to 
comprise a 3633 bp-long open reading frame as well as a 50bp and 664bp long 5‟ 
and 3‟ untranslated regions respectively. At the protein level, Fbln2 translated 
into a 26-residue long signal peptide and a 1195-residues long mature protein.  
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Figure 4-4 The overview of domain models for Fbln2 (M. musculus and H. sapiens and 
Fbln1C (M. musculus). 
Names of domains are indicated on the top of each diagram. Blue boxes at the left hand side 
denote the N-terminus domain (N-term). The N-term domain consists of Na and Nb subdomains. 
Pink diamonds in domain I indicated three motifs related to anaphylatoxins. Yellow circles in 
domain II denote EGF-like repeats and those with asterisk in the middle posses Ca
2+
 binding 
consensus sequence. The first EGF-like repeat is linked to domain I and the second EGF-like 
repeat with aa linkers (arrow head). The yellow circle with red outline represents exon 9. The gray 
box at the right hand site denotes the C-terminal domain (III) Annotation seen at the bottom of each 
diagram indicate positions of the potential N-glycosylation sites (N1, N2, N3 and N4) and the 
position of RGD consensus (RGD).      
(A) Murine Fbln1C. Fbln1 C is the closest relative to Fbln2 with 43% aa identity. It lacks the N-
terminal domain, has 9 EGF-like repeats and its C-terminal domain is shorter (B) Murine Fbln2 V1 
(top model) and (C) Fbln2 V2 (bottom model). Fbln2 V2 lacks EGF-like domain 3 which is encoded 
by exon 9. Potential glycosylation site 2 (N2) is also absent (D) The human Fbln2 lacks exon 9 and 
thus does not encode EGF-like repeat 3. Potential glycosylation site 2 (N2) and the RGD 
consensus sequence are absent. 
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Fbln2 V1 (195 kDa) consists of four domains (N, I, II and III). The N-terminus (N-
domain) is unique to Fbln2. It incorporates two sub domains spanning over 408 
aa residues. The first sub domain is cysteine rich (Na) and the second is cysteine 
free (Nb). Domain I consists of three anaphylatoxin-like motifs (each ~ 40 aa long 
and containing six cysteines) and is connected to the domain II via a 50 aa long 
link. Domain II consists of 11 EGF-like repeats, 10 of which contain consensus 
motifs for Ca2+ binding that are hypothesized to regulate protein-protein 
interactions [434] [436]. In general EGF-like repeats are postulated to 
participate in the interactions of ECM proteins with cellular receptors [437] as 
well as play a role in the stabilization of protein structure due to the presence of 
multiple disulfide bridges which in conjunction with other copies of Fbln2 
protein facilitate the formation of rod-like structures [438]. Recombinant Fbln2 
incorporates three disulfide bridges and is produced and secreted by human cell 
clones as a disulfide-bonded trimer. The final, domain III (C-terminal) of Fbln2 
V1 is composed of a single globular module. Furthermore, as indicated by the aa 
sequence prediction study, there are four potential N-linked glycosylation sites 
at the aa positions 179, 497, 737 and 1072 and a single Arg-Gly-Asp (RGD) 
attachment site, indicative of adhesive properties, at position 395-397 (Figure 
4-4 B).  
Fbln2 V2 shares all of the above sequence characteristics but for the presence of 
exon 9 which encodes the EGF-like domain 3 (709-755 aa) and contains a single 
potential N-linked glycosylation site (aa 737) (Figure 4-4 C).        
Fbln2 shows a high degree of interspecies conservation as the human protein 
shares around 90% aa identity with the domains Na, I, II and III and 62% with the 
domain Nb of the murine counterpart. The human gene thus far characterised 
lacks the EGF-like repeat on exon 9, hence encodes only the shorter (V2) Fbln2 
isoform and fails to contain the predicted RGD domain, which results in a 
substantial difference in cell adhesion activity and RGD-dependent integrin 
receptor binding between the two species [435] (Figure 4-4 D).      
The promoter region of Fbln2 has been shown to contain the trans-acting 
transcription factor 1 (Sp1)-, activator protein 2 (AP-2)- and CCAAT enhancer 
binding protein (C/EBP) binding sites [439]. The Sp1 consensus sequence is 
involved in gene expression in early development and confers high promoter 
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activity while the AP-2 and C/EBP transcription factors are known to regulate 
gene expression during embryogenesis and differentiation respectively. 
Expression of Fbln2 is detected mostly at the BMs and stroma of many mouse 
embryonic and adult tissues. During embryogenesis it is prominently expressed 
at embryonic sites of EMT during cardiac valvuloseptal formation [343] or 
precartilage formation [440]. In adulthood it is still associated with the valves 
and septa of heart [343], endothelial cells (EC) of the aortic arch and coronary 
blood vessels [441] and it can further be seen in skin (epidermal cell layer, 
dermis and adipose tissue), keratinocytes of hair follicles, epithelial cell layer 
and Bowman‟s and Descemet‟s membranes and stroma of cornea and 
surrounding the extracellular spaces around the muscle fibres in the skeletal and 
heart muscles. A lower level of Fbln2 mRNA expression has also been detected in 
the lung, liver, kidney, brain, spleen and testis [434]. 
Based on in vitro studies the function of Fbln2 may be in forming intramolecular 
bridges which link and stabilize the organisation of supramolecular ECM 
structures, i.e. basement membranes, elastic fibres and fibronectin matrix [442] 
[443] [444]. Furthermore, Fbln2 co-localises and interacts with Fbn1 in the 
bundles of microfibrils that appear to intersect the lamina densa of kidney 
glomeruli and perichondrium [344]. The timing of expression, tissue localisation 
and spatial localisation within the tissues also suggest that it may promote either 
proliferation or differentiation or migration of mesenchymal cells during 
organogenesis and endorse structural stability during adulthood. The detection 
of Fbln2 expression in testis [445] and ovaries [435] in connection with the 
recently discovered involvement of Fbln2 in the sequestering of sex hormone 
binding globulin (SHBG) within the stroma of uterus and thus regulating the 
access of SHBG to target cells [446], suggest functional association of Fbln2 with 
the female and male reproduction systems. Finally, since it is over-expressed 
during wound repair processes, Fbln2 may also be involved in tissue remodelling 
[447] [448]. In contrast to the in vitro studies, however, an in vivo Fbln2 KO-/- 
based study did not confirm the need for Fbln2 in elastogenesis, development 
and fertility as the Fbln2-null mice were shown to be viable, fertile and lacking 
any gross anatomical abnormalities or dysfunction in assembly of elastic fibres 
[266]. Very recently, however, the generation of double KO mice for Fbln2 and 
Fbln5 shone a new light onto Fbln2 function, demonstrating that both of the 
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proteins function cooperatively to redirect the assembly of elastic fibres to form 
the internal elastic lamina in blood vessels during postnatal development [449].   
Finally, the dysfunction of Fbln2 has been associated with some pathological 
conditions. Deposition of Fbln2 in elastic fibres was demonstrated in solar 
elastosis, a skin condition caused by sun damage [450]. In tumourigenesis, Fbln2 
has been identified to have opposing functions. On the one hand, it was found 
amongst the metastasis-associated genes in adenocarcinomas [451], was over-
expressed in a HER2/Neu –driven mouse model of breast cancer [452] and was 
associated with poor prognosis and metastatic potential of primary solid tumours 
of different types [451]. On the other hand, however it was identified as 
frequently methylated in breast tumors [453] and down-regulated in breast 
cancer cell lines and primary breast tumours [342].   
Given the association of Fbln2 with organogenesis, tissue remodelling and 
tumourigenesis and its documented involvement in the regulation of cell 
adhesion and migration in different biological systems, together with the up to 
date lack of reported Fbln2 expression and association with mouse mammary 
gland development, Fbln2 arose as a promising novel target in the study of 
pubertal regulators of mouse mammary gland morphogenesis. Thus, we aimed to 
confirm and examine the Fbln2 expression pattern during normal mouse 
mammary gland development, with a focus on puberty. Furthermore, we set out 
to study the role of Fbln2 in pubertal morphogenesis by examining the 
morphology of the ductal tree in Fbln2 KO-/- mice, exploring the expression 
patterns of its binding partners, estimating the influence of systemic hormones 
on its expression in vivo and investigating its role in the regulation of cell 
migration and adhesion in vitro. Finally, we set out to establish a TEB explant 
culture model to facilitate the study Fbln2 expression in vitro.  
4.2.2.2 Validation of Fbln2 expression during pubertal mouse mammary 
gland development.  
Fbln2 was amongst the 65 genes commonly up-regulated in the epithelium of 
TEBs (TEBs vs ducts) (5% LFC Model) (See 3.2.6.1.1) and Post-LN strip (Post-LN 
vs Pre-LN) (Partek® Genomics™ Suite software) (See 3.2.6.1.2) by 2.16 fold (# 
182) and 1.75 fold (# 285) (p-value<0.001) respectively (Figure 4-5 A). The  
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Figure 4-5 Fbln2 expression profiling in the pubertal mouse mammary gland by microarray 
analysis. 
(A) Level of Fbln2 up-regulation in the TEBs (TEBs vs ducts) and Post-LN strips (Post-LN vs Pre-
LN). Microarray analysis of TEB and duct data sets were performed using 5% LFC Model (See 
2.2.5.5.1), while the Post-LN and Pre-LN data sets were compared using Partek® Genomics™ 
Suite software (See 2.2.5.5.2). Rank number was assigned based on the FC level. Calculated FCs 
were statistically significant i.e. p-value≤0.05 for genes over-expressed in Post-LN and within 5% 
LFC Model for genes over-expressed in isolated epithelium of TEBs. (B) Absolute Fbln2 
expression levels throughout all microarray replicates. Absolute gene expression in each 
microarray replicate was calculated using Expression Console™. RMA was performed prior to 
gene expression analysis and the gene expression is denoted as log2 value. 
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increase of Fbln2 expression in association with TEBs was confirmed when the 
level of absolute gene expression was compared across all replicates used in the 
microarray experiment. The comparison of absolute gene expression also 
revealed the expression of Fbln2 within the empty Fat pad. The Fat pad was 
excised at a significant distance from the epithelium to prevent its 
contamination with epithelium and its associated stroma. The absolute level of 
Fbln2 expression was highest in isolated TEBs, Fat pad and Post-LN strips with 
Fat pad showing similar and Post-LN -1.2 fold lower gene expression levels than 
isolated TEBs. Some variability between the replicates could be seen for the Fat 
pad strips. The absolute level of Fbln2 expression was lower in the remaining 
samples, with isolated duct epithelium, Pre-LN strip and V12 showing 2.16, 1.9 
and 1.6 fold lower expression than that calculated in the isolated TEB epithelium 
respectively (Figure 4-5 B).     
Expression of Fbln2 within the epithelium of TEBs was further confirmed by Q RT 
PCR analysis of total RNA extracts collected from isolated TEBs and ducts and 
Post-LN and Pre-LN mammary gland tissue strips. The Fat pad associated 
expression of Fbln2 was not taken into consideration in these as well as most of 
the subsequent experiments since at the time of the study Fbln2 was thought to 
be mostly expressed in the epithelium and only low expression was thought to be 
associated with stroma (absolute gene expression profiling and some of the 
protein localisation studies were performed as one of the last analyses). As seen 
in Figure 4-6 A and B Fbln2 expression was 3.4 fold higher in both, isolated TEBs 
compared to ducts, and Post-LN strip compared to Pre-LN. Expression levels of 
Sprr1A and Ltf, genes previously associated with TEB and duct epithelium 
respectively were used as experimental controls. As only the epithelium 
associated expression of Fbln2 was taken into consideration in this experiment, 
Krt18 (an epithelial marker) instead of ß-actin (expressed ubiquitously in the 
tissue) was used for normalisation. Krt18 aids the normalisation of the 
calculated gene levels to the amount of epithelium. It is worth noting, however, 
that Post-LN and Pre-LN strips consist of both epithelium and its associated 
stroma, which as suggested by the high absolute expression of Fbln2 in Fat pad 
(Figure 4-5 B) and further demonstrated in succeeding experiments (Figure 4-
7), also expresses Fbln2. Therefore despite using Krt18 normalisation to examine  
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Figure 4-6 Validation of Fbln2 expression in pubertal mouse mammary gland. 
(A) (B) Q RT PCR. (A) Mean expression level of Fbln2 and Sprr1a mRNA in isolated TEBs relative 
to isolated ducts and (B) Fbln2, Sprr1a and Ltf mRNA in the Post-LN strips relative to Pre-LN 
tissue strips. Sprr1a and Ltf served as controls for TEBs and ducts respectively. Krt18 expression 
was used as an internal control for normalisation. In (A) n=pooled from 300 mice and error bars 
denote technical variability. In (B) error bars are S.E.M. and (*) denotes statistical significance, (*) 
p-value≤0.05 (**) p-value≤0.01 (***) p-value≤0.001, n=3 
(C) Western Blotting. Representative analysis of Fbln2 expression in the Pre-LN strips, Post-LN 
strips and skin (positive control). Fbln2 protein (195 kDa) was identified using rabbit polyclonal anti- 
Fbln2 antibody. Asterisks (*) denote two additional, uncharacterised bands of a lower molecular 
weight (150 kDa, 135 kDa). ß-actin was used as loading control. n=3. Densitometry was carried out 
to calculate relative expression of Fbln2 protein normalised to ß-actin protein levels for the same 
set of samples. 
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epithelial gene expression, some of the detected signal might be attributed to 
the stromal compartment.  
Pubertal expression of Fbln2 (195 kDa) was further confirmed at the protein 
level by Western Blotting using protein lysates, extracted with RIPA buffer from 
murine skin and Post-, Pre-LN tissue strips and blotted under denaturing 
conditions (Figure 4-6 C). The level of Fbln2 expression was 1.6 and 6.2 fold 
higher in the Post-LN strip than the Pre-LN strip and skin respectively (positive 
expression control) as revealed in densitometry analysis. Previously reported, 
uncharacterised bands of the mobility below the predicted protein (150 kDa and 
135 kDa) (denoted by asterisks in Figure 4-6 C) were also present. 
4.2.2.3 Localisation of Fbln2 in the pubertal mouse mammary gland 
To assess the localisation of Fbln2 within the pubertal mouse mammary gland, 6 
week old mammary glands were fixed in 10 % Neutral Buffered Formalin, 
paraffin wax embedded and sectioned. Chosen sections were H&E stained to 
assess tissue morphology and ensure the presence of TEB and duct epithelium. 
Positively evaluated tissue sections were stained with routine anti-Fbln2 
antibody using IHC and IF. Haematoxylin and DAPI were used as nuclear 
counterstains for IHC and IF respectively. The obtained results were consistent 
with the Fbln2 expression profile determined by microarray analysis. 
As seen in Figure 4-7, Fbln2 expression was localised to both the epithelium and 
the stroma of pubertal mouse mammary gland. Stromal expression was 
restricted to the proximal zone surrounding the TEB and duct epithelium, with 
the former appearing stronger; and the distal capsule located at the very edge 
of the Fat pad. While Fbln2 was present in the stroma surrounding both TEBs and 
ducts its epithelial expression was almost exclusively associated with TEBs. As 
seen by IHC on transverse sections through the isolated TEBs and TEBs 
surrounded by the stroma (Post-LN strip) most Fbln2 expression was localised to 
the cap cells (the outermost cell layer in TEBs) (Figure 4-8 A). The additional 
expression of Fbln2 in the TEBs was present in the body cells (Figure 4-8 A). In 
comparison to the TEBs, ductal epithelial expression of Fbln2 was very weak 
(Figure 4-8 B).  
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Figure 4-7 Localisation of Fbln2 expression in pubertal mouse mammary gland by IHC. 
(A) Longitudinal section through 6 week old mouse mammary gland stained with rabbit polyclonal 
anti-Fbln2 antibody and horse radish peroxidase conjugated secondary antibody (brown). 
Haematoxylin (blue) was used to stain nuclei. Fbln2 expression was associated with epithelium of 
TEBs (arrow), stroma around TEBs and ducts (dotted arrow), stromal capsule around the edge of 
the fat pad (arrow head). (B) negative (no primary antibody) control. Scale bars are 100 um. 
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Figure 4-8 Localisation of Fbln2 expression in the pubertal TEBs and ducts by IHC. 
(A) Longitudinal (left) and transverse (top right) sections through a TEB and its surrounding stroma 
(left) and transverse section through an enzymatically isolated TEB (bottom right) (B) Longitudinal 
section through a duct and its surrounding stroma. (C) Negative (no primary antibody) control. 
Staining in (A) (B) was performed using anti-Fbln2 antibody (brown). Haematoxylin was used to 
stain nuclei (blue). In (A) most Fbln2 expression was associated with the outer cell layer of TEBs 
(cap cells) (arrow). Some expression was also detectable within body cells (dotted arrow) and the 
stroma around TEB (asterisk). Fbln2 expression seemed to localise to the cell membranes, 
cytoplasm and extracellular spaces. (B) In the duct, Fbln2 expression was weak and mostly 
associated with the stroma around ductal epithelium (asterisk). Scale bars are 50 µm. 
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A similar pattern of expression was observed when longitudinal sections through 
the TEBs and ducts were stained for Fbln2 using IF (Figure 4-9). Fbln2 
expression was almost absent from ductal epithelium (Figure 4-9 C), but was 
present abundantly in the cap cell- and at a lower level in body cell-region of 
TEBs (transverse and longitudinal sections) (Figure 4-9 A-B). In the cap cells, 
Fbln2 staining appeared membrane bound, cytoplasmic and extracellular (Figure 
4-10 A) while within the body cells it was present in cytoplasm or between the 
cells and was not uniformly expressed across all body cells (Figure 4-10 B). 
Some Fbln2 positive staining could also be seen in the BM region (Figure 4-10 
A). The expression of Fbln2 in cap cell membranes and low cytoplasmic 
expression in ductal epithelium were further demonstrated when 3D 
reconstruction was performed on the series of transverse sections through 
pubertal mouse mammary gland (Figure 4-11). 
The observed staining pattern was specific to Fbln2-antibody binding as 
demonstrated by the absence of staining in the epithelium of the negative (no 
primary antibody) controls (Figure 4-8 C) (Figure 4-9 D). Positive Fbln2 
expression was also noted in the blood vessels throughout mammary gland tissue 
(in all IHC and IF sections) (data not shown). 
IHC and IF of pubertal mouse mammary glands demonstrated that Fbln2 
expression was stronger in the TEBs and their surrounding stroma than in the 
ducts, thus confirming our microarray, Q RT-PCR and Western blot results. 
4.2.2.4 Fbln2 expression across the different stages of mouse mammary 
gland development. 
Post-natal mouse mammary gland morphogenesis can be divided into the 
following six distinct developmental stages: pre-puberty, puberty, adulthood, 
pregnancy, lactation and involution. Each of these stages is characterised by 
diverse events and regulated in a different manner. Therefore, the expression of 
Fbln2 at the RNA level and its tissue localisation was investigated throughout the 
various developmental stages using whole tissue strips and whole mouse 
mammary glands (Figure 4-12 A). The experiments were performed using Q RT 
PCR and IHC. Relative to the Post-LN strip, the level of Fbln2 expression was 3.6 
fold up-regulated in whole mammary glands during pre-puberty but similar 
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Figure 4-9 Localisation of Fbln2 expression in the pubertal epithelium of TEBs and ducts by 
IF. 
(A) Transverse and (B) longitudinal sections through TEB and (C) longitudinal sections through 
duct of 6 week old mouse mammary glands are shown. (D) is a negative control (no primary 
antibody). Staining was performed using Alexa Fluor 488 conjugated anti-Fbln2 antibody (green) 
and nuclear DAPI (blue). Fbln2 expression was associated with cap cells (arrow) (A) (B). Weak 
staining could be seen in body cells (arrow head). Very weak Fbln2 staining could be detected in 
the duct (C) Images were captured by confocal microscopy. Scale bars are 50 µm. 
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Figure 4-10 Localisation of Fbln2 expression in the pubertal TEB by IF. 
Images show representative areas of the pubertal TEBs stained with anti-Fbln2 antibody that are 
shown in Figure 4-9. (A) Cap cells showing membrane (arrow) and cytoplasmic (dashed arrow) 
staining pattern (B) Body cells showing Fbln2 staining in the cytoplasm or extracellular spaces 
(arrow head). Images were acquired by confocal microscopy. Scale bars are 10 µm. 
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Figure 4-11 3D reconstruction of pubertal TEBs and ducts stained with anti-Fbln2 antibody. 
3D reconstruction of the series of (A) transverse sections through the TEB and (B) longitudinal 
sections through the duct of a 6 week mouse mammary gland. 3D reconstruction was performed 
using Velocity software. Images were acquired every 0.7-0.8 µm. (A) Fbln2 staining in the TEB was 
restricted to cap cells and BM region (white arrow). Duct epithelium was negative for Fbln2 
expression. Weak staining visible in B was nonspecific (See Figure 4-9 D). Images were captured 
by confocal microscopy. Scale bars are 20 µm.    
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Figure 4-12 Fbln2 mRNA expression throughout different stages of mouse mammary gland 
development by Q RT PCR. 
(A) Mean expression levels of Fbln2 in whole glands collected at pre-puberty, puberty, adulthood, 
pregnancy, lactation and involution. Post-LN strip served as a positive control. Expression levels 
were normalised against Krt18. Error bars denote technical variability, n=1, as only 1 animal was 
used per time point but experiments were repeated 3 times.  
(B) (C) Mean expression levels of Fbln2 in whole glands collected at pre-puberty (2 and 3 weeks) 
relative to puberty 6 weeks. Expression levels were normalised against Krt 18 (B) and ß-actin (C). 
Error bars are S.E.M, (*) denotes statistical significance (**) p≤0.01, n=3. Experiments were done in 
triplicates for each sample. 
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during puberty, which served as a good experimental control. Furthermore, 
moderate Fbln2 expression (although significantly lower than in the Post-LN 
strip) was also noted in the following samples: pregnancy day 3, lactation days 1 
and 7. However, this experiment was performed on samples collected from a 
single set of animals, hence detected expression levels might not be fully 
representative. Since Fbln2 was expressed at the protein level in both 
epithelium and stroma of the pubertal mouse mammary gland, Fbln2 RNA 
expression profiling was repeated at chosen time points (pre-puberty, puberty) 
to compare the levels of Fbln2 expression relative to the amount of epithelium 
or to the total number of cells. This was calculated by normalising the gene 
expression to Krt18 and ß-actin expression levels respectively. Initially only 
Krt18 was used for normalisation, but with the expression of Fbln2 in stroma 
noted on IHC, IF and absolute gene expression profiling, data was re-normalised 
against ß-actin since its expression is ubiquitous. This showed that the level of 
Fbln2 expression varied depending on whether its expression was normalised to 
the amount of epithelium or to the total number of cells. When normalised to 
Krt18, pre-pubertal Fbln2 expression at 2 and 3 weeks was on average 25 and 16 
fold higher than its pubertal (6 weeks) expression respectively (Figure 4-12 B) 
and all of these FCs were statistically significant. In contrast when normalised to 
ß-actin, Fbln2 expression levels were similar between all of the three time 
points, with only the pre-puberty week 3 sample showing  slightly lower 
expression (Figure 4-12 C). None of these FCs, however, reached statistical 
significance. 
A similar pattern of Fbln2 expression was observed at the protein level. In 
concordance with the mRNA expression profile, IHC stained sections of the 
mouse mammary gland developmental stages demonstrated positive Fbln2 
expression during pre-puberty, puberty, adulthood and early pregnancy (Figure 
4-13, 4-14). In discrepancy with the mRNA data, however, no Fbln2 expression 
was detected during lactation (Figure 4-15 A). In the pre-pubertal and pubertal 
mammary gland Fbln2 localised to the epithelium (cap cells and body cells) and 
stroma around TEB-like structure and TEBs respectively (Figure 4-13 A-C). 
During puberty, protein expression was also detectable in the duct epithelium 
and stroma, as discussed in 4.1.2.3 (Figure 4-13 C). This ductal expression 
pattern, although very diminished, was further detectable in the 12 week old  
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Figure 4-13 Fbln2 protein expression and localisation during virgin mouse mammary gland 
development by IHC. 
Longitudinal and transverse sections through (A) (B) 3, (C) 6 and (D) (E) 12 weeks old mouse 
mammary glands showing representative fragments of epithelium stained with anti-Fbln2 antibody 
(brown). Nuclei were stained with haematoxylin (blue). (B) and (E) are higher magnification images 
of the areas highlighted by asterisks in images A and D respectively. (F) shows a negative (no 
primary antibody) control. Fbln2 expression was localised to the TEBs (black arrows) (A) (C) and in 
much lesser extend to the pubertal ducts (black arrow heads) (C). In the adult mammary gland 
some weak Fbln2 expression was associated with the stroma around ducts (arrow head) (D). Scale 
bars are 200 µm. At least 3 animals (6 glands) were examined per developmental stage. 
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Figure 4-14 Fbln2 protein expression and localisation in the mouse mammary gland during 
pregnancy time points by IHC. 
Longitudinal sections through mammary glands collected from pregnant mice (left) and magnified 
fragments of representative epithelium (right) (highlighted by asterisk on the left) stained with anti-
Fbln2 antibody (brown). Nuclei were stained with Haematoxylin (blue). Fbln2 expression switched 
on 48h after conception, increased by 72h and disappeared by pregnancy day 4.5. Some Fbln2 
positive staining could be seen at 14.5 days. Scale bars are 200 µm. At least 3 animals (6 glands) 
were examined per developmental stage. 
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Figure 4-15 Fbln2 protein expression and localisation in the mouse mammary gland during 
lactation and involution by IHC. 
Longitudinal sections through (A) lactating and (B) involuting mouse mammary glands showing 
representative fragments of epithelium stained with anti-Fbln2 antibody (brown). Nuclei were 
stained with Haematoxylin (blue). No Fbln2 expression could be detected. Scale bars are 200 µm. 
At least 3 animals (6 glands) were examined per developmental stage. 
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adult mammary glands (Figure 4-13 D and E). Prominent Fbln2 expression, 
comparable to that in the pre-pubertal or pubertal TEBs was detectable during 
early pregnancy, with the onset at 48h, a peak at 72h and disappearance by day 
4.5 (Figure 4-14). At these time points, Fbln2 appeared localised exclusively to 
the cell membranes and cytoplasm of the outer most, presumably myoepithelial 
layer of the ductal epithelium and the stroma around it (as seen at puberty). 
The expression of Fbln2 in the distal stromal capsule was very prominent at pre-
puberty (3 weeks), puberty (6 weeks) and pregnancy 72h; largely reduced by the 
onset of adulthood and pregnancy day 14.5 and absent from involution day 7 and 
lactation day 3 (Figure 4-16 A-G).  
All of the observed staining was specific to Fbln2-antibody binding as 
demonstrated by the lack of staining in the negative (no primary antibody) 
controls (Figure 4-13 F) (Figure 4-16 H). 
4.2.2.5 Localisation of Fbln2 expression using a preliminary in vitro model 
of TEB explant culture 
The confocal images and light microscopy suggested that the Fbln2 was present 
in the cytoplasm, on the membrane and possibly in the extracellular spaces in 
TEBs at puberty. In order to analyse the localisation more precisely we decided 
to attempt to culture TEBs as explants, with the assumption that the cap cells 
and the body cells would migrate out from the explant as a monolayer or 
multilayer and thus be more amenable to study. Consideration was given to 
using TEBs embedded in Matrigel, but this would have involved histological 
sectioning.  The methodology was based on that used previously for keratinocyte 
explant cultures [454] with modifications which were thought might help to 
maintain the cells. Briefly, TEBs were isolated as previously described (2.2.1.5) 
and plated out on fibronectin (10ug/ml) coated chamber slides, with a thin film 
of culture medium (Dulbecco‟s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12) supplemented with 2mM L-glutamine and Leukaemia Inhibitory 
Factor (LIF) (1000U/ml). LIF was used in an attempt to prevent differentiation. 
Fibronectin was used to improve attachment. Explants were cultures in Galaxy S 
tissue culture incubator at 37°C in a humidified atmosphere with 5% CO2.  
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Figure 4-16 Fbln2 protein expression in the stromal capsule throughout the developmental 
time points of mouse mammary gland morphogenesis by IHC. 
Sections through mouse mammary glands collected at different time points during mammary 
morphogenesis showing representative fragments of stromal capsule (arrow head) stained with 
anti-Fbln2 antibody (brown). Nuclei are stained with Haematoxylin (blue). Strong Fbln2 expression 
could be seen at pre-puberty (3 weeks) (A), puberty (6 weeks) (B) and pregnancy 72h (D). Weaker 
Fbln2 expression could be noted in adulthood (12 weeks) (C) and pregnancy 14.5d (E). No Fbln2 
staining could be seen in lactation day 7 (F), involution day 3 (G) and negative (no primary 
antibody) control (H). Scale bars are 100 µm. At least 3 animals were examined for each time 
point. 
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After 24h, explants attached and further medium was added to a level of 2mm, 
with care not to disturb the explants. Cells spread out from the periphery of the 
explant over the next 4 days and the cultures were then terminated by fixation 
in absolute alcohol. A pavement of epithelial cells formed around the explant 
(Figure 4-17). Cell division was seen in the outgrowths, but the majority of the 
outgrowth was through migration and cell spreading. The preliminary IHC 
analysis of outgrowths demonstrated: i) positive Ktr18 staining in all of the cells 
within the outgrowth, suggesting their epithelial origin (Figure 4-17 A); ii) 
positive Krt14 staining in some of the cells, confirming their epithelial origin 
(Figure 4-17 B); iii) positive SMA staining seen in the cells at the periphery of 
the outgrowths, suggesting their myoepithelial/cap cell character (Figure 4-17 
C). On the basis of this preliminary characterisation of the epithelial nature of 
the outgrowths we stained the cultures with routine anti-Fbln2 antibody. 
Explants showed positive Fbln2 expression which localised to the cytoplasm, cell 
membranes and cellular processes that protruded from some cells and resembled 
cob-web-like structure which seems to run around, above and between cells like 
intracellular glue (Figure 4-18). The cytoplasmic and cell-membrane associated 
expression of Fbln2 is consistent with the sites of its expression in the epithelium 
of TEB in vivo (Figure 4-10). No double labelling was performed, but there was 
no correlation between the distribution of the CK14 and SMA positive cells and 
the Fbln2 expression. This was a very preliminary study, but enabled us to 
localise the Fbln2 in vitro and to confirm the localisation of the protein and its 
apparent secretion into the extracellular compartment. Clearly this explant 
system also has limitations, with lack of stroma, the all important immune 
system and loss of the in vivo 3D cellular organisation, but may have some role 
in studies of body and cap cells if further characterised. 
4.2.2.6 Fbln2 splice variants and their pubertal expression pattern.  
As mentioned previously, there are two alternative splice variants of Fbln2 gene, 
known as Fbln2 V1 and Fbln2 V2. The former includes 18 exons while the latter 
lacks the sequence for exon 9 and hence consists of 17 exons (Figure 4-19 A). 
The distribution pattern of the two splice variants appears tissue specific. As 
shown by Grässel et al. (1990), using PCR and exon 9 flanking primers to amplify 
the cDNA of Fbln2, Fbln2 V1 is predominantly expressed in the heart while Fbln2 
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Figure 4-17 Preliminary analysis of the morphological characteristics of explant culture 
outgrowths by ICH. 
TEB explant outgrowths stained with (A) anti-Ktr18, (B) anti-Krt14 and (C) anti-SMA antibodies. (A) 
(B) Positive Krt18 (uniform) and Krt14 (some cells) staining suggests the epithelial character of 
outgrowths. (C) Positive SMA staining, seen at the periphery of the outgrowths, suggests a 
myoepithelial/cap cell character of these cells. At least 3 TEB outgrowths were stained with each 
antibody and examined. Scale bars are 100µm. 
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Figure 4-18 Preliminary investigation of Fbln2 expression in the outgrowths of TEB explants 
by ICH. 
(A) Image of TEB explant outgrowth (B) (C) (D) Representative fragments of TEB explant shown in 
A. Fbln2 expression appeared to be associated with the cytoplasm (arrow), cell membranes 
(asterisk) and cellular processes of some cells within the outgrowths. At least 3 TEB outgrowths 
were stained with anti-Fbln2 antibody and examined. Scale bars are 100µm (right) and 25µm (left).       
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V2 is more abundant in the kidney. The NIH3T3 cell line expresses only full 
length Fbln2, i.e. Fbln2 V1 [439]. 
In this project, two distinct methods of splice variant detection were used to 
analyse the mammary gland specific pattern of Fbln2 V1 and Fbln2 V2 
expression. Firstly, the expression of each exon was analysed and compared 
between the isolated TEBs and ducts using the XRAY Excel® Array based 
microarray analysis (See 2.2.5.7). Secondly, the cDNA produced from the RNA 
extracted from the Post-LN, Pre-LN tissue strips and isolated TEBs and ducts was 
PCR amplified as described by Grässel et al. [439] and resolved by using agarose 
gel electrophoresis. Primer location is demonstrated in Figure 4-19 A. 
Fbln2 exon expression analysis showed a comparable exon expression pattern 
between the isolated TEBs and ducts. As demonstrated in Figure 4-19 B, the two 
lines indicating mean expression of Fbln2 in TEBs (blue line) and ducts (red line) 
were roughly parallel and where present, the divergence from this parallel co-
localisation (exons that are contained within the two vertical lines) was too 
small to be significant. Thus, a lack of variation in alternative RNA splicing 
between TEBs and ducts was demonstrated. A more detailed, probe set based 
gene expression analysis of the probe set number 9 which is complimentary to 
the DNA fragment between nucleotide positions 91209637-91209763, thus 
corresponding to exon 9 of Fbln2 gene (91209624-91209764) confirmed the above 
mentioned finding (Figure 4-19 C). No significant difference in the expression 
pattern was seen either when the 9th probe set was compared to other probe 
sets which suggested that exon 9 was expressed at a similar level to the 
remaining exons or when the 9th probe set was compared between TEB and duct 
samples, suggesting a similar level of exon 9 expression in both samples (Figure 
4-19 C). Given that exon 9 is only present in Fbln2 V1 it would suggest this 
isoform is prevalent in both the TEB and duct samples.  
PCR based analysis further revealed the presence of both V1 and V2 Fbln2 splice 
variants in the Post-LN and Pre-LN mammary tissue strips and isolated TEBs and 
ducts. As seen in Figure 4-19 D, the corresponding electrophoresis gels 
presented two amplification bands of 394 and 254 bp consistent with the size 
predicted for V1 and V2 Fbln2 variants respectively. The V1 splice isoform of 
Fbln2 appeared stronger in the Post-LN strips and isolated TEBs and ducts which  
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Figure 4-19 The expression of Fbln2 splice variants in the pubertal mouse mammary gland. 
(A) Graphical comparison of Fbln2 V1 and Fbln2 V2 genomic DNA organisation. Red boxes 
indicate common exons. Blue box denotes exon 9 (exclusive for Fbln2 V1). The approximate 
locations of primer annealing sites are denoted with arrows. Green arrows show primers used for 
PCR experiments. Blue arrows show primers used in Q RT PCR experiments. (B) (C) Comparison 
of Fbln2 expression in isolated TEBs (blue) and duct (red). Analysis shown at (B) the exon level 
and (C) probe set level. Each probe set represents a different exon cluster and there is one exon 
cluster per exon. Comparison was carried out using XRAY Excel® Array Analysis v.2.5 Microsoft® 
Excel® add-in. Probe set number 9 was designed against a fragment of DNA located in exon 9 
(absent from Fbln2 V2). Although 12 exons showed non parallel expression level between TEB and 
duct samples (denoted by two vertical black lines) the differences in expression were not significant 
enough to indicate differences in alternative splicing between the samples. Error bars indicate 
standard deviation at each (B) probe set or (C) probe. (D) PCR. Electropherogram illustrating 
presence of Fbln2 V1 (394 bp) and V2 (254 bp) splice variants expression in Post-LN and Pre-LN 
strips and isolated TEBs and ducts. +ve contains cDNA from mouse kidney (positive control). -ve 
are PCR quality controls (-RT). Tissue strips were collected from two individual mice. Fbln2 V1 
seems to be prevalent in Post-LN strip and isolated TEBs or ducts samples. V1:V2 ratio in Pre-LN 
strip is inconclusive, n=pooled from 300 mice for the isolated TEBs and ducts for tissue strips 1 
animal was used for each Pre-LN and Post-LN strips. Experiment was repeated 4 times with similar 
results. 
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was consistent with the exon expression data. No difference in band strength, 
however, was seen for the V1/V2 ratio in the Pre-LN strips. The observed 
expression pattern of Fbln2 splice variants was representative of mammary gland 
tissue strips collected from 4 individual mice and isolated TEBs and ducts pooled 
from 300 mice. cDNA synthesized from kidney RNA served as a positive control. 
4.2.2.7 Characterisation of the additional, 150 kDa and 135 kDa proteins, 
detected by the routine anti-Fbln2 antibody. 
Although the molecular weight of the mature, monomeric Fbln2 protein is 195 
kDa, two major, additional bands of a molecular weight of 150 kDa and 135 kDa 
were detectable using the anti-Fbln2 antibody throughout most of the Western 
blotting experiments. Bands of similar molecular weight have also been reported 
by other research groups (using the same antibody) and speculated to arise as a 
result of proteolytic cleavage, but their true nature has not yet been elucidated 
[434] [455].  
To investigate the identity of the two bands further and check for differences in 
their expression in different components of mouse mammary gland, experiments 
were designed to test the following hypotheses: (1) 195 kDa band stands for 
Fbln2 V1 while 150 kDa or 135 kDa denotes Fbln2 V2; (2) both bands (135 kDa 
and 150 kDa) arise due to the N- or C-terminus targeted proteolytic cleavage; (3) 
the proteolytic cleavage pattern could vary depending on the stromal 
environment of proteases present.  
HYPOTHESIS 1: The first hypothesis resulted from molecular mass prediction 
studies carried out for Fbln2 V1 and V2. The mass of the V1 isoform was 
predicted as 131 kDa, revealing that the remaining 64 kDa of the mature protein 
is attributed to post-translational modifications, such as N-glycosylation. Fbln2 
V2 was predicted to weigh 126 kDa. However, since there are 4 potential N-
glycosylation sites in the Fbln2 V1 sequence and one of them is located within 
exon 9 which is absent from its V2 counterpart, it is likely that the actual size 
difference between the V1 and V2 isoforms is much greater than 5 kDa, and thus 
the V2 isoform of Fbln2 could in fact weigh 150 kDa. To test this hypothesis, we 
used protein extracts from NIH3T3 (mouse fibroblasts), EpH4 and HC11 (mouse 
mammary epithelial) cell lines. These cell lines were chosen on the basis of 
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cDNA profiling by PCR as described in 4.2.2.6 which showed that NIH3T3 express 
both Fbln2 V1 and Fbln2 V2 isoforms, EpH4 express only the Fbln2 V2 isoform 
while HC11 show no Fbln2 at all and thus when studied collectively they serve a 
good system to investigate the identity of Fbln2 bands. As seen on the 
representative gels in Figure 4-20 A, the amplification bands of 394 (V1) and 
254 (V2) bp were seen in the NIH3T3 cell line while only the lower weight one of 
254 bp (V2) was detectable in the EpH4 amplicon. No amplicons were produced 
from HC11 cDNA. Q RT PCR further confirmed these results (Figure 4-20 B). By 
using two sets of primers, designed to amplify the common region of V1 and V2 
isoforms or Fbln2 V2 exclusively (designed against cDNA fragment spanning exon 
8 and 10) the exact same pattern of Fbln2 splice variant expression, as 
demonstrated by cDNA profiling by PCR, was seen. Primer location is 
demonstrated in Figure 4-19 A. On the basis of these findings, Fbln2 protein 
expression was compared between EpH4, NIH3T3 and HC11 cells. The Western 
blot, however, showed no major differences in the Fbln2 banding pattern 
between the protein extracts from the EpH4 and NIH3T3 cells, as all three main 
bands (195 kDa, 150 kDa, and 135 kDa) were visible. There was no loss of 195 
kDa (putative V1) either (Figure 4-20 C). The only slight difference was visible 
when the mobility of the top two bands was compared between lanes. In the 
EpH4 cells protein extracts the top band, corresponding to the mature Fbln2 
protein showed a slightly lower molecular weight than that seen in NIH3T3 cells 
at 195 kDa. The middle band, on the other hand, appeared to migrate slower, 
corresponding to a higher molecular weight than its NIH3T3 counterpart. All of 
the bands detected were specific for Fbln2-anti-Fbln2 antibody binding as 
demonstrated by the lack of bands in the negative control (HC11 cells). 
Collectively, it was demonstrated that it is unlikely for either the 150 kDa band 
or the 135 kDa band to correspond to Fbln2 V2.  
HYPOTHESIS 2: To test the second hypothesis, that both of the lower molecular 
weight bands arise due to N- or C-terminus targeted proteolytic cleavage, we 
initially aimed to use two additional, commercial antibodies, raised against N- or 
C-terminus of Fbln2 (See Figure 4-4 B and C). It was, however, not possible to 
test this hypothesis as the anti-C-terminus antibody could not be used due to 
problems with its optimisation (data not shown). As a result, we used the anti-N-
terminus antibody only and thus tested for the presence of the potential  
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Figure 4-20 Fbln2 expression profiling in the mouse cell lines and identification of Fbln2 V2 
expression in EpH4 cells. 
(A) PCR. Electrophoretogram illustrating Fbln2 V2 (254 bp) expression in EpH4 cells. HC11 cells 
were used as a negative Fbln2 expression control. –RT was used as PCR quality control, n=1 (B) 
Q RT PCR. Fbln2 and Fbln2 V2 expression profiling in NIH3T3, EpH4 and HC11 cells. Total Fbln2 
expression was estimated using primers designed against the common region of Fbln2 V1 and V2 
splice variants. Expression of Fbln2 V2 was identified using PCR primers designed to span exon 8 
and 10 (Fbln2 V2 lacks exon 9). ß-actin expression was used as an internal control for 
normalisation. Graph shows exclusive Fbln2 V2 expression in EpH4 cells and lack of Fbln2 or 
Fbln2 V1 expression in HC11 cells. NIH3T3 cells were used as positive control (express both splice 
variants. Error bars denote technical variability (S.E.M.), n=1 (C) Western blotting. Fbln2 (195 kDa) 
expression in the protein extracts collected from two different EpH4 cell cultures, NIH3T3 cells 
(positive control) and HC11 cells (negative control). Protein extracts were collected using RIPA 
buffer. Expression analysis was performed using anti-Fbln2 antibody. ß-actin was used as loading 
control. 
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variation in proteolytic cleavage solely within the N-terminus of Fbln2. The N-
terminus anti-Fbln2 antibody was used to detect Fbln2 expression in the NIH3T3 
protein extracts (RIPA lysis buffer) and the resulting expression pattern was 
compared with that detected with the anti-Fbln2 antibody routinely used in this 
project (raised against the whole protein) [434]. As demonstrated in Figure       
4-21, the largest two bands (195 kDa and 150 kDa) were detectable with both 
the full-length and N-terminus anti-Fbln2 antibodies. The discrepancies in the 
signal intensities seen between the two antibodies were most probably 
attributed to the difference in the protein-antibody binding affinities. The 135 
kDa band, however, was absent from the blot incubated with the anti-N-
terminus antibody indicating either the absence of protein‟s N-terminus within 
the sequence denoted by this band or the lack of cross-reactivity between the 
antibody and protein sequence in this instance. Nonetheless, this suggested that 
proteolytic cleavage could be responsible for the banding pattern.  HC11 protein 
extract was used as negative control to ensure the antibody specificity. 
HYPOTHESIS 3: This experiment was designed to test whether the banding 
pattern detected by the anti-Fbln2 antibody (full length) was dependent on the 
origin of mammary stroma, i.e. if it was TEB- or duct-associated, and at the 
same time to test whether the lysis buffer used for Fbln2 extraction had an 
effect. Protein extracts from Post-LN and Pre-LN strips were prepared using four 
lysis buffers to investigate the varied efficiency in Fbln2 solubilisation and were 
compared by Western blotting. The lysis buffers used in this experiment 
included: RIPA, NP-40, EDTA and Urea. Both RIPA and NP-40 belong to the group 
of detergent lysis buffers. EDTA and Urea buffers, on the other hand, do not 
contain detergents. EDTA buffer binds Ca2+ which is essential for the 
maintenance of the trimeric structure of Fbln2 while the Urea buffer causes the 
denaturation of proteins. Both the EDTA and Urea buffers were previously shown 
to solubilise 80% of Fbln2 [444]. Post- and Pre-LN tissue strips were selected as 
they contain the epithelium and stroma of both TEBs and ducts or only the 
ductal compartment respectively, hence enabling the comparison of TEB and 
duct environments. As seen in Figure 4-22 there was no obvious difference 
between the banding patterns detected in the Post-LN and Pre-LN protein 
extracts. However, although the three main bands were detectable in NP-40, 
EDTA and Urea protein lysates there was some difference between the signal  
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Figure 4-21 Comparison of Fbln2 expression pattern detected using different antibodies. 
Western blotting showing Fbln2 expression in two mouse cell lines; HC11 (negative control) (lane 
1) and NIH3T3 (lane 2). Expression analysis was performed with two antibodies raised against N-
terminus of Fbln2 (left) and the whole protein (right). Protein extracts were collected using RIPA 
lysis buffer. Blot was cut in two to allow different antibody probing on the same blot. Experiment 
was performed using protein lysates extracted upon three different cell passages. Bands of interest 
are highlighted by asterisks. 
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Figure 4-22 Comparison of Fbln2 expression pattern detected using different lysis buffers. 
Western blotting. Analysis of Fbln2 expression pattern in Post-LN (lanes 1-4 on the left) and Pre-
LN strips (lanes 1-4 on the right) protein extracts prepared using following lysis buffers: RIPA (lane 
1), NP-40 (lane 2), EDTA (lane 3) and Urea (lane 4). Protein extract collected from NIH3T3 (RIPA 
buffer) was used as a positive control (lane 5). Expression analysis was performed using anti-Fbln2 
antibody. ß-actin was used as loading control. n=1 
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intensities of the 150 kDa and 135 kDa bands. The 195 kDa was prominent in all 
the protein lysates. The 150 kDa band was the least visible in NP-40 and EDTA 
protein lysates while the 135 kDa band was the least detectable one in the Urea 
protein lysate. Although, the expression of all three bands that correspond to 
Fbln2 has previously been shown to be detectable in Post-LN and Pre-LN RIPA 
buffer protein extracts (See Figure 4-6 C), no evident expression of the 150 kDa 
and 135 kDa bands could be demonstrated in RIPA protein lysate used in this 
experiment. This could be due to the degradation of this protein extract. 
Furthermore, an additional ~220 kDa band was present in all of the lysates 
except for the Urea lysate. It is unclear what the ~220 kDa band corresponds to. 
NIH3T3 cells protein lysate extracted in RIPA buffer served as a positive control. 
The direct comparison of protein lysates was valid as demonstrated by uniform 
ß-actin expression levels throughout the samples. Taken together, these results 
show that the observed cleavage pattern is uniform across the TEB and duct 
microenvironments which suggests that the processing of Fbln2 does not rely on 
any of the proteases that are exclusive to the either TEB or duct stroma. 
Secondly, as seen in Figure 4-22, different lysis buffers extract the 150 kDa and 
135 kDa Fbln2 bands with different efficiencies and thus it may be beneficial to 
employ the identified optimal extraction conditions to further study each of 
these bands. 
4.2.2.8 The impact of systemic hormones on the regulation of Fbln2 
expression in mouse mammary gland.   
Hormonal regulation of Fbln2 has already been documented by Okada et al. 
(2003) and Gu et al. (2007) who demonstrated its stimulation by P in human 
endometrial stromal cells in vitro [456] and down-regulation by hydrocortisone 
in the bone marrow stroma in vitro respectively [457]. Taking this into 
consideration along with knowledge of the importance of systemic hormones in 
pubertal mouse mammary development, the impact of E2 and P on mouse 
mammary gland Fbln2 expression was examined. Hormone induced changes in 
Fbln2 expression and tissue localisation were assessed using mouse mammary 
glands collected from 4.5 week old mice primed for a week with E2, E2+P or 
placebo hormone pellets prior to gland excision.  
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As shown by the Q RT PCR, expression of Fbln2 was highly up-regulated by both 
the E2 and E2+P hormonal treatments (Figure 4-23). The mean expression of 
Fbln2 in the E2+P and E2 primed glands was 40.4 fold and 36.2 fold higher 
respectively than that calculated in the Pre-LN strip (negative control). Glands 
primed with placebo pellets showed a 7.1 fold up-regulation in Fbln2 expression 
when compared with Pre-LN strip. Furthermore, a 3.5 fold up-regulation of 
Fbln2 was calculated in the Post-LN strip when compared to Pre-LN strip and it 
was used as a positive control. When gene expression was compared only 
between the treated mammary glands, using the placebo as a reference, Fbln2 
was 4 fold and 3.6 fold up-regulated in the E2+P and E2 treated glands 
respectively. The difference in Fbln2 expression was statistically significantly 
only when comparing placebo and E2+P treatments. The level of Fbln2 over-
expression in the E2 treated glands compared to placebo ones failed to reach 
statistical significance probably due to considerable biological variation and a 
low number of replicates (4 mice). It is possible, however, that the calculated 
FC(s) may differ slightly as at the time of commencing these experiments, prior 
to localisation studies, Fbln2 was thought to be associated only with mammary 
epithelium and so levels of Fbln2 were normalised using Krt18 expression, i.e. 
the amount of epithelium instead of the total number of cells.  
Thus, to confirm the Q RT PCR results, the impact of E2 and E2+P on Fbln2 
expression and spatial localisation was analysed at the protein level by IHC, 
using the routine anti-Fbln2 antibody (Figure 4-24). The obtained results 
provided further insights into hormone induced changes in Fbln2 expression and 
localisation in mouse mammary gland. In the placebo primed mice (control), the 
mammary gland associated expression of Fbln2 was similar to that seen in pre-
pubertal/pubertal mice (Figure 4-24 A). Fbln2 was mostly localised to the 
epithelium and stroma of TEBs. Some Fbln2 expression was also detectable in 
the ductal stroma and stromal capsule at the edge of Fat pad. The pattern of 
Fbln2 expression in the mammary TEBs and ducts of the E2+P primed mice was 
similar to that seen in placebo. Fbln2 was consistently localised to the 
epithelium and stroma of TEBs and on a much lower level to the stroma of ducts 
(Figure 4-24 B). What was different between the two treatments, however, was 
the significant increase in Fbln2 expression at the stromal capsule at the edge of 
Fat pad (Figure 4-24 A and B). This stromal capsule-specific increase in Fbln2 
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Figure 4-23 Hormonal regulation of Fbln2 expression at the mRNA level by Q RT PCR. 
Mean expression level of Fbln2 in Post-LN tissue strip (6 weeks old) and hormone primed glands 
(4.5 weeks old) – placebo, oestrogen-progesterone (E2+P) and oestrogen (E2), relative to Pre-LN 
tissue strip (6 weeks old). Post-LN and placebo were used as positive controls. Pre-LN was used 
as negative control. Krt18 expression was used as an internal control for normalisation. Error bars 
are S.E.M. (***) denotes statistical significance of p-value≤0.001, n=1 (Pre-LN and Post-LN) n=3 
(placebo and E+P) n=4 (E). N stands for number of animals. Both glands were used from each 
animal. 
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Figure 4-24 Hormonal regulation of Fbln2 expression on protein level by IHC. 
(A) (B) (C) Sections through 4.5 week old mouse mammary glands obtained from mouse primed 
with (A) placebo, (B) E+P and (C) E hormone pellets for 1 week prior to tissue collection. 
Mammary glands were stained with anti-Fbln2 antibody (brown) and Haematoxylin (blue) to 
visualise nuclei. (D) Negative (no primary) antibody control. Images on the left show mammary 
epithelium. Images on the right show stromal capsule around the edge of Fat pad. (A) Placebo 
treated glands showed normal Fbln2 staining pattern – prevalent in TEB epithelium, weaker in duct 
epithelium and present in the stroma around epithelium and in the capsule around the edges. (B) 
E+P treated glands showed similar epithelial staining pattern to placebo treated glands. Higher 
Fbln2 staining, however, could be noted in the stromal capsule around the edge of the Fat pad. (C) 
E primed glands showed lack of Fbln2 expression in the ductal epithelium and its high abundance 
in the stromal capsule. Arrows denote TEBs and dotted arrows indicate ducts. At least 3 mice (6 
mammary glands) were studied for each treatment. Scale bars are 100 µm. 
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expression was even more pronounced when the mammary glands obtained from 
the E2 treated animals were examined while the ductal localisation of Fbln2 
seemed completely absent from these glands (Figure 4-24 C). All of the 
observed staining patterns were specific to Fbln2-antibody binding as 
demonstrated by the lack of the staining in the negative (no primary antibody) 
control (Figure 4-24 D). 
4.2.2.9 Investigation of Fbln2 functions in non malignant mouse mammary 
epithelial cells in vitro by the over-expression of Fbln2 in HC11 cells. 
As shown in this project, pubertal mammary expression of Fbln2 is mainly 
localised to the BM, outer membranes, cytoplasm of cap cells and most probably 
the cytoplasm and extracellular spaces between the body cells of mouse 
mammary TEBs. Given this specific epithelial localisation of Fbln2 and widely 
recognised importance of TEBs for promoting the directional outgrowth of the 
ductal tree, we examined the involvement of Fbln2 in cellular migration and 
adhesion in vitro using HC11 cells. The HC11 cell line originates from normal 
mammary epithelial cells [458] and, as demonstrated previously, lacks Fbln2 
expression (both at the RNA and protein level) (Figure 4-20). It therefore 
provides a good system for studying the impact of Fbln2 over-expression on 
normal mouse mammary epithelium. Over-expression of Fbln2 was performed by 
transfecting the HC11 cells with a Fbln2 expressing plasmid (pRc/CMV-Fbln2) 
(See 2.2.2.3).  
4.2.2.9.1 Optimisation of transfection 
 
Optimal experimental conditions were established by transfecting equal amounts 
of HC11 cells with pEGFP reporter plasmid, using varied volumes of two different 
transfection reagents (Lipofectamine™ and DharmaFECT®) and DNA (in a 
transfection reagent to DNA ratio of 1:1) and examining the number and 
appearance of cells 24h after transfection, using a fluorescent microscope (See 
2.2.2.4.1). As demonstrated in Figure 4-25 A, maximal transfection efficiency 
and minimal cell toxicity were achieved using 4 µl of Lipofectamine™ and 4µg of 
DNA, thus making it standard for all further experiments. A representative image  
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Figure 4-25 In vitro over-expression of Fbln2 in HC11 cells. 
(A) Optimisation of transfection efficiency. Different volumes of transfection reagents, either 
Lipofectamine™(left) or DharmaFECT
®
 Duo (right) Transfection Reagents were used to transfect 
equal amount of HC11 cells with pEGFP (transfection reagent to DNA ratio 1:1). Green fluorescent 
cells (living and dead) were counted. Error bars are S.E.M. Experiments were repeated 3 times (B) 
Representative image of HC11 cells transfected with pEGFP using optimal transfection conditions - 
4µl of Lipofectamine™ Transfection Reagent and 4µg DNA – used for all subsequent transfections. 
Living cell is denoted with white arrow. Dead cell is highlighted with white dotted arrow. Scale bar is 
500 µm (C) Western blot. Fbln2 (195 kDa) expression in HC11 cells transfected with pRc/CMV-
Fbln2 (lanes 2-4) and pcDNA3 (negative control) (lanes 5-7). Fbln2 expression was analysed 24h 
after the transfections. Protein extract obtained from NIH3T3 cells (lane 1) was used as positive 
control. ß-actin was used as a loading control. Experiments were repeated 3 times. 
 
  272 
 
of cells transfected using the identified optimal conditions is shown in Figure 4-
25 B. Once the optimal conditions were found, transient transfections were used 
to over-express Fbln2 V1 in HC11 cells. Western blotting confirmed the 
introduction of Fbln2 V1 into HC11 cells (Figure 4-25 C). All three bands 
corresponding to various Fbln2 fragments were seen on the blot (lane 2, 3 and 
4). The largest, 195 kDa band, however, appeared much stronger than the two 
smaller ones (150 kDa, 135 kDa). The appearance of these bands was specific to 
Fbln2 V1-antibody binding detected by the anti-Fbln2 antibody as none of these 
bands were detected in the negative control (HC11 cells transfected with the 
empty vector, pcDNA3) (lane 5, 6 and 7). NIH3T3 cells (lane 1) were used as a 
positive control. No morphological changes could be seen in the transfected 
cells.    
4.2.2.9.2 The effect of Fbln2 on the migratory properties of HC11 
cells 
 
Fbln2 over-expressing HC11 cells were used to assess the impact of Fbln2 on cell 
migration. Empty vector transfected HC11 cells were used as a negative control 
(Figure 4-26 A). The migratory properties of pRc/CMV-Fbln2 transfected HC11 
cells were studied on confluent cells using a wound healing assay (scratch assay) 
(See 2.2.2.5). The percentage of wound closure was compared at each time 
point (4h, 7h, 11h, 24h and 36h) after creating the scratch for Fbln2 over-
expressing- and control cells. There was no difference in the speed of wound 
closure between the two types of HC11 cells, suggesting that Fbln2 does not 
have an impact on the speed of cellular migration in HC11 cells under the given 
conditions (Figure 4-26 B).  
4.2.2.9.3 The effect of Fbln2 on the adhesiveness of HC11 cells    
 
The pRc/CMV-Fbln2 and empty vector transfected (control) HC11 cells were 
further used to investigate the impact of Fbln2 on regulating the adhesiveness of 
cells to plastic or ECM proteins coated surfaces (See 2.2.2.6). ECM molecules 
used in this assay included: ColI, ColII, ColIV, Fn, Lama1, Tn and Vtn. Blank wells 
were coated with BSA and served as a negative control for the ECM substrates  
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Figure 4-26 The effect of Fbln2 on the regulation of HC11 cells migration using a wound 
healing assay. 
(A) Western blot showing the levels of Fbln2 expression in HC11 cells, used in wound healing 
assays. Protein extracts were prepared using RIPA buffer, at the conclusion of each assay. Fbln2 
(195 kDa) expression in HC11 cells transfected with pRc/CMV-Fbln2 (lanes 1-3) and pcDNA3 
(negative control) (lanes 4-6). Protein extract obtained from NIH3T3 cells (lane 7) was used as 
positive control. The same amount of protein (50µg) was loaded to each well. (B) Representative 
graph illustrates the speed of wound closure in HC11 cells transfected with pRC/CMV-Fbln2 (to 
express Fbln2 V1) or pcDNA3 (negative control). The assay was performed on confluent cells (48h 
after transfections). No difference in the speed of cell migration could be noted in Fbln2 expressing 
HC11 cells in comparison to empty vector transfected HC11 cells. Error bars are S.E.M. 
Experiments were performed 3 times. 
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(experimental noise) while the HC11 cells transfected with empty vector served 
as a negative control for Fbln2 expression. The adhesion assay was performed 
using HC11 cells plated at a density of 1.5x106 cells/well which was chosen to 
give optical density (OD) values within the optimal OD detection range (0.5-1), 
after optimisation of experimental conditions (Figure 4-27 A).  
Fbln2 over-expression increased the adhesiveness of HC11 cells to four ECM 
proteins, i.e. increased OD significantly - Vtn (0.369), Tn (0.307), Fn (0.289) and 
Lama1 (0.239). Furthermore, these four ECM molecules appeared successful in 
stimulating the adhesion of HC11 cells as the ODs for both Fbln2 transfected- 
and control cells were distinguishably higher than these seen for the remaining 
three ECM molecules (ColI, ColII and ColIV) where in general a much lower level 
of adhesiveness of HC11 cells, with no major difference between Fbln2 over-
expressing- or control cells, was noted (Figure 4-27 B). Similarly, as seen in 
Figure 4-27 C, Fbln2 over-expression appeared to have no significant effect on 
the adhesion of HC11 cells to plastic surfaces. Dry wells (no cells added) were 
used as a negative control. 
4.2.2.10 Fbln2 binding partners and their expression during pubertal 
mouse mammary gland development.  
Based on the finding that Fbln2 interaction with some ECM proteins increases 
their adhesiveness to HC11 cells (See 4.2.2.9.3) and published evidence for the 
presence of an extensive array of protein-protein interactions between Fbln2 
and some ECM proteins or cell membrane receptors, the pubertal mammary 
gland associated expression of Fbln2 binding partners was investigated.  
Depending on the type of the biological or experimental system or studied 
protein function, different proteins have been reported to bind to Fbln2. None 
of these molecules, however, have yet been studied in association with Fbln2 in 
the mouse mammary gland.  An up to date literature search identified 13 
proteins as Fbln2 binding partners (Figure 4-28). 11 of these proteins were 
located to ECM, i.e. versican (Vcan), Lama1, Fbn1, collagen VIαIII (ColVIαIII), 
collagen IVαI (ColIVαI), collagen XVIIIαI (ColXVIIIαI), Eln, Fn, perlacan (Per), 
aggrecan (Acan), Nid. The remaining two, the integrin ß3 (Itgb3) and integrin α5 
(Itga5) were previously shown to function as membrane receptors for Fbln2. 
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Figure 4-27 Effect of Fbln2 on the regulation of adhesive properties of HC11 cells using 
adhesion assays. 
(A) (B) Cell adhesion to ECM proteins (A) Optimisation of assay sensitivity. Untransfected HC11 
cells at 3 different cell/ml concentrations (0.5X10
6
, 1X10
6
 and 2X10
6
) were used. A concentration of 
1.5X10
6
 cells/ml was regarded as optimal and used in all subsequent adhesion assays. Data was 
calculated based on one transfection experiment. One well per condition was seeded (B) HC11 
cells either transfected with pRC/CMV-Fbln2 (to express Fbln2 V1) or pcDNA3 (negative control) 
vectors for 24h – comparison of adhesiveness to ECM proteins. Blank wells were coated with BSA.  
Error bars denote technical variability (S.E.M), (**) denotes statistical significance p-value≤0.01, 
(***) p-value≤0.001. Data is based on one transfection experiment. Cells were seeded in triplicates 
for each condition. (C) Cell adhesion to plastic surfaces. HC11 cells either transfected with 
pRC/CMV-Fbln2 (to express Fbln2 V1) or pcDNA3 (negative control) vectors for 24h. Blank lacks 
any cells. Data is based on single experiment. Cells were seeded in triplicates for each 
experimental condition. Error bars are S.E.M. and denote technical variability. 
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Figure 4-28 Potential binding partners for Fbln2 in the mouse mammary gland and their 
pubertal gene expression level. 
Selection of Fbln2 binding partners and their cellular compartmentalization was based on a 
literature search. All 13 proteins were shown to interact with Fbln2 in different experimental 
systems. Pubertal gene expression was examined using Post-LN up-regulated gene set (Post-LN 
vs Pre-LN) (See 3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1.). Genes 
identified as up-regulated in Post-LN strips and TEBs are marked as yellow and blue circles 
respectively. White circles denote genes showing unaltered expression in the Post-LN and Pre-LN 
strips. A circle denotes an ECM protein while a T-like shape represents a transmembrane receptor. 
This image was created using IPA software. 
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In order to identify which of these proteins could potentially serve as Fbln2 
binding partners in pubertal mouse mammary gland, expression of each of these 
factors was assessed in our microarray data set. Since Fbln2 appeared to be 
over-expressed in the epithelium and stroma of TEBs and the stromal capsule 
around the edge of the Fat pad, these tissue compartments were used to 
examine the level of pubertal expression for the known Fbln2 binding partners. 
The Post-LN up-regulated gene set (Post-LN vs Pre-LN) (See 3.2.6.1.2) and 
isolated TEBs up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1) were used 
to identify genes up-regulated in TEB stroma and epithelium and TEB epithelium 
respectively, while the empty Fat pad up-regulated gene set (See 3.2.6.1.3) 
was used to determine genes over-expressed in the distal Fat pad (stromal 
capsule). Nearly half of the examined genes (6/13) were shown to be up-
regulated in the Post-LN strip, i.e. TEB epithelium and surrounding stroma. The 
highest up-regulation (2.64 fold) was noted for Vcan. A further two potential 
binding partners (ColIVaI, ColXVIIIaI) were identified as over-expressed in the 
isolated epithelium of TEB. None of the molecules of interest, however, was 
shown to be significantly over-expressed in the empty Fat pad. The names of the 
classified genes and the levels of their up-regulation (FC values) are summarized 
in Table 4-1. The remaining 5 genes, that is Fn, Per, Acan, Nid2 and Itga5 did 
not differ in their expression level between the Post-LN and Pre-LN tissue strips 
(Table 4-2). Fn, Per and Itga5 were expressed at a high level in both tissue 
compartments. Acan and Nid2, in contrast were minimally expressed during 
pubertal morphogenesis. A summary of the Fbln2 binding partners‟ pubertal 
expression pattern is shown in Figure 4-28.      
4.2.2.10.1 Fibronectin and Fbln2 co localisation study.   
 
The best documented binding partner for Fbln2 is Fn. It is associated with Fbln2 
in the bone marrow stroma in vivo [459] and during skin regeneration [460] and 
shows binding in protein interaction studies in vitro [442]. Based on the existing 
documentation of Fbln2-Fn interaction in vivo and the evidence that of all 
binding partners, Fbln2 shows the strongest binding affinity to Fn (equal for both 
mouse and human proteins) [442], a potential interaction between Fbln2 and Fn 
during pubertal mouse mammary morphogenesis was investigated further. 
Although, Fn was not shown to be significantly over-expressed in the TEB  
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Gene name Gene symbol FC Original Reference 
GENES UP-REGULATED IN THE POST-LN STRIP 
Versican Vcan 2.64 [461] [448] 
Laminin Lama1 1.88 [462] 
Integrin beta 3 Itgb3 1.59 [463] 
Fibrillin 1 Fbn1 1.54 [344] 
Collagen 6a3 Col6a3 1.61 [442] 
Elastin Eln 1.75 [464] [443] 
GENES UP-REGULATED IN THE ISOLATED TEBS 
Collagen 4a1 Col4a1 1.73 [442] 
Collagen 18a1 Col18a1 1.87 [443] 
Table 4-1 List of Fbln2 binding partners up-regulated during pubertal mouse mammary 
gland development. 
Selection of Fbln2 binding partners was based on a literature search with reference given in 
column 4. Pubertal gene expression was examined using Post-LN up-regulated gene set (Post-LN 
vs Pre-LN) (See 3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1). All FCs 
were statistically significant. 
Gene name Gene symbol Level of expression Original Reference 
Fibronectin Fn1 High [444] [442] [460] [459] 
Perlecan Per High [442] 
Aggrecan Acan Low [461] 
Nidogen 2  Nid2 Low [442] 
Integrin alpha 5 Itga5 High [463] 
Table 4-2 List of Fbln2 binding partners shown to exhibit an unaltered expression level 
during pubertal mouse mammary gland development. 
Selection of Fbln2 binding partners was based on a literature search. Firstly, pubertal gene 
expression was examined using Post-LN up-regulated gene set (Post-LN vs Pre-LN) (See 
3.2.6.1.2) and TEB up-regulated gene set (TEBs vs ducts) (See 3.2.6.1.1). Secondly, each gene’s 
expression level in the Post-LN and Pre-LN strip was compared using RMA normalised gene 
expression data. The expression level for each gene was denoted as low, medium or high. 
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epithelium or stroma (Post-LN) its expression was high in the Post-LN strip where 
Fbln2 was shown to be over-expressed. To examine the possibility of the two 
proteins interacting during the outgrowth of TEBs, IF was used to examine the 
co-localisation of the two proteins in the 6 week old mouse mammary gland. The 
co-localisation was performed using serial tissue sections since both antibodies 
used in this experiment were raised in the same host. As seen in the 
representative confocal images of mammary epithelium, shown in Figure 4-29, 
Fbln2 failed to co-localise with Fn. As previously demonstrated, Fbln2 was 
expressed in the epithelium and stroma of TEBs and to a much lower extent in 
the ductal epithelium (Figure 4-29 A-B) while Fn appeared to be exclusively 
localised to the stroma around ducts (Figure 4-29 B). The trace of Fn expression 
visible in the TEBs epithelium (Figure 4-29 A) is nonspecific, as it also appears 
to be present in the negative (no primary antibody) control (Figure 4-29 C).   
4.2.2.10.2 Elastin and Fbln2 co-localisation study 
 
Eln, after Fn is the second most investigated binding partner of Fbln2. In vivo, it 
is mostly present in blood vessels, lung and skin tissue where it interacts with 
Fbn1 to form elastic fibres which are critical for tissue elasticity [465]. Based on 
the recently suggested role of Fbln2 in elastic fibre assembly in internal elastic 
lamina of blood vessels [449] and significant up-regulation of Eln expression in 
TEB environment (See Table 4-1), preliminary experiments were carried out to 
assess the potential of Fbln2 and Eln interaction during pubertal mouse 
mammary morphogenesis. The localisation of Eln expression in 6 week old mouse 
mammary glands was carried out using EVG staining (See 2.2.6.7) and the 
obtained expression pattern was compared to that determined for Fbln2. As 
shown in representative light microscopy images, although mostly absent from 
the epithelium and stroma of TEB (a single Eln fibre can be seen in TEB stroma) 
(Figure 4-30 A), a positive Eln expression, as shown in positive staining control 
(Figure 4-30 C), could be seen in the distal stromal capsule (Figure 4-30 B) of 
pubertal mouse mammary gland. Since Fbln2 is seen to localise to this region it 
may be that the two proteins interact during pubertal mammary morphogenesis 
but further investigation is needed to assess this possibility.      
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Figure 4-29 Co-localisation of Fbln2 and Fn expression in the pubertal mouse mammary 
gland using IF. 
Transverse sections through a 6 week mouse mammary gland showing (A) TEB and (B) duct 
stained with anti-Fbln2 (green) or anti-Fn (red) antibodies and nuclear DAPI (blue). (C) shows 
negative (no primary antibody) controls. Fbln2 and Fn did not co-localise in the epithelium or its 
surrounding stroma in pubertal mouse mammary gland. Images were acquired using confocal 
microscopy. Scale bars are 50 µm. 
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Figure 4-30 Localisation of Eln expression in pubertal mouse mammary gland using Elastica 
van Gieson staining. 
Sections through a 6 week mammary gland showing (A) TEB (B) distal stromal capsule and (C) 
vein. (C) is a positive staining control. Elastin (blue) localised to the distal stromal capsule but was 
mostly absent from TEB epithelium and stroma. A single Eln fibre could be seen in TEB stroma 
(arrow head). Black arrows denote elastin fibres. Scale bars are 50 um. Mammary glands from at 
least 3 mice were used.  
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4.2.2.11 Fbln2 is not essential for pre-pubertal and pubertal mouse 
mammary gland development.  
Since Fbln2 is highly expressed in virgin mice during pre-pubertal and pubertal 
mouse mammary gland development and is associated and localised to TEB it has 
potential to serve as a regulator of TEB structure, organisation or migration or to 
play a role in ductal tree morphogenesis. Thus, in order to evaluate whether the 
presence of Fbln2 is essential for normal ductal morphogenesis and TEB 
morphology, mammary wholemounts, collected from Fbln2 KO-/- and WT mice, 
were examined to assess the impact of Fbln2 deficiency on pre-pubertal and 
pubertal mammary development. Both transgenic and WT mice were of the same 
genetic background (C57BL/6). 
Total loss of Fbln2 expression in these glands was confirmed by IHC. 6 week old 
mouse mammary glands collected from Fbln2 KO-/- and WT mice were processed, 
embedded in molten wax, sectioned and stained with the routinely used anti-
Fbln2 antibody. No Fbln2 expression could be seen in the epithelium, its 
surrounding stroma or the distal stromal capsule of Fbln2 KO-/- mouse mammary 
glands (Figure 4-31 A). The appearance of the section closely resembled that 
seen in the negative (no primary antibody) control (Figure 4-31 B). WT mouse 
mammary glands were used as a positive staining control. When stained with 
anti-Fbln2 antibody, a normal mouse mammary gland associated Fbln2 staining 
pattern was detected in the WT control. As seen in Figure 4-31 C, Fbln2 
expression was localised to both the epithelial (cap and body cells) and stromal 
microenvironment of TEBs and the distal stromal capsule, thus verifying the 
antibody reactivity.  
Wholemounts of Fbln2 KO-/- and WT controls were then examined in triplicates 
for each time point. Analysis of the wholemounts revealed no major 
morphological differences between Fbln2 KO-/- and WT mice. Both the length 
and degree of branching of the ductal tree appeared similar for Fbln2 KO-/- and 
WT mice both at pre-puberty (3 weeks) and puberty (6 weeks) (Figure 4-32). 
Although TEBs appeared slightly smaller and more elongated in Fbln2 KO-/- when 
compared to WT (Figure 4-32 inserts) further histological examination of these 
structures by H&E staining failed to demonstrate any significant differences  
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Figure 4-31 Comparison of Fbln2 expression in Fbln2 WT and Fbln2 KO-/- pubertal mouse 
mammary glands by IHC. 
Sections through a 6 week mammary glands collected from (A) Fbln2 KO
-/-
 and (B) (C) WT mice 
showing representative fragment of epithelium – TEB (left hand side) and stromal capsule (right 
hand side) stained with anti-Fbln2 antibody (brown). Nuclei were stained with haematoxylin (blue) 
(A) (B) No Fbln2 expression could be noted (B) is a negative (no primary antibody control) (C) 
Prominent Fbln2 staining could be seen in both the epithelium of TEB and its surrounding stroma 
and the stromal capsule. Scale bars are 50 µm. 3 Fbln2 KO
-/-
 and 3 WT mice were examined. 
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Figure 4-32 Wholemount analysis of pre-pubertal and pubertal Fbln2 KO-/- mouse mammary 
gland. 
Representative wholemounts of 3 week (A) WT (+/+) and (B) Fbln2 KO (-/-) and 6 week (C) WT 
(+/+) and (D) Fbln2 KO (-/-) mammary glands stained with carmine alum. Inserts (on the right) 
show representative parts of the ductal tree and TEBs. No significant difference in the ductal 
outgrowth could be seen in Fbln2 KO
-/-
 mammary glands in comparison to WT mammary glands. 
TEBs in the KO
-/-
 mammary glands, however, appeared smaller and more elongated than those 
seen in their WT counterparts. Scale bars are 1mm (wholemounts) and 200 µm (inserts). 
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between the TEB from the pubertal Fbln2 KO-/- and WT mammary glands (Figure 
4-33).    
Finally, based on previous reports of compensatory up-regulation of Fbln1 
expression in Fbln2 KO-/- aorta [266], tissue sections through the pubertal Fbln2 
KO-/- and WT mouse mammary glands were further stained with anti-Fbln1 
antibody. The level and pattern of mammary gland associated Fbln1 expression 
was compared between the Fbln2 deficient and WT mouse mammary glands and 
it was revealed that when compared to WT mammary glands, the expression of 
Fbln1 in the epithelium of Fbln2 KO-/- glands was significantly increased (Figure 
4-34 A and B). Furthermore, the epithelial localisation of Fbln1 in both types of 
mammary glands was also different. In WT mammary glands, the expression of 
Fbln1 in TEBs was diffused throughout their epithelium and surrounding stroma 
rather than localised to specific cell types (Figure 4-34 A). In Fbln2 KO-/- 
mammary glands, on the other hand, the expression of Fbln1 appeared closely 
associated with the epithelium of TEBs: body cells (cytoplasm and extracellular 
spaces), membranes, cytoplasm, extracellular spaces of cap cells and BM and 
their surrounding stroma (Figure 4-34 B), where Fbln2 preferentially localises 
(Figure 4-34 C). The observed Fbln1 staining was specific as demonstrated by 
the presence of minimal background staining in the negative (no primary 
antibody) control (Figure 4-34 D). The expression of Fbln1 in distal stromal 
capsules of Fbln2 KO-/- and WT pubertal mouse mammary glands did not seem to 
differ (data not shown).  
Collectively, these results demonstrate that in the presence of Fbln1, Fbln2 is 
not essential for virgin mammary gland development and suggest potential 
functional redundancy and compensation between Fbln1 and Fbln2 during 
pubertal mouse mammary gland development. 
4.2.2.12 Summary 
In summary, this study was carried out to examine the potential of Upk3a and 
Fbln2 to serve as novel regulators of pubertal mouse mammary gland 
morphogenesis. Due to the absence of Upk3a protein detection in the pubertal 
mouse mammary gland all further research was focused exclusively on Fbln2 and  
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Figure 4-33 Comparison of TEB histology in WT and Fbln2 KO-/- pubertal mouse mammary 
glands by H&E staining. 
Longitudinal sections through 6 week mammary glands collected from (A) WT and (B) Fbln2 KO
-/-
 
mice. Representative TEBs are shown. Nuclei were stained with haematoxylin while the cytoplasm 
was stained with eosin. No major morphological differences could be seen between the two TEBs. 
Cap cells are denoted by arrow. Body cells are denoted by dotted arrow. Scale bars are 50 µm. 
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Figure 4-34 The up-regulation and spatial localisation of Fbln1 in the epithelium of Fbln2  
KO
-/-
 pubertal mouse mammary glands. 
Longitudinal and transverse sections through 6 week (A) (C) (D) WT and (B) Fbln2 KO
-/-
 mouse 
mammary glands showing representative fragments of epithelium (TEB) stained with anti-Fbln1 
antibody (A) (B) or anti-Fbln2 (C) antibody. (D) is a negative (no primary antibody) control for 
Fbln1. Fbln1 in WT gland was contained in the stroma around TEB (arrow) (A). In Fbln2 KO
-/-
 
glands, however Fbln1 was over-expressed and localised to BM (arrow head) cap cells (dotted 
arrow) and cytoplasm and extracellular spaces between body cells (asterisk) (B). This expression 
pattern was similar to that seen for Fbln2 in WT pubertal mouse mammary glands (C). Scale bars 
are 50 µm. Three animals were examined for each experiment.     
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its mammary gland associated expression, localisation and function. Fbln2 was 
shown to be expressed in the mouse mammary glands during pre-puberty, 
puberty, adulthood (very low level) and early pregnancy (24-72h). During 
puberty its localisation was mostly confined to the stroma and epithelium of 
TEBs (cap cells and some body cells) and the stromal capsule located at the edge 
of fat pad with only residual expression seen in the stroma and epithelium of the 
ducts. Preliminary experiments that aimed to develop a TEB explant culture, 
showed a similar pattern of Fbln2 expression in TEB outgrowths in vitro, with 
Fbln2 associating with cell membranes, cytoplasm and cellular processes. At the 
mRNA level, Fbln2 was expressed in the form of two splice variants (Fbln2 V1 
and Fbln2 V2) with the former predominant in the TEB environment and ductal 
epithelium. Furthermore, the expression and localisation of Fbln2 in the mouse 
mammary gland appeared to be positively regulated by systemic hormones (E2 
and P). The in vitro functional studies revealed Fbln2-mediated increase in 
adhesiveness of the HC11 cells to Vtn, Tn, Lama1 and Fn coated surfaces, and 
hence suggested the possibility of these proteins interacting with Fbln2 in the 
mammary gland in vivo. However, Fbln2 failed to co-localise with Fn in vivo. In 
silico analysis further revealed the over-expression of 8 out of 13 binding 
partners of Fbln2 in the TEB compartment (as seen for Fbln2) while 3 out of the 
remaining 5, even though expressed at a similar level in TEB and duct 
compartments, were still expressed in TEBs at a very high level. One of these 
binding partners was Eln which, as previously seen for Fbln2, was demonstrated 
to localise to distal stromal capsule of pubertal mouse mammary gland. Finally, 
despite the given expression pattern, Fbln2 was shown not to be necessary for 
ductal morphogenesis and TEB formation in pre-puberty and puberty. As 
suggested by the over-expression of Fbln1 in the epithelium of Fbln2 KO-/- 
mammary glands, however, the lack of a mammary phenotype in these mice 
might be attributed to the possible functional redundancy and compensation 
between Fbln1 and Fbln2. 
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4.3 Disscussion 
Genome-wide gene expression screening, such as microarray analysis of pubertal 
mammary gland discussed in Chapter 3, is useful not only for global comparison 
and functional characterisation of different transcriptomes, but it can also be 
used to identify new genes with potential to regulate pubertal outgrowth. 
Several strategies, already discussed in Chapter 3 (3.3), can be used to select 
candidate genes. The two that were used in this project include i) ranking of 
genes according to the highest up-regulation level and ii) candidate gene 
approach. It was through these two screening methods that Upk3a and Fbln2 
first came to the attention of our research group.  
Based on the microarray analysis, the expression of both genes was associated 
with migrating TEBs. They were both up-regulated in the isolated epithelium of 
TEBs (TEB vs ducts) (See 3.2.6.1.1) and TEB microenvironment (Post-LN vs Pre-
LN) (See 3.2.6.1.2). Upk3a was the most differentially expressed RNA in the 
epithelium of TEBs compared to epithelium of ducts and although the most 
abundant gene in TEB epithelium is not necessarily the most important in 
orchestrating its motility, as most of the TEB up-regulated genes are cell cycle 
regulators ([256] and our observations) (See Table 3-5), the function of Upk3a 
was unknown and it therefore seemed an obvious target for further 
investigation. Fbln2, on the other hand, despite being ranked only to position 
182 and 285 within the list of genes up-regulated in the epithelial and stromal-
epithelial compartment of TEB respectively, was demonstrated by literature 
search to be associated with biological processes known to share similarities 
with ductal morphogenesis. As discussed in Chapter 3 (3.3.2.1), there are many 
molecules known to be pivotal in developmental processes such as 
embryogenesis (e.g. Fgf2br [159] [20]), branching morphogenesis of lung or 
kidney (e.g. TGF-ß [379]) or axonal guidance (e.g. Ntn1 and Neo1 [120] [117]) 
that have recently also been described as crucial for mammary pubertal 
morphogenesis.             
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4.3.1 Uroplakin 3a 
At the time of study (2008) fairly little was known about Upk3a. The majority of 
its associated research was focused on urinary bladder where Upk3a was shown 
to be strongly expressed and assembled as plaques (AMU) on the apical side of 
urothelial umbrella cells [420] [421]. The only other organs where Upk3a was 
localised included renal pelvis, urethra and prostatic urethra, all of which also 
derive from urothelium [430]. In mammary gland research, only one study 
mentioned Upk3a. It was a microarray study, conducted on microdissected 
microenvironments of TEBs and ducts to find new regulators of mouse mammary 
branching morphogenesis that identified Upk3a as one of the most highly 
enriched RNAs of TEB transcriptome [256] therefore confirming our results. No 
further investigation into its role in pubertal mammary morphogenesis, however, 
was carried out.  
To date, the only suggested function of Upk3a is the structural stabilisation of 
the luminal side of terminally differentiated umbrella cells during bladder 
contraction and expansion [422]. Although the mechanism by which AMU 
stabilises the urothelial lining has not yet been elucidated it has been proposed 
that AMU might interact with the actin cytoskeleton of umbrella cells to regulate 
its dynamics [425]. Actin filaments are present and essential for the survival of 
most cells types. Polymerised actin filaments, in conjunction with several actin-
binding/severing proteins, are critical components of the cytoskeletal scaffold 
which provides an internal mechanical support and maintains and regulates 
cellular shape. There are over 100 proteins that have been shown to regulate 
either the polymerisation, length, assembly, turnover or cross-linking of actin 
filaments. Furthermore, when interacting with myosin motor proteins, actin 
filaments have also been shown to provide the force for cell movement by 
pulling up the rear of moving cells or providing tracks for short distance 
movement of intracellular materials (reviewed in [466]).  
Motile behaviour (migration, bifurcation and spatial positioning) and change of 
shape in response to systemic hormones at estrus cycle are characteristic of TEB 
at puberty (See 1.2.3.2.1). Furthermore, there is evidence demonstrating the 
importance of actin-binding proteins for sustaining the motile character of TEB 
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and thus promoting ductal outgrowth at puberty. Crowley et al. (2000) showed 
that lack of Gsn (Gsn KO mice), a major regulator of actin cytoskeleton 
formation and function, severely delays the migration and bifurcation of TEB at 
puberty [243]. TEB formation and ductal outgrowth is inhibited until week 9 with 
the epithelial tree remaining rudimentary and even when the epithelium 
eventually fills the fat pad, no side branching can be seen [243]. Taking into 
account the possible role of Upk3a in stabilising the actin cytoskeleton of 
urothelial umbrella cells, the high Upk3a mRNA expression in the epithelium of 
TEBs at puberty and the importance of proper regulation of actin dynamics 
during TEB outgrowth at puberty, it is tempting to speculate that Upk3a may 
stabilize the cellular actin cytoskeleton during migration and shape remodelling 
of TEBs at puberty.  
Despite its promising potential as a new regulator of pubertal morphogenesis, 
Upk3a expression in the mammary gland could not be confirmed at the protein 
level (Western blot and IHC) thus preventing further investigations into its role. 
Such discrepancies between the mRNA and protein levels are not unusual. It has 
been long observed and described by many different studies that differential 
expression of mRNA can capture 40-50% of the variation in protein expression 
[467] [468] [469]. This incongruent expression between mRNA and protein is 
most commonly attributed to post-transcriptional regulatory mechanisms which 
control the stability and distribution of mRNA transcripts. The main players in 
this process are RNA binding proteins (RBPs) which interact with mRNA through 
their RNA binding motif to regulate events such as alternative splicing, mRNA 
processing, export, surveillance, degradation, turnover or microRNAs (miRNAs) 
which facilitate gene silencing. Since prominent expression of Upk3a was 
detected in protein extracts and tissue sections collected from bladder but none 
found in mouse mammary gland (See Figure 4-3) it is possible that post-
transcriptional regulation of Upk3a expression differs between the two tissues. 
Another possibility is that Upk3a does undergo translation in the mammary gland 
but, due to the presence of different post-translational modifications (N-
glycosylation or possibly phosphorylation) than those seen in the bladder, it is 
non-immunoreactive. In the bladder, Upk3a exists in two forms, as an immature 
(43 kDa) and mature (47 kDa) protein. The immature protein is synthesised in 
the endoplasmic reticulum of umbrella cells. It has three N-linked high mannose 
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oligosaccharides that are attached to an extracellular domain [418]. In order to 
mature, Upk3a is required to form a heterodimer with Upk1b [425]. Formation of 
the Upk3a/Upk1b heterodimer stabilises the Upk3a subunit and enables its exit 
from the endoplasmic reticulum and transit to the plasma membrane where the 
mature 47 kDa Upk3a protein can be seen. The molecular weight of mature 
protein increases which is indicative of additional post-translational 
modifications that occur on the way [418]. Hence, both the presence of post-
translational modifications and the formation of the Upk3a/Upk1b heterodimer 
are prerequisites for Upk3a maturation. Since the AU1 antibody used in this 
project (specific mouse IgG1 monoclonal antibody that recognizes an unspecified 
epitope residing within the extracellular domain) stains only the apical side of 
umbrella cells [419], it recognises the mature form of Upk3a. It is therefore 
possible that either the mature form of Upk3a does not exist in mammary gland 
due to the failure to form a heterodimer with Upk1b or the epitope on Upk3a, 
which is recognised by AU1 antibody in the bladder, is masked by different post-
translational modifications in the mammary gland. It is worth noting, however, 
that data obtained from the microarray analysis indicated that Upk1b is 
expressed in the isolated TEBs (data not shown). This suggests that unless it does 
not get translated, the failure to form a Upk3a/Upk1b heterodimer can not be 
attributed to the lack of Upk1b expression. As only a single anti-Upk3a antibody 
(AU1) was available when this study was carried out it would be of benefit, to 
stain mammary gland- and bladder (positive control) tissue sections with 
different antibodies raised against Upk3a and compare the immunoreactivity of 
its different epitopes and thus assess the possibility for the post-translationally 
modified version of Upk3a being expressed in mammary gland. However, it was 
decided not to pursue this line of investigation and to focus on Fbln2.  
4.3.2 Fibulin 2 
As for Upk3a at the time of study, little was known about the function of Fbln2 
and most research concentrated on its localisation and role in the embryonic and 
adult cardiovascular development. Further investigation of Fbln2 expression 
showed its localisation in skin, hair follicles, skeletal and heart muscles and at a 
lower level in lung, liver, kidney, brain, spleen, testis, uterus and ovaries, 
suggesting it is ubiquitously expressed during adulthood [434] [435] [445] [446]. 
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Despite being this widely expressed, however, the significance of its expression 
has only recently been addressed in the cardiovascular system (See below). 
Furthermore, although Fbln2 has been studied in breast cancer [452] [453] [342], 
its role in normal mouse mammary gland has not been investigated. Currently, in 
vitro protein interaction studies and in vivo cardiac system investigations 
suggest that Fbln2 is likely to stabilise the organisation of ECM [442] [443] [444] 
and promote migration of mesenchymal cells during organogenesis and tissue 
remodelling in response to injury [343] [342] [447] [448]. Since ECM structure, 
assembly and signalling are vital to tissue remodelling during ductal outgrowth 
at puberty and TEBs are migratory at this time point, Fbln2 arose as a promising 
new potential regulator of pubertal mouse mammary gland development. The 
following aspects of Fbln2 expression in the mammary gland were therefore 
addressed in this project: 
 the localisation of Fbln2 within pubertal mammary gland and other stages   
of morphogenesis (See 4.3.2.1) 
 characterisation of Fbln2 expression at puberty (See 4.3.2.2) 
 hormonal regulation of Fbln2 expression (See 4.3.2.3) 
 potential functions of Fbln2 in pubertal mouse mammary gland (See 
4.3.2.4) 
As a result, we demonstrated that Fbln2 is expressed in and localised to the 
mouse mammary gland at pre-puberty, puberty and early pregnancy where 
although possibly playing a role in TEB outgrowth (puberty) and perhaps tertiary 
branching morphogenesis (pregnancy) it may also have a structural function. 
Furthermore, the functions of Fbln2 are probably exerted by interaction with 
some of its known binding partners and its expression may be hormone 
regulated, but its loss does not produce an obvious mammary pubertal 
phenotype in vivo.  
4.3.2.1 Localisation of Fbln2 in pubertal mouse mammary gland 
Our initial microarray analysis identified Fbln2 as highly expressed in the 
epithelium and stroma of the TEBs and also the distal stromal capsule of the 
pubertal mouse mammary gland (Figure 4-7). The accompanying protein 
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localisation study further confirmed that Fbln2 expression is indeed not confined 
to a single tissue compartment.   
Within mammary stroma, Fbln2 protein was strongly localised to the region of 
the BM and fibrous connective tissue of the ECM surrounding TEBs and the distal 
stromal capsule of the mammary gland (Figure 4-7 A) (Figure 4-35). When the 
longitudinal sections of TEB were examined it was clear that the deposition of 
Fbln2 in the fibrous ECM was not uniform. Fbln2 staining was more condensed 
around the flank and neck of TEBs rather than at their tip (Figure 4-35). This 
pattern is consistent with the general spatial localisation of interstitial fibrous 
connective ECM in pubertal mouse mammary gland which is denser at the neck 
region of TEB or around the ducts and looser at the TEB‟s tip [53]. The 
localisation of Fbln2 in the region of BM was not continuous either (Figure 4-35). 
This could be explained by the plane of sectioning or Fbln2 not being uniform 
throughout the whole BM of TEBs. The latter justification can be supported by 
the fact that the composition of BM of TEBs varies, for example the BM at their 
tip is composed of hyaluronate whereas the neck of TEBs contains S-GAGs [50]. 
Fbln2 was also found, at a very high level within the distal stromal capsule – a 
thin tissue layer that envelopes the edges of the mammary gland and facilitates 
the attachment of the excised gland to the glass slide during wholemounting 
(personal observation). To the best of our knowledge, the presence of this 
capsule in the mouse mammary gland has not been described in the literature 
before. In rat mammary glands, a similar structure has been described as a 
highly vascularised capsule of fibrillar connective tissue that determines the 
margins of the mammary gland and serves as a boundary for epithelial expansion 
[470]. Some weak Fbln2 expression was also localised to the fibrous connective 
tissue around ducts (Figure 4-8 B). The level of this expression, however, was 
very low and not uniform throughout the whole mammary gland. Generally, 
Fbln2 localisation to ductal stroma was stronger in Post-LN strips and weaker in 
Pre-LN strips. Since ducts form and elongate by incorporating cells that 
previously belonged to TEBs, the stroma around ducts which are close to TEB, is 
likely to share more similarities with TEB associated stroma than that seen 
around distal ducts, hence the level of Fbln2 expression in ductal stroma may 
depend on its proximity to TEBs. Although the association of Fbln2 with the 
stromal compartment of the mammary gland may not have been surprising, since  
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Figure 4-35 Localisation of Fbln2 expression in pubertal TEB by IHC. 
Longitudinal sections through a TEB and its surrounding stroma stained with anti-Fbln2 antibody 
(brown). Haematoxylin was used to stain nuclei (blue). Fbln2 expression was not uniform. It could 
be seen in some parts of BM – black arrow while black dotted arrow denotes the area where BM is 
absent. Fbln2 could be also seen in fibrous ECM around the flanks (red arrows) and neck of TEB 
(red dotted arrows). No Fbln2 could be seen at the tip of TEB (red asterisk). Scale bar is 50µm.   
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Fbln2 has previously been localised to the ECM of other organs (BM of kidney 
glomeruli, internal elastic lamina of blood vessels and the stroma surrounding 
cornea and skeletal or heart muscles [344] [449] [434]) its localisation to the 
epithelium was unexpected as this has not been detected before.  
Fbln2 could be detected in both cap- and body cells of TEBs, but as shown by 
confocal microscopy, the pattern of abundance in these cell types was not 
uniform. In cap cells, most protein appeared to be associated with cell 
membranes while a slightly weaker and more diffuse signal could be detected in 
what appeared to be the cytoplasm and extracellular spaces (Figure 4-10 A). A 
similarly diffuse, although more punctated pattern, was seen in body cells. 
Here, Fbln2 appeared to localise to extracellular spaces or cytoplasm rather 
than cell membranes and was not uniformly present throughout the entire mass 
of body cells (Figure 4-10 B). In the ducts, on the other hand, the pattern of 
Fbln2 was heterogeneous. Although predominantly negative (especially in the 
Pre-LN region) there were some ducts and ductules that showed a weak but 
similar staining pattern to that seen in TEBs. Here, however, the staining was 
stronger in the region of BM and ECM than the epithelium. Although confocal 
microscopy allowed us to localise Fbln2 to some extent, immunoelectron 
microscopy is needed to clarify its intracellular localisation and potential 
association with ECM proteins.  
In pubertal mouse mammary gland, the components of BM are synthesised by 
both cap cells and stromal fibroblasts while the fibrous ECM is mostly secreted 
by fibroblasts [50] [93]. Fibroblasts may also act as a source of Fbln2 across a 
range of biological systems. Mouse embryonic fibroblasts (NIH3T3), human 
embryonic, dermal or corneal fibroblast have all been shown to express and 
secrete Fbln2 in vitro [444] [471]. Together, these results suggest that the 
expression of Fbln2 in the epithelium, demonstrated by microarray analysis, is 
mainly associated with cap cells, while the stromal Fbln2 may be synthesised by 
fibroblasts. Fbln2 is an extracellular protein and therefore after being 
synthesised it is probably secreted. It is most likely that fibroblasts secrete Fbln2 
to BM and fibrous ECM or just fibrous ECM, while Fbln2 expressed by cap cells 
gets incorporated into BM. As for the epithelium localised Fbln2, while it is most 
probable that the Fbln2 found in the cap cell membrane, cytoplasm and 
extracellular spaces is synthesised in the cap cells themselves the source of 
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Fbln2 expression in body cells is less clear. It is possible that body cells either 
synthesise and secrete Fbln2 themselves or perhaps derive it from cap cells. To 
validate these hypotheses however it would be necessary to carry out in situ 
hybridisation. The secretion of Fbln2 by cap cells towards the body cells of TEBs 
may result from the poor apical-basal polarity of cap cells. This may lead to 
Fbln2 being non directionally secreted to the inner epithelial layers of the TEB 
instead of the BM, as is sometimes seen for hyaluronate and laminin [56] which 
could also explain the non-uniform abundance of Fbln2.  
Our preliminary primary culture experiments on TEB clearly demonstrated that 
the epithelial cells in culture secrete Fbln2. The cytoplasmic and cell membrane 
associations of Fbln2 in these cultures (Figure 4-18) was consistent with that 
seen in TEBs in vivo (Figure 4-10) while the association of Fbln2 with cellular 
processes may resemble the pattern seen in TEB stroma in vivo (Figure 4-8 A). It 
would be beneficial, therefore, to develop this model to study regulation of 
Fbln2 in vitro.   
In addition to its pubertal expression, we also detected Fbln2 in mouse 
mammary glands during pre-puberty and early pregnancy. Pre-puberty is 
regarded as a period of around 3-4 weeks which starts at birth and lasts till the 
onset of puberty which is defined by three events: the vaginal opening, first 
oestrus and the following increase in the production and secretion of 
gonadotrophins and E2 [45]. Here, we reported the expression of Fbln2 in the 2 
and 3 week old mouse mammary glands by Q RT PCR (Figure 4-12 B and C) and 
showed that its spatial localisation in these glands resembled that seen at 
puberty, with Fbln2 expressed in: i) the epithelial (cap cells and body cells) and 
stromal milieu of TEB-like structures (Figure 4-13 A and B) and ii) throughout 
the distal stromal capsule (Figure 4-16 A). This suggests that the expression of 
Fbln2 in the pubertal mouse mammary gland instead of being novel serves a 
continuation of that present at pre-puberty. While given that the pre-pubertal 
mammary gland consists of a rudimentary ductal tree that resembles that seen 
at the E18.5 (reviewed in [3]) and Fbln2 has previously been associated with 
cardiac- [343] and cartilage embryogenesis [440] it is further plausible that the 
presence of Fbln2 at pre-puberty originates and is a continuation of that 
commenced during the embryonic development of mammary gland. The 
association of Fbln2 with mammary embryogenesis, however, has not been 
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studied to date and thus IHC or in situ hybridisation on embryonic tissue 
sections, neonatal and pre-pubertal mouse mammary gland tissue sections would 
be needed to test this hypothesis.  
While the association of Fbln2 with pre-pubertal and pubertal mouse mammary 
glands appeared fairly steady (until it distinctly fades away with the onset of 
adulthood) the recurrence of Fbln2 at early pregnancy was sudden and restricted 
to only a short time frame of around 60h, between day 2 and 4.5 of pregnancy. 
It is first visible at day 2, peaks at day 3 and disappears by day 4.5. In these 
glands Fbln2 localised to ductal myoepithelium and stroma (Figure 4-14) and 
the distal stromal capsule (Figure 4-16 D). The presence of Fbln2 in 
myoepithelium is consistent with myoepithelium being derived from cap cells 
and thus might share some of its characteristics. Stromal Fbln2, on the other 
hand, is most probably expressed by stromal fibroblasts or myoepithelial cells 
both of which can synthesise BM components. Although very obvious at the 
protein level using IHC, these changes were not apparent by Q RT PCR on the 
RNA level. As demonstrated in Figure 4-12 A the level of Fbln2 expression at 
pregnancy day 3 was almost baseline. It is worth noting, however, that the RNA 
used for each time point was obtained from a single animal and normalised only 
to the amount of epithelium (Krt18) instead of the entire number of cells and 
thus might not be fully representative. Nonetheless, the expression of Fbln2 at 
early pregnancy is intriguing and might provide some further clues into its 
function in the future.  
The current knowledge of systemic and morphological events in early pregnancy 
is limited and only few conclusions can be made. All that is known is that early 
pregnancy is characterised by increased proliferation of epithelial cells [36], 
ducts become dilated between day 2 and 3 and epithelium starts to bud at the 
tips and along ducts to form either alveolar buds or tertiary side branches [48]. 
This could suggest a potential role of Fbln2 during the initiation of ductal 
budding and perhaps that the expression of Fbln2 is initiated in response to 
other genes or hormones. Some of the genes known to be active at early 
pregnancy include BMP2, Msx2 and Msx1 [218] but their association with Fbln2 
has not been reported to date. Furthermore, although many hormones, such as 
P, E2, PRL, placental lactogen, oxytocin, GH, PTH, insulin, corticosteroids, 
PTHrP and leptin are thought to regulate proliferation and differentiation of 
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mammary epithelium at pregnancy (reviewed in [36]), to the best of our 
knowledge the exact timing of their expression has not yet been elucidated. The 
two most likely candidates to stimulate Fbln2 expression, however, are P and 
PRL. Prl promotes P expression and the levels of both hormones rise with the 
onset of pregnancy [472]. Furthermore, when primed in vivo with E2+P pellets, 
mouse mammary glands show higher Fbln2 expression than that seen in placebo 
controls (Figure 4-23) (See 4.2.2.8). E2 is known to be particularly elevated 
during the second rather than the first half of gestation when the extensive 
lobuloalveolar growth takes place [473].  
Together, the temporal and spatial expression of Fbln2 during mouse mammary 
gland development suggests its association with the active stages (puberty, early 
pregnancy and possibly embryogenesis) and sites (TEBs at puberty and ducts at 
early pregnancy) of its morphogenesis. 
4.3.2.2 The characteristics of Fbln2 expression in mammary gland 
Fbln2 RNA exists as one of two splice variants: Fbln2 V1 or Fbln2 V2, and as 
shown by Grässel et al. (1990) the distribution of these splice variants is tissue 
specific [439]. It has been reported that Fbln2 V1 is predominantly expressed in 
heart and NIH3T3 cells while Fbln2 V2 is more abundant in the kidney [439]. In 
this study, we demonstrated that both Fbln2 V1 and Fbln2 V2 are expressed in 
mouse mammary gland at puberty (Figure 4-19 B-D). However, we failed to 
replicate the NIH3T3 Fbln2 expression data observed by Grässel et al. (1990) as 
in our experiments, even when repeated using a number of different low passage 
aliquots of NIH3T3, the cells expressed both splice variants (RNA level). This 
discrepancy could be due to potential transformation of either of the NIH3T3 
cell lines. Although neither the XRAY Excel® Array based microarray splicing 
analysis nor the PCR are fully quantitative, the results they generated were 
consistent. Fbln2 V1 appeared to be prevalent in Post-LN strips and isolated TEBs 
and ducts, but no clear difference between the V1/V2 ratio could be seen in 
Pre-LN strips (Figure 4-19 B-D). These preliminary data suggest differences in 
Fbln2 splice variant expression between the stroma around TEBs and that around 
ducts which in turn could suggest different functions of Fbln2 in the two 
environments. However, this possibility still needs to be verified by repeating 
the experiments with a bigger array of samples or using Q RT PCR or northern 
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blotting for quantitative measurement of gene expression. Furthermore, it is 
also questionable whether the two isoforms exhibit different functions. Fbln2 V1 
and Fbln2 V2 differ only by the RNA sequence which encodes a single EGF-like 
repeat which although postulated to participate in the interactions between ECM 
proteins [437] and stabilization of protein structure [438], when absent (human 
Fbln2 expresses only the V2 isoform) does not affect protein-protein interactions 
[435].     
Since Fbln2 V1 and Fbln2 V2 proteins differ only by a single EGF-like repeat their 
molecular weight is predicted to differ by only 5 kDa. However, the presence of 
a potential N-glycosylation site within the alternatively spliced domain raised 
the possibility that the difference in molecular weights of the two proteins was 
greater. Using protein extracts from NIH3T3, EpH4 and HC11 cells, which 
expressed Fbln2 V1 and Fbln2 V2, just Fbln2 V2 and no Fbln2 respectively 
(Figure 4-20 C), and comparing the obtained banding pattern to that seen in 
protein extracts from mammary tissue strips (Figure 4-6 C) we showed that 
Fbln2 V1 and Fbln2 V2 can not be separated using either Bis-Tris or Tris-Acetate 
(better resolution for larger proteins) 1D electrophoresis and Western blotting. 
This suggests a small difference between their sizes which could be attributed to 
either the presence of small polysaccharide chain on Fbln2 V1 or complete 
absence of a potential N-glycosylation at that site.         
Fbln2 is known to be sensitive to proteolysis. In vitro, soluble Fbln2 is cleaved by 
matrix metalloproteinases (stromelysin, matrilysin), circulating proteases 
(thrombin, plasmin and kallikrein) and granule stored proteases (leucocyte 
elastase, mast cell chymase), and, when immunoblotted with the routine full 
length anti-Fbln2 antibody, gives rise to fragments ranging from 15-150 kDa 
[455]. The two bands of 150 kDa and 135 kDa that are additional to the main 195 
kDa band have also been detected in protein extracts from cultured murine 
fibroblasts that were immunoblotted using the same anti-Fbln2 antibody. They 
were suggested to result from proteolytic cleavage of the mature 195 kDa 
protein but no research was carried out to unravel their true nature [455]. Here, 
we report for the first time, that the 135 kDa and 150 kDa Fbln2 exist in vivo 
(Figure 4-6 C) and add to their understanding by demonstrating that in pubertal 
mouse mammary gland the 135 kDa Fbln2 peptide lacks the N-terminus (Figure 
4-21). This finding, along with the fact that none of these bands correspond to 
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Fbln2 V2, and the known sensitivity of Fbln2 to proteolytic cleavage agree with 
the proposal of Sasaki et al. (1996) [455], that both of these additional peptides 
are products of proteolytic cleavage of mature Fbln2. Furthermore, by 
demonstrating that no significant differences in Fbln2 banding pattern exist 
between Pre- and Post-LN strip protein extracts (Figure 4-22) we suggest that 
the protease(s) responsible for Fbln2 cleavage are generic to pubertal mouse 
mammary gland stroma rather than specific to the migratory environment of TEB 
or the more static ductal milieu.  
Since a similar Fbln2 binding pattern can be detected in cultured mouse 
fibroblasts and the fibroblasts in mammary gland are likely to synthesise stromal 
Fbln2, it is tempting to speculate that the proteases in question are associated 
with fibroblasts. Furthermore, based on the similarities between the sizes of 
Fbln2 fragments identified from pubertal mouse mammary gland protein extract 
and those generated by proteases in vitro [455], kallikrein and stromelysin 
(MMP-3) are the most likely candidates to facilitate some of Fbln2 cleavage in 
mammary gland. When treated with kallikrein, two types of Fbln2 products can 
be detected: mature undigested 195 kD protein and the 150 kDa cleavage 
product. In addition Klkb1, the gene which encodes the inactivated form of 
kallikrein (prekallikrein), is ubiquitously expressed throughout the body with 
particularly high expression in mammary gland during stromal remodelling 
periods, i.e. puberty and involution, where it localises to mast cells, and is 
critical for stromal ECM remodelling during involution [474]. Stromelysin, on the 
other hand, cleaves Fbln2 more effectively and only the 150 kDa band can be 
noted [455]. Again, the expression of stromelysin, although ubiquitous, is highly 
associated with pubertal mouse mammary gland where it is important for 
pubertal outgrowth. Mammary glands of MMP3 deficient mice (MMP3 KO-/-) 
display a ductal tree that is thinner and characterised by a lower number of side 
branches than that seen in the WT controls [235]. Since Fbln2 is one of the ECM 
components in pubertal mouse mammary gland and since normal ECM 
composition and remodelling are important for ductal morphogenesis at puberty, 
it would be beneficial to further characterise the 135 kDa and 150 kDa Fbln2 
peptides by mass spectrometry to establish their sequence. It would also be 
helpful to screen for other ECM remodelling proteases that are expressed in the 
mammary gland but are neither mammary gland specific nor expressed in front 
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of the advancing TEB and examine their potential to facilitate the cleavage of 
Fbln2. Some of these potential candidates could include MMP2, MMP9, MMP11 or 
MMP14 [235].     
4.3.2.3 Hormonal regulation of Fbln2 expression 
Our data also highlighted the possibility that Fbln2 expression in the mammary 
gland is regulated by systemic hormones. We demonstrated a significant increase 
of Fbln2 expression in mouse mammary glands collected from 4.5 week old mice 
that were primed with E2 or E2+P pellets for a week (Figure 4-23). Although the 
Fbln2 expression level was normalised to the amount of epithelium rather than 
the total number of cells which, as shown in Figure 4-12 B and C, could have 
impacted upon the level of calculated gene expression, the Q RT PCR results 
were consistent with the IHC data (Figure 4.24). Interestingly, while Fbln2 
localised to the TEB and duct environments and the distal stromal capsule in 
both the placebo and E2+P treated glands, in E2 primed mammary glands Fbln2 
expression was switched off in ductal epithelium and stroma (Figure 4-24). 
Since Fbln2 expression was seen within the ductal environment at puberty, 
which are regulated by E2 and P, it suggests that the observed effect of E2 on 
ducts might be unnatural and caused by an excessive level of E2 and thus may 
not reflect the Fbln2 regulation by E2 in vivo. This can be further substantiated 
by the unnatural appearance, thickness and decreased mechanical elasticity of 
the fat pad in these glands (Figure 4-36 B). The E2+P pellets used in this study 
consisted mostly of P and when used for the week-long priming, evoked a 
pregnancy-like state in the pubertal mouse mammary gland (Figure 4-36 C), 
mimicking the hormonal milieu of pregnancy where P is high and E2 levels are 
much less pronounced. The previously described up-regulation of Fbln2 
expression during early pregnancy where P is present implies that P may play a 
role in promoting Fbln2 expression. This hypothesis is complicated, however, by 
the fact that no difference in Fbln2 expression can be seen between pre-puberty 
and puberty (Figure 4-12 C) suggesting that the levels of pubertal E2 and P do 
not affect Fbln2 expression in vivo. Collectively, it appears that while expression 
of Fbln2 in virgin glands is not regulated by systemic hormones (E2 and P), high 
levels of P characteristic of pregnancy and seen in our in vivo experiments, 
might mediate the expression of Fbln2. This hypothesis can further be supported 
by the identification of Fbln2 amongst the genes over-expressed in human  
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Figure 4-36 Wholemounts collected from hormone primed TG mice. 
3.5 week old mice primed with (A) placebo, (B) E2 and (C) E2+P pellets for 7 days. Images were 
acquired using a fluorescence dissecting microscope (Stemi SV6). Scale bar is 50µm.          
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endometrial stromal short-term cell culture in response to P treatment [456]. To 
explore the potential role of P in mediating the expression of Fbln2 during 
mammary morphogenesis in the future it would be beneficial to use the PR KO-/- 
mice and examine the expression of Fbln2 during different stages of mouse 
mammary gland development in the absence of P signalling. The in vitro model 
for TEB explant culture (See 4.2.2.5) may also facilitate the study of Fbln2 
expression in response to hormones. 
4.3.2.4 Potential functions of Fbln2 in pubertal mouse mammary gland   
At puberty, Fbln2 is mostly associated with the epithelium and stroma around 
TEBs which are known to be a driving force of ductal development. Thus, based 
on its mammary location and its to date suggested functions in different 
biological systems, we propose two potential functions that Fbln2 may have in 
pubertal mouse mammary gland:  
 Stabilising the structure of TEB 
 Facilitating the motility of TEBs  
4.3.2.4.1 Structural function 
 
Numerous in vitro protein interaction studies and analyses of recently generated 
double KO-/- (Fbln2 and Fbln5), mice as well as the presence of multiple EGF-like 
repeats with Ca2+ binding sites, which are postulated to facilitate and regulate 
protein-protein and protein-cellular receptor interactions [436] [437], suggest 
that Fbln2 is involved in stabilising the organisation of ECM structures, especially 
BM, elastic fibres and fibronectin matrix [442] [443] [444] [449]. Thus, given the 
partly stromal localisation of Fbln2 in mouse mammary gland it is possible that 
Fbln2 may function in a similar way in pubertal mouse mammary gland.  
As demonstrated in this study, Fbln2 localised to the BM region of TEBs where it 
is likely to exert its function by interacting with Lama1. Lama1 is one of the 
molecules that have previously been identified, by protein binding studies, to 
interact with Fbln2 in vitro [462] [442]. It is one of the main components of BM 
in the mammary gland (reviewed in [91]) and, as highlighted by our microarray 
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study, it was highly expressed in the Post-LN strip (Table 4-1 and 4-2). When 
used to study the effect of Fbln2 over-expression on the adhesiveness of HC11 to 
ECM matrices, the increased adhesion of HC11 cells to Lama1 could be seen 
(Figure 4-27 B). In the mammary gland, Lama1 is crucial for normal TEB 
development at puberty as its deficiency results in the formation of fewer TEBs 
and consequently reduced ductal outgrowth when compared to WT controls 
[227]. Together these results suggest that Fbln2 may stabilise the 
supramolecular network of Lama1 in BM and therefore contribute to the 
machinery that maintains TEB structure and function during pubertal 
morphogenesis. Further co-localisation and protein binding studies, however, are 
required to validate this hypothesis. 
The presence of Fbln2 expression in the stroma of TEBs and the distal stromal 
capsule of mammary gland suggest that this structural role of Fbln2 may also 
extend to the fibrous connective tissue of the ECM in pubertal mammary gland. 
The fibrous connective ECM in mammary gland consists of an extended network 
of cross-linked ECM components which include Fn, Col, Tn, Eln, SLRP or SPARC 
(reviewed in [91]). Previous evidence indicating presence of protein-protein 
interactions between Fn, ColVIaIII and Eln and Fbln2 in other experimental 
systems [442] [443] [444] [459] [460] [464] together with the identification of  
Fn, ColIVa and Eln as highly expressed in the TEB environment by our microarray 
analysis (Table 4-1, 4-2) suggests that Fbln2 may be functionally associated with 
any of these molecules in mouse mammary gland at puberty.  
As for Fn, an interaction between Fbln2 and Fn has been demonstrated both in 
vitro and in vivo. Fbln2 strongly binds to Fn in protein binding assays [442], co-
localises with Fn in murine dermal and human embryonic fibroblasts cultures [460] 
and in Fn fibrils as shown by IF, and localises to Fn fibrils in human fibroblasts as 
shown by EM [444]. In the mammary gland, lack of Fn delays ductal outgrowth and 
decreases ductal branching at puberty [232] and, as demonstrated in this study, 
the HC11 cells over-expressing recombinant Fbln2 adhered more strongly to Fn 
than the controls (Figure 4-27 B). Although all these findings suggest Fbln2 may 
interact with the Fn matrix in mammary gland at puberty, no co-localisation of 
the two proteins in the mammary stroma could be noted (Figure 4-29) making it 
unlikely for Fbln2 and Fn to act as binding partners during TEB outgrowth in vivo.  
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In contrast potential co-localisation of Fbln2 with Eln in the mammary gland 
could be seen in preliminary localisation studies. Eln was demonstrated to 
localise mostly to the stromal capsule of pubertal mouse mammary glands. A 
single Eln fibre could also be seen in the stroma around TEBs (Figure 4-30 A-B). 
Eln is the second most investigated binding partner of Fbln2 after Fn. In vivo, it 
is mostly present in blood vessels, lung and skin tissue where it interacts with 
Fbn1 to form elastic fibres which are critical for tissue elasticity [465]. This 
process of elastic fibre assembly is dependent on specific protein-protein 
interactions between Eln and/or Fbn1 and their associated proteins. As 
demonstrated by Chapman et al. (2010) when functioning cooperatively with 
Fbln5, Fbln2 is likely to be one of the key players required for normal assembly 
of elastic fibres in internal elastic lamina of blood vessels [449]. Together these 
findings not only present the potential for Fbln2 and Eln interactions in the 
mammary gland but also provide further insights into the structure of the as yet 
uncharacterised stromal capsule.  
Another potential Fbln2 binding partner in mouse mammary gland at puberty 
might be Vcan as it interacts with Fbln2 in other systems [461] [448] [344] and is 
up-regulated in the TEB stroma (Table 4-1 and 4-2), however, to date it has not 
been studied in mammary gland.  
Taken together, the characteristic multistructural and cross linked composition 
of ECM in the mammary gland, the presence of Fbln2 in mammary ECM and its 
multifunctional binding properties, suggest that Fbln2 may serve as a global 
“glue” forming an intramolecular bridge which integrates into ECM using several 
routes to link and stabilise the structure of the mammary stroma and that in 
turn provides the scaffold for the associated stromal and epithelial cells. The 
proposed stabilising property of Fbln2 is consistent with the absence of Fbln2 
expression at the tip of TEB but its deposition at its flank and neck and can 
further be exerted onto cap- and body cells of TEBs where the Fbln2 expression 
appears to be associated with cellular membranes, cytoplasm and extracellular 
spaces and thus may be involved in the maintenance of TEB integrity, as seen for 
Ntn1 and Neo1 [117].  
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4.3.2.4.2 Migratory function 
 
The high expression of Fbln2 in both the stroma and epithelium of TEBs, which 
are very motile structures and serve as key drivers of ductal morphogenesis at 
puberty, could suggest a potential role for Fbln2 in the regulation of TEB 
migration and hence ductal outgrowth. To date, the role of Fbln2 in migration 
has only been studied in terms of single cell migration and was shown to differ 
depending on the experimental system. Down-regulation of Fbln2 occurred in 
both the breast cancer cell lines (MDA-MB-231 and BT-20) and breast tumours 
and, when over-expressed in vitro, it reduced cell motility and invasiveness of 
breast cancer cells [342]. It was present in murine non-neoplastic vascular 
lesions in vivo and when up-regulated it increased smooth muscle cell migration 
in response to injury in vitro [448]. Furthermore, in embryonic cardiovascular 
development Fbln2 has been identified as up-regulated during EMT where it 
selectively localised to mesenchymal cells, i.e. migrating cells of developing 
cardiac valves and aortic arch vessels [441]. Our data, however, does not 
support these findings as it demonstrates that the over-expression of Fbln2 in 
non-malignant mouse mammary epithelial cells (HC11) did not alter the ability 
of these cells to migrate (Figure 4-26 B). It is worth noting, however, that the 
wound healing assay, which was used to study cell migration in this project, was 
carried out on a plastic surface. Based on the fact that Fbln2 belongs to ECM 
molecules and closely interacts with other ECM components it would be 
beneficial to validate these primary findings using additional methods which 
incorporate substances that mimic extracellular environment such as surfaces 
coated with synthetic ECM molecules or fibroblasts (2D assays). On the account 
of the structural complexity and varied composition of ECM in vivo it may further 
be of use to study the impact of Fbln2 expression on mammary epithelial cell 
migration using the 3D matrix based techniques. An example of such assay is a 
Matrigel coated Boyden migration chamber which uses chemoattraction to 
promote cell migration and heterogenic composition of Matrigel (ColIV, Lama1, 
proteoglycans, EMC degrading proteins and their inhibitors, growth factors and 
many others) to reconstitute stromal environment of mammary gland and thus 
can be, and in fact already has been [475], used to study the HC11 cell 
migration. 
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Although the exact mechanism is yet unknown, the migration of TEB does not 
appear to be based on single cells but most likely is characterised by collective 
cell migration – a coherent movement of a group of cells whose leading edge, in 
the in vitro cultured TEB-like organoids, is agglomerated as demonstrated by the 
positive E-cadherin and P-cadherin staining, and appears to migrate despite 
lacking cellular extensions or protrusions [105]. Although the underlying 
mechanism for this activity is yet to be elucidated there are several potential 
ways in which Fbln2 could positively regulate this mechanism of migration.  
Firstly, its localisation to BM and cellular membranes of cap cells and 
extracellular spaces of body cells means Fbln2 may facilitate collective cell 
migration by maintaining the tissue integrity of TEB. It may physically strengthen 
the architecture of BM by binding and cross-linking it with other ECM molecules 
and by assisting in maintaining the adhesion between cap cells and body cells. 
The presence of a single RGD site within its structure supports this theory since 
it is indicative of adhesive properties [434] and, as shown in this study and by 
Sasaki et al. (1990), Fbln2 was able to promote adhesiveness of mammary cell 
lines to ECM coated surfaces (Figure 4-27 B) [463].  
Secondly, the stroma expressed Fbln2 may not only have the structural role 
discussed above but, since ECM is critical for epithelial-stromal cross talk and 
ECM remodelling is essential for TEB migration at puberty, stromal Fbln2 may 
also take part in regulating pubertal outgrowth. In vitro, Fbln2 shows strong 
binding affinity to Itgb3 and Itga5, the BM associated receptors which connect 
the ECM with the epithelial cell cytoskeleton [463] and as demonstrated by our 
microarray study, were highly expressed in TEBs (Table 4-1 and 4-2). Fbln2 may 
therefore mediate signal transmission between the stroma and epithelium and 
hence influence the phenotype and behaviour of TEBs.  
A third possibility, however, is that Fbln2 may influence TEB migration by 
remodelling of ECM. This property of fibulins has been long observed in 
Caenorhabditis elegans where fibulin-1 (FBL-1) which corresponds to mammalian 
Fbln1C is involved in directing the cellular migration of gonadal distal tip cells 
during gonad organogenesis in vivo [476] [477]. FBL-1 is expressed in the stroma 
around migrating cells where it appears to interact with „Abnormal GONad 
Development‟ (GON-1), a non vertebrate homolog of ADAM metallopeptidase 
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with thrombospondin type 1 motif (ADAMTS). It was concluded that FBL-1 drives 
gonadal migration by antagonising the action of GON-1 by interacting with other 
ECM molecules, which are substrates for ADAMTS directed cleavage. One of 
these ECM molecules could be Acan which both binds Fbln1C and is known to be 
cleaved by ADAMTS [478]. Since Fbln1C is the closest relative to Fbln2 [434] its 
involvement in directing gonadal distal tip cell migration might provide insights 
into its potential regulatory function in mammary morphogenesis at puberty.  
Finally, as the expression of Fbln2 was concentrated around the neck and flanks 
of TEBs, in a similar expression pattern to that described for ColI, it may play a 
similar role to that proposed for ColI in acting as a girdle to contain and direct 
the pressure generated during reshaping of TEB into ductal dimensions and thus 
create the force to promote their forward movement [53].  
Thus, there are several ways in which the formation of the Fbln2 network in ECM 
or epithelium of TEBs might provide a structural backbone for mammary ductal 
tree development or facilitate ductal elongation in pubertal mouse mammary 
gland. Furthermore, it is worth adding that Fbln2 expression in the mammary 
myoepithelium and its surrounding stroma at early pregnancy indicates its 
potential in priming the ducts for tertiary branching, a process characteristic for 
this developmental stage, and as discussed for puberty this may be achieved by 
Fbln2 either i) providing a structural scaffold that  maintains tissue integrity or 
ii) priming ductal epithelium and stroma for cellular migration via preparing the 
cells for collective migration, mediating epithelial-stromal cross talk or 
promoting/regulating ECM remodelling (See paragraphs above). Further 
experiments, however, are required to test these hypotheses.  
Despite its specific localisation and rich array of potential functions loss of Fbln2 
did not result in a mammary phenotype, but showed comparable TEB 
morphology (slight differences in TEB size and shape could be seen in the Fbln2 
KO-/- mammary glands which appeared smaller and more oval than their WT 
counterparts but a larger number of mouse mammary glands should be studied 
to substantiate this observation), length and degree of branching of the ductal 
tree to that seen in WT controls (Figure 4-32) (Figure 4-33). This is consistent 
with the results of earlier study by Sicot et al. (2007) which showed the 
dispensability of Fbln2 for general mouse development [266]. This general lack 
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of a phenotype in response to Fbln2 deficiency is probably due to compensation 
by Fbln1 expression, which in fact was not only up-regulated in TEB environment 
in Fbln2 KO-/- mouse mammary glands when compared to WT controls (Figure 4-
34 A and B) but also localised to cap cells and BM, places associated with Fbln2 
but not Fbln1 expression in WT controls (Figure 4-35 A, B and C). This indicates 
that loss of Fbln2 triggers an increase in expression and an alteration in the 
localisation of Fbln1 in mammary gland. Since IHC is not quantitative, further 
studies should be carried out to quantify the level of Fbln1 in Fbln2 KO-/- and WT 
mice. Fbln1 binds to most of the molecules that interact with Fbln2, such as Fn, 
Lama1, Nid, Col18a1, Vcan and Acan [443] [442] and therefore it is possible that 
the compensatory expression of Fbln1 is sufficient to rescue the Fbln2 KO-/- 
phenotype. Further studies should be carried out to evaluate this hypothesis. It 
would be necessary to generate a mouse model lacking the expression of both 
Fbln1 and Fbln2. Since Fbln1 KO-/- mice are prenatally lethal mainly due to 
haemorrhage (defective BM of small blood vessels) [479], however, it would be 
necessary to generate Fbln2 KO-/- mice expressing loxP flanked Fbln1 gene and a 
transgene construct consisting of full-length Cre recombinase cDNA under the 
control of MMTV promoter. The mammary gland expressed Cre would bind to 
loxP sequences and splice the loxP flanked DNA and thus KO Fbln1 expression in 
a selective, tissue specific manner. Given the presence of the potential 
mechanism by which Fbln2 deficiency is immediately compensated by the Fbln1 
expression it is tempting to speculate that rather than being indispensable for 
the pubertal mammary morphogenesis or general mouse development, as 
suggested before [266], it is perhaps that Fbln2 is so essential for these 
processes that just in case it is lost an alternative mechanism, such as 
compensation with Fbln1 expression, are in place. This can further be supported 
by the results of recently generated and studied double knockout mice for Fbln2 
and Fbln5 genes which present a severe phenotype within the cardiovascular 
system (severe disorganisation of the elastic lamina in blood vessels which can 
not be seen in single Fbln2 or Fbln5 KO-/- mouse models) suggesting that when 
interacting with Fbln5,  Fbln2 is essential for elastic fibre formation [449]. At 
the time of this study the double KO mouse model was not available to us but an 
examination of mammary glands collected from these mice would be essential to 
further study the role of Fbln2 during in vivo mouse mammary gland 
development in the future.  
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4.3.2.5 Summary  
In summary, this study is the first to demonstrate and research the expression of 
Fbln2 in pubertal mouse mammary gland. We propose that Fbln2 might be 
expressed in response to P and although its deficiency does not result in an 
obvious pubertal mammary phenotype, its diverse localisation throughout the 
mammary stroma and epithelium suggests it is likely to interact with different 
ECM structures at different places and thus contribute to an array of different 
structural and migratory functions during pubertal mammary morphogenesis and 
possibly pre-puberty and early pregnancy.          
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5 Final conclusions and future work 
5.1 Final Conclusions 
This thesis demonstrates the benefit of DNA microarray analysis in studying 
pubertal development of mouse mammary gland to either identify putative 
regulators („candidate gene approach‟) or unravel global trends in gene 
expression („pathway analysis‟) and thus add to the understanding of biological 
mechanisms that underlie the TEB driven morphogenesis and ductal branching at 
puberty and reveal many potential avenues for further investigations.  
Using RNA obtained from isolated epithelium of TEBs, ducts and whole mouse 
mammary tissue strips not only did we identify gene sets associated with each of 
the pubertal compartments (the epithelium or stroma of TEBs, epithelium or 
stroma of ducts or the epithelium free distal Fat pad) but we also characterised 
each milieu. We are the first to identify and characterise stromal transcriptomes 
of TEBs and ducts and together with the detailed analysis of pubertal epithelium 
this thesis provides the most comprehensive comparison analysis of the 
functional characteristics of TEBs and ducts to date.  
We focused our analysis on an individual gene level and selected Upk3a and 
Fbln2 as potential regulators of pubertal mouse mammary morphogenesis. While 
our studies on Upk3a were limited since it could not be detected at the protein 
level we demonstrated strong expression of Fbln2 in both the epithelium and 
stroma of TEBs and the distal stromal capsule of mouse mammary gland at 
puberty. In addition, we showed that Fbln2 was expressed in TEB-like structures 
and distal stromal capsule in pre-pubertal mammary glands and myoepithelium, 
its surrounding stroma and distal stromal capsule in mammary glands during 
early pregnancy (day 2 - day 4.5). This suggested that Fbln2 expression switches 
on at embryogenesis (embryonic expression of Fbln2 has been demonstrated 
during the cardiovascular development) and continues during pre-puberty and 
puberty. We postulated that Fbln2 may be expressed in response to P during 
puberty and early-pregnancy and that the lack of an obvious mammary 
phenotype in Fbln2 KO-/- mice at puberty might be attributed to the over-
compensation of Fbln2 loss by Fbln1. The diverse localisation of Fbln2 
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throughout the mammary stroma and epithelium suggested its potential to 
interact with various ECM structures at different places and thus contribute to 
an array of different structural and migratory functions during mammary 
morphogenesis.          
5.2 Future directions 
5.2.1 Further analysis of TEB and duct transcriptomes to study 
mouse mammary gland development at puberty 
In this study we hypothesised that the TEB associated genes are involved in 
promoting and regulating the development of mouse mammary gland. We 
suggested many candidates with a potential to serve as these regulators from 
which we further researched association of two with pubertal morphogenesis 
(Upk3a and Fbln2). In the future, it would be beneficial, therefore, to study 
some of the other identified genes in more detail, to asses their role in pubertal 
morphogenesis (e.g. adhesion associated genes - Emb, Fbn2; EMT associated 
genes - Lad1, Slp1, migration associated genes or others as suggested in Chapter 
3.3). The signals from the stroma are as important for mammary morphogenesis 
as these originating from the epithelium (reviewed in 1.2.3.2) and although not 
yet demonstrated for pubertal morphogenesis of mouse mammary gland, the 
down-regulation of genes has been proven essential in morphogenesis of other 
systems (HL-60 monocytic differentiation or EMT). Thus, in the future, the 
search for the potential regulators of pubertal mammary morphogenesis should 
be broadened to include the identified in this project, 579 TEB-only stroma 
associated genes (See 3.2.6.2.2) and the 186 TEB epithelium down-regulated 
(duct up-regulated) genes (See 3.2.6.1.1). 
Moreover, although the „pathway analysis‟ carried out in this study suggested 
the associations of TEB and duct transcriptomes with a range of different 
biological processes/functions, and highlighted the candidate genes associated 
with each one of them, this type of analysis may not be fully representative of 
functional processes activated in vivo and should only be used as a start point 
for further investigation (See 3.3.3.5). To take this analysis forward, therefore, 
the highlighted by IPA associations of given pathways/biological functions with 
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mammary gland morphogenesis should be examined at functional level. The 
„Cardiovascular System Development‟ and „Immune Response‟ are the examples 
of such processes. To date, only three types of innate immune system 
components – macrophages, eosinophils and mast cells have been documented to 
associate with TEBs and ducts at puberty. The „pathway analysis‟ presented in 
this thesis, however, suggested possible association of pubertal epithelium with 
other immune system components (e.g. neutrophils, T lymphocytes, B 
lymphocytes, NKTL, phagocytes or Langerhans cells) (on the basis of their 
marker gene expression) (See 3.3.3.2).  In the future, therefore it would be of 
benefit to use Q RT PCR to confirm the up-regulation of these marker genes in 
mouse mammary gland at puberty and IHC or IF to investigate their spatial 
expression. Moreover, since no active blood vessel development has been 
associated with mammary gland at puberty, to date, it may be of interest to 
follow up the link between angiogenesis and TEBs, suggested by the „pathway 
analysis‟ and gene expression analysis. Our microarray analysis showed VEGF to 
be up-regulated in TEB epithelium, and the epithelial expression of VEGF during 
pregnancy and lactation has previously been shown to promote angiogenesis 
[480]. It may be that migrating TEBs express genes which take part in promoting 
vascular outgrowth or vascular outgrowth promotes directional migration of 
TEBs. It would be necessary to validate the expression VEGF and VEGF receptors 
(FMS-like tyrosine kinase 1 - Flt-1 and Kinase insert domain protein receptor - 
Flk-1) at the protein level and examine the effects of their deficiency on ductal 
outgrowth. Since, the VEGF KO-/- mice are embryonically lethal [481] it would be 
essential to generate a mouse model that would knock out VEGF under the 
control of MMTV promoter in a cre-lox system, to enable its selective silencing at 
the different stages of mammary gland development. The other possibility would 
be to implant mouse mammary glands with the slow release VEGF pellets (e.g. 
Elvax 40P implants [52]) and examine the indirect effect of VEGF on local 
angiogenesis and TEB outgrowth.  
The data generated by IPA could further be analysed to gain information about 
the processes already known to be associated with pubertal morphogenesis, but 
which underlying mechanisms are still to be elucidated, such as lumen formation 
in TEBs. This could be commenced by researching the association of TEB 
epithelium with the apoptosis/cell death-linked genes. 
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Finally, during the course of this project, we also compared the exon expression 
levels between the isolated TEBs and ducts and mouse mammary gland tissue 
strips to study the alternative splicing. This analysis, however, has not been 
addressed in this thesis due to time constraints. Since the alternative splicing of 
mRNA is one of the mechanisms regulating gene expression in higher Eukaryotes 
the comparison of splicing changes between the transcriptomes of TEBs and 
ducts might provide valuable information on their transcriptomics.  
5.2.2 Further analysis of TEB and duct transcriptomes to study 
breast cancer 
It has recently emerged that TEB migration might share similarities with breast 
cancer cell invasion. These are reflected in the rapid growth, epithelial invasion 
of surrounding stroma and its dependence on stromal-epithelial interactions seen 
in both tissues (reviewed in [100]) and the similarities in systemic and local 
regulation of the outgrowths. E2 and its receptor ERα are both crucial for TEB 
development, ductal outgrowth at puberty [126] [127] [133] (See 1.2.3.2.1) and 
breast cancer progression, as demonstrated by the sensitivity of some cancers to 
E2 and the positive impact of Tamoxifen (a synthetic molecule which binds to ER 
and modulates its transcriptional capabilities) on the treatment of ER+ tumours 
(reviewed in [482]). Both TEBs and breast cancer cells have been also suggested 
to migrate in similar manner and the collective cell migration (previously 
discussed in 4.1.3.3 and demonstrated in fully dedifferentiated breast cancers, 
such as lobular breast cancer) (reviewed in [388]) and EMT (previously discussed 
in 4.1.2.1) have been suggested as the candidate drivers. Finally, individual 
genes such as ErbB2 (Her2), an EGF-like receptor which localises to TEBs during 
pubertal development and is critical for their normal morphology and ductal 
elongation [118] have been shown to serve as an important therapeutic target in 
breast cancer (reviewed in [483]).  
In further studies the TEB transcriptome associated genes, identified in this 
thesis (425 TEB epithelium up-regulated genes (3.4.1.1.1) and 565 TEB 
epithelium-stroma up-regulated genes (3.4.1.1.2)), could be used to assess their 
expression levels in breast cancer microarray data sets, e.g. the Netherlands 
Cancer Institute microarray data set, comprising of 295 breast cancer patients 
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(NIK 295) [484], and correlate the results with outcome and metastatic 
potential. Preliminary work from our laboratory showed that human orthologues 
of mouse genes that were identified as up-regulated in isolated TEBs compared 
to ducts by Morris et al. (2006) [113] may distinguish breast cancers with good 
prognosis in the NKI 295 breast cancer data set [484] (unpublished data). Thus, it 
would be interesting to carry out further in silico analysis (hierarchical 
clustering) using our more comprehensive TEB signature to validate these 
results. This and other breast cancer data sets, such as a 99 breast cancer data 
set by Sotiriou et al. [485], could be used to test whether the TEB signature 
clusters with any of the clinical variables (e.g. presence of metastasis, cancer 
grade, LN status, Her2, ER, PR status). As the mitosis-associated genes 
constitute a large part of TEB transcriptome it would be essential that these are 
subtracted prior to analysis. If any associations were found, the individual genes 
may be identified and further studied. In addition, if carried out the „pathway 
analysis‟ of these signatures might provide further information on the signalling 
pathways associated with breast cancer and its progression.  
5.2.3 The use of microRNA profiling to study pubertal 
development of mouse mammary gland 
Finally, it may be beneficial to carry out the microRNA (miRNA) expression 
profiling on isolated TEB and ducts and mammary gland tissue strips and 
compare the TEB signature with breast cancer data sets, as described above.  
MiRNAs are non-coding negative regulators of gene expression (reviewed in 
[486]). Their expression pattern is unique to different organs and processes. It 
can distinguish between normal and tumour tissues [487] [488] or even aid the 
classification of cancers based on their lineage and differentiation state. miRNA 
signature is more stable, reproducible and conserved between the species (~20%) 
than that associated with mRNA profiling [489]. Thus, when used for pubertal 
gene expression analysis, miRNA profiling would not only complement the mRNA 
results but it may also provide new insights into the mechanisms of the TEB 
driven ductal morphogenesis at puberty, identify new regulators or define novel 
signalling pathways involved. This could further define possible links between 
the TEB signature and breast cancer, and thus reveal new avenues for further 
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research on both the normal mammary gland morphogenesis and its malignant 
counterparts. 
5.2.4 Further investigation into the role of Upk3a and Fbln2 in 
pubertal morphogenesis of mouse mammary gland 
Since only a single anti-Upk3a antibody has been tested during the course of this 
project, further evaluation of the expression of Upk3a in mouse mammary gland 
should be carried out using antibodies raised against different epitopes of the 
protein.   
The first line for future investigation into the role of Fbln2 in pubertal 
morphogenesis of mouse mammary gland, on the other hand, would be to use 
the mouse models to study the effect of its loss on the pubertal mouse mammary 
gland in vivo. Although, the initial morphological comparison of pre-pubertal and 
pubertal mouse mammary glands from Fbln2 KO-/- mice and their WT 
counterparts has already been performed during the course of this project, that 
study was based on a limited number of animals only (See 4.2.2.11). Although it 
did not demonstrate any major morphological differences in the length or the 
degree of branching of the ductal tree between the mammary glands, some of 
the TEBs in the mammary glands from pubertal Fbln2 KO-/- mice appeared 
slightly smaller and more elongated than those seen in their WT counterparts. A 
more comprehensive analysis based on higher number of replicates, therefore, 
ought to be performed in the future to validate these results. Moreover, as we 
have shown that the loss of Fbln2 in Fbln2 KO-/- mouse mammary glands 
appeared to be over-compensated by the expression of Fbln1 (also seen in Fbln2 
KO-/- aorta [266]) and this phenomenon may rescue the pubertal phenotype, it 
would be further essential to generate a double (Fbln2 and Fbln1) KO. Since 
Fbln1 KO-/- mice are prenatally lethal [479] it would be necessary, however, to 
generate Fbln2 KO-/- mice expressing loxP flanked Fbln1 gene and a transgene 
construct consisting of full-length Cre recombinase cDNA under the control of 
MMTV promoter. The mammary gland expressed Cre would bind to loxP 
sequences and splice the loxP flanked DNA and thus KO Fbln1 expression in a 
selective tissue specific manner. Furthermore, during the write up of this thesis, 
the double KO-/- (Fbln2 and Fbln5) mouse model was generated. It showed 
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vascular phenotype (disorganised internal elastic lamina in blood vessels) that 
could not be seen in either of the single KO(s) (Fbln2 KO-/- or Fbln5 KO-/-) [449], 
but due to the time constraints of this project we could not carry out its 
examination. The assessment of Fbln5 expression in mouse mammary gland and 
its co-localisation with the mammary Fbln2, alongside with morphological 
examination of mammary glands, collected from these mice, therefore, would 
be essential to progress with studying the role of Fbln2 during in vivo mouse 
mammary gland development in the future. If present, the potential phenotype 
would provide further suggestions on role of Fbln2 in mouse mammary gland 
morphogenesis. 
Most of the functional studies for Fbln2 in pubertal mammary gland development 
were based on the in vitro 2D cell adhesion- or wound healing assays and in vivo 
mouse models. Both systems, however, have clear disadvantages. Mouse models 
are expensive to produce, subject to potential over-compensation/redundancy 
effects and stringent regulation which often results in studies utilising low 
replicate numbers while the 2D in vitro assays fail to mimic the complex 
structure and composition of ECM in vivo. Furthermore, no cell line to date, has 
been generated from the pubertal mammary epithelium (mammary epithelial 
cell lines available to date derive from pregnant mice – HC11, EpH4 cells). Thus, 
no epithelial structures, with morphological similarity to TEBs in vivo, have been 
reported to form from epithelial cells in culture. Future research, therefore, 
should focus on the development of TEB explant culture model. Preliminary 
analyses showing its potential to act as a good in vitro model for pubertal mouse 
mammary gland research have been described in 4.2.2.5. Future work should 
address further characterisation of cells within the outgrowths to further ensure 
that their characteristics resemble those of TEB epithelium in vivo and can be 
maintained in culture. Moreover, given the importance of epithelial-stromal 
interactions during pubertal mammary morphogenesis it would be of benefit to 
identify the most suitable matrix for mimicking stromal environment of TEBs in 
vivo.  
When successfully developed and validated this explant culture model may be 
used in studying the regulation of Fbln2 expression. For example, upon the 
positive ER and PR expression in explant cultures, this system could be used to 
further study the regulation of Fbln2 expression by systemic hormones. 
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Furthermore, the developed experimental conditions could be also used to 
culture the pre-pubertal TEB-like structures and mammary epithelium extracted 
from mammary glands at early pregnancy, both of which have been also shown 
to express Fbln2. These cultures could be then utilised to compare the 
histological characteristics of TEBs and TEB-like outgrowths (it is not yet clear if 
TEB-like structures are equivalent of TEBs at puberty). Furthermore, when 
compared, these three models might provide insights into the regulation of 
Fbln2 expression at different stages of mouse mammary gland morphogenesis. 
Similarly, the explant culture model might also be used to further characterise 
and compare the histology of TEBs collected from WT and Fbln2 KO mouse 
models. Finally, as Fbln2 may play the structural role in mammary gland by 
stabilising the organisation of ECM and, as shown in our study, Fbln2 enhanced 
the adhesiveness of HC11 cells to Lama1, Vtn and Tn it may be of benefit to 
further validate these findings and test the level of adhesiveness of TEB explants 
to each one of these matrices.  
Finally, when fully developed and optimised, in the future, the TEB explant 
culture model may provide a relevant and accessible tool for studying the 
expression and regulation of any of the chosen, TEB associated genes, in vitro. 
 
  320 
 
6 Appendices 
 
 
Appendix 1 Fbln2 V1 expression vector. 
 
 
Appendix 2 List of genes over-expressed in TEB and duct epithelium. 
Appendix 3 List of genes over-expressed in Post- and Pre-LN mouse mammary gland tissue 
strips. 
Appendix 4 List of genes over-expressed in the epithelium free mammary Fat pad. 
Appendix 5 List of genes expressed in TEB-only and duct-only epithelium. 
Appendix 6 List of genes expressed in TEB-only and duct-only stroma. 
Appendix 7 List of genes associated with the identified ‘Molecular and Cellular Function’ 
categories. 
Appendix 8 List of genes associated with the identified ‘Physiological System Development 
and Function’ categories. 
Appendix 9 List of functional sub-group associated with 'Cellular Movement'', 'Nervous 
System Development and Function' and 'Embryonic Development' and their associated 
genes. 
 
Appendices 2-9 are provided in the Supplementary DVD. 
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Appendix 10 List of presentations prepared on the data from this thesis. 
 
 „Stromal-epithelial interactions during ductal morphogenesis of mouse 
mammary gland‟ – Oral presentation at the departmental seminar, University 
of Glasgow (Glasgow, UK; 2007) 
 „Pubertal development of mouse mammary gland‟ – Oral presentation at the 
departmental seminar, University of Glasgow (Glasgow, UK; 2008) 
 „Epithelial and stromal transcriptome analysis of pubertal mouse mammary 
gland‟ – Poster presentation at Breast Cancer Breakthrough Annual Meeting 
(Oxford, UK; 2008) 
 „Epithelial and stromal transcriptome analysis of the pubertal mouse 
mammary gland and identification of Fbln2 as a novel pubertal regulator of 
mouse mammary gland morphogenesis‟ – Poster presentation at Gordon 
Research Conference on Mammary Gland Biology (New Port, USA; 2009)    
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